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A B S T R A C T
Background
Intensive Case Management (ICM) is a community-based package of care aiming to provide long-term care for severely mentally ill people
who do not require immediate admission. Intensive Case Management evolved from two original community models of care, Assertive
Community Treatment (ACT) and Case Management (CM), where ICM emphasises the importance of small caseload (fewer than 20) and
high-intensity input.
Objectives
To assess the eIects of ICM as a means of caring for severely mentally ill people in the community in comparison with non-ICM (caseload
greater than 20) and with standard community care. We did not distinguish between models of ICM. In addition, to assess whether the
eIect of ICM on hospitalisation (mean number of days per month in hospital) is influenced by the intervention's fidelity to the ACT model
and by the rate of hospital use in the setting where the trial was conducted (baseline level of hospital use).
Search methods
We searched the Cochrane Schizophrenia Group's Trials Register (last update search 10 April 2015).
Selection criteria
All relevant randomised clinical trials focusing on people with severe mental illness, aged 18 to 65 years and treated in the community care
setting, where ICM is compared to non-ICM or standard care.
Data collection and analysis
At least two review authors independently selected trials, assessed quality, and extracted data. For binary outcomes, we calculated risk
ratio (RR) and its 95% confidence interval (CI), on an intention-to-treat basis. For continuous data, we estimated mean diIerence (MD)
between groups and its 95% CI. We employed a random-eIects model for analyses.
We performed a random-eIects meta-regression analysis to examine the association of the intervention's fidelity to the ACT model and
the rate of hospital use in the setting where the trial was conducted with the treatment eIect. We assessed overall quality for clinically
important outcomes using the GRADE approach and investigated possible risk of bias within included trials.
Main results
The 2016 update included two more studies (n = 196) and more publications with additional data for four already included studies.
The updated review therefore includes 7524 participants from 40 randomised controlled trials (RCTs). We found data relevant to two
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comparisons: ICM versus standard care, and ICM versus non-ICM. The majority of studies had a high risk of selective reporting. No studies
provided data for relapse or important improvement in mental state.
1. ICM versus standard care
When ICM was compared with standard care for the outcome service use, ICM slightly reduced the number of days in hospital per month
(n = 3595, 24 RCTs, MD -0.86, 95% CI -1.37 to -0.34,low-quality evidence). Similarly, for the outcome global state, ICM reduced the number
of people leaving the trial early (n = 1798, 13 RCTs, RR 0.68, 95% CI 0.58 to 0.79, low-quality evidence). For the outcome adverse events, the
evidence showed that ICM may make little or no diIerence in reducing death by suicide (n = 1456, 9 RCTs, RR 0.68, 95% CI 0.31 to 1.51, low-
quality evidence). In addition, for the outcome social functioning, there was uncertainty about the eIect of ICM on unemployment due to
very low-quality evidence (n = 1129, 4 RCTs, RR 0.70, 95% CI 0.49 to 1.0, very low-quality evidence).
2. ICM versus non-ICM
When ICM was compared with non-ICM for the outcome service use, there was moderate-quality evidence that ICM probably makes little
or no diIerence in the average number of days in hospital per month (n = 2220, 21 RCTs, MD -0.08, 95% CI -0.37 to 0.21, moderate-quality
evidence) or in the average number of admissions (n = 678, 1 RCT, MD -0.18, 95% CI -0.41 to 0.05, moderate-quality evidence) compared to
non-ICM. Similarly, the results showed that ICM may reduce the number of participants leaving the intervention early (n = 1970, 7 RCTs, RR
0.70, 95% CI 0.52 to 0.95,low-quality evidence) and that ICM may make little or no diIerence in reducing death by suicide (n = 1152, 3 RCTs,
RR 0.88, 95% CI 0.27 to 2.84, low-quality evidence). Finally, for the outcome social functioning, there was uncertainty about the eIect of
ICM on unemployment as compared to non-ICM (n = 73, 1 RCT, RR 1.46, 95% CI 0.45 to 4.74, very low-quality evidence).
3. Fidelity to ACT
Within the meta-regression we found that i.) the more ICM is adherent to the ACT model, the better it is at decreasing time in hospital
('organisation fidelity' variable coeIicient -0.36, 95% CI -0.66 to -0.07); and ii.) the higher the baseline hospital use in the population, the
better ICM is at decreasing time in hospital ('baseline hospital use' variable coeIicient -0.20, 95% CI -0.32 to -0.10). Combining both these
variables within the model, 'organisation fidelity' is no longer significant, but the 'baseline hospital use' result still significantly influences
time in hospital (regression coeIicient -0.18, 95% CI -0.29 to -0.07, P = 0.0027).
Authors' conclusions
Based on very low- to moderate-quality evidence, ICM is eIective in ameliorating many outcomes relevant to people with severe mental
illness. Compared to standard care, ICM may reduce hospitalisation and increase retention in care. It also globally improved social
functioning, although ICM's eIect on mental state and quality of life remains unclear. Intensive Case Management is at least valuable
to people with severe mental illnesses in the subgroup of those with a high level of hospitalisation (about four days per month in past
two years). Intensive Case Management models with high fidelity to the original team organisation of ACT model were more eIective at
reducing time in hospital.
However, it is unclear what overall gain ICM provides on top of a less formal non-ICM approach.
We do not think that more trials comparing current ICM with standard care or non-ICM are justified, however we currently know of no
review comparing non-ICM with standard care, and this should be undertaken.
P L A I N   L A N G U A G E   S U M M A R Y
Intensive case management for people with severe mental illness
Background
Severe mental illnesses are defined by diagnosis, degree of disability and the presence of some abnormal behaviour.  Including
schizophrenia and psychosis, severe mood problems, and personality disorder, severe mental illness can cause considerable distress over
a long period of time to both the person aIected and his or her family and friends.
Until the 1970s, it was common for those suIering from these disorders to remain in an institution for most of their lives, but in most of
the countries of the world, they are now managed in the community with one of several diIerent types of intervention. Intensive Case
Management (ICM) is one such intervention. It consists of management of the mental health problem and the rehabilitation and social
support needs of the person concerned, over an indefinite period of time, by a team of people who have a fairly small group of clients
(fewer than 20). Twenty-four-hour help is oIered and clients are seen in a non-clinical setting.
Aims of the review
To find and present good-quality evidence concerning the eIectiveness of ICM compared with non-ICM (where people receive the same
package of care, but the professionals have caseloads of more than 20 people) and standard care (where people are seen as outpatients,
but their support needs are less clearly defined) for people with severe mental illness.
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Searching for evidence
We carried out electronic searches for randomised controlled trials comparing ICM with non-ICM or standard care in 2009, 2012, and 2015.
Results
We included 40 trials involving 7524 people. The trials took place in Australia, Canada, China, Europe, and the USA. When ICM was compared
to standard care, those in the ICM group were more likely to stay with the service, have improved general functioning, get a job, not be
homeless, and have shorter stays in hospital (especially when they had had very long stays in hospital previously). When ICM was compared
to non-ICM, the only clear diIerence was that those in the ICM group were more likely to be kept in care.
Conclusions
None of the evidence for the main outcomes of interest was high quality; at best the evidence was of moderate quality. In addition, the
healthcare and social support systems of the countries where the studies took place were quite diIerent, so it was diIicult to make valid
overall conclusions. Furthermore, we were unable to use much of the data on quality of life and patient and carer satisfaction because the
trials used many diIerent scales to measure these outcomes, some of which were not validated.  The development of an overall scale and
its validation would be very beneficial in producing services that people favour.
(Plain language summary initially prepared for this review by Janey Antoniou of RETHINK, UK (rethink.org))
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Summary of findings for the main comparison.   Intensive Case Management versus standard care for severe mental illness
Intensive Case Management versus standard care for severe mental illness
Patient or population: people with severe mental illness
Settings: community
Intervention: Intensive Case Management versus standard care
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Intensive Case Managementversus stan-
dard care
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Service use: 1. Average number
of days in hospital per month - by
about 24 months
- The mean service use: 1. average number
of days in hospital per month - by about 24
months in the intervention groups was
0.86 lower
(1.37 lower to 0.34 lower)
- 3595
(24 studies)
⊕⊕⊝⊝
low1,2
 
Adverse event: 1b. Death - sui-
cide - by long term
20 per 1000 13 per 1000
(6 to 30)
RR 0.68 
(0.31 to 1.51)
1456
(9 studies)
⊕⊕⊝⊝
low1,4
 
Global state: 1. Relapse - by long
term
- - - - - No data avail-
able
Global state: 1. Leaving the study
early - by long term
331 per 1000 225 per 1000
(192 to 262)
RR 0.68 
(0.58 to 0.79)
1798
(13 studies)
⊕⊕⊝⊝
low1,3
 
Social functioning: 2. Employ-
ment status (various measure-
ments) - by long term - not em-
ployed at the end of the trial
766 per 1000 536 per 1000
(375 to 766)
RR 0.7 
(0.49 to 1)
1129
(4 studies)
⊕⊝⊝⊝
very low1,5
 
Mental state: not improved to an
important extent - by long term
- - - - - No data avail-
able
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one step for risk of bias: randomisation not well described; problematic to blind.
2Downgraded one step for inconsistency: substantial heterogeneity (I2 = 74%).
3Downgraded one step for selective reporting bias: only 13 studies reported fully on the flow of participants through the study.
4Downgraded one step for imprecision: the 95% CI includes both appreciable benefit and appreciable harm.
5Downgraded two steps for inconsistency: considerable heterogeneity (I2 = 94%).
 
 
Summary of findings 2.   Intensive Case Management versus non-Intensive Case Management for severe mental illness
Intensive Case Management versus non-Intensive Case Management for severe mental illness
Patient or population: people with severe mental illness
Settings: community
Intervention: Intensive Case Management versus non-Intensive Case Management
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Intensive Case Manage-
ment versus non-Inten-
sive Case Management
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Service use: 1. Average number of days in hospital
per month - by about 24 months
- The mean service use: 1.
average number of days
in hospital per month -
by about 24 months in
the intervention groups
was
0.08 lower
(0.37 lower to 0.21 high-
er)
- 2220
(21 studies)
⊕⊕⊕⊝
moderate1
 
Service use: 3b. Average number of admissions
(skewed data - sample size ≧ 200) - by long term - The mean service use:3b. average number of
admissions (skewed da-
ta - sample size ≧ 200) -
- 678
(1 studies)
⊕⊕⊕⊝
moderate1
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by long term in the inter-
vention groups was
0.18 lower
(0.41 lower to 0.05 high-
er)
Adverse event: 1b. Death - suicide - by long term 12 per 1000 11 per 1000
(3 to 35)
RR 0.88 
(0.27 to 2.84)
1152
(3 studies)
⊕⊕⊝⊝
low1,3
 
Global state: 1. Relapse - by long term - - - - - No data avail-
able
Global state: 1. Leaving the study early - by long term 159 per 1000 111 per 1000
(83 to 151)
RR 0.7 
(0.52 to 0.95)
1970
(7 studies)
⊕⊕⊝⊝
low1,2
 
Social functioning 2. Employment status - by medi-
um term - spent > 1 day employed
111 per 1000 162 per 1000
(50 to 527)
RR 1.46 
(0.45 to 4.74)
73
(1 study)
⊕⊝⊝⊝
very low1,4
 
Mental state: not improved to an important extent -
by long term
- - - - - No data avail-
able
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one step for risk of bias: randomisation not well described; problematic to blind.
2Downgraded one step for selective reporting bias: only 7 studies reported fully on the flow of participants through the study.
3Downgraded one step for imprecision: the 95% CI includes both appreciable benefit and appreciable harm.
4Downgraded two steps for imprecision: the 95% CI includes both appreciable benefit and appreciable harm, and only 73 participants were included.
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B A C K G R O U N D
Description of the condition
Worldwide, more than 25% of people develop one or more
mental or behavioural disorders during their lifetime (WHO 2001).
Schizophrenia is one illness that heavily contributes to the numbers
of people considered severely mentally ill. The lifetime prevalence
of schizophrenia is 0.58% in the adult population (Warner 1995).
It is currently 26th on the list of diseases ranked according to
contribution to overall burden in term of disability-adjusted life
years (DALYs). Its ranking is projected to rise to 20th by the
year 2020, with more than 17 million DALYs lost (accounting for
1.25% of overall burden) (Murray 1996). However, other psychiatric/
psychological conditions can also profoundly aIect a person's
functioning. Many people with other types of non-organic psychotic
illness, or even non-psychotic disorders such as personality
disorder, can be considered to be severely mentally ill.
There has been lack of consensus over the definition of 'severe
mental illness', but the most common dimensions used to identify
this group are i.) diagnosis, ii.) disability, iii.) duration, and iv.)
abnormal behaviour. However, there is little consistency between
dimensions and thresholds used in diIerent settings (Slade 1997).
The definition of severe mental illness with the widest consensus
is that of the National Institute of Mental Health (NIMH) (Schinnar
1990). Their definition is based on three criteria: i.) diagnosis
of non-organic psychosis or personality disorder; ii.) duration
characterised as involving 'prolonged illness' and 'long term
treatment' and operationalised as a two-year or longer history
of mental illness or treatment; and iii.) disability, which includes
dangerous or disturbing social behaviour, moderate impairment in
work and non-work activities, and mild impairment in basic needs
(National Institute of Mental Health 1987).
A survey conducted in Europe to calculate prevalence rates of
severe mental illness according to the NIMH definition put the total
population-based annual prevalence at approximately 2 per 1000
(Ruggeri 2000).
Description of the intervention
Since the 1960s, there has been an almost worldwide trend towards
the closure of institutions for the mentally ill. Coupled with these
closures, many government policies have focused on reducing the
number of hospital beds for people with severe mental illness
in favour of providing care in a variety of non-hospital settings
- outpatient clinics, day centres, or community mental health
centres. These changes were consistent with the increasing shiP
from hospital-based care in favour of a more community-focused
approach (Malone 2007).
Assertive Community Treatment and Case Management (Table 1)
are community-based packages of care developed in the early
1970s. They were initially conceived to co-ordinate the care
of severely mentally ill people discharged from closing mental
hospitals. However, they were soon more widely applied as a
means of caring for severely mentally ill people who did not require
immediate admission (Thompson 1990).
Core features of Assertive Community Treatment (ACT) were clearly
stated since the first paradigm-shiPing study of Stein and Test
(Stein 1980), and successively critical ingredients of ACT have
operationally defined by developing fidelity scale (McGrew 1994;
McGrew 1995).
Case Management was not likewise defined; brokerage case
management was rapidly abandoned in favour of Clinical Case
Management (Holloway 1995), and more sophisticated, but poorly
defined models were developed. In these models case managers
have clinical training, provide at least some clinical services, and
operate with low caseloads (Rubin 1992; Solomon 1992).
Assertive Community Treatment and Case Management do
share common goals such as maintaining contact, reducing
hospitalisation (and hence cost), and improving outcome.
However, there are, at least in theory and with respect to
the original models, important structural distinctions between
them. Nonetheless, across time through clinical practice the
two interventions have evolved and tended to converge into a
package of care known as Intensive Case Management, which
contains elements from the two original models (Burns 2008;
Scott 1995). In both clinical trials and clinical practice, what is
currently called 'Case Management' is thus likely to contain some
elements of ACT practice. These models can be called 'Clinical
Case Management', 'Intensive Case Management', and 'Strengths
Case Management' (Solomon 1992). However, 'Intensive Case
Management' is a broader term oPen used interchangeably with
Assertive Community Treatment but distinguished from it on the
grounds that it oPen lacks one or more ACT programme elements
(Burns 2001). Intensive Case Management (ICM) emphasises
the importance of small caseload (usually considerably fewer
than 20) and high-intensity input. Intensive case managers are
usually clinicians who act as therapist in addition to their case
management duties (Marshall 2008).
Until a few years ago, the approaches to care within community
mental health teams diIered. These approaches (evolved over the
last 30 years) fell into two main categories: i.) services with well-
delimited aims, such as crisis resolution and home treatments
teams, vocational rehabilitation, and early intervention service;
and ii.) services aimed at meeting a wide range of patient needs,
such as ACT and Case Management (CM) (merging in the Intensive
Case Management model) (Ruggeri 2008).
In the last decade such a distinction has no longer been so relevant.
Intensive Case Management partly lost its purity and closeness
to the original models (ACT and CM), where many services are
oIering a less intensive but more flexible and responsive form
of assertive outreach (Drukker 2008), investing on the 'critical
ingredients' of ICM research helped to identify (Burns 2007)
(Killaspy 2012). Many emerging practices are developed within
ICM framework, where their aim is to address specific target
populations and outcome domains (Bond 2015). Specifically, many
specialised models of intervention within community mental
health teams are based on adaptation of key principles of
ICM, where they are addressing specific population subgroups
(diIicult to engage in traditional settings, high-risk and revolving
door, with comorbidity) (Brewer 2015). Among these, there are
packages of care for homeless populations with severe mental
illness (Coldwell 2007); populations with severe mental illness and
substance abuse (Pettersen 2014), substance abuse, Kirk 2013 or
alcohol dependence only (Gilburt 2012), and early intervention in
first-episode psychosis (Brewer 2015). The recent proliferation of
models inspired by ICM that focus on a special issue was permitted
by the structure and flexibility of the original ACT model, but
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exploring this emerging area goes beyond the objectives of this
review.
How the intervention might work
The theory behind care in the community is that it enables people
to live as independently as possible within their own homes or
'homely settings' out of hospital, because unnecessary hospital
care is wasteful, untherapeutic, and stigmatising. It was hoped
that living in the community would increase opportunities for
people with severe mental illness to achieve their full potential
as autonomous members of society (Department of Health 1990).
Community care policies are also aimed at promoting choice and
independence for people experiencing mental health diIiculties.
Intensive Case Management is an intervention at the level of
local service organisation. It is a way of organising teams, rather
than a specific treatment model (Johnson 2008). Intensive Case
Management should provide a mental health service that is
a reliable, systematic, flexible, and co-ordinated care method,
addressed to answer the unique combination of health and social
care needs of people with severe mental illness. It represents a
long-term intensive approach to the patient in the community
(Killaspy 2008), providing a comprehensive range of treatment,
rehabilitation, and support services (Scott 1995); in the last
decade ICM has absorbed the recovery principle of promoting
emancipation, through policies encouraging graduation (Finnerty
2015). Intensive Case Management aims to help people with severe
mental illness acquire material resources (such as food, shelter,
clothing, and medical care) and to improve their psychosocial
functioning; to provide suIicient support to keep the patient
involved in community life and to encourage growth towards
greater autonomy; to develop coping skills to meet the demands of
community life; and to ensure continuity of care among treatment
agencies (Stein 1980). Key purposes of ICM are to improve outcome,
reduce hospitalisation, and prevent loss of contact with services.
A cornerstone in the research field was a study by Burns and
colleagues exploring the mechanism for ICM to be eIective (Burns
2007). It suggested that the success of ICM depends on its fidelity
to the ACT model (i.e. if a team approach is properly implemented)
and on the setting (i.e. it would work better where there is a high
baseline level of bed use).
Why it is important to do this review
With the evolution of the original intervention models, there was
a need to update and merge two previous relevant Cochrane
reviews (Marshall 2000a; Marshall 2000b), and to take into account
the findings of work by the same authoring team (Burns 2007).
During the last 15 years, not only have intervention models been
modified, merged, and become more diIicult to distinguish in
practice, but also research has been more widespread, with new
studies evaluating these approaches outside of the USA.
Since early 2000, ICM has been a very implemented and widespread
intervention in the community care setting, with many nations in
Europe, North America, and Australia, investing great eIorts and
resources in its promotion and dissemination (in England Care
Programme Approach promoting ACT team (Department of Health
1999)).
Since then, research providing long-term follow-up outcomes and
data on the impact of ACT teams on inpatient service use in
specific national settings has been published with emerging data
casting doubt on the opportunity of such an initial enthusiastic
approach, especially in England, one of the nations where there
had been stronger investments in it (Glover 2006). This topic is
therefore still under an international debate (Burns 2009; Burns
2010; Burns 2012; Killaspy 2012; Rosen 2013). Almost in the same
years (since the mid-2000s), ICM landed in Asia, where the idea
of comprehensive community programmes is gradually catching
on, and wide implementation of both programs has inspired
programmes highly faithful to ICM (Low 2013; Nishio 2014).
The eIects of the currently implemented packages of care in
diIerent settings should be fully understood across a range of
outcomes.
O B J E C T I V E S
To assess the eIects of ICM as a means of caring for severely
mentally ill people in the community in comparison with non-ICM
(caseload greater than 20) and with standard community care. We
did not distinguish between models of ICM. In addition, to assess
whether the eIect of ICM on hospitalisation (mean number of days
per month in hospital) is influenced by the intervention's fidelity to
the ACT model and by the rate of hospital use in the setting where
the trial was conducted (baseline level of hospital use).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials, and
economic evaluations conducted alongside included randomised
controlled trials. We excluded quasi-randomised studies, such as
those allocating by alternate days of the week. Where trials were
described in some way as to suggest or imply that the study was
randomised and where the demographic details of each group's
participants were similar, we included these trials and undertook a
Sensitivity analysis.
Types of participants
We required the majority of participants to be:
1. within the age range of 18 to 65 years;
2. suIering from severe mental illness, preferably as defined by
National Institute of Mental Health 1987, or in the absence
of this, from illness such as schizophrenia, schizophrenia-like
disorders, bipolar disorder, depression with psychotic features
or/and personality disorder; and
3. not acutely ill.
We did not consider substance abuse to be a severe mental disorder
in its own right, however studies were eligible if they dealt with
people with both diagnoses, that is those with severe mental
illness plus substance abuse. Dementia and mental retardation
are not considered to be severe mental disorders, hence we
excluded studies focusing on these populations. We considered
only participants treated in the community care setting.
Types of interventions
We considered only interventions and management packages not
focused primarily on alternatives to acute hospital admission.
Intensive case management for severe mental illness (Review)
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1. Intensive Case Management
We defined Intensive Case Management as where the majority of
people received:
a. a package of care shaped on the:
• Assertive Community Treatment model, being based on
the Treatment in Community Living, Assertive Community
Treatment (Stein 1980);• Assertive Outreach model (Witheridge 1982; Witheridge
1991) (i.e. multidisciplinary team-based approach, practising
'assertive outreach', oIering 24-hour emergency cover,
providing care themselves) (McGrew 1995); or• Case Management model (Intagliata 1982), however described
as such in the trial report.
b. with a caseload up to and including 20 people.
2. Non-Intensive Case Management
We defined non-Intensive Case Management as where the majority
of people received:
a. a package of care shaped on the:
• Assertive Community Treatment model, being based on
the Treatment in Community Living, Assertive Community
Treatment (Stein 1980);• Assertive Outreach model (Witheridge 1982; Witheridge
1991) (i.e. multidisciplinary team-based approach, practising
'assertive outreach', oIering 24-hour emergency cover,
providing care themselves) (McGrew 1995); or• Case Management model (Intagliata 1982), however described
as such in the trial report.
b. with a caseload over 20 people.
3. Standard care
We defined standard care as where the majority of people received
a community or outpatient model of care not specifically shaped
on either the model of Assertive Community Treatment and Case
Management, and not working within a designated named package
or approach to care. If data were available on the standard care
caseload, we undertook a final sensitivity analysis testing how
prone the primary outcomes were to change when trials comparing
Intensive Case Management with standard community care only
(caseload greater than 20) were included.
Types of outcome measures
We grouped outcomes by time into short term (up to and including
6 months), medium term (7 months to up to and including 12
months), and long term (over 12 months). Where available, 24
months was the preferred follow-up point for calculating mean
days per months in hospital. If more than one follow-up point
within the same period was available, we reported the latest one.
During this period, participants remained allocated in their trial
arm.
We grouped outcomes assessed aPer active intervention was
stopped or aPer participants could choose to which arm they were
transferred, by time into short-term follow-up (up to and including
one year), medium-term follow-up (from one to five years), and
long-term follow-up (over five years). We calculated follow-up
length as time since intervention stopped.
To simplify distinguishing between outcomes assessed during and
aPer the active intervention, we entered ones explicitly reporting
follow-up (FUP) length.
Primary outcomes
1. Service use
1.1 Hospitalisation: mean number of days per month in hospital
1.2 Not remaining in contact with psychiatric services
Secondary outcomes
1. Service use
1.1 Admitted to hospital
1.2 Hospital admission rate
1.3 Use of services outside of mental health provision (i.e.
emergency services)
2. Adverse e;ects
2.1 Death - all causes and suicide
3. Global state
3.1 Leaving the study early (lost to follow-up)
3.2 Relapse (as defined in trial)
3.3 Not improved to a clinically meaningful extent (as defined in
trial)
3.4 Not improved
3.5 Average endpoint score
3.6 Average change score
3.7 Compliance with medication
3.8 Average endpoint score
3.9 Average change score
4. Social functioning
4.1 Contact with legal system (i.e. police contacts, arrests,
imprisonments)
4.2 Employment status (number unemployed at end of study)
4.3 Accommodation status (number homeless or not living
independently during or at the end of the study, mean days
homeless and mean days in stable accommodation per month in
study)
4.4 Alcohol use
4.5 Illicit drug use
4.6 Average endpoint score
4.7 Average change score
5. Mental state
5.1 General symptoms
5.1.1 Not improved to a clinically meaningful extent (as defined in
trial)
5.1.2 Not improved
5.1.3 Average endpoint score
5.1.4 Average change score
5.2 Specific symptoms
5.2.1 Positive symptoms (delusions, hallucinations, disordered
thinking)
5.2.1.1 Not improved to a clinically meaningful extent (as defined in
trial)
Intensive case management for severe mental illness (Review)
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5.2.1.2 Not improved
5.2.1.3 Average endpoint score
5.2.1.4 Average change score
5.2.2 Negative symptoms (poor volition, poor self care, blunted
aIect)
5.2.2.1 Not improved to a clinically meaningful extent (as defined in
trial)
5.2.2.2 Not improved
5.2.2.3 Average endpoint score
5.2.2.4 Average change score
5.2.3 Mood depression
5.2.3.1 Not improved to a clinically meaningful extent (as defined in
trial)
5.2.3.2 Not improved
5.2.3.3 Average endpoint score
5.2.3.4 Average change score
6. Behaviour
6.1 General behaviour
6.2 Not improved to a clinically meaningful extent (as defined in
trial)
6.3 Not improved
6.4 Average endpoint score
6.5 Average change score
6.6 Specific behaviours (i.e. self harm; injury to others or property)
7. Quality of life
7.1 Not improved to a clinically meaningful extent (as defined in
trial)
7.2 Not improved
7.3 Average endpoint score
7.4 Average change score
8. Satisfaction
8.1 Participant satisfaction
8.1.1 Not improved to a clinically meaningful extent (as defined in
trial)
8.1.2 Not improved
8.1.3 Average endpoint score
8.1.4 Average change score
8.2 Carer satisfaction
8.2.1 Not improved to a clinically meaningful extent (as defined in
trial)
8.2.2 Not improved
8.2.3 Average endpoint score
8.2.4 Average change score
9. Costs
9.1 Direct costs of psychiatric hospital care
9.2 Direct healthcare costs (including all medical and psychiatric
care and the costs of case management, but excluding
accommodation other than hospital care)
9.3 Direct costs of all care (including costs of accommodation and
subtracting benefits, such as earnings, where these are known)
Summary of findings
We used the GRADE approach to interpret findings, Schünemann
2008, and GRADEpro, GRADEpro, to import data from Review
Manager 5, Review Manager, to create 'Summary of findings' tables.
These tables provide outcome-specific information concerning
the overall quality of evidence from each included study in the
comparison, the magnitude of eIect of the interventions examined,
and the sum of available data on all outcomes we rated as
important to patient care and decision making. We selected the
following main outcomes for inclusion in the 'Summary of findings'
table.
1. Service use: average number of days in hospital per month by
about 24 months
2. Service use: average number of admissions (skewed data -
sample size ≥ 200) by long term (> 12 months)
3. Adverse event: death - suicide by long term (> 12 months)
4. Global state: relapse
5. Global state: leaving the study early by long term (> 12 months)
6. Social functioning: employment status – spent less than 1 day
employed - by medium term (6 to 12 months)
7. Mental state: not improved to an important extent
Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group’s Trials Register
On 10 April 2015, the Information Specialist searched the Register
using the following search strategy:
(*ca?e manag* OR *cpa* OR *community treat* OR *community
team* OR *community cent* OR *community care* OR *madison
model* OR *outreach* OR *hostel* OR *aPercare* OR *residential*
OR *housing* OR *transitional* OR *post?hospital* OR *partial
hospitali?ation* OR *foster* OR *guardianship* OR *daily living
program* OR *crisis interven* OR *early interven* OR *ambulatory*
OR *community liv* OR *social support* OR *patient care team* OR
*community mental health* OR *patient participation* OR *drop?
in* OR *day hospital* OR *day care* OR *day treat* OR *day cent*
OR *day unit* OR *intensive care* OR *intensive interven* OR
*intensive treat* OR *intensive therap* OR *intensive manag* OR
*intensive model* OR *intensive program* OR *intensive team*
OR *intensive service* OR *mobile care* OR *mobile interven*
OR *mobile treat* OR *mobile therap* OR *mobile manag*
OR *mobile model* OR *mobile program* OR *mobile team*
OR *mobile service* OR *community interven* OR *community
therap* OR *community manag* OR *community model* OR
*community program* OR *community service* OR *community
base* OR *home care* OR *home interven* OR *home treat*
OR *home therap* OR *home manag* OR *home model* OR
*home program* OR *home team* OR *home service* OR *home
base* OR *broker* OR *care program*) in Title, Abstract, and
Index Terms of REFERENCE OR (*ca?e manag* OR *community*
OR *outreach* OR *hostel* OR *aPercare* OR *residential* OR
*hous* OR *transitional* OR *foster* OR *crisis interven* OR *early
interven* OR *ambul* OR *social support* OR *drop-in* OR *day *
OR *(intensive)* OR *(home)* OR *care program*) in Intervention of
STUDY
The Cochrane Schizophrenia Group’s Register of Trials is compiled
by systematic searches of major resources (including MEDLINE,
Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and registries
of clinical trials) and their monthly updates, handsearches, grey
literature, and conference proceedings (see Group Module). There
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is no language, date, document type, or publication status
limitations for inclusion of records into the register.
For search methods of previous versions of this review, please see
Appendix 1.
Searching other resources
References
Should an included or excluded study suggest that another study
was relevant, we identified the reference and acquired the full text.
Personal contact
We contacted authors of trials for additional data where required.
We did not systematically contact all authors for additional papers.
Data collection and analysis
Methods used for this version are presented below; previous
methods are presented in Appendix 2.
Selection of studies
Two review authors (HB, MK) inspected results of the update search
and identified potentially relevant reports. Disagreements were
resolved by discussion, or where there was still doubt, we aquired
the full article for further inspection. We obtained the full articles
of relevant reports for reassessment and inspected them carefully
to decide on inclusion or exclusion (see Criteria for considering
studies for this review). Review authors were not blinded to the
names of the authors, institutions, or journal of publication. Where
diIiculties or disputes arose, we discussed; if we were unable
decide, we added these studies to those awaiting assessment and
contacted the authors of the papers for clarification.
Data extraction and management
1. Extraction
1.1 Data extraction for criteria and outcomes
Three review authors (MD, HB, MK) independently extracted
data from the included studies and compared results of the
data extraction. We would have discussed any disagreements,
documented our decisions, and contacted the authors of studies
for clarification where necessary. Whenever possible, we would
have extracted data presented only in graphs and figures and
included the data if two review authors independently reached
the same result. In order to obtain any missing information or
for clarification, we attempted to contact authors through an
open-ended request. Where possible, we would have extracted
data relevant to each component centre of multicentre studies
separately.
1.2 Additional data extraction
1.2.1 Fidelity
We rated fidelity of the ICM intervention to ACT on the 'team
membership' and 'team structure and organisation' subscales of
the Index of Fidelity to Assertive Community Treatment (IFACT)
(McGrew 1994). This index was derived from a survey of 20 clinical
experts in ACT and validated in a survey of 18 programmes.
a. The 'team membership' subscale comprises four items:
• ratio of patients to staI;
• total size of team;• extent of psychiatric input;• extent of nursing input to the team.
b. The 'structure and organisation' subscale comprises seven items,
whether the team is:
• the primary source of care for its patients;• situated away from the hospital;• meets daily;• shares responsibility for caseloads;• is available 24 hours a day;• has a team leader who is also a case manager;• oIers unlimited time for its services.
We chose IFACT because the subscales are brief and can be
completed from published or unpublished text. For each item
on the index, a score of 1 indicates high fidelity to the model.
Score ranges from 0 to 11, where the maximum score available
on the 'team membership' subscale is 4 and on the 'structure and
organisation' subscale is 7, with higher scores indicating higher
fidelity to the model.
We obtained fidelity data from published and unpublished trial
reports, direct contact with trialists, and data previously obtained
directly from trialists reported by previous reviews (Burns 2001;
Burns 2007; Catty 2002). Two raters (MD and CBI) independently
combined these data into a single fidelity score. Multicentre trials of
ICM oPen struggle to implement a uniform approach, with centres
operating at diIering degrees of fidelity. Where possible, we rated
each component centre separately.
1.2.2 Baseline hospital use
We extracted data relating to the average number of days per
month in hospital for all participants in the two years before
the study began. We obtained this data from published and
unpublished trial reports and from direct contact with trialists.
1.2.3 Service use: hospitalisation
We obtained the primary outcome mean number of days per
month in hospital for the included studies from published and
unpublished trial reports, direct contact with trialists, and data
previously obtained directly from trialists reported by a previous
review (Burns 2007).
2. Management
2.1 Forms
Two review authors (HB, MK) extracted data onto simple, standard
forms.
2.2 Data from multicentre trials
For the original version, where possible review authors MD and CBI
verified independently calculated centre data against original trial
reports.
2.3 Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000);
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b. the measuring instrument was not written or modified by one of
the trialists for that particular trial; and
c. the measuring instrument was either i.) a self report or ii.)
completed by an independent rater or relative.
2.3 Endpoint versus change data
Both endpoint and change data have advantages. Change
data can remove a component of between-person variability
from the analysis. On the other hand, calculation of change
needs two assessments (baseline and endpoint), which can be
diIicult in unstable and diIicult-to-measure conditions such as
schizophrenia. We decided to primarily use endpoint data, and only
use change data if the former were not available. When relevant, we
combined endpoint and change data in the analysis, as we aimed
to use mean diIerences rather than standardised mean diIerences
throughout (Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are oPen not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards to
relevant continuous data before inclusion.
We entered all relevant data from studies of more than 200
participants in the analysis irrespective of the following rules,
because skewed data pose less of a problem in large studies. We
also entered all relevant change data, as when continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is diIicult to tell whether data are skewed
or not.
For endpoint data from studies of fewer than 200 participants, we
used the following methods.
a. If a scale started from the finite number zero, we subtracted
the lowest possible value from the mean, and divided this by the
standard deviation (SD). If this value is lower than 1, it strongly
suggests a skew, and we excluded these data. If this ratio is higher
than 1 but below 2, there is suggestion of skew. We entered these
data to test whether their inclusion or exclusion changed the results
substantially. Finally, if the ratio was larger than 2, we included
these data, because skew is less likely (Altman 1996; Higgins 2011).
b. If a scale starts from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS), which can have values from 30
to 210) (Kay 1986), we modified the calculation described above to
take the scale starting point into account. In these cases skew is
present if 2 SD > (S - S min), where S is the mean score and 'S min'
is the minimum score.
Exception to above rules - mean number of days in hospital
We implemented one exception to the above rules in order to
present more data, recognising that this is a post hoc decision,
but also that the rules with regards to management of skewed
data and how robust skewed data are within meta-analysis are
unclear (Higgins 2011). Where mean number of days in hospital
data were skewed, and they were provided by studies of fewer than
200 participants, we entered those data into a subgroup of the
overall analysis. We also presented the overall eIect from all data
pooled.
2.5 Common measure
To facilitate comparison between trials, we converted variables that
can be reported in diIerent metrics, such as days in hospital (mean
days per year, per week, or per month) to a common metric (e.g.
mean days per month).
2.6. Conversion of continuous to binary
Where possible, we attempted to convert outcome measures to
dichotomous data. This can be done by identifying cutoI points on
rating scales and dividing participants accordingly into 'clinically
improved' or 'not clinically improved'. It was generally assumed
that if there had been a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS), in Overall 1962,
or the PANSS (Kay 1986), this could be considered to be a clinically
significant response (Leucht 2005a; Leucht 2005b). If data based
on these thresholds were not available, we used the primary cutoI
presented by the original authors.
2.7. Direction of graphs
Where possible, we entered data in such a way that the area to the
leP of the line of no eIect indicated a favourable outcome for ICM.
Assessment of risk of bias in included studies
For this version of the review, two review authors (HB, MK) assessed
risk of bias of all new included studies using the tool described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
This set of criteria is based on evidence of associations between
overestimate of eIect and high risk of bias of the article
such as sequence generation, allocation concealment, blinding,
incomplete outcome data, and selective reporting.
If the raters had disagreed, we planned to make the final rating by
consensus. Where inadequate details of randomisation and other
characteristics of trials were provided, we contacted the authors of
the studies to obtain further information. We would have reported
non-concurrence in quality assessment, and if disputes had arisen
as to which category a trial was to be allocated, again, we would
have resolved this by discussion.
We noted the level of risk of bias in Risk of bias in included
studies, Summary of findings for the main comparison, Summary
of findings 2, and Figure 1.
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Figure 1.   Methodological quality summary: review authors' judgements about each methodological quality item
for each included study.
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Figure 1.   (Continued)
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Figure 1.   (Continued)
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Measures of treatment e;ect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
random-eIects risk ratio (RR) and its 95% confidence interval. It has
been shown that RR is more intuitive than odds ratios (OR), and that
clinicians tend to interpret ORs as RR (Boissel 1999; Deeks 2000).
Within the 'Summary of findings' table, we aimed to calculate the
lowest control risk applied to all data. We assumed the same for
the highest-risk groups. We used the 'Summary of findings' table to
calculate absolute risk reduction for primary outcomes.
2. Continuous data
For continuous outcomes, we estimated the mean diIerence
between groups. We preferred not to calculate eIect size measures
(standardised mean diIerence). However, if in future versions of
this review scales of very considerable similarity are used, we
will presume there is a small diIerence in measurement and will
calculate eIect size and transform the eIect back to the units of one
or more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ 'cluster randomisation' (such as
randomisation by clinician or practice), but analysis and pooling of
clustered data pose problems. Firstly, authors oPen fail to account
for intraclass correlation in clustered studies, leading to a 'unit
of analysis' error (Divine 1992), whereby P values are spuriously
low, confidence intervals unduly narrow, and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering is not accounted for in primary studies, we would
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. If we find such studies in
subsequent versions of this review, we will attempt to contact
first authors of studies to obtain intraclass correlation coeIicients
for their clustered data and to adjust for this by using accepted
methods (Gulliford 1999). Where clustering has been incorporated
into the analysis of primary studies, we would present these data as
if from a non-cluster randomised study, but adjust for the clustering
eIect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a 'design
eIect'. This is calculated using the mean number of participants per
cluster (m) and the intraclass correlation coeIicient (ICC) [Design
eIect = 1 + (m - 1)*ICC] (Donner 2002). If the ICC is not reported, we
would assume it to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed taking into
account intraclass correlation coeIicients, and relevant data
documented in the report, synthesis with other studies would be
possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over eIect,
which occurs if an eIect (e.g. pharmacological, physiological, or
psychological) of the treatment in the first phase is carried over
to the second phase. As a consequence, on entry to the second
phase the participants can diIer systematically from their initial
state despite a wash-out phase. For the same reason, cross-over
trials are not appropriate if the condition of interest is unstable
(Elbourne 2002). As both eIects are very likely in severe mental
illness, we only used data from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, we
presented the additional treatment arms in comparisons if
relevant. Where the additional treatment arms were not relevant,
we did not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up data loses credibility (Xia 2009).
For any particular outcome, should more than 50% of data be
unaccounted for, we did not reproduce these data or use them
within analyses. If, however, more than 50% of participants in one
arm of a study were lost, but the total loss was less than 50%, we
marked such data with (*) to indicate that such a result may well be
prone to bias.
2. Binary
Where attrition for a binary outcome was between 0 and 50%, and
where these data were not clearly described, we presented data on
a 'once-randomised-always-analyse' basis (an intention-to-treat
analysis). We assumed all those leaving the study early to have
the same rates of negative outcome as those who completed, with
the exception of the outcome of death. We undertook a Sensitivity
analysis testing how prone the primary outcomes were to change
when we compared data from only those who completed the study
with intention-to-treat data using the assumption outlined above.
Where number of deaths was more than 10% of the sample overall,
we applied the above statement but did not impute attrition due to
death.
3. Continuous
3.1 Attrition
Where attrition for a continuous outcome was between 0 and 50%,
and data from only those who completed the study were reported,
we reproduced these.
3.2 Standard deviations
3.2.1 General
Where there were missing measures of variance for continuous
data, but exact standard errors or confidence intervals for group
means, or either ‘P’ or 't' values for diIerences in means, we
calculated standard deviation value according to the method
described in Section 7.7.3 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). If standard deviations were
not reported and could not be calculated from the available data,
we asked authors to supply the data. In the absence of data from
authors, we used the mean standard deviation from other studies.
3.2.2 Standard deviation mean number of days per month in hospital
For the primary outcome mean number of days per month in
hospital, if standard deviations were not reported and could not be
Intensive case management for severe mental illness (Review)
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calculated from available data, we asked the authors for additional
information. In the absence of data from authors, we imputed
the missing standard deviations using a regression analysis of SD
against mean from those trials that provided both. We documented
in what studies we imputed SDs according to the above technique
in Table 2.
3.3 Last observation carried forward
We anticipated that in some studies the method of last observation
carried forward (LOCF) would be employed within the study report.
As with all methods of imputation to deal with missing data,
LOCF introduces uncertainty about the reliability of the results.
Therefore, where LOCF data had been used in the trial, if less than
50% of the data had been assumed, we reproduced these data and
indicated that they were the product of LOCF assumptions.
3.4 Incomplete data for meta-regression
We anticipated that in some cases not all IFACT score variables
would be available. If we could not calculate IFACT score from the
available data, we imputed it by multiple imputation using the
Multiple Imputation with Diagnostics (mi) library in R (R 2008). As
explained above, we only made these assumptions if we were able
to directly rate over 50% of the data. We documented in what
studies we calculated IFACT score according to the above technique
in Table 3.
We anticipated that in some cases not all baseline hospital use
data would be available. We imputed missing data as for the IFACT
scores. As explained above, we only made these assumptions if we
were able to directly rate over 50% of the data. We documented for
which studies we calculated baseline hospital use data according
to the above technique (Table 3).
We undertook a Sensitivity analysis testing how prone the results
from meta-regression were to change when we compared data
from only those who completed the studies with the imputed data
using the assumption outlined above.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing
comparison data, to judge clinical heterogeneity. We simply
inspected all studies for clearly outlying situations or people
that we had not predicted would arise. When such situations or
participant groups arose, we discussed these fully.
In addition, we specified two potential sources of heterogeneity a
priori (fidelity and baseline level of hospital use) (Data extraction
and management). We extracted these data as described above.
2. Methodological heterogeneity
We considered all included studies initially, without seeing
comparison data, to judge methodological heterogeneity. We
simply inspected all studies for clearly outlying methods that we
had not predicted would arise. If such methodological outliers
arose, we discussed these fully.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I2statistic
We investigated heterogeneity between studies by considering
the I2 statistic alongside the Chi2 P value. The I2 provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I2
depends on i.) magnitude and direction of eIects, and ii.) strength
of evidence for heterogeneity (e.g. P value from Chi2 test, or a
confidence interval for I2). We interpreted an I2 estimate greater
than or equal to 50% accompanied by a statistically significant
Chi2 statistic, as evidence of substantial levels of heterogeneity
(Section 9.5.2; Higgins 2011). When we found substantial levels
of heterogeneity in the primary outcome, we explored reasons
for the heterogeneity (Subgroup analysis and investigation of
heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Chapter 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases but
are of limited power to detect small-study eIects. We did not use
funnel plots for outcomes where there were 10 or fewer studies,
or where all studies were of similar size. In other cases, where
funnel plots were possible, we sought statistical advice in their
interpretation.
Data synthesis
Where possible, we employed a random-eIects model for analyses.
We understand that there is no closed argument for preference
for use of fixed-eIect or random-eIects models. The random-
eIects method incorporates an assumption that diIerent studies
are estimating diIerent, yet related, intervention eIects. According
to our hypothesis of an existing variation across studies, to be
explored further in the meta-regression analysis, despite being
cautious that random-eIects methods do put added weight onto
the smaller of the studies, we favoured using random-eIects
model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We anticipated conducting two subgroup analyses. For the first
version of the protocol for this review, we did not anticipate any
subgroup analyses. On further consideration, we now realise that
analysis at separate time periods could be thought of as subgroups.
The second subgroup is within the primary outcome and relates
to skewed and non-skewed data. We introduced this late into the
protocol, and it could be considered post hoc. However, we are also
aware that our original rule for management of these data could be
considered overly cautious and result in some important data not
being presented (Higgins 2011).
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2. Investigation of heterogeneity
2.1 Anticipated heterogeneity - outcome of mean days per month in
hospital
Investigation of heterogeneity formed part of the secondary
objectives of the review. We hypothesised that the eIect of ICM on
one of our primary outcomes (mean number of days per month
in hospital) diIers according to fidelity of intervention to the ACT
model and the baseline level of hospital use.
We examined the association of the IFACT score and the baseline
number of days in hospital with the treatment eIect by performing
random-eIects meta-regression analysis in R (R 2008). The script
we used to perform meta-regression analyses is reported in
Appendix 3. We also carried out meta-regression using both
variables within the same model. In addition, we examined the
relationship between the treatment eIect and the two variables
using a thin plate spline. If possible, we aimed to enter data from
multicentre studies in the meta-regression disaggregated into the
component centre with outcome and fidelity data for each.
Meta-regression was performed only if at least 10 studies per
comparison were available (Higgins 2011). rWe also tested
comparison type as an additional regressor in the model.
2.2 Unanticipated heterogeneity - other outcomes
2.2.1 For outcomes other than the second primary outcome (not
remaining in contact with psychiatric services)
We reported if inconsistency was high and undertook no
exploration.
2.2.2 For outcome 'not remaining in contact with psychiatric services'
We reported if inconsistency was high. First we investigated
whether data had been entered correctly. Second, if data was
correct, we visually inspected the graph and successively removed
studies outside of the company of the rest to see if homogeneity
was restored. Should this occur with no more than 10% of the data
being excluded, we presented the data. If not, these data were not
pooled.
Should unanticipated clinical or methodological heterogeneity
have been obvious, we simply stated hypotheses regarding these
for future reviews or versions of this review. We did not anticipate
undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the
primary outcomes, we included these studies, and if there was no
substantive diIerence when the implied randomised studies were
added to those with a better description of randomisation, then we
employed all data from these studies.
2. Standard-care caseload
If data were available, we undertook a sensitivity analysis testing
how prone the primary outcomes were to change when trials
comparing ICM to standard community care caseload less than
or equal to 20 were compared with trials comparing ICM to
standard community care caseload greater than 20. If there was a
substantial diIerence, we reported the results and discussed them
but continued to pool the data.
3. Assumptions for lost binary data
Where we needed to make assumptions regarding participants lost
to follow-up (see Dealing with missing data), we compared the
findings of the primary outcomes when we used our assumption
compared with completer data only. If there was a substantial
diIerence, we reported the results and discussed them but
continued to employ our assumption.
4. Assumptions for incomplete data for meta-regression
Where we needed to make assumptions regarding missing SDs
data in studies entering meta-regression (see Dealing with missing
data), we compared the findings of the meta-regression on our
primary outcome when we used our assumption compared with
data taken from only those who completed the studies. We tested
how prone results from meta-regression were to change when
we compared data from those who completed with imputed data
using the assumption outlined above. If there was a substantial
diIerence, we reported results and discussed them but continued
to employ our assumption.
R E S U L T S
Description of studies
Results of the search
We have presented the results of the latest update search below; for
previous results, please see Appendix 4.
The April 2015 update search of Cochrane Schizophrenia Group's
Register of Trials yielded 299 references. We selected 87 for
further inspection. One hundred and twenty-seven references
(corresponding to 96 studies with 31 companion papers) were
available from the 'awaiting classification' section of the previous
version of the review and were all selected for further inspection.
We excluded a total of 85 studies from the review. Only two
trials met the inclusion criteria and were included (Chan-Hong
Kong 2000; Cusack-North Carolina). There were 26 new companion
papers to previously included studies such as Morse-Missouri3
2005, OPUS-Denmark 1999, REACT-UK 2002, and UK700-UK 1999.
We have entered 20 trials in the 'awaiting classification' section and
have sought further information. We added five new studies to the
ongoing studies.
Problematic trials
There were two problematic trials worth special mention.
Jerrell-SCarolina1 1991 was a three-arm trial, with two of the arms
qualifying as Intensive Case Management (Programme Assertive
Community Treatment and Intensive Broker Case Management)
and one a control (standard care). As results were reported
separately for each arm, it was not possible to present continuous
data from two ICM arms pooled together. One option was to treat
each arm as a separate 'site', eIectively treating the study as two
trials, but with the same control group. A second option was to
include only one of the experimental arms. Although aware of
excluding potentially useful data on an arbitrary basis, we decided
to include only one of the arms compared to standard care, per
the second option. The main reason for this was to avoid a unit of
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analysis error, which would have occurred in the first option. We
undertook a sensitivity analysis testing how prone results were to
change when this trial was not included in meta-analysis.
Curtis-New York 1992 was a trial comparing ICM with standard
care presenting two main diIiculties. The first was regarding ICM
caseload size. The study reported caseload ratio as 1:35 (above the
1:20 ratio defining an ICM intervention). As we derived estimation
of caseload size by dividing the number of intervention participants
by the number of whole-time equivalent clinical staI in the team
(not just those formally classified as 'case managers'), we found
that the actual staI:participant ratio was about 1:17. We therefore
found this trial eligible for inclusion in the review. The second
issue was regarding the peculiar way this trial provided the ICM
intervention. Both experimental and control interventions were
community-oriented and fit fully into the review's inclusion criteria,
but the ICM team was located in hospital. While undesirable,
the team oIice being based in hospital is not unusual. In any
case, the case management was provided in the community. We
therefore confirmed inclusion of the study, not wanting to penalise
it because it reported details that were not available for all trials.
However, we found a discrepancy in the data the study provided
on service use outcomes (average number of days in hospital per
month, admitted to hospital). Curtis-New York 1992 was an outlier,
being the only study clearly favouring standard care over ICM. We
undertook a sensitivity analysis testing how prone results were
to change when this trial was not included in the meta-analysis.
Neither results for the primary outcome 'average number of days
per month in hospital' nor for the outcome 'admitted to hospital'
changed significantly when this study was dropped, but it did
significantly aIect the level of heterogeneity. We could just advance
the hypothesis that the reason for heterogeneity could be the
unusual way the intervention was provided in this trial (Table 4).
For a summary of the trial selection from the 2015 search, please
see Figure 2.
 
Figure 2.   Study flow diagram 2015 update
 
Included studies
See: Characteristics of included studies.
The previous updates of two reviews included 176 reports
describing 38 studies. This review now includes these 38 separate
trials with an additional two studies including data on 196
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
21
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
participants (Chan-Hong Kong 2000; Cusack-North Carolina). These
40 trials provide data on 7524 randomised people. Twenty-four of
these studies had already been included in two original reviews
(as included or awaiting assessment), with 14 more derived from
the 2008 search and two more derived from the 2015 search.
Twenty-eight trials provided data for the ICM versus standard care
comparison, 11 for the ICM versus non-ICM comparison, and only
one for both comparisons. Both of the two newly included studies
provided data for the ICM versus standard care comparison. Please
note that it was possible to report data for several separate centres
of seven multicentre trials (Bond-Indiana1 1988 (3); Chandler-
California1 1991 (2); Drake-NHamp 1998 (7); Hampton-Illinois 1992
(2); McDonel-Indiana 1997 (2); Rosenheck-USA 1993 (9); and UK700-
UK 1999 (4)). Several of these centres are reported separately in the
Characteristics of included studies table.
1. Study length
Only one study fell into the short-term category, with a maximum
length of six months (Bond-Indiana1 1988); nine studies reported
medium-term data, with only one study reporting data by seven
months, Okpaku-Tennessee 1997, and the remaining eight studies
reporting data by 12 months (Bond-Chicago1 1990; Bush-Georgia
1990; Hampton-Illinois 1992; Johnston-Australia 1998; Lehman-
Maryland1 1994; Morse-Missouri1 1992; Solomon-Pennsylvania
1994; Sytema-Netherlands 1999). The remaining 29 studies all fell
into the long-term category, with a maximum length of four years
(Test-Wisconsin 1985), and an average length of 23.5 months.
One study reported data only on short-term follow-up (five
months of active intervention followed by six months' follow-up)
(Chan-Hong Kong 2000), not reporting data assessed during the
intervention. Newly retrieved companion papers provided data
from medium- and long-term follow-up for two studies already
included in the previous version of this review. Those two studies
were OPUS-Denmark 1999, now reporting data at three and eight
years aPer active intervention was discontinued (i.e. 5 and 10 years
aPer randomisation), and REACT-UK 2002, now reporting data at 18
months and 8.5 years aPer participants could choose to which arm
they were allocated (i.e. 3 and 10 years aPer randomisation). During
the follow-up period, all participants in OPUS-Denmark 1999
received the control intervention, where participants in REACT-UK
2002 could remain in the originally allocated intervention or be
transferred to the control one.
2. Design
All included studies were randomised with a parallel longitudinal
design. Twelve were multicentre trials, but only seven of these
provided data for single centres (see above).
3. Participants
We included a total of 7524 participants from 40 trials. Most trials
included from the previous review were conducted in Australia,
Canada, and the USA. Specifically, most of the trials included from
the previous two reviews were conducted in the USA (16 trials; 3474
participants), and only five were European (345 participants). In
the first update of 2010, we added 1964 participants from seven
trials conducted in Europe, and 1545 participants from 10 studies
conducted in Australia, Canada, and the USA. In the current version
of the review, we added 62 participants from one trial conducted in
China (Chan-Hong Kong 2000), and 134 participants from one trial
conducted in the USA (Cusack-North Carolina).
The review now provides data on 27 trials, including 5153
participants, conducted in Australia, Canada, and the USA; 12 trials,
including 2309 participants, conducted in Europe; and one trial,
including 62 participants, conducted in China.
Twenty studies included participants with severe mental illness.
None of these studies provided operationalised definitions
addressing dimensions of diagnosis, duration, and disability.
However, 14 provided criteria for either the diagnosis, impairment,
or level of service use. The remaining six studies provided no criteria
for defining serious mental illness. Diagnoses of 'severe mental
illness' varied across studies, from schizophrenic disorder alone
to wider diagnostic groups including schizophrenic, aIective, and
personality disorder.
Of the remaining 20 studies, 18 involved participants with various
diagnoses, but the great majority had some psychotic disorder, and
most trials reported criteria for service use or impairment, or both.
Two studies included participants with a high level of impairment
or service use due to psychiatric illness, but provided no diagnostic
criteria for inclusion (Harrison-Read-UK 2000; Okpaku-Tennessee
1997).
Most trials (23) involved participants that had been diagnosed
using operationalised criteria (DSM, ICD, OPCRIT, RDC, SADS, see
Characteristics of included studies footnotes), whilst 17 (10 in
the group including participants with serious mental illness and
six in the group including participants with various diagnoses)
did not report using any diagnostic tool, but only stated type of
illness or level of impairment. Only OPUS-Denmark 1999 included
participants with a first episode of psychotic illness.
Four studies included a total of 742 dually diagnosed participants
(Drake-NHamp 1998; Essock-Connecticut2 2006; Morse-Missouri3
2005; Muller-Clemm-Canada 1996), and eight studies included a
total of 1337 homeless participants.
Information on mean age was available from 32 trials (6473
participants). The average age was about 38 years old. Only Macias-
Utah 1994 did not report information on participant age.
4. Settings
As stated in the inclusion criteria, all of the included studies took
place in a community setting, provided both by private and public
mental health services. No study was carried out in a low-income
country, as the included studies were conducted in Australia,
Canada, the USA, Europe, and China.
5. Interventions
Twenty-nine trials were included in the comparison ICM versus
standard care, and 12 in the ICM versus non-ICM comparison.
Quinlivan-California 1995 was a three-arm trial (ICM, non-ICM,
and standard care) and provided data for both comparisons.
We considered REACT-UK 2002 to be an ICM versus non-ICM
comparison due to our assumption that standard care could be
considered to be Care Programme Approach, even if not clearly
reported by trial authors. The Care Programme Approach was
introduced in England in the mid-1990s and become standard care
thereaPer; it is a combination of non-Intensive Case Management
and care from a Community Mental Health Team (Department of
Health 1999), hence to be considered as non-ICM according to the
definitions in this review.
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5.1 Intensive Case Management
On average, the ICM included in this review was well defined. The
majority of experimental interventions were explicitly modelled on
the ACT model, being based on the Treatment in Community Living
model of Stein 1980. Only a few studies based ICM on the Case
Management model. The experimental intervention was provided
either by an already existing team or ICM services newly established
for the trial. Cusack-North Carolina was the only trial that included
ICM as forensic adaptation of ACT compared with standard care.
5.2 Non-Intensive Case Management
There were no discernable diIerences between the practice of
non-ICM and ICM except for the intensity of contact. The degree
of training and skill of the staI was similar in the ICM and non-
ICM teams. In some studies, non-ICM was itself an experimental
intervention, but it mostly represented the average standard care,
as what in this review we call 'standard care' has increasingly
shiPed towards non-ICM across decades. Mental health systems
increasingly included elements from ICM, melding them with
community mental health service. English mental health policy is
one example, where the Care Programme Approach was introduced
in the UK in the mid-1990s and become standard care thereaPer.
It is a combination of non-ICM and care from a Community Mental
Health Team, hence to be considered as non-ICM, according to
the definitions in this review. Therefore the REACT-UK 2002  study
was considered in the ICM versus non-ICM comparison due to
our assumption that standard care could be considered as Care
Programme Approach, even if not clearly reported by trial authors.
5.3 Standard care
On average, the definition of standard care was blurred, as this
intervention was modelled on a generalist model. Its core was
being provided by a community mental health service, but its
features were variable across trials run in diIerent countries at
diIerent time periods. Presence of further specialised services,
such as rehabilitation or psychotherapist services, were variable
within standard care services. In a few studies, both ICM and
standard care incorporated services for substance abuse treatment
and homelessness care.
6. Outcome measures
6.1 Overall
The outcomes for which we could obtain usable data were:
service use, adverse eIects, global state, social functioning, mental
state - general and specific symptoms, behaviour, quality of life,
satisfaction, and costs.
Many trials used diIerent scales in assessing treatment eIects in
various outcomes (global state, social functioning, mental state
- general and specific symptoms, behaviour, quality of life, and
satisfaction). As most of the scales were used by only one study in
each comparison group, it was not possible to enter these data in a
unique analysis. Even where studies used the same scale, they oPen
applied diIerent rating scores. Therefore, again, data could not
be entered together in the analysis. Some studies failed to clearly
report the rating score they used for a pre-stated scale. We noted
this in the 'Risk of bias' tables (see 'Outcomes' in Characteristics
of included studies table). No studies assessed improvement by
measuring it on scales. We did not calculate eIect size measures
(standardised mean diIerence, see Measures of treatment eIect).
6.2 Outcome scales
Only details of the scales that provided usable data are shown
below. Reasons for exclusions of data are provided under
'Outcomes' in Characteristics of included studies table.
6.2.1. Global Assessment Scale (GAS) (Endicott 1976): in Audini-UK
1994, Muijen-UK2 1994, Rosenheck-USA 1993
This is an observer-rated scale for evaluating the overall functioning
of a person during a specified time period on a continuum from
psychological or psychiatric sickness to health. The score ranges
from 0 to 100, where a higher score indicates a better outcome.
A modified version of the GAS was included in the Diagnostic
and Statistical Manual of Mental Disorders (DSM-III) as the Global
Assessment of Functioning Scale (GAF) (APA 1987): in Bjorkman-
Sweden 2002. Outcomes from the two scales are reported together
as GAF, as these two scales are very similar, and they report results
on the same score range.
6.2.2 Health of the Nation Outcome Scale (HoNOS) (Stein 1999; Wing
1998): in Harrison-Read-UK 2000, REACT-UK 2002
This scale provides a systematic summary of behaviours and
functioning, measuring mental health and social/behavioural
functioning. It consists of four areas (behaviour, impairment,
symptoms, and social), each assessed through 12 items on a five-
point scale (0 to 4). Ratings are from 0 to 48; high score means severe
dysfunction.
6.2.3 Rating of Medication Influence (ROMI) (Weiden 1994): in
Harrison-Read-UK 2000, REACT-UK 2002
This 20-item scale measures the influence of factor on medication
adherence. Each item is rated according to the degree of influence
on medication-taking behaviour: none (1), mild (2), and strong (3).
It has two subscales: patient-reported compliance (items 1 to 7) and
patient-reported non-compliance (items 8 to 20). A high score on
the compliance subscale indicates high compliance; a high score
on the non-compliance subscale indicates high non-compliance.
Results from the two studies are presented on a diIerent range
score (Harrison-Read-UK 2000 range score of 1 to 3; REACT-UK 2002
range score not clearly reported).
6.2.4 Disability Assessment Schedule (DAS) (WHO 2001a): in
Holloway-UK 1996
The World Health Organization's Psychiatric Disability Assessment
Schedule (DAS) is a measure of functioning and disability. It
contains 36 items with six domains of functioning, including:
understanding and communicating, getting around, self care,
getting along with others, household and work activities, and
participation in society. Higher scores indicate a worse outcome.
6.2.5 Interview Schedule for Social Interaction - abbreviated version
(ISSI) (Henderson 1980; Unden 1989): in Bjorkman-Sweden 2002
The ISSI scale is a self report scale consisting of 30 items that
measures social integration and attachment. The maximum score
is 30 points; higher scores indicate better social integration and
attachment.
6.2.6 Life Skills Profile (LSP) (Parker 1992; Rosen 1989): in REACT-UK
2002
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The Life Skills Profile is a clinician-rated questionnaire developed
in Australia primarily for use with people with psychotic illnesses.
Thirty-nine items and five subscales assess the general domain of
disability over the last three months. The five subscales measure
self care, non-turbulence, social contact, communication, and
responsibility. Each of the 39 items on the scale range from 'not at
all disabled' to 'extremely disabled'.
6.2.7 REHAB Scale (REHAB) (Baker 1983): in Marshall-UK 1995
The REHAB Scale is an observer-rated measure of social
functioning, covering social activity, self care, speech disturbance,
and community skills. It rates the frequency of items of
embarrassing or disruptive behaviour, such as violence, self
harm, shouting and swearing, and sexual oIensiveness (deviant
behaviour - REHAB DB); and lack of general skills (general behaviour
- REHAB GB). The scale ranges from 0 to 144, with higher scores
indicating poorer functioning.
6.2.8 Role Functioning Scale (RFS) (Green 1987): in Jerrell-SCarolina2
1994
This is a self report scale whereby the total of four subscales
measures global role functioning. Higher scores indicate better
functioning.
6.2.9 Social Adjustment Scale (SAS) (Weissman 1971; Weissman
1974): in Audini-UK 1994, Muijen-UK2 1994
Measures social functioning in a number of life domains (work,
social, extended family, marital, parental, family unit, and
economic adequacy). Score ranges from 1 to 7, with higher score
indicating poorer outcome.
6.2.10 Social Adjustment Scale-II (SAS-II) (Schooler 1979): in Jerrell-
SCarolina1 1991
Revised version of the Social Adjustment Scale (see above), used
to assess social adjustment. Self reported scale similar to SAS, but
adapted for schizophrenia; it comprises 24 items covering seven
areas including social, family, and work functioning. The scoring
system of the two versions appears to diIer, perhaps because this
was an adapted version. Higher score indicates better outcome.
6.2.11 Social Functioning Questionnaire (SFQ) (Tyrer 1990; Tyrer
2005): in Harrison-Read-UK 2000
An eight-item self report scale (score range is 0 to 24). It provides
a quick assessment of perceived social function. Higher score
indicates poorer social functioning.
6.2.12 Strauss-Carpenter Outcome Scale (Strauss 1972; Strauss
1974): in Bjorkman-Sweden 2002
The Strauss-Carpenter Outcome Scale assesses a 21 items
exploring frequency of social contacts, employment duration,
symptomatology, and duration of rehospitalisation. The scaling
of each item extends from 0 (maximal negative) to 4 (maximal
positive). The scoring range of the scale extends from 0 (maximal
negative) to 84 (maximal positive).
6.2.13 Alcohol Use Scale (AUS) (Drake 1996; Mueser 1995): in Drake-
NHamp 1998
A five-point scale based on clinicians' ratings of the severity of the
disorder, ranging from 1 (abstinence) to 5 (severe dependence).
6.2.14 Dartmouth Assessment of Lifestyle Interview (DALI)
(Rosenberg 1998): in Sytema-Netherlands 1999
An 18-item, interviewer-administered scale addressing the
detection of substance use disorder in people with severe mental
illness. DALI focuses on alcohol, cannabis, and cocaine use
disorders. DALI-alcohol: scores range from -4 to +6, higher scores
indicate higher risk of alcohol abuse. DALI-drugs: scores range from
-4 to +4, higher scores indicate higher risk of drug abuse. As scale
ranges from negative to positive value, skew is diIicult to detect.
We therefore entered data from this scale in Additional tables rather
than into an analysis.
6.2.15 Substance Abuse Treatment Scale (SATS) (Drake 1996; McHugo
1995): in Drake-NHamp 1998
An eight-point scale indicating progression toward recovery,
ranging from 1 (early stages of engagement) to 8 (relapse
prevention). Higher scores indicate greater progression.
6.2.16 Timeline Followback (TLFB) (Sobell 1980): in Drake-NHamp
1998
Scale administered by an interviewer to assess days of alcohol and
drug use over the previous six months. Outcome reported as binary
data.
6.2.17 Brief Psychiatric Rating Scale (BPRS) (Overall 1962): in Audini-
UK 1994, Drake-NHamp 1998, Muijen-UK2 1994, REACT-UK 2002,
Sytema-Netherlands 1999 (BPRS 24-item - Velligan 2005); in Chan-
Hong Kong 2000, Ford-UK 1995, Rosenheck-USA 1993 (BPRS 18-
item)
The BPRS measures positive symptoms, general psychopathology,
and aIective symptoms. The original scale has 16 items, but a
revised 18-item scale is commonly used. Symptoms are reported in
several ways (i.e. on a scale of 0 to 6 or 1 to 7), but it is most common
for each item to be rated on a seven-point scale (1 = not present to
7 = extremely severe). The 18-item scale can range from 18 to 126
or from 0 to 108 (as in Ford-UK 1995 and Rosenheck-USA 1993).A
further version is a 24-item scale ranging from 24 to 168. For all of
the scales, higher scores indicate more severe symptoms.
6.2.18 Brief Symptom Inventory (BSI) (Derogatis 1983): in Rosenheck-
USA 1993
A brief rating scale used by an independent rater to assess the
severity of psychiatric symptoms. Scores range from 0 to 4, with
higher scores indicating more symptoms.
6.2.19 Comprehensive Psychopathological Rating Scale (CPRS)
(Asberg 1978): in Holloway-UK 1996, UK700-UK 1999
This is an interview rating scale covering a wide range of psychiatric
symptoms; it can be used in total or as subscales. CPRS consists
of 65 items that cover the range of psychopathology over the
preceding week (40 symptom items are rated by the participant,
and 25 observed items are rated by the rater during the interview).
Each item is rated on a 0 to 3 scale ranging from 'not present'
to 'extremely severe', with higher scores indicating more severe
symptoms.
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6.2.20 Colorado Symptom Index (CSI) (Shern 1994): in Lehman-
Maryland1 1994, Shern-USA1 2000
A brief rating scale used by an independent rater to assess the
severity of a range of psychiatric symptoms. A lower score indicates
more symptoms.
6.2.21 Krawiecka Scale (KS) alias Manchester Scale (Krawiecka
1977): in Harrison-Read-UK 2000
This scale rates severity of psychiatric symptoms. It consists of
eight categories of symptoms assessed on a five-point scale, which
are depression, anxiety, hallucinations, delusions, flattened and
incongruous eIect, psychomotor retardation, incoherence and
irrelevance of speech, and poverty of speech. A score of 0 or 1
denotes an absence of pathology, while ratings of 2, 3, or 4 denote
the presence of the target symptoms in increasing severity. Rating
is from 0 to 36. Higher scores indicate a worse outcome.
6.2.22 Present State Examination (PSE) (Wing 1974): in Audini-UK
1994, Muijen-UK2 1994
This is a clinician-rated scale measuring mental status. The scale
rates and combines 140 symptom items to give various syndrome
and subsyndrome scores. A short version covering the first 40
'neurotic' symptoms has been used in several population surveys.
Score ranges from 1 to 120. Higher scores indicate greater clinical
impairment.
6.2.23 Symptom Checklist-90 (SCL-90) (Hopkins Symptoms Checklist)
(Derogatis 1974): in Bjorkman-Sweden 2002
This is a self report clinical rating scale of psychiatric
symptomatology comprised of 90 symptom-related questions. Out
of 90 items, 83 items represent nine subscales: somatisation (12
items), obsessive-compulsive (10 items), interpersonal sensitivity
(9 items), depression (3 items), anxiety (10 items), anger-hostility
(6 items), phobic anxiety (7 items), paranoid ideation (6 items),
and psychoticism (10 items). Seven additional items include
disturbances in appetite and sleep. The SCL-90 also utilises
three global distress indices: Global Severity Index (GSI), Positive
Symptom Distress Index (PSDI), and Positive Symptom Total (PST).
The participant assesses the degree of severity of each symptom.
Items are rated on a five-point Likert scale, ranging from 'not at
all distressing' (0) to 'extremely distressing' (4), with higher scores
indicating greater symptomatology.
6.2.24 Beck Depression Inventory (BDI) (Beck 1979): in Holloway-UK
1996
A 21-item self rating scale for depression. Each item comprises 4
statements (rated from 0 to 4) describing increasing severity of
the abnormality concerned. The person completing the scale is
required to read each group of statements and identify the one
that best describes the way they have felt over the preceding week.
Score ranges from 0 to 84, with higher score indicating more severe
symptoms.
6.2.25 Hospital Anxiety and Depression Scale (HADS) (Zigmond 1983):
Harrison-Read-UK 2000
This scale is a questionnaire composed of statements relevant to
either generalised anxiety or depression referring to the past week.
Seven items in the questionnaire reflect anxiety, and seven reflect
depression. The participant answers each item on a four-point (0
to 3) response category; the possible scores range from 0 to 21 for
anxiety and 0 to 21 for depression. Higher score indicates a worse
outcome.
6.2.26 Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen 1982; Andreasen 1989): in Holloway-UK 1996, UK700-
UK 1999
This scale assesses five symptom complexes to obtain clinical
ratings of negative symptoms in people with schizophrenia over the
preceding week. They are: aIective blunting, alogia (impoverished
speech), avolition/apathy, anhedonia/asociality, and disturbance
of attention. The final symptom complex seems to have less
obvious relevance to negative symptoms than the other four
complexes. Assessments are conducted on a six-point scale (from 0
indicating 'not at all' to 5 indicating 'severe'). Higher scores indicate
a worse outcome.
6.2.27 Scale for the Assessment of Positive Symptoms (SAPS)
(Andreasen 1984): in OPUS-Denmark 1999
The SAPS measures positive symptoms in schizophrenia. It is
intended to serve as a complementary instrument to the Scale
for the Assessment of Negative Symptoms (SANS). SAPS is split
into four domains: hallucinations, delusions, bizarre behavior, and
positive formal thought disorder. Within each domain, separate
symptoms are rated from 0 (absent) to 5 (severe). Higher scores
indicate a worse outcome.
6.2.28 Social Behaviour Schedule (SBS) (Wykes 1986): in Holloway-
UK 1996
The SBS is a 21-item scale designed to assess a range of areas
of functioning in people with long-term mental illness. The scale
covers areas such as social behaviour and communication, self
care, and inappropriate behaviour. The respondent's behaviour on
each item during the previous month is scored by a person familiar
with him or her. Each item is rated on a five-point Likert scale (from
0 to 4), with higher scores indicating greater deficits.
6.2.29 Lancashire Quality of Life Profile (LQoLP) (Oliver 1996; Oliver
1997): in Bjorkman-Sweden 2002, Holloway-UK 1996, UK700-UK
1999
A structured self report interview with 105 items, combining
objective and subjective measures in the following nine life
domains (range of values 1 to 7): living situation, social
relationships, work and education, legal status and safety, religion,
family relations, leisure activities, finances, and health. The LQoLP
also measures the following additional areas: positive and negative
aIect (with the Bradburn AIect-Balance Scale), self esteem,
global well-being (Cantril's Ladder and Happiness Scale), perceived
quality of life, and the quality of life of the patient independent of
the patient's own opinion (with the Quality of Life Uniscale). The
measures from LQoLP used in Bjorkman-Sweden 2002 were: overall
quality of life (which is the mean of subjective quality of life in nine
life domains) and global well-being. Higher score indicates better
subjective quality of life/satisfaction.
6.2.30 Manchester Short Assessment of Quality of Life (MANSA)
(Priebe 1999): REACT-UK 2002, Sytema-Netherlands 1999
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A 16-item scale composed of 4 objective and 12 subjective
questions. The 12 subjective items are rated on a 7-point scale
(from 'couldn't be worse' to 'couldn't be better', scored from 1 to
7, range 12 to 84) assessing satisfaction with life 'in general', and
in a range of domains such as vocational, financial, friendships,
leisure, personal safety, physical health, and mental health. Four
objective items, answered yes or no, assess the existence of a close
friend, contacts with friends per week, accusation of a crime, and
victimisation of physical violence. Higher score indicates better
quality of life. In REACT-UK 2002 and Sytema-Netherlands 1999,
score is reported as a mean ranging from 1 to 7.
6.2.31 Lehman's Quality of Life Interview (QOLI) (Lehman 1988): in
Drake-NHamp 1998, Lehman-Maryland1 1994, Shern-USA1 2000;
(Lehman 1993) in Ford-UK 1995; (Lehman 1983) in Marshall-UK 1995
The QOLI contains 153 items that measure global life satisfaction as
well as objective and subjective quality of life, in eight life domains
(living situation, daily activities and functioning, family relations,
social relations, finances, work and school, legal and safety issues,
and health). The QOLI is rated on a seven-point scale, with higher
scores indicating better quality of life. Subjective assessment of
general life satisfaction ranges from 1 to 7 (terrible to delighted).
Ford-UK 1995 reported objective quality of life, and Marshall-UK
1995 reported subjective quality of life.
6.2.32 Camberwell Assessment of Need interview (CAN) (Phelan
1993): in Bjorkman-Sweden 2002, Harrison-Read-UK 2000, UK700-
UK 1999
The Camberwell Assessment of Need assesses the health and social
needs of people with mental health problems. It measures 22
areas to yield numbers of met and unmet needs as rated by the
participant. Possible scores range from 0 to 22, with a higher score
indicating poorer level of met needs.
6.2.33 Camberwell Assessment of Need Short Appraisal Schedule
(CANSAS) (Phelan 1995; Slade 1999): in REACT-UK 2002, Sytema-
Netherlands 1999
This is an abbreviated form of the above CAN.
6.2.34 Client Satisfaction Questionnaire (CSQ) (Larsen 1979): in
Audini-UK 1994, Muijen-UK2 1994, OPUS-Denmark 1999, Sytema-
Netherlands 1999
The CQS is a self report instrument designed to measure patient's
global satisfaction with services. Items are concerned with quality
of services received, how well services met the client's needs,
and general satisfaction. The CSQ is substantially correlated with
treatment attrition, number of therapy sessions attended, and
change in client-reported symptoms. It consists of eight items that
are scored on four-point Likert scales (1 to 4). Total score ranges
from 8 to 32. Higher scores indicate greater satisfaction.
6.2.35 Client Satisfaction Questionnaire (CSQ) - modified version
(Gerber 1999; Larsen 1979): in REACT-UK 2002
This survey has 35 questions covering the location of services,
services clients expect, delays in obtaining services, client's
input into treatment, information received about drug treatment,
satisfaction with treatment, access to clinical files, satisfaction
with the therapist, family involvement in treatment, the treatment
process, and overall satisfaction. Possible responses to most items
range from 1 (most negative) to 7 (most positive). A rating of
zero on certain items enables the respondent to indicate that
the question was not relevant to his or her situation. Six items
within the questionnaire, also on a seven-point scale, form a
general satisfaction questionnaire. Higher score indicates greater
satisfaction.
6.2.36 Patient's satisfaction with health services (Tyrer 1979): in
UK700-UK 1999
A self reporting questionnaire that rates nine components of
satisfaction with services, each on a four-point scale (1 to 4).
Scores can range from 9 to 36, with higher values indicating less
satisfaction.
6.2.37 Patient Satisfaction Instrument (PSI) (Risser 1975): in Chan-
Hong Kong 2000
The PSI assesses patient and client satisfaction. It is a 26-
item questionnaire designed to measure clients' satisfaction with
nursing care in the community setting.
6.2.38 Specific Level of Functioning Scale (SLOF) (Schneider 1983): in
Chan-Hong Kong 2000
The SLOF assesses clients' behavioural functioning and daily skills.
It is a 43-item behavioural rating scale designed for use in clients
with chronic mental illness in the community.
6.3 Missing outcomes
No trial reported or rated relapse, mental state: not improved, or
carer satisfaction.
Excluded studies
See: Characteristics of excluded studies.
Eighty-one studies were excluded from the previous versions of this
review, while a total of 85 studies were excluded from this version.
The earlier update excluded four trials included in the original
reviews as the trials did not match the new inclusion criteria. (De
Cangas-Canada 1994; Franklin-Texas 1987; Lafave-Canada 1996;
Marx-Wisconsin 1973). Morse-Missouri2 1997 was also excluded,
as it did not report the number of people randomised to each
treatment group.
One further trial (Tyrer-UK 1995), originally included in the
Case Management (CM) review, was now excluded because of a
methodological issue. Tyrer-UK 1995 is a trial comparing ICM to
standard care. The first issue was to clarify the ICM caseload. Thanks
to further information provided from the author, we clarified
that there were 25 key workers in the service looking aPer 400
patients on the register, therefore each key worker had a caseload
of 1 to 16, or 'high-intensity' case management by this review's
definition. The second issue that arose was that the case managers
in the treatment group were also workers in the control group.
The problem was therefore one of contamination, as requiring
someone to carry out close monitoring of one participant in the
treatment group could aIect their care of a similar participant in the
control group in an unpredictable way. We decided to exclude this
study on the grounds that we could not be sure that high-intensity
case management was really being compared with standard care.
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We also excluded three trials that had been awaiting assessment
in the original Case Management and Assertive Case Management
reviews (see Other published versions of this review) for varying
reasons (Godley-Illinois 1994; Jerrell-California 1989; Mulder-
Missouri 1985) (for more details see Characteristics of excluded
studies).
Jerrell-California 1989 was a partially published trial previously
classified as 'awaiting further assessment' because we needed
information on number of people excluded aPer randomisation
(participants were excluded if they refused to participate aPer
randomisation or if they had not been discharged from hospital
within six months of entering the study). As these data have not
become available, we have now excluded the trial.
Godley-Illinois 1994 was an unpublished, two-centre trial initially
classified as 'awaiting further assessment' because we could not
determine if the intervention was ACT or CM. During the current
update we classified the intervention as ICM versus standard care.
We had to exclude this study because it contained no usable
data due to incomplete data reporting, and no further information
became available (i.e. there was an apparent error in the reporting
of numbers admitted to hospital: in one table admission rates were
reported as 31/52 experimental group and 33/45 control group,
while in another table admission rates were reported as 31/52
experimental and 25/45 control).
Mulder-Missouri 1985 was a report of data from randomised and
non-randomised participants. We excluded this study because
these data were not reported separately and, in addition, the
intervention did not fit our inclusion criteria (ICM was compared to
acute hospital admission).
Overall, we excluded 42 studies because they were not randomised
or because randomisation was compromised (Jerrell-California
1989). We had to exclude five studies because participants
required immediate hospital admission (Fenton-Canada 1978;
Hoult-Australia 1981; Muijen-UK1 1992; Mulder-Missouri 1985;
Stein-Wisconsin), one study because participants were dually
diagnosed with intellectual disability and mental illness (Martin-
UK 2005), and one additional study because the majority of
participants were simply homeless and not clearly ill (Toro-
New York 1997). Most trials had to be excluded because of
the intervention: 54 because the experimental intervention was
not ICM. We had to exclude Modcrin-Kansas 1988 as caseload
was not reported in either the experimental or the control
group. We excluded 48 trials as the comparison intervention
was neither standard care nor non-ICM. We excluded 10 trials
as the intervention administered to the experimental group
was not only ICM (Chandler-California2 2006; COAST-UK 2004;
Cosden-California 2005; Gold-SCarolina 2006; Grawe-Norway 2005;
Lehman-Maryland2 1993; LEO-UK 1994; McHugo-Washington DC
2004; Shern-USA2; Shern-USA3). We excluded 10 trials as they did
not present with relevant comparisons. Finally, we excluded two
trials, Godley-Illinois 1994 and Morse-Missouri2 1997, because we
could extract no usable data from the study report (as previously
explained).
Awaiting classification
See: Characteristics of studies awaiting classification.
Five trials described as 'awaiting classification' in the previous
review have now been excluded as more data have become
available (Agius-Croatia 2007; Kane-Virginia 2004; Klotz-California
2001; Li-China 2004; NCT00781079); two more have now been
excluded based only on the abstract, and so they were not included
in the excluded studies section (Huang-China and Johnson-UK).
Twenty trials, of which three are in the Chinese language, are
awaiting classification, and their authors have been contacted for
further clarification.
Ongoing studies
See: Characteristics of ongoing studies.
We are aware of six currently ongoing trials, five more than the
ongoing studies in the previous version of this review (Walsh-
Connecticut).
Risk of bias in included studies
For multicentre trials that provided data for individual single
centres, we did not assess the risk of bias for each centre. Our
judgements regarding the overall risk of bias in individual studies
are illustrated in Figure 1.
Allocation
All 40 studies were stated to be randomised, but only 11 provided
descriptions of the methods used to generate the sequence. We
therefore classified these studies as at low risk of selection bias. The
most common method of randomisation was random allocation
according to a sequence of random numbers generated by a
computer program in one of two sites (Bjorkman-Sweden 2002;
Essock-Connecticut2 2006; Ford-UK 1995; Harrison-Read-UK 2000;
OPUS-Denmark 1999), while Cusack-North Carolina employed
randomisation using a random number table, assigned in blocks of
two. Three trials used permuted block (Marshall-UK 1995; REACT-
UK 2002; Sytema-Netherlands 1999), one used a table of random
permutation (Pique-California 1999), and one used coin tossing
(Rosenheck-USA 1993). In one of the two sites of the OPUS-
Denmark 1999 trial (Aahrus site), allocation was performed by
drawing lots – from among five red and five white lots from a black
box. Overall, however, most studies, including Chan-Hong Kong
2000, were classified as at unclear risk of selection bias with an
overestimate of positive eIect, as no description of the methods
used to generate the sequence was provided.
Regarding the allocation concealment, we rated only four studies as
low risk of bias as they provided descriptions of the methods used
to conceal random allocation (OPUS-Denmark 1999; REACT-UK
2002; Sytema-Netherlands 1999; UK700-UK 1999). All four studies
used centralised allocation carried on by telephone, fax, or mail. We
classified the remaining 33 studies as at unclear risk of selection
bias with an overestimate of positive eIect.
Blinding
We classified blinding with respect to only primary outcomes. Due
to intervention characteristics, that is being a model of service
organisation, we assumed participants and clinicians implicitly
not being blind to treatment assignment. We also assumed that
primary outcomes were likely to be influenced by participant and
clinician lack of blinding, as the knowledge of treatment allocation
could determine both performance and attrition bias at a level
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that is diIicult to predict/quantify. Whereas we did not consider
the primary outcomes as interviewer mediated, we assumed that
lack of interviewer blinding would produce less detection bias.
We therefore classified all studies providing primary outcome
data as at unclear risk of performance and attrition bias. This
creates further potential for overestimate of positive eIects and
underestimate of negative ones.
We have reported blinding to secondary outcomes in the 'Risk of
bias' table, but we did not account for it in the global rating of
the study blinding risk of bias. Again, if the secondary outcome
was clinician/participant mediated, we rated it as unclear. If it was
interviewer rated, we assessed it according to information provided
in the study. We rated only Shern-USA1 2000 as at high risk of
bias, as it provided only secondary outcome data and was only
interviewer mediated, and it was therefore possible to assess risk
of bias for this study with greater confidence. We rated Chan-Hong
Kong 2000 as at unclear risk of performance and detection bias, as
it did not clearly report any information on blinding.
Incomplete outcome data
Where information was available, we assessed incomplete
outcome data separately for primary and secondary outcomes
and presented both assessments in Figure 1. However, we only
rated risk of bias with respect to primary outcome. Only three
trials provided separate information for incomplete primary and
secondary outcome data, and so we could assess the risk of bias
separately (Holloway-UK 1996; Johnston-Australia 1998; REACT-UK
2002). We judged nine trials as adequately addressing incomplete
outcome data and rated them as at low risk of attrition bias. We so
rated four of these studies because there were no missing outcome
data (Bush-Georgia 1990; Holloway-UK 1996; REACT-UK 2002;
Sytema-Netherlands 1999); three because they made the number
and reason for missing data explicit, and the missing data were
balanced across groups (Audini-UK 1994; Essock-Connecticut1
1995; Johnston-Australia 1998); and two because they undertook
intention-to-treat (ITT) analysis (OPUS-Denmark 1999; UK700-UK
1999).
In Cusack-North Carolina, all analyses were intention to treat
and outcomes were observed regardless of active or continued
participation. Although Chan-Hong Kong 2000 reported the
analyses as ITT, it was not clearly reported whether any participants
leP early.
We judged Bond-Chicago1 1990 and Ford-UK 1995 as at high
risk of attrition bias because, although clearly reporting number
and reasons for missing data, the reasons for missing outcome
data were likely to be related to true outcome, with imbalance
either in numbers or reasons for missing data across intervention
group. However, our protocol compensated for this somewhat (see
Dealing with missing data), and despite the high rating, information
from these studies remains included.
We rated the remaining trials as at unclear risk of attrition bias.
Either they did not address this issue or presented insuIicient
information of attrition/exclusions to permit judgement (i.e.
no reasons for missing data provided or number randomised
not stated. Jerrell-SCarolina1 1991 reported only number of
randomised participants completing the study period).
Some specific examples may serve to illustrate the diIiculty in
rating this issue. Essock-Connecticut2 2006 was not an ITT analysis
(seven participants were excluded from the study immediately
aPer randomisation because they were lost to follow-up), but the
authors failed to provide information on to what intervention those
participants had been allocated and reason for leaving the study
early. As this study provided only continuous outcome data, we
reproduced completer-only data that were reported. No action was
undertaken to deal with other missing data.
Macias-Utah 1994 had three problems. First, the study was not
an ITT analysis: seven participants were excluded from the study
because they were lost to follow-up. The authors of this study
broke with standard practice by failing to provide any data on
participants lost to follow-up, in particular data on admissions
to hospital. Second, one participant (presumably randomised to
the treatment group) was excluded aPer randomisation, having
refused to participate (again, it was unclear whether this person
had been admitted to hospital). Third, five further participants were
added (randomly) to the treatment and control groups part way
through the study, some as late as "late 1990" (final assessments
took place in February 1991). No further information has become
available since first review publication, which potentially could
substantially aIect findings.
In Morse-Missouri1 1992, 28 further participants were added
(randomly) to the initial randomised sample, to replace
participants leaving the study within the first month aPer entering.
As replacement was carried out through randomised assignment,
we did not raise any questions on the replacement issue and
included the study. We presented data from the final sample,
obtained aPer randomised replacement had occurred.
In Muller-Clemm-Canada 1996, the number randomised was not
clearly reported; authors declared that "Clients who withdrew from
the study within the first 6 months were replaced by other clients".
Finally, Sytema-Netherlands 1999 randomised 119 participants,
but one was excluded because he or she moved to another area
directly aPer randomisation. (We performed ITT analysis on the
remaining 118 participants.)
Selective reporting
We rated most of the trials (24) as at high risk of reporting bias, as
their data was presented in such a way that we could not consider
it to be free of the suggestion of selective outcome reporting (i.e.
prespecified outcomes were not reported, or they were reported
incompletely so that they could not be entered in the analysis, or
outcomes were reported that were not prespecified). We rated 16
studies as at low risk of reporting bias. We assessed two studies as
at unclear risk of reporting bias.
Other potential sources of bias
Only Hampton-Illinois 1992 was rated as at unclear risk of other
potential sources of bias, as it was unclear whether the study was
interrupted early in one of the two centres.
We rated all of the remaining trials as at low risk of other potential
sources of bias, as we found no evidence of other bias. Most of these
studies were publicly funded. No declaration of interest was made
by authors, and we assume there was none to be made. However,
many study authors were active pioneers in the development and
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implementation of the experimental intervention model across the
scientific community and the clinical world. This raises the issue of
how researcher beliefs could aIect the entire process of evaluating
an intervention in a randomised clinical trial. Although conscious
of this issue, we decided not to make any attempt in rating it as it
is very diIicult to judge, and erroneous quantification could drive
bias into our conclusions.
E;ects of interventions
See: Summary of findings for the main comparison Intensive
Case Management versus standard care for severe mental illness;
Summary of findings 2 Intensive Case Management versus non-
Intensive Case Management for severe mental illness
We categorised studies into two comparisons: Intensive
Case Management versus standard care, and Intensive Case
Management versus non-Intensive Case Management. The nine
main indices of outcome were:
1. service use;
2. adverse eIects;
3. global state;
4. social functioning;
5. mental state;
6. behaviour;
7. quality of life;
8. satisfaction; and
9. direct costs.
We considered each index in turn for each of the two comparisons.
We were able to extract numerical data from 40 randomised trials,
among which seven multicentre trials provided data for individual
single centre.
1. COMPARISON 1: INTENSIVE CASE MANAGEMENT versus
STANDARD CARE
(Summary of findings for the main comparison). There were 45
outcomes in this comparison.
1.1 Service use: 1. Average number of days in hospital per month
- by about 24 months
Data were available from five studies presenting skewed data from
a sample size greater than or equal to 200 participants and from 19
trials reporting skewed data from sample sizes less than 200. We
entered these data in separate subgroups, but we also presented
the overall data.
1.1.1 Skewed data (sample size ≧ 200)
In the first subgroup analysis (i.e. skewed data from studies with
sample size greater than or equal to 200 participants), we found
no significant diIerence in length of hospitalisation per month
(n = 1812, 5 randomised controlled trials (RCTs), mean diIerence
(MD) -0.46, confidence interval (CI) -0.95 to 0.03), although data
suggested a trend favouring ICM (P = 0.06). This subgroup had
moderate levels of heterogeneity (Chi2 = 6.36; df = 4.0; P = 0.17; I2
= 37%; Analysis 1.1).
1.1.2 Skewed data (sample size < 200)
In the second subgroup analysis (i.e. skewed data from study
sample size less than 200 participants), there was a significant
diIerence between groups, favouring the ICM group in reducing
length of hospitalisation (n = 1783, 19 RCTs, MD -1.01, 95% CI -1.74
to -0.28), but these data were highly heterogeneous (Chi2 = 79.27;
df = 18.0; P = 0.0; I2 = 77%; Analysis 1.1).
1.1.3 Overall data (skewed data: sample size ≧ 200 and sample size <
200)
When synthesising data from the two subgroups, we found that
length of hospitalisation was significantly reduced in the ICM group
(n = 3595, 24 RCTs, MD -0.86, 95% CI -1.37 to -0.34), but the level
of heterogeneity was high (Chi2 = 89.43; df = 23.0; P = 0.0; I2 =
74%; Figure 3). We investigated the heterogeneity by checking again
for correctness of data and removing one outlier study from the
analysis (Curtis-New York 1992), as it was the only study favouring
standard care. APer excluding Curtis-New York 1992, the level of
heterogeneity was still high (I2 = 59%; P < 0.0002). We therefore
removed the second-most outlier study from the analysis (Bond-
Indiana1 (A), one of three centres from a multicentre study), as
this was the most extreme result (favouring ICM). By excluding
Bond-Indiana1 (A), data remained significant, favouring ICM (n =
3245, 22 RCTs, MD -0.79, 95% CI -1.22 to -0.36). The heterogeneity
was reduced to just within our cutoI point (I2 = 49%; P = 0.005).
Removing two further outliers (Bond-Indiana1 (C) and Quinlivan-
California 1995) reduced heterogeneity still further (I2 = 36%; P
= 0.05) as well as the overall estimate, but ICM still seemed to
significantly decrease time in hospital (n = 3143, 20 RCTs, MD -0.62,
95% CI -1.00 to -0.23, Figure 4).
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Figure 3.   Forest plot of comparison: 1 Intensive Case Management versus standard care, outcome: 1.1 Service use:
1. Average number of days in hospital per month - at about 24 months.
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Figure 4.   Service use: 1. Average number of days in hospital per month - at about 24 months - restoring
homogeneity - 4 studies removed from analysis.
 
No substantial reporting biases were highlighted when investigated
through visual inspection of funnel plot (Figure 5). Two studies -
Bond-Indiana1 (A) and Quinlivan-California 1995 - seemed most
heterogeneous (see above).
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Figure 5.   Funnel plot of comparison: 1 Intensive Case Management versus standard care, outcome: 1.1 Service use:
1. Average number of days in hospital per month - by about 24 months.
 
We ran meta-regression on trials providing data for the primary
outcome 'average number of days in hospital per month - at
about 24 months' (combining data from all ICM studies within
Comparison 1 and 2). Within the meta-regression we found that
i.) the more ICM is adherent to the organisation model, the better
it is at decreasing time in hospital ('organisation fidelity' variable
coeIicient -0.36, 95% CI -0.66 to -0.07, Figure 6); and ii.) the
higher the baseline hospital use in the population, the better ICM
is at decreasing time in hospital ('baseline hospital use' variable
coeIicient -0.20, 95% CI -0.32 to -0.10, Figure 7). Combining both
these variables within the model, 'organisation fidelity' is no longer
significant (regression coeIicient -0.24, 95% CI -0.52 to 0.04, P =
0.089), but 'baseline hospital use' resultstill significantly influences
time in hospital, although it seems to lose some of its potency
(regression coeIicient -0.18, 95% CI -0.29 to -0.07, P = 0.0027)
(Figure 8). Figure 8 shows the interaction of the two variables on
study outcome graphically through the use of thin plate spline
modelling. The plot provides a locally weighted two-dimensional
representation of the collinearity between the variables used in the
regression.
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Figure 6.   Meta-regression: Scatterplot of IFACT organisation subscore versus mean days per month in hospital.
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Figure 7.   Meta-regression: Scatterplot of mean baseline days in hospital versus mean days per month in hospital.
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Figure 8.   Weighted thin plate spline regression showing combined e;ect of baseline days in hospital and
organisational fidelity score on treatment e;ect.
 
1.2 Service use: 1 Number of days in hospital - by follow-up
(skewed data, sample size # 200)
We identified one study relevant to this outcome, providing data by
medium- and long-term follow-up (FUP) and measuring outcome
during the previous year.
1.2.1 By medium-term FUP (3 years) (previous year)
We found one trial to be relevant to this subgroup, with a total of
547 participants. For this subgroup, we did not find evidence of a
clear diIerence between the two treatments (MD 0.1, 95% CI -10.26
to 10.46; Analysis 1.2).
1.2.2 By long-term FUP (8 years) (previous year)
There was a single trial in this subgroup, with a total of 547
participants. There was no clear diIerence between ICM and
standard care within this subgroup (MD 4.3, 95% CI -4.63 to 13.23;
Analysis 1.2).
1.3 Service use: 2. Not remaining in contact with psychiatric
services
We found nine relevant studies (total n = 1633) for this outcome,
providing data on diIerent follow-up length. Overall, when pooling
studies from diIerent time subgroups, we found a significant
advantage to the ICM group, where people were less likely to be lost
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to psychiatric services than people in the standard care group (n
= 1633, 9 RCTs, risk ratio (RR) 0.43, 95% CI 0.30 to 0.61, Figure 9).
Heterogeneity was moderately high for this outcome (Chi2 = 15.57;
df = 8.0; P = 0.05; I2 = 48%).
 
Figure 9.   Forest plot of comparison: 1 Intensive Case Management versus standard care, outcome: 1.2 Service use:
2. Not remaining in contact with psychiatric services by short, medium, long term and overall.
 
As there were fewer than 10 studies for this outcome, we did not use
a funnel plot (see Assessment of reporting biases).
1.3.1 By short term
We included only one short-term study and found no significant
diIerence between treatment groups (n = 95, 1 RCT, RR 0.54, 95%
CI 0.28 to 1.05; Analysis 1.3).
1.3.2 By medium term
Medium-term data available from three studies showed a
significant diIerence between treatment groups, favouring the ICM
group, where participants had a lower risk of not remaining in
contact with psychiatric services compared with participants in the
standard care group (n = 1063, 3 RCTs, RR 0.51, 95% CI 0.36 to 0.71).
Heterogeneity was moderately high for this subgroup (Chi2 = 3.02;
df = 2.0; P = 0.22; I2 = 33%; Analysis 1.3).
1.3.3 By long term
Six long-term studies data confirmed the trend favouring ICM,
showing a significant advantage for the ICM group (n = 653, 6 RCTs,
RR 0.35, 95% CI 0.18 to 0.68), but data were heterogeneous (I2 =
63%; P = 0.02). Herinckx-Oregon 1996 seemed to be the sole cause
of this, and on further consideration post hoc, we think we were
in error in including the outcome from this study because it was
defined so diIerently from the other trials. Herinckx-Oregon 1996
did not include refusing to re-interview, moving out, and death -
as all the other studies had done - and it was impossible to amend
this at this stage. We therefore feel justified in removing this study
altogether from this part of the review outcomes. Once Herinckx-
Oregon 1996 was removed, the five remaining trials confirmed the
significant advantage for the ICM group (n = 475, 5 RCTs, RR 0.27,
95% CI 0.11 to 0.66), and heterogeneity was restored to a moderate
level (Chi2 = 7.19; df = 4.0; P = 0.13; I2 = 44%; Analysis 1.3).
1.4 Service use: 3a. Admitted to hospital
We identified 16 studies relevant to this outcome and categorised
data into five subgroups (in keeping with our protocol).
1.4.1 By short term
Data were available from two short-term studies and showed no
significant diIerences between treatment groups (n = 244, 2 RCTs,
RR 0.61, 95% CI 0.22 to 1.69), but these data were heterogeneous
(Chi2 = 5.36; df = 1.0; P = 0.02; I2 = 81%; Analysis 1.4).
1.4.2 By medium term
Five studies reported medium-term data, and these favoured the
ICM group, which had less admission to hospital across time
compared with standard care (n = 1303, 5 RCTs, RR 0.85, 95% CI 0.77
to 0.93; Analysis 1.4).
1.4.3 By long term
Eleven studies provided long-term data. As with the short-term
data, they showed no significant diIerences between treatment
groups (n = 1516, 11 RCTs, RR 0.96, 95% CI 0.74 to 1.23), but data
were heterogeneous (Chi2 = 32.88; df = 10.0; P = 0.0; I2 = 69%;
Analysis 1.4).
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1.4.4 By long term- during previous 12 months
Only one study reported data by long term, but referring to the
number of admissions across the previous year. We therefore could
not enter this data in the long-term data subgroup analysis. This
data showed a significant eIect favouring the ICM group (n = 547,
1 RCT, RR 0.67, 95% CI 0.52 to 0.86), therefore not consistent with
long-term data shown above. As these findings were based on data
from one study only, we consider them less robust than the findings
from the 11 long-term studies Analysis 1.4.
1.4.5 By short term FUP - unplanned admission through emergency
department (ED)
We found one trial to be relevant to this subgroup (total n = 62).
For this subgroup, we did not find evidence of a clear diIerence
between the two treatments (RR 1.0, 95% CI 0.07 to 15.28; Analysis
1.4).
1.5 Service use: 3b. Average number of admissions per month
(skewed data)
Data describing the average number of admissions per month
were available from one medium-term and three long-term studies.
All of these data were skewed and did not enter the analysis.
Data from the medium-term study suggested a trend favouring
the ICM group. Data from the long-term studies showed no trend
favouring one group over the other. Audini-UK 1994 and Muller-
Clemm-Canada 1996 did not report variance measurements. We
assumed consistency between studies and used the fully reported
variance for Sytema-Netherlands 1999, and employed these data
for Audini-UK 1994 and Muller-Clemm-Canada 1996 as well.
1.6 Service use: 4a. Admitted to ER - by long term
The only study identified describing 'number admitted to ER'
showed a non-significant diIerence between the two groups (n =
178, 1 RCT, RR 1.13, 95% CI 0.72 to 1.76).
1.7 Service use: 4b. Average number of admissions to ER (skewed
data) - by medium term
The two studies describing the average number of admissions to
ER reported skewed data. Skewed data were not consistent, as one
study did not show any trend in the direction of eIect, and the other
study showed a trend favouring the ICM group. As in one study the
variance measurement was not reported (Jerrell-SCarolina1 1991),
we carried the standard deviation over from the other available
study (Lehman-Maryland1 1994).
1.8 Service use: 5a. Received day hospital care - by short-term
FUP
We identified only one study relevant to this outcome (total n = 62).
There was not a significant diIerence between ICM and standard
care (RR 2.0, 95% CI 0.19 to 20.93; Analysis 1.8).
1.9 Service use: 5b. Outpatient visits - by short-term FUP (6
months)
We identified only one study relevant to this outcome. There was
not a significant diIerence between ICM and standard care (n = 62,
1 RCT, MD 0.29, 95% CI -0.14 to 0.72; Analysis 1.9).
1.10 Service use: 5c. Outpatient visits - by medium term (skewed
data)
One more small study provided data for this outcome (n = 134), but
as data were skewed and the total sample less than 200, we entered
them as 'Other' data. Data showed a trend favouring ICM, where the
ICM group received more outpatient visits than the standard care
group by medium term (Analysis 1.10).
1.11 Service use: 5d. Received home visits - by short-term FUP
We found a single study showing a significant diIerence between
ICM and standard care in the mean number of home visits received,
favouring the ICM group (n = 62, 1 RCT, MD 4.32, 95% CI 3.42 to
5.22). Note that for this outcome the right graph label favours ICM
(experimental group).
1.12 Adverse event: 1a. Death - any cause
We found 14 relevant studies for this outcome, the data from which
we divided into five subgroups according to diIerent time to follow-
up. We found similar results in mortality across diIerent subgroups,
none of which showed a significant diIerence between ICM and
standard carefor overall mortality.
1.12.1 By short term
We found two trials relevant to this subgroup, with a total of 161
participants. For this subgroup, two deaths occurred in the 81
people treated with ICM compared with two deaths in the 80 people
treated with standard care (n = 161, 2 RCTs, RR 1.04, 95% CI 0.16 to
6.91; Analysis 1.12).
1.12.2 By medium term
There were six relevant trials in this subgroup (total n = 901). For
this subgroup, five deaths occurred in 453 people treated with ICM
compared with six deaths in 448 people treated with standard care
(n = 901, 6 RCTs, RR 0.78, 95% CI 0.23 to 2.62; Analysis 1.12).
1.12.3 By long term
We found nine trials relevant to this subgroup, with a total of 1456
participants. For this subgroup, 24 deaths occurred in 741 people
treated with ICM compared with 27 deaths in 715 people treated
with standard care (n = 1456, 9 RCTs, RR 0.84, 95% CI 0.48 to 1.47;
Analysis 1.12).
1.12.4 By medium-term FUP (3 years)
There was a single trial in this subgroup, in which six deaths
occurred in 275 people treated with ICM compared with 10 deaths
in 272 people treated with standard care, showing no significant
diIerence between ICM and standard care (n = 547, 1 RCT, RR 0.59,
95% CI 0.22 to 1.61; Analysis 1.12).
1.12.5 By long-term FUP (8 years)
There was a single trial in this subgroup, in which 14 deaths
occurred in 275 people treated with ICM compared with 15 deaths
in 272 people treated with standard care, showing no significant
diIerence between ICM and standard care (n = 547, 1 RCT, RR 0.92,
95% CI 0.45 to 1.88; Analysis 1.12).
1.13 Adverse event: 1b. Death - suicide
We found 12 relevant studies for this outcome and categorised data
into four subgroups. Our results for mortality due to suicide were
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
similar to those found for mortality due to all causes, that is no
significant diIerence in suicide rate between the two intervention
groups.
1.13.1 By short term
Data by short term were available from two studies, where no
suicides occurred in 62 people treated with ICM compared with two
suicides in 65 people treated with standard care (n = 127, 2 RCTs, RR
0.35, 95% CI 0.04 to 3.27; Analysis 1.13).
1.13.2 By medium term
Data by medium term were available from four studies, where two
suicides occurred in 412 people treated with ICM compared with
two suicides in 407 people treated with standard care (n = 819, 4
RCTs, RR 0.98, 95% CI 0.17 to 5.60; Analysis 1.13).
1.13.3 By long term
Data by long term were available from nine studies, where 10
suicides occurred in 741 people treated with ICM compared with 14
suicides in 715 people treated with standard care (n = 1456, 9 RCTs,
RR 0.68, 95% CI 0.31 to 1.51; Analysis 1.13).
1.13.4 By medium-term FUP (3 years)
Data by medium-term follow-up (3 years) were available from one
study, where three suicides occurred in 275 people treated with ICM
compared with four suicides in 272 people treated with standard
care (n = 547, 1 RCT, RR 0.74, 95% CI 0.17 to 3.28; Analysis 1.13).
1.14 Global state: 1. Leaving the study early
We identified 21 studies relevant to this outcome and categorised
data into five subgroups (in keeping with our protocol).
1.14.1 By short term
We included five short-term studies and found no significant
diIerences between treatment groups for number of participants
leaving the study early (n = 598, 5 RCTs, RR 0.79, 95% CI 0.44 to 1.41),
but data were heterogeneous (Chi2 = 80.24; df = 4.0; P = 0.0; I2 = 95%;
Analysis 1.14).
1.14.2 By medium term
We included eight medium-term studies and found the risk of
leaving the study early was lower for participants in the ICM group
(n = 1699, 8 RCTs, RR 0.60, 95% CI 0.51 to 0.70; Analysis 1.14).
1.14.3 By long term
Data from 13 long-term studies confirmed data from medium-term
studies, showing a significant advantage for ICM (n = 1798, 13 RCTs,
RR 0.68, 95% CI 0.58 to 0.79; Analysis 1.14).
1.14.4 By medium-term FUP (3 years)
There was a single trial in this subgroup, showing no significant
diIerence between ICM and standard care (n = 547, 1 RCT, RR 1.01,
95% CI 0.84 to 1.21; Analysis 1.14).
1.14.5 By long-term FUP (8 years)
We found one trial relevant to this subgroup, showing no significant
diIerence between ICM and standard care (n = 547, 1 RCT, RR 0.88,
95% CI 0.7 to 1.09; Analysis 1.14).
1.15 Global state: 2. Average endpoint score (Global Assessment
of Functioning Scale, high = good)
We identified five studies relevant to this outcome and categorised
data into three subgroups. Note that for this outcome the right
graph label favours ICM (experimental group).
1.15.1 By short term
There were four relevant trials in this subgroup (total n = 797). For
this subgroup, the Global Assessment of Functioning Scale (GAF)
score favoured ICM (MD 2.07, 95% CI 0.28 to 3.86; Analysis 1.15).
1.15.2 By medium term
Medium-term GAF data from three studies (n = 722, 3 RCTs, MD
0.09, 95% CI -3.11 to 3.28) showed no significant diIerence between
groups. This subgroup had important levels of heterogeneity (Chi2
= 4.42; df = 2.0; P = 0.11; I2 = 54%; Analysis 1.15).
1.15.3 By long term
We found five trials relevant to this subgroup, with a total of 818
participants. For this subgroup, the GAF score favoured the ICM
group (MD 3.41, 95% CI 1.66 to 5.16; Analysis 1.15).
1.16 Global state: 3. Not compliant with medication - by long
term
We only found data from one long-term study, which favoured the
ICM group (n = 71, 1 RCT, RR 0.35, 95% CI 0.15 to 0.81).
1.17 Social functioning: 1a. Contact with legal system (various
measurements)
We found 11 relevant studies for this outcome and categorised data
into six subgroups, according to diIerent time to follow-up and
diIerent outcomes described.
1.17.1 By short term - contact with the police
We only found data from one study for short-term outcomes,
describing the outcome 'contact with the police'. This study did
not reveal any significant diIerence in the rate of contact with the
police between treatment groups (n = 61, 1 RCT, RR 2.57, 95% CI 0.73
to 9.04; Analysis 1.17).
1.17.2 By medium term - arrested
We found three studies describing the outcome 'number of
arrested'. These studies failed to show a significant diIerence
between the two intervention groups (n = 604, 3 RCTs, RR 1.08, 95%
CI 0.61 to 1.90; Analysis 1.17).
1.17.3 By medium term - contact with the police
Only one medium-term study was available providing data on
'contact with the police'. These data favoured the ICM group in
reducing the number of contacts with the police (n = 88, 1 RCT, RR
0.23, 95% CI 0.09 to 0.55; Analysis 1.17).
1.17.4 By medium term - imprisoned
We found four medium-term studies describing 'number of
imprisoned'. These studies showed no significant advantage for the
ICM group (n = 804, 4 RCTs, RR 0.80, 95% CI 0.39 to 1.64). This
subgroup had important levels of heterogeneity (Chi2 = 6.21; df =
3.0; P = 0.1; I2 = 51%; Analysis 1.17).
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1.17.5 By long term - arrested
We found data from one study for long-term outcomes, describing
the outcome 'number of arrested' , and it showed no significant
advantage for ICM (n = 178, 1 RCT, RR 0.66, 95% CI 0.32 to 1.37;
Analysis 1.17).
1.17.6 By long term - imprisoned
We found also five long-term studies reporting data on 'number of
imprisoned', again not showing any significant advantage for ICM in
reducing the number of participants imprisoned by long term (n =
908, 5 RCTs, RR 0.86, 95% CI 0.45 to 1.65; Analysis 1.17).
1.18 Social functioning: 1b. Mean contacts with legal system
(skewed data) - by medium term
Data were available from one medium-term trial, describing three
diIerent outcomes: bookings, jail days, and convictions. All these
data were skewed and did not enter the analysis, therefore we have
presented them in Analysis 1.18. Data on booking and jail days
suggested a trend favouring the ICM group, reducing contacts with
legal system. Data on convictions did not show a trend favouring
one group over the other.
1.19 Social functioning: 2. Employment status (various
measurements)
We found six relevant studies for this outcome and categorised data
into six subgroups, according to diIerent time to follow-up and
various outcomes described.
1.19.1 By medium term - not competitively employed at the end of the
trial
One study reported data on 'not competitively employed at the end
of the trial', and these data did not show a significant advantage for
ICM in improving the number of competitively employed people (n
= 88, 1 RCT, RR 1.00, 95% CI 0.91 to 1.10; Analysis 1.19).
1.19.2 By medium term - not employed at the end of the trial
We found four trials relevant to this subgroup; these also failed to
show a significant diIerence between groups, although data did
suggest a trend favouring ICM (n = 1136, 4 RCTs, RR 0.89, 95% CI 0.79
to 1.0). However, heterogeneity was present (Chi2 = 11.86; df = 3.0;
P = 0.01; I2 = 74%; Analysis 1.19).
1.19.3 By long term - not employed at the end of the trial
We found four trials relevant to this subgroup. As in the medium-
term comparison, data failed to show a significant diIerence,
although they suggested a trend favouring the ICM group (n = 1129,
4 RCTs, RR 0.70, 95% CI 0.49 to 1.00). However, again, there was
considerable heterogeneity (Chi2 = 46.48; df = 3.0; P = 0.0; I2 = 93%;
Analysis 1.19).
1.19.4 By long term - not working/studying in the previous year
We found one trial relevant to this subgroup, with a total of 547
participants. Data showed a significant diIerence between groups,
favouring ICM in reducing the risk of being 'not working or not
studying' compared to standard care (n = 547, 1 RCT, RR 0.86, 95%
CI 0.74 to 0.99). Heterogeneity for this outcome was high (Chi2 = 0.0;
df = 0.0; P = 0.0; I2 = 100%; Analysis 1.19).
1.19.5 By medium-term FUP (3 years) - not working/studying in the
previous year
There was a single trial in this subgroup. Data failed to show a
signiifcant diIerence between groups (n = 547, 1 RCT, RR 1.02, 95%
CI 0.9 to 1.16; Analysis 1.19).
1.19.6 By long-term FUP (8 years) - not working/studying in the
previous year
We found one trial relevant to this subgroup. Again, we did not find
evidence of a clear diIerence between the two treatments (n = 547,
1 RCT, RR 0.99, 95% CI 0.88 to 1.11; Analysis 1.19).
1.20 Social functioning: 3a. Accommodation status (various
measurements)
We found 10 relevant studies for this outcome, the data from which
we divided into six subgroups according to diIerent time to follow-
up and various outcomes described.
1.20.1 By short term - homelessness
We found data on the outcome 'homelessness' from one short-term
study. This small study revealed a significant reduction in the rate
of homelessness in the ICM group (n = 95, 1 RCT, RR 0.04, 95% CI 0.00
to 0.70; Analysis 1.20).
1.20.2 By medium term - homelessness
Medium-term data on the outcome 'homelessness' were available
from one small study. Data did not reveal any significant diIerence
between groups in the rate of homelessness by the medium term (n
= 88, 1 RCT, RR 0.32, 95% CI 0.03 to 2.95; Analysis 1.20).
1.20.3 By medium term - not living independently
We found five trials relevant to this subgroup. These data showed
a significant advantage for ICM in reducing the number of
participants not living independently (n = 1303, 5 RCTs, RR 0.80, 95%
CI 0.66 to 0.97). Heterogeneity for this subgroup was moderately
high (Chi2 = 5.81; df = 4.0; P = 0.21; I2 = 31%; Analysis 1.20).
1.20.4 By long term - homelessness
We found 'homelessness' data in three long-term studies, which did
not reveal any significant diIerence between intervention groups
(n = 418, 3 RCTs, RR 0.78, 95% CI 0.34 to 1.82). This subgroup had
moderate levels of heterogeneity (Chi2 = 3.27; df = 2.0; P = 0.19; I2 =
38%; Analysis 1.20).
1.20.5 By long term - not living independently
There were four relevant trials in this subgroup. Data for this
subgroup favoured the ICM group, where the incidence of not living
independently was lower compared with the standard care group
(n = 1185, 4 RCTs, RR 0.65, 95% CI 0.49 to 0.88). This subgroup had
moderate levels of heterogeneity (Chi2 = 5.39; df = 3.0; P = 0.15; I2 =
44%; Analysis 1.20).
1.20.6 By long term - not living in stable accommodation
The outcome 'not living in stable accommodation' was only
available from one study. We found that data favoured the ICM
group in reducing the number of participants not living in stable
accommodation (n = 168, 1 RCT, RR 0.80, 95% CI 0.65 to 0.98;
Analysis 1.20).
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1.21 Social functioning: 3b. Accomodation status: mean number
of days in supported house (skewed data, sample size # 200)
We identified only one study relevant to this outcome, providing
data at diIerent times, but always referring to the previous year of
follow-up. Note that for this outcome the right graph label favours
ICM (experimental group).
1.21.1 By long term (previous year)
There was no significant diIerence between ICM and standard care
within this subgroup (n = 547, 1 RCT, MD 0.3, 95% CI -13.98 to 14.58;
Analysis 1.21).
1.21.2 By medium-term FUP (3 years) (previous year)
We found evidence of a significant diIerence between ICM and
standard care within this subgroup, with data favouring standard
care over ICM (n = 547, 1 RCT, MD -22.2, 95% CI -38.47 to -5.93;
Analysis 1.21).
1.21.3 By long-term FUP (8 years) (previous year)
We did not find evidence of a significant diIerence between the two
treatments for this subgroup (n = 547, 1 RCT, MD -6.7, 95% CI -19.35
to 5.95; Analysis 1.21).
1.22 Social functioning: 3c. Accommodation status (various
measurements, skewed data)
Data on this outcome were available from three studies; as all of
these data were skewed and did not enter the analysis, we have
presented them in Analysis 1.22.
Two studies provided medium-term data on 'average days in stable
accommodation', which showed a trend favouring the ICM group,
consistent with results previously described for 'not living in stable
accommodation' by long term.
Two studies provided long-term data on 'average days per month
in sheltered homes'. These data were equivocal, as data from one
study favoured ICM, whilst data from the second study favoured the
standard care group.
1.23 Social functioning: 4a. Substance abuse
We identified only one study relevant to this outcome, providing
various measures at diIerent time of follow-up.
1.23.1 Alcohol abuse - by long term
We found one trial relevant to this subgroup (total n = 547). There
was no significant diIerence between ICM and standard care within
this subgroup (n = 547, 1 RCT, RR 0.55, 95% CI 0.26 to 1.17; Analysis
1.23).
1.23.2 Illicit drug abuse - by long term
As for alcohol abuse, data failed to show a significant diIerence
between groups for this subgroup (n = 547, 1 RCT, RR 0.96, 95% CI
0.63 to 1.47; Analysis 1.23).
1.23.3 Substance abuse - by medium-term FUP (3 years)
We found one trial relevant to this subgroup (total n = 547). As
for the two previous outcomes, data failed to show a significant
diIerence between groups (RR 0.91, 95% CI 0.67 to 1.24; Analysis
1.23).
1.24 Social functioning: 4b. Substance abuse (Dartmouth
Assessment of Lifestyle Interview (DALI), skewness not
detectable) - by medium term
We were unable to enter two types of data into the analysis:
medium-term data assessing alcohol and drug abuse on DALI scale.
As the DALI scale averages values from positive to negative, skew is
very diIicult to detect, we did not enter these data in the analysis.
These data tended to favour the standard care group for both the
alcohol and drug abuse outcomes; we have presented them in
Analysis 1.25.
1.25 Social functioning: 4c. Substance abuse - days used per
month (skewed data)
One study provided medium- and long-term data from the outcome
'days of substance use per month', which were equivocal, but
skewed; we have therefore presented them in Analysis 1.25.
1.26 Social functioning: 5a. Average endpoint score (various
scales)
Three studies provided data from five diIerent scales (Disability
Assessment Scale (DAS), Interview Schedule for Social Interaction
(ISSI), Role Functioning Scale (RFS), Social Adjustment Scale (SAS-
adapted version), Strauss-Carpenter Outcome Scale) assessing
social functioning by short, medium, and long term. As no more
than one study used the same scale per time period, we did not
enter more than one study per subgroup. Data from each available
time period failed to show any significant diIerence between
treatment groups, with the exception of two outcomes by long term
(1.26.7 on ISSI and 1.26.8 on RFS), the first favouring the standard
care group, and the second favouring the ICM group.
1.26.1 By short term (RFS, low = poor)
One trial providing data, no significant diIerence between groups
(n = 80, 1 RCT, MD -0.62, 95% CI -2.23 to 0.99; Analysis 1.26).
1.26.2 By short term (SAS-adapted version, low = poor)
One trial providing data, no significant diIerence between groups
(n = 80, 1 RCT, MD -3.34, 95% CI -7.55 to 0.87; Analysis 1.26).
1.26.3 By medium term - social role performance (DAS, high = poor)
One trial providing data, no significant diIerence between groups
(n = 55, 1 RCT, MD 0.1, 95% CI -0.4 to 0.6; Analysis 1.26).
1.26.4 By medium term (RFS, low = poor)
One trial providing data, no significant diIerence between groups
(n = 80, 1 RCT, MD -0.86, 95% CI -2.72 to 1.0; Analysis 1.26).
1.26.5 By medium term (SAS-adapted version, low = poor)
One trial providing data, no significant diIerence between groups
(n = 80, 1 RCT, MD -3.3, 95% CI -7.83 to 1.23; Analysis 1.26).
1.26.6 By long term - social role performance (DAS, high = poor)
One trial providing data, no significant diIerence between groups
(n = 58, 1 RCT, MD -0.2, 95% CI -0.67 to 0.27; Analysis 1.26).
1.26.7 By long term (ISSI, low = poor)
One trial providing data, showing a significant diIerence between
groups favouring standard careover ICM (n = 62, 1 RCT, MD 3.2, 95%
CI 0.11 to 6.29; Analysis 1.26).
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1.26.8 By long term (RFS, low = poor)
One trial providing data, showing a significant diIerence between
groups favouring ICM over standard care (n = 80, 1 RCT, MD -2.35,
95% CI -4.05 to -0.65; Analysis 1.26).
1.26.9 By long term (SAS-adapted version, low = poor)
One trial providing data, no significant diIerence between groups
(n = 80, 1 RCT, MD -2.75, 95% CI -7.13 to 1.63; Analysis 1.26).
1.26.10 By long term (Strauss-Carpenter Outcome Scale, low = poor)
One trial providing data, no significant diIerence between groups
(n = 60, 1 RCT, MD 0.1, 95% CI -1.17 to 1.37; Analysis 1.26).
1.27 Social functioning: 5b. Average endpoint score (various
scales, skewed data)
Skewed data on SAS score were available by short, medium, and
long term from two studies. These data were equivocal and not
consistent between the two studies. One study provided long-term
data on REHAB Scale score, which tended to favour the ICM group,
but were also skewed. We have presented them in Analysis 1.27.
1.28 Mental state: 1a. General symptoms - average endpoint
score (various scales)
Two sets of data were available: i.) non-skewed data or skewed data
from a sample size greater than or equal to 200 participants per
study: entering analysis together; and ii.) skewed data: not entering
analysis.
We identified four studies relevant to this outcome entering
analysis, providing data from three diIerent scales (Brief
Psychiatric Rating Scale (BPRS-18 items), Brief Symptom Inventory
(BSI), Colorado Symptom Index (CSI)) per diIerent time period.
1.28.1 By short term (BPRS-18 items, high = poor)
We found two trials relevant to this subgroup. There was no
significant diIerence between ICM and standard care within this
subgroup (n = 668, 2 RCTs, MD -1.56, 95% CI -6.85 to 3.73), but data
were heterogeneous (Chi2 = 12.58; df = 1.0; P = 0.0; I2 = 92%; Analysis
1.28).
1.28.2 By short term (BSI, high = poor)
Short-term mental state scores assessed with the BSI were available
from the same two studies providing BPRS short-term data. Again,
data were not significantly diIerent (n = 668, 2 RCTs, MD -0.06, 95%
CI -0.19 to 0.06; Analysis 1.28); however, diIerent from the BPRS
results, these data were homogeneous.
1.28.3 By short term (CSI, low = poor)
One further trial was available providing short-term data on mental
state assessed with the CSI. These data showed a significant
diIerence between groups favouring the ICM group (n = 125, 1 RCT,
MD -0.56, 95% CI -0.84 to -0.28; Analysis 1.28).
1.28.4 By medium term (BPRS-18 items, high = poor)
We found two trials relevant to this subgroup, with a total of 662
people. We did not find evidence of a significant diIerence between
ICM and standard care within this subgroup (MD -0.96, 95% CI -2.42
to 0.51; Analysis 1.28).
1.28.5 By medium term (BSI, high = poor)
We found two trials relevant to this subgroup (total n = 662). We
did not find evidence of a significant diIerence between ICM and
standard care within this subgroup (MD -0.02, 95% CI -0.15 to 0.1;
Analysis 1.28).
1.28.6 By medium term (CSI, low = poor)
There was a single trial in this subgroup. We found evidence
favouring the ICM group over the standard care group (n = 125, 1
RCT, MD -0.35, 95% CI -0.65 to -0.05; Analysis 1.28).
1.28.7 By long term (BPRS-18 items, high = poor)
We found three trials relevant to this subgroup (total n = 777). There
was no significant diIerence between ICM and standard care within
this subgroup (n = 777, 3 RCTs, MD -1.48, 95% CI -3.69 to 0.74), but
data were heterogeneous (Chi2 = 13.13; df = 2.0; P = 0.0; I2 = 84%;
Analysis 1.28).
1.28.8 By long term (BSI, high = poor)
We found two trials relevant to this subgroup, with data favouring
the ICM group, in which participants reached a better mental state
score by long term compared to the standard care group (n = 647, 2
RCTs, MD -0.18, 95% CI -0.31 to -0.06; Analysis 1.28).
1.29 Mental state: 1b. General symptoms - mean change from
baseline (CSI, low = poor ) - by long term
Finally, one study assessed the mean change from baseline on the
CSI, with data showing no diIerence between groups (n = 168, 1
RCT, MD -0.32, 95% CI -0.53 to -0.11).
1.30 Mental state: 1c. General symptoms - average endpoint
score (various scales, skewed data)
Skewed data were available from six studies assessing mental
state by diIerent time periods and with diIerent scales (BPRS-18
items, BPRS-24 items, CPRS, PSE, SCL-90). Data failed to show a
significant trend favouring one group over the other, this report
being consistent across diIerent studies and diIerent rating scales.
We considered these data to not be robust as they were skewed, but
they were in accordance with short-, medium-, and long-term data.
We have presented them in Analysis 1.30.
1.31 Mental state: 2a. Specific symptoms - depression at follow-
up interview
We found data on specific symptoms from only one study, which
provided data on depression incidence per diIerent time period.
There was no significant diIerence between groups by medium
term, long term, and medium-term follow-up (three years).
1.31.1 By medium term
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, RR 0.77, 95% CI 0.56 to 1.04; Analysis 1.31).
1.31.2 By long term
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, RR 0.83, 95% CI 0.57 to 1.21; Analysis 1.31).
1.31.3 By medium term FUP (3 years)
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, RR 1.25, 95% CI 0.91 to 1.72; Analysis 1.31).
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
41
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
1.32 Mental state: 2b. Specific symptoms - average endpoint
score (various scales, skewed data, sample size # 200)
We identified only one study (n = 547) relevant to this outcome,
providing data on two diIerent dimensions (positive and negative
symptoms) assessed at diIerent times. Although skewed, data
entered the analyses, as the sample size was greater than or equal
to 200 participants per study. Only one comparison showed a
significant advantage for the ICM group, in reducing risk of negative
symptoms by long term.
1.32.1 By long term - positive symptoms (Scale for the Assessment of
Positive Symptoms (SAPS), high = poor)
One trial providing data, showing no significant diIerence between
groups, although tending to favour the ICM group (n = 547, 1 RCT,
MD -0.22, 95% CI -0.45 to 0.01; Analysis 1.32).
1.32.2 By long term - negative symptoms (Scale for the Assessment of
Negative Symptoms (SANS), high = poor)
One trial providing data, showing evidence of a significant
diIerence between groups favouring ICM over standard care (n =
547, 1 RCT, MD -0.42, 95% CI -0.62 to -0.22; Analysis 1.32).
1.32.3 By medium-term FUP (3 years) - positive symptoms (SAPS, high
= poor)
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, MD 0.12, 95% CI -0.15 to 0.39; Analysis 1.32).
1.32.4 By medium-term FUP (3 years) - negative symptoms (SANS, high
= poor)
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, MD -0.1, 95% CI -0.33 to 0.13; Analysis 1.32).
1.32.5 By long-term FUP (8 years) - positive symptoms (SAPS, high =
poor)
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, MD 0.03, 95% CI -0.21 to 0.27; Analysis 1.32).
1.32.6 By long-term FUP (8 years) - negative symptoms (SANS, high =
poor)
One trial providing data, no significant diIerence between groups
(n = 547, 1 RCT, MD 0.06, 95% CI -0.13 to 0.25; Analysis 1.32).
1.33 Mental state: 2c. Specific symptoms - average endpoint
score (various scales, skewed data)
We found a second small study (n = 70) providing skewed data
on depression symptoms assessed with the Beck Depression
Inventory, and negative symptoms assessed with SANS. Neither
data set was entered into the analysis. Skewed depression scores
favoured the ICM group at medium and long term, whilst skewed
negative symptoms scores by medium and long term were
equivocal. We have reported these data in Analysis 1.33.
1.34 Behaviour: 1. Specific behaviour - self harm
We found three relevant studies for this outcome providing data
per diIerent time period. We detected no significant diIerence
between ICM and standard care in either reducing the risk for self
harm or reducing the risk for attempting suicide.
1.34.1 By medium term
There were two relevant trials in this subgroup, in which 30 events
occurred in 312 people treated with ICM compared with 30 events
in 308 people treated with standard care. There was no significant
diIerence in number of participants who committed self harm
between the groups (n = 620, 2 RCTs, RR 0.99, 95% CI 0.61 to 1.59;
Analysis 1.34).
1.34.2 By long term
There is a single relevant trial in this subgroup, in which 2 events
occurred in 63 people treated with ICM compared with 2 events
in 60 people treated with standard care. There was no significant
diIerence in number of participants who committed self harm
between the groups (n = 123, 1 RCT, RR 0.95, 95% CI 0.14 to 6.55;
Analysis 1.34).
1.34.3 Attempted suicide - by long term (during last 12 months)
Long term data on self harm during the previous 12 months
available from a single study confirmed medium- and long-term
data (n = 547, 1 RCT, RR 0.81, 95% CI 0.47 to 1.38; Analysis 1.34), that
is failing to show any significant diIerence between the two groups.
1.34.4 Attempted suicide - by medium-term FUP (during last 3 years)
The above data were again confirmed, from medium-term follow-
up data on suicide attempts during the previous three years
available from a single study. There was no significant diIerence
between ICM and standard care (n = 547, 1 RCT, RR 0.95, 95% CI 0.56
to 1.62; Analysis 1.34).
1.35 Behaviour: 2. Social behaviour - average endpoint score
(Social Behaviour Scale, high = poor)
Skewed data were available from one small study (n = 70) assessing
behaviour with the Social Behaviour Scale by medium and long
term. These data tended to favour the ICM group.
1.36 Quality of life: 1a. Average endpoint score (various scales)
We found seven studies assessing quality of life with various scales
by diIerent time periods, and categorised data into five subgroups.
Note that for this outcome the right graph label favours ICM
(experimental group).
1.36.1 By short term - general well-being (Lehman's Quality of Life
Interview (QOLI), high = better)
The only significant result we found was by short term: data were
available from a single study and showed a significantly higher
quality of life in the ICM group as assessed on the QOLI general well-
being subscale (n = 125, 1 RCT, MD 0.53, 95% CI 0.09 to 0.97; Analysis
1.36).
1.36.2 By medium term (Lancashire Quality of Life Profile (LQoLP),
high = better)
Medium-term data assessing quality of life with LQoLP (one study)
did not show a significant diIerence between groups (n = 52, 1 RCT,
MD 0.09, 95% CI -0.60 to 0.78; Analysis 1.36).
1.36.3 By medium term (Manchester Short Assessment of Quality of
Life (MANSA) - range 1 to 7, high = better)
Medium-term data assessing quality of life with MANSA (one study)
did not show a significant diIerence between groups (n = 81, 1 RCT,
MD 0.20, 95% CI -0.29 to 0.69; Analysis 1.36).
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1.36.4 By long term (LQoLP, high = better)
As with the medium-term data, long-term data assessing quality of
life with LQoLP (three studies) did not show a significant diIerence
between groups (n = 274, 3 RCTs, MD -0.13, 95% CI -0.38 to 0.12;
Analysis 1.36).
1.36.5 By long term (QOLI, high = better)
Again, as with the medium-term data, long-term data assessing
quality of life with QOLI (two studies) did not show a significant
diIerence between groups (n = 132, 2 RCTs, MD 0.09, 95% CI -0.24
to 0.42; Analysis 1.36).
1.37 Quality of life: 1b. Mean change from baseline (QOLI, high =
better, skewed data) - by long term
We found one further study providing data by long term for this
comparison, but as data were skewed, measuring mean change
from baseline on the QOLI, the study was not entered into the
analysis. These data tended to favour the ICM group. We have
reported these data in Analysis 1.37.
1.38 Participant satisfaction: 1a. Average endpoint score (Client
Satisfaction Questionnaire (CSQ), high = better)
We found three relevant studies for this outcome, providing data
per diIerent time period. We found that participant satisfaction
assessed with the CSQ was significantly greater in the ICM group
compared with the standard care group in all three time period
assessments. Note that for this outcome the right graph label
favours ICM (experimental group).
1.38.1 By short term
Short-term data were available from only one small study and
showed a significant diIerence between groups, favouring the ICM
intervention (n = 61, 1 RCT, MD 6.2, 95% CI 2.6 to 9.8; Analysis 1.38).
1.38.2 By medium term
Medium-term data from two studies confirmed the above results (n
= 500, 2 RCTs, MD 1.93, 95% CI 0.86 to 3.01; Analysis 1.38).
1.38.3 By long term
Long-term data also favoured the ICM group (n = 423, 2 RCTs, MD
3.23, 95% CI 2.31 to 4.14; Analysis 1.38).
1.39 Participant satisfaction: 1b. Average endpoint score (CSQ,
high = better, skewed data) - by short term
One further small trial provided short-term data, but the data were
skewed: attrition in the standard care arm was higher than 50%.
Participant satisfaction was assessed with the CSQ, and it tended to
favour the ICM group. We have reported these data in Analysis 1.39.
1.40 Participant need: 1. Average endpoint score (various scales,
skewed data)
We found more skewed data from two studies assessing participant
need on two other scales (Camberwell Assessment of Need
Interview (CAN), Camberwell Assessment of Need Short Appraisal
Schedule (CANSAS)). Medium-term data from one study assessed
on CANSAS failed to show any diIerence between groups. Long-
term data assessed in one study with the CAN tended to favour the
ICM group. We have reported these data in Analysis 1.40.
1.41 Costs: 1a. Direct costs of psychiatric hospital care - by
medium term (unit cost = USD, fiscal year 1990)
Direct medium-term costs of psychiatric hospital care were
available from two studies reporting skewed data, but with a
sample size greater than 200 (Chandler-California1 (A); Chandler-
California1 (B)). Data favoured ICM (n = 426, 2 RCTs, MD USD -143.74,
95% CI -272.40 to -15.08; Analysis 1.41).
1.42 Costs: 1b. Direct costs of psychiatric hospital care - skewed
data
Five additional studies did describe 'direct costs of psychiatric
hospital care', but data were markedly skewed. Some of these data
showed a trend favouring ICM, while some favoured standard care,
therefore we could not highlight any trend confirming the findings
from meta-analysis. We have presented these data in Analysis 1.42.
1.43 Costs: 2a. Direct healthcare costs - by long term (unit cost =
USD, fiscal year 1988)
Long-term data for direct healthcare cost were available from two
studies; again studies reported skewed data, but with a sample
size greater than 200, and so these data could be entered into a
meta-analysis. These data were inconclusive (n = 873, 2 RCTs, MD
USD -529.24, 95% CI -2143.59 to 1085.1; Analysis 1.43), as they were
highly heterogeneous (Chi2 = 17.83; df = 1.0; P = 0.0; I2 = 94%) with
inconsistency in direction of eIect.
1.44 Costs: 2b. Direct healthcare costs - skewed data
Other skewed data from two studies with a sample size of less
than 200 could not be entered into the meta-analysis. These studies
assessed direct healthcare costs by medium term (one study) and
by short-term follow-up (the other study). Medium-term data did
not show any significant diIerence between interventions, whilst
short-term FUP data seemed to favour standard care in reducing
direct healthcare costs. We have reported these data in Analysis
1.44.
1.45 Costs: 3. Direct costs - other data - skewed data
Five studies described direct costs for "all care" by short, medium,
and long term, and one more study described direct costs for
"specific" outcome (outpatient care and prison) by medium term.
As these data were skewed and from studies with a sample size of
less than 200, they could not be entered into the meta-analysis. We
have presented these data in Analysis 1.45.
Costs for all care by short term seemed to favour the ICM group,
where costs were reduced (one study); by medium term one study
favoured standard care (where costs were reduced), whilst the
other study failed to show any diIerence between the two groups;
and five studies provided data by long term: some of these data
showed a trend favouring ICM, and some favoured standard care;
these data were therefore inconclusive, and we could not highlight
any trend.
Medium-term data from one study on cost for outpatient care
showed costs were higher in the ICM group compared to standard
care. Data from the same study on cost for prison showed costs
were higher for the standard care group compared to ICM.
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2. COMPARISON 2: INTENSIVE CASE MANAGEMENT versus NON-
INTENSIVE CASE MANAGEMENT
Summary of findings 2. This comparison has 36 outcomes.
2.1 Service use: 1. Average number of days in hospital per month
- by about 24 months
We found 21 relevant studies for this outcome and categorised data
into two subgroups (skewed data but with a sample size greater
than or equal to 200, and skewed data with a sample size of less
than 200). Overall, combining the two pools of studies, we found no
clear diIerence between ICM and non-ICM (n = 2220, 21 RCTs, MD
-0.08, 95% CI -0.37 to 0.21, Figure 10). A funnel plot did not show any
significant reporting bias (Figure 11).
 
Figure 10.   Forest plot of comparison: 2 Intensive Case Management versus non-Intensive Case Management,
outcome: 2.1 Service use: 1. Average number of days in hospital per month - at about 24 months.
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Figure 11.   Funnel plot of comparison: 2 Intensive Case Management versus non-Intensive Case Management,
outcome: 2.1 Service use: 1. Average number of days in hospital per month - by about 24 months.
 
2.1.1 Skewed data (sample size ≧ 200)
We found three studies reporting skewed data but with a sample
size greater than or equal to 200. There was no significant diIerence
between groups for reducing length of hospitalisation (n = 694, 3
RCTs, MD -0.58, 95% CI -1.93 to 0.76; Analysis 2.1). These findings
were in accordance with the second subgroup analysis, skewed
data from studies with a sample size of less than 200 participants.
2.1.2 Skewed data (sample size < 200)
There were 18 relevant trials in this subgroup, with a total of 1526
people. Again, these data did not show a significant diIerence
between groups (n = 1526, 18 RCTs, MD -0.03, 95% CI -0.33 to 0.28;
Analysis 2.1).
2.2 Service use: 1a. Average number of days in hospital per
month - by medium/long-term follow-up (skewed data, sample
size # 200)
One study provided data by medium- and long-term follow-up, and
as the sample size was greater than 200, skewed data entered the
analysis.
2.2.1 By medium-term FUP (18 months)
One study provided data on medium-term follow-up (18 months),
confirming the results described above by 24 months. There was no
clear diIerence between ICM and non-ICM within this subgroup (n
= 237, 1 RCTs, MD 0.6, 95% CI -1.25 to 2.45; Analysis 2.2).
2.2.2 By long-term FUP (8.5 years)
The same study provided data on long-term follow-up (8.5 years),
again showing no significant diIerences between interventions in
reducing number of days in hospital (n = 203, 1 RCTs, MD 0.8, 95%
CI -1.47 to 3.07; Analysis 2.2).
2.3 Service use: 2. Not remaining in contact with psychiatric
services
We found four relevant studies for this outcome and categorised
data into three subgroups, by diIerent time period. Short-term
data were not available. When we pooled studies from medium
and long term, data did not show significant diIerences between
interventions, but heterogeneity was substantial (n = 1255, 4 RCTs,
RR 0.63, 95% CI 0.27 to 1.49, I2 = 81%, P = 0.001). We addressed
this finding by checking again for correctness of data and explored
heterogeneity by dropping each study out of the analysis. Only
by removing both Drake-NHamp 1998 and UK700-UK 1999 was
homogeneity restored. As we could not ascertain any clear reason
for the heterogeneity, we have therefore chosen not to pool these
data, as it could be misleading to quote an average value for
the intervention eIect - particularly in this case, when there is
inconsistency in direction of eIect. We did not use a funnel plot
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for this outcome because there were fewer than 10 studies (see
Assessment of reporting biases).
2.3.1 By medium term
One small study provided medium-term data showing a significant
diIerence favouring the ICM group (n = 73, 1 RCT, RR 0.27, 95% CI
0.08 to 0.87; Analysis 2.3).
2.3.2 By long term
Long-term data were available from three studies. Pooled data
were not statistically significant (n = 1182, 3 RCTs, RR 0.82, 95% CI
0.34 to 1.98), but data were heterogeneous (Chi2 = 10.86; df = 2.0; P =
0.0; I2 = 81%) with inconsistency in direction of eIect (Analysis 2.3).
2.3.3 By medium-term FUP (18 months)
One single trial provided data for this outcome, and we found no
evidence of a clear diIerence between the two treatments (n = 251,
1 RCT, RR 0.42, 95% CI 0.17 to 1.05; Analysis 2.3).
2.4 Service use: 3a. Admitted to hospital - by long term
Binary data describing this outcome were available from three
long-term studies, reporting 'number of admitted to hospital'.
These data showed a non-significant diIerence in number of
participants admitted to hospital between groups (n = 1132, 3 RCTs,
RR 0.91, 95% CI 0.75 to 1.12; Analysis 2.4). Heterogeneity was high
for this outcome (Chi2 = 5.26; df = 2.0; P = 0.07; I2 = 62%).
2.5 Service use: 3b. Average number of admissions (skewed data
- sample size # 200)
We identified two studies relevant to this outcome, one providing
data by long term, the other by medium- and long-term follow-up.
Data were skewed, but as the trial sample size were greater than
or equal to 200, we entered these data in the analysis. Data from
diIerent time periods failed to show any significant diIerences
between ICM and non-ICM in average number of admissions.
2.5.1 By long term (24 months)
Data from one long-term study failed to show any significant
diIerences between groups (n = 678, 1 RCT, MD -0.18, 95% CI -0.41
to 0.05; Analysis 2.5).
2.5.2 By medium term FUP (18 months)
One single study provided data by medium-term follow-up (18
months). Data failed to show any significant diIerences between
groups (n = 237, 1 RCT, MD -0.1, 95% CI -0.6 to 0.4; Analysis 2.5).
2.5.3 By long-term FUP (8.5 years)
One single study provided data by medium-term follow-up (8.5
years). Data failed to show any significant diIerences between
groups (n = 203, 1 RCT, MD 1.0, 95% CI -0.25 to 2.25; Analysis 2.5).
2.6 Service use: 3c. Average number of admissions (skewed data)
- by medium term
A trial that included fewer than 200 participants presented skewed
data that could not be entered into the meta-analysis. Data were
reported for the outcome 'average number of admissions' by
medium term. As with previous findings, they failed to show any
trend in eIect between groups.
2.7 Adverse event: 1a. Death - any cause
We found seven relevant studies for this outcome and categorised
data into five subgroups, by diIerent time period.
2.7.1 By short term
Short-term data on mortality were available from one study (n =
193) reporting no deaths, therefore a measure of eIect was not
estimable (Analysis 2.7).
2.7.2 By medium term
Medium-term data were available from three studies, where 1 death
occurred in 148 people treated with ICM, compared with no deaths
in 146 people treated with non-ICM. There were no significant
diIerences in mortality between groups (n = 294, 3 RCTs, RR 2.92,
95% CI 0.12 to 69.43; Analysis 2.7).
2.7.3 By long term
We found long-term data in five studies, reporting 16 deaths
occurring in 816 people treated with ICM, compared with 18 deaths
in 821 people treated with non-ICM. These data confirmed medium-
term findings showing no diIerences in mortality between groups
(n = 1637, 5 RCTs, RR 0.90, 95% CI 0.46 to 1.75; Analysis 2.7).
2.7.4 By medium-term FUP (18 months)
Medium-term follow-up data were available from one study, where
6 deaths occurred in 127 people treated with ICM, compared with 6
deaths in 124 people treated with non-ICM. These data confirmed
the above results, showing no diIerences in mortality between
groups (n = 251, 1 RCT, RR 0.98, 95% CI 0.32 to 2.95; Analysis 2.7).
2.7.5 By long-term FUP (8.5 years)
Long-term follow-up data were available from one study, where 20
deaths occurred in 127 people treated with ICM, compared with 17
deaths in 124 people treated with non-ICM. These data confirmed
the above results, showing no diIerences in mortality between
groups (n = 251, 1 RCT, RR 1.15, 95% CI 0.63 to 2.09; Analysis 2.7).
2.8 Adverse event: 1b. Death - suicide
We found eight relevant studies for this outcome and categorised
data into four subgroups, by diIerent time period.
2.8.1 By short term
Short-term data on suicide mortality were available from one study
(n = 193), again reporting no deaths, and therefore a measure of
eIect was not estimable.
2.8.2 By medium term
Medium-term data were available from six studies, where 5 suicides
occurred in 464 people treated with ICM, compared with 3 suicides
in 465 people treated with non-ICM. There were no significant
diIerences in the suicide rate between groups (n = 929, 6 RCTs, RR
1.61, 95% CI 0.26 to 9.85; Analysis 2.8).
2.8.3 By long term
Long-term data were available from three studies, reporting 6
suicides occurring in 577 people treated with ICM, compared with 7
suicides in 575 people treated with non-ICM. These data confirmed
medium-term data on overall mortality and on suicide, with no
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significant diIerences in the suicide rate between groups (n = 1152,
3 RCTs, RR 0.88, 95% CI 0.27 to 2.84; Analysis 2.8).
2.8.4 By medium-term FUP (18 months)
Medium-term follow-up data on suicide mortality were available
from one study, reporting 1 suicide occurring in 127 people treated
with ICM, compared with 3 suicides in 124 people treated with non-
ICM. These data confirmed also in the follow-up period, medium-
and long-term data on overall mortality and on suicide, with no
significant diIerences in the suicide rate between groups (n = 251,
1 RCT, RR 0.33, 95% CI 0.03 to 3.09; Analysis 2.8).
2.9 Global state: 1. Leaving the study early
We found nine studies providing medium- and long-term data, but
not short-term data. When pooling data from sub-groups for two
time periods, we found data still significant, showing an advantage
for ICM in reducing the number of participants lost to follow-up (n =
2195, 9 RCTs, RR 0.72, 95% CI 0.52 to 0.99). Although heterogeneity
was reduced in comparison to the medium-term subgroup data,
heterogeneity was still substantial (Chi2 = 19.58; df = 8.0; P = 0.01;
I2 = 59%) (Analysis 2.9).
2.9.1 By medium term
Medium-term data from two trials showed no treatment eIect in
reducing number of participants lost to follow-up (n = 225, 2 RCTs,
RR 0.64, 95% CI 0.13 to 3.07), but these data presented a substantial
level of heterogeneity (Chi2 = 6.38; df = 1.0; P = 0.01; I2 = 84%). In
addition, there was inconsistency in the direction of eIect between
the two studies (Analysis 2.9).
2.9.2 By long term
Long-term data were available from seven studies, and we found
a significant advantage for ICM in reducing the number of
participants lost to follow-up (n = 1970, 7 RCTs, RR 0.70, 95% CI 0.52
to 0.95). DiIerent from the medium-term data, long-term subgroup
analyses did not show substantial heterogeneity (Chi2 = 9.88; df =
6.0; P = 0.13; I2 = 39%) (Analysis 2.9).
2.10 Global state: 2a. Average endpoint score (Health of the
Nation Outcome Scale (HoNOS), high = poor) - by long term
One study reported long-term data on global state assessed with
HoNOS. These data were skewed, but as the study sample size was
greater than or equal to 200 participants they entered the analysis.
Data failed to show a significant diIerence between interventions
(n = 239, 1 RCT, MD -0.40, 95% CI -1.77 to 0.97; Analysis 2.10).
2.11 Global state: 2b. Average endpoint score (HoNOS, high =
poor) - skewed data
We found skewed data describing global state with HoNOS by
medium and long term from one trial. These data tended to favour
the standard care group (Analysis 2.11).
2.12 Global state: 3a. Not compliant with medication - by
medium term
One study reported medium-term data for the binary outcome
'number of participants not compliant with medication'. There was
no significant diIerence between groups (n = 73, 1 RCT, RR 1.14,
95% CI 0.42 to 3.05; Analysis 2.12).
2.13 Global state: 3b. Compliance with medication - average
endpoint subscale score (Rating of Medication Influences
(ROMI)) - by long term
Long-term compliance scores assessed with the ROMI compliance
and non-compliance subscales were not significantly diIerent
(compliance subscale: n = 239, 1 RCT, MD 0.60, 95% CI -0.05 to 1.25;
non-compliance subscale: n = 239, 1 RCT, MD -0.60, 95% CI -1.63
to 0.43), although both subscale scores tended to favour ICM. Note
that for the compliance subscale (high = good), the right side of the
graph favours experimental (ICM).
2.13.1 Compliance subscale (high = good)
There was a single trial in this subgroup, with a total of 239 people.
There was no clear diIerence between ICM and non-ICM within this
subgroup (MD 0.6, 95% CI -0.05 to 1.25; Analysis 2.13).
2.13.2 Non-compliance subscale (high = poor)
There was a single trial in this subgroup, with a total of 239 people.
There was no clear diIerence between ICM and non-ICM within
this subgroup (MD -0.6, 95% CI -1.63 to 0.43). This subgroup had
important levels of heterogeneity (Chi2 = 0.0; df = 0.0; P = 0.0; I2 =
100%) (Analysis 2.13).
2.14 Global state: 3c. Compliance with medication - average
endpoint subscale score (ROMI, score 1 to 3, skewed data)
Medium- and long-term skewed data were available from one study
assessing compliance scores with the ROMI compliance and non-
compliance subscales. These data tended to favour standard care,
where participants had a higher level of compliance (Analysis 2.14).
2.15 Social functioning: 1. Contact with legal system (various
measurements)
We identified three studies relevant to this outcome, providing data
on diIerent time periods and diIerent measures.
2.15.1 By medium term - contact with the police
Medium-term data were available from one study reporting
'contact with the police'. We found no significant diIerence
between groups (n = 73, 1 RCT, RR 0.32, 95% CI 0.04 to 2.97; Analysis
2.15).
2.15.2 By long term - imprisoned
Long-term data were available on both binary outcomes of
'imprisoned' and 'arrested'. We found two studies reporting the
outcome 'imprisoned', and data failed to show any diIerence in the
number of people imprisoned (n = 959, 2 RCTs, RR 1.15, 95% CI 0.64
to 2.08; Analysis 2.15).
2.15.3 By long term - arrested
Only one study provided data on the outcome 'arrested'. Again,
there was no clear diIerence between groups (n = 251, 1 RCT, RR
0.87, 95% CI 0.53 to 1.42; Analysis 2.15).
2.15.4 By medium-term FUP (18 months) - imprisoned
We found one trial relevant to this subgroup, with a total of 251
participants. There was no clear diIerence between ICM and non-
ICM within this subgroup (n = 251, 1 RCT, RR 1.07, 95% CI 0.47 to
2.44; Analysis 2.15).
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2.15.5 By long-term FUP (8.5 years) - imprisoned
There was a single trial in this subgroup. There was no clear
diIerence between ICM and non-ICM within this subgroup (n = 214,
1 RCT, RR 0.70, 95% CI 0.43 to 1.14; Analysis 2.15).
2.16 Social functioning 2. Employment status (various
measurements)
We identified two studies relevant to this outcome: one medium-
term study, reporting 'participant who spent more than one
day employed' and 'participants on paid employment', and one
long-term follow-up study, reporting 'unemployed'. Both medium-
term outcomes showed no significant diIerence between groups.
The long-term follow-up outcome confirmed medium-term data,
showing no significant diIerence between ICM and non-ICM in
employment status.
2.16.1 Spent > 1 day employed - by medium term
There was no significant diIerence between ICM and non-ICM in
increasing number of days of employment (n = 73, 1 RCT, RR 1.46,
95% CI 0.45 to 4.74; Analysis 2.16).
2.16.2 On paid employment - by medium term
There was no significant diIerence between ICM and non-ICM in
increasing the chance of being on paid employment by medium
term (n = 73, 1 RCT, RR 0.97, 95% CI 0.14 to 6.54; Analysis 2.16).
2.16.3 Unemployed - by long-term FUP (8.5 years)
There was no significant diIerence between ICM and non-ICM in
decreasing the risk of unemployment (n = 214, 1 RCT, RR 1.10, 95%
CI 0.91 to 1.34; Analysis 2.16).
2.17 Social functioning: 3a. Accommodation status (various
measurements)
We found two relevant studies for this outcome, one providing
data only for the outcome 'living in supported accomodation' by
medium term. The second study provided data for all of the other
outcomes, using diIerent measures to assess accomodation status.
The data failed to show significant diIerences between groups at
any time period.
2.17.1 By medium term - living in supported accommodation
The outcome 'living in supported accommodation' was only
available for the medium term from one study. Data failed to show
a significant diIerence between groups (n = 73, 1 RCT, RR 2.59, 95%
CI 0.75 to 9.01; Analysis 2.17).
2.17.2 By long term - homelessness
The outcome 'homelessness' was available for the long term from
one study. There were no significant diIerences between treatment
groups in the number of people who were homeless (n = 251, 1 RCT,
RR 0.69, 95% CI 0.34 to 1.38; Analysis 2.17).
2.17.3 By medium-term FUP (18 months) - living independently
One study provided data and failed to show a significant diIerence
between groups (n = 251, 1 RCT, RR 0.98, 95% CI 0.84 to 1.13; Analysis
2.17).
2.17.4 By medium-term FUP (18 months) - living in supported
accomodation
One study provided data and failed to show a significant diIerence
between groups (n = 251, 1 RCT, RR 0.83, 95% CI 0.38 to 1.77). This
subgroup had important levels of heterogeneity (Chi2 = 0.0; df = 0.0;
P = 0.0; I2 = 100%; Analysis 2.17).
2.17.5 By medium-term FUP (18 months) - homelessness
One study provided data and failed to show a significant diIerence
between groups (n = 251, 1 RCT, RR 0.84, 95% CI 0.47 to 1.49).
Heterogeneity was high for this outcome (Chi2 = 0.0; df = 0.0; P = 0.0;
I2 = 100%; Analysis 2.17).
2.17.6 By long-term FUP (8.5 years) - living in supported accomodation
One study provided data and failed to show a significant diIerence
between groups (n = 214, 1 RCT, RR 1.05, 95% CI 0.75 to 1.48; Analysis
2.17).
2.17.7 By long-term FUP (8.5 years) - homelessness
One study provided data and failed to show a significant diIerence
between groups (n = 214, 1 RCT, RR 0.92, 95% CI 0.55 to 1.53; Analysis
2.17).
2.18 Social functioning: 3b. Accommodation status - average
days per month in stable accommodation
The continuous outcome 'average days per month in stable
accommodation' was available for short, medium, and long term (2
RCTs). Data did not show significant diIerences between groups at
any time period.
2.18.1 By short term
One trial was relevant to this subgroup. We did not find evidence of
a clear diIerence between the two treatments (n = 203, 1 RCT, MD
-0.2, 95% CI -2.48 to 2.08; Analysis 2.18).
2.18.2 By medium term
One trial was relevant to this subgroup. We did not find evidence
of a clear diIerence between the two treatments (n = 203, 1 RCT,
MD 0.1, 95% CI -2.15 to 2.35). This subgroup had important levels of
heterogeneity (Chi2 = 0.0; df = 0.0; P = 0.0; I2 = 100%; Analysis 2.18).
2.18.3 By long term
We found two trials relevant to this subgroup (total n = 901). We did
not find evidence of a clear diIerence between ICM and non-ICM
within this subgroup (n = 901, 2 RCTs, MD -0.19, 95% CI -1.37 to 1.0;
Analysis 2.18).
2.19 Social functioning: 4a. Substance abuse - by long term
We found two relevant studies for this outcome. Long-term binary
data on 'substance abuse' diIerentiated between 'alcohol abuse'
and 'illicit drug abuse'. Data did not show significant diIerences
between groups with any measures.
2.19.1 Alcohol abuse
There was no diIerence between ICM and non-ICM in the number
of people abusing alcohol (n = 251, 1 RCT, RR 1.10, 95% CI 0.67 to
1.83; Analysis 2.19).
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2.19.2 Illicit drug abuse
There was no diIerence between ICM and non-ICM in the number
of people abusing illicit drugs (n = 251, 1 RCT, RR 1.08, 95% CI 0.69
to 1.71; Analysis 2.19).
2.19.3 Alcohol - remission from alcohol use disorder (Alcohol Use Scale
(AUS) score < 3)
Binary data on 'remission from alcohol use disorder' (defined AUS
score < 3) also did not show any significant diIerence between
groups by long term (n = 223, 1 RCT, RR 0.86, 95% CI 0.65 to 1.14;
Analysis 2.19).
2.20 Social functioning: 4b. Substance abuse - average endpoint
score (Substance Abuse Treatment Scale (SATS), low = poor)
Short-, medium-, and long-term continuous data were available
from one study, assessing substance abuse with the SATS. These
data failed to show a significant diIerence between groups at any
time period assessment.
2.20.1 By short term
We did not find evidence of a clear diIerence between ICM and non-
ICM within this subgroup (n = 203, 1 RCT, MD 0.07, 95% CI -0.28 to
0.42; Analysis 2.20).
2.20.2 By medium term
We did not find evidence of a clear diIerence between ICM and non-
ICM within this subgroup (n = 203, 1 RCT, MD -0.11, 95% CI -0.55 to
0.33; Analysis 2.20).
2.20.3 By long term
We did not find evidence of a clear diIerence between ICM and non-
ICM within this subgroup (n = 203, 1 RCT, MD 0.11, 95% CI -0.41 to
0.63). This subgroup had important levels of heterogeneity (Chi2 =
0.0; df = 0.0; P = 0.0; I2 = 100%; Analysis 2.20).
2.21 Social functioning: 4c. Alcohol - abuse (various
measurements, skewed data)
Skewed data were available from one study assessing 'days using
alcohol' and 'AUS score' by short, medium, and long term. Data
on 'days using alcohol' showed a trend towards a higher alcohol
consumption in the ICM group in each assessed time period. This
trend was confirmed by the short- and medium-term findings on
the AUS, where the ICM group rating had a worse outcome than the
non-ICM group; however, long-term data showed a worse outcome
in the non-ICM group (Analysis 2.21).
2.22 Social functioning: 5a. Average endpoint score (Life Skill
Profile (LSP), high = poor) - by long term
We found the LSP social functioning score did not favour one group
over the other by long term (n = 239, 1 RCT, MD 4.0, 95% CI -0.61 to
8.61).
2.23 Social functioning: 5b. Average endpoint score (Social
Functioning Questionnaire (SFQ), high = poor) - skewed data
Skewed data on SFQ social functioning scores showed equivocal
results by medium term, and a worse outcome in the ICM group by
long term. We entered these data as 'other' data (Analysis 2.23).
2.24 Mental state: 1a. General symptoms - average endpoint
score (various scales)
We identified two studies relevant to this outcome, assessing
'mental state: general symptoms' on two diIerent scales (BPRS-24
items and CPRS) at diIerent time periods. We found BPRS mental
state scores favoured neither group during the short-, medium-,
and long-term analysis. These data were confirmed by long-term
findings on the CPRS, where there was no significant diIerence
between ICM and non-ICM.
2.24.1 By short term (BPRS-24 items, high = poor)
The single trial in this subgroup showed no diIerence between the
two treatments (n = 203, 1 RCT, MD -0.65, 95% CI -3.99 to 2.69;
Analysis 2.24).
2.24.2 By medium term (BPRS-24 items, high = poor)
The single trial in this subgroup showed no diIerence between the
two treatments (n = 203, 1 RCT, MD -1.62, 95% CI -4.76 to 1.52;
Analysis 2.24).
2.24.3 By long term (BPRS-24 items, high = poor)
The single trial in this subgroup showed no diIerence between the
two treatments (n = 203, 1 RCT, MD -0.22, 95% CI -3.32 to 2.88;
Analysis 2.24).
2.24.4 By long term (CPRS, high = poor)
The single trial in this subgroup showed no diIerence between
the two treatments (n = 595, 1 RCT, MD 0.40, 95% CI -1.83 to 2.63;
Analysis 2.24).
2.25 Mental state: 1b. General symptoms - average endpoint
scores (various scales, skewed data)
Medium- and long-term skewed data from the Krawiecka Scale and
long-term skewed data from the BPRS scale could not be entered
into meta-analysis. These data, provided from two diIerent trials,
consistently suggested a better mental state outcome in the non-
ICM group.
2.26 Mental state: 2a. Specific symptoms: negative symptoms -
average endpoint score (SANS, high = poor) - by long term
Long-term continuous data on negative symptoms from one long-
term trial did not favour either group (n = 593, 1 RCT, MD 0.20, 95%
CI -2.32 to 2.72).
2.27 Mental state: 2b. Specific symptoms - average endpoint
scores (various scales, skewed data)
Skewed data were available on anxiety and depression symptoms
assessed with the Hospital Anxiety and Depression Scale (HADS)
anxiety and depression subscale by medium and long term. These
data, provided by the same study, were not consistent between
medium and long term, as they showed a better outcome in the ICM
group by medium term and a worse outcome in the ICM group by
long term, compared with the non-ICM group (Analysis 2.27).
2.28 Behaviour: 1. Specific behaviour (various measurements)
We found three relevant studies for this outcome, assessing the
outcome at diIerent time periods and using diIerent measures.
Data failed to show a significant diIerence between groups at any
time period for any outcomes.
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2.28.1 By medium term - harm to self or others
Medium-term data reporting 'harm to self or others' did not show a
significant diIerence between groups (n = 73, 1 RCT, RR 0.88, 95%
CI 0.4 to 1.9; Analysis 2.28).
2.28.2 By long term - self-harm
We found two trials relevant to this subgroup. There was no clear
diIerence between ICM and non-ICM within this subgroup (n = 959,
2 RCTs, RR 1.00, 95% CI 0.69 to 1.46; Analysis 2.28).
2.28.3 By long term - injury/assault to others
We found two trials relevant to this subgroup. There was no clear
diIerence between ICM and non-ICM within this subgroup (n = 959,
2 RCTs, RR 1.09, 95% CI 0.85 to 1.4; Analysis 2.28).
2.28.4 By medium-term FUP (18 months) - self harm
There was a single trial in this subgroup. We did not find evidence
of a clear diIerence between the two treatments (n = 251, RR 0.85,
95% CI 0.44 to 1.67; Analysis 2.28).
2.28.5 By medium-term FUP (18 months) - injury/assault to others
There was a single trial in this subgroup. We did not find evidence
of a clear diIerence between the two treatments (n = 251, 1 RCT, RR
1.35, 95% CI 0.87 to 2.1; Analysis 2.28).
2.28.6 By long-term FUP (8.5 years) - self harm
There was a single trial in this subgroup. We did not find evidence
of a clear diIerence between the two treatments (n = 214, 1 RCT, RR
0.81, 95% CI 0.51 to 1.27; Analysis 2.28).
2.28.7 By long-term FUP (8.5 years) - injury/assault to others
There was a single trial in this subgroup. We did not find evidence
of a clear diIerence between the two treatments (n = 214, 1 RCT, RR
0.95, 95% CI 0.83 to 1.09; Analysis 2.28).
2.29 Quality of life: 1. Average endpoint score (various scales)
We found three studies assessing quality of life with three diIerent
scales (LQoLP, MANSA, QOLI) at diIerent time periods. There were
no significant diIerences between ICM and non-ICM in any of
these measures at any time period. Data on QOLI scores were
available by short and medium term from one study. Long-term
data were available from three diIerent studies measuring quality
of life with three diIerent scales, therefore not entering the analysis
together. No results showed any significant diIerence between
groups. Note that for this outcome the right graph label favours ICM
(experimental group).
2.29.1 By short term - overall life satisfaction (QOLI, high = better)
One study provided data, showing no diIerence between groups (n
= 203, 1 RCT, MD -0.02, 95% CI -0.43 to 0.39; Analysis 2.29).
2.29.2 By medium term - overall life satisfaction (QOLI, high = better)
One study provided data, showing no diIerence between groups (n
= 203, 1 RCT, MD -0.04, 95% CI -0.43 to 0.35; Analysis 2.29).
2.29.3 By long term (LQoLP, high = better)
One study provided data, showing no diIerence between groups (n
= 526, 1 RCT, MD 0.03, 95% CI -0.10 to 0.16; Analysis 2.29).
2.29.4 By long term (MANSA, range 1 to 7, high = better)
One study provided data, showing no diIerence between groups (n
= 166, 1 RCT, MD 0.10, 95% CI -0.19 to 0.39).
2.29.5 By long term - overall life satisfaction (QOLI, high = better)
One study provided data, showing no diIerence between groups (n
= 203, 1 RCT, MD 0.1, 95% CI -0.25 to 0.45; Analysis 2.29).
2.30 Participant satisfaction/need: 1. Average endpoint scores
(various scales) - by long term
Long-term data were available from one study, assessing
participant need with CAN, and participant satisfaction with health
service scale. There were no significant diIerences between groups
as assessed with the two scales.
2.30.1 Patient need: CAN (high = poor)
One study provided data, showing no diIerence between groups (n
= 585, 1 RCT, MD -0.29, 95% CI -0.69 to 0.11; Analysis 2.30).
2.30.2 Patient Satisfaction With Health Services (high = poor)
One study provided data, showing no diIerence between groups (n
= 490, 1 RCT, MD -0.4, 95% CI -1.25 to 0.45; Analysis 2.30).
2.31 Participant need: 1. Average endpoint scores (various
scales, skewed data)
One study provided data suggesting a diIerence between
interventions in participant need as assessed with CAN scores,
showing a worse outcome in the ICM group in the medium and long
term, but these data were skewed. A second study provided data on
participant need, assessed with CANSAS by long term. These data
failed to show any diIerence between groups. We have presented
these data as 'other' data (Analysis 2.31).
2.32 Participant satisfaction: 1. Average endpoint scores (CSQ-
modified, high = better, skewed data) - by long term
Skewed data from a diIerent study suggested long-term better
satisfaction with treatment for the ICM group (data assessed with
CSQ). We have reported these data as 'Other' data, (Analysis 2.32).
2.33 Costs: 1. Direct costs of psychiatric hospital care (skewed
data)
Costs were assessed measuring 'direct costs of psychiatric hospital
care' and 'direct cost of all care'. No data were available on 'direct
healthcare costs'.
Skewed data on direct costs of psychiatric hospital care were
available from two studies by medium and long term. Medium-
and long-term data from one study found no significant diIerence
between groups, whilst the second long-term study data found
costs were significantly lower for the ICM group. The latter study
was small (Quinlivan-California 1995, n = 60), where the former one
was larger (Harrison-Read-UK 2000, n = 193). We have presented
these data as 'Other' data, (Analysis 2.33).
2.34 Costs: 2a. Direct costs of all care - by long term (2 years) -
unit cost GBP, fiscal year 1997/98
Direct costs of all care were available from one study reporting
skewed data (UK700-UK 1999), but with a sample size greater
than 200. There was no significant diIerence between groups for
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reducing direct costs of all care (n = 667, 1 RCT, MD 77.00, 95% CI
-66.63 to 220.63), but findings showed a trend suggesting greater
cost in the ICM group. This trend suggested a cost increase of GBP
77 per person per month by long term, referred to as fiscal year
1997/98.
2.35 Costs: 2b. Direct costs of all care (skewed data) - by medium
term
One study (n = 58) reported skewed data on the same outcome
(direct costs of all care) (Johnston-Australia 1998). This data set
showed no significant diIerences between groups by medium
term, substantially confirming data by long term. We have reported
these data as 'Other' data, (Analysis 2.35).
2.36 Costs: 3. Total costs of care per patient - unit cost GBP)
Total costs of care were available from two studies reporting
skewed data (REACT-UK 2002; UK700-UK 1999), but with a sample
size greater than 200. Total costs of care included direct and indirect
costs (i.e. informal care, prison, court, probation oIicer, police
custody, etc.).
2.36.1 By 24 months, fiscal year 1997/1998
There was no significant diIerence between groups for reducing
total costs of care (n = 667, 1 RCT, MD 1849.00, 95% CI -1598.23 to
5296.23), but findings showed a trend suggesting greater cost in the
ICM group (Analysis 2.36).
2.36.2 By 18 months, fiscal year 2003/2004 (GBP 1 = USD 1.58)
There was no significant diIerence between groups for reducing
total costs of care (n = 243, 1 RCT, MD 4031.00, 95% CI -2724.13 to
10,786.13), but findings showed a trend suggesting greater cost in
the ICM group (Analysis 2.36).
3. SENSITIVITY ANALYSES
As anticipated in the Methods section (see Methods, Sensitivity
analysis), we performed the following sensitivity analyses.
3.1 Implication of randomisation
3.1.1 COMPARISON 1: INTENSIVE CASE MANAGEMENT versus
STANDARD CARE
All of the included studies were described as randomised, and none
were described in a way as to imply randomisation, therefore we
did not include any trials in a sensitivity analysis.
3.1.2 COMPARISON 2: INTENSIVE CASE MANAGEMENT versus NON-
INTENSIVE CASE MANAGEMENT
All of the included studies were described as randomised, and none
were described in a way as to imply randomisation, therefore we
did not include any trials in a sensitivity analysis
3.2 Standard care caseload is over 20
3.2.1 COMPARISON 1: INTENSIVE CASE MANAGEMENT versus
STANDARD CARE
Among studies reporting on our primary outcomes, only six studies
reported the ratio of staI to participants, and for each study it
was greater than 1:20 (Bond-Chicago1 1990; Bond-Indiana1 1988;
Herinckx-Oregon 1996; Jerrell-SCarolina1 1991; OPUS-Denmark
1999; Sytema-Netherlands 1999).
When we entered these studies (where standard care group
caseload was greater than 20) in the analysis, the first primary
outcome 'average days per month in hospital' showed a
significantly favourable eIect in the ICM group in reducing the
length of hospitalisation (n = 951, 7 RCTs/study centres, MD -2.01,
95% CI -3.36 to -0.67), but heterogeneity was substantial (I2 = 70%,
P = 0.003). These findings confirm those obtained when all studies
were entered in the analysis, regardless of caseload in the standard
care comparison group.
The second primary outcome 'not remaining in contact with
psychiatric services' showed that participants in the ICM group
were significantly less likely to lose contact with psychiatric
services than participants in the standard care group by medium
term, long term, and overall (n = 931, 4 RCTs, MD 0.38, 95% CI
0.23 to 0.63), but heterogeneity was substantial (I2 = 67%, P =
0.03). These findings confirm those obtained when all studies were
entered in the analysis, regardless of caseload in the standard care
comparison group, however data in the sensitivity analysis showed
a substantial level of heterogeneity not present when all studies
were entered in the analysis.
3.3 Assumptions for lost binary data
3.3.1 COMPARISON 1: INTENSIVE CASE MANAGEMENT versus
STANDARD CARE
No assumptions needed to be made regarding people lost to follow-
up for the primary binary outcome 'not remaining in contact with
psychiatric services' for this comparison, therefore we did not
include any trials in a sensitivity analysis.
3.3.2 COMPARISON 2: INTENSIVE CASE MANAGEMENT versus NON-
INTENSIVE CASE MANAGEMENT
For the second comparison, we needed to make assumptions
regarding people lost to follow-up for the primary binary outcome
'not remaining in contact with psychiatric services' for one trial
(REACT-UK 2002). When we compared the findings of the outcome
when we used our assumption to when we used completer data
only, results did not diIer substantially.
3.4 Assumptions for lost continuous data (for meta-regression)
We undertook sensitivity analysis, removing 13 out of 52 trials
originally entering meta-regression. These were trials where
primary outcome standard deviation was imputed (see Table
3). Meta-regression was therefore run on the remaining pool of
39 non-imputed studies. Results no longer reached significance
for both variables 'organisation fidelity subscore' and 'baseline
hospital use' as P is at trend ˜ 0.07 ('organisation fidelity subscore':
regression coeIicient -0.2, 95% CI -0.48 to 0.02, P = 0.067; 'baseline
hospital use': regression coeIicient -0.18, 95% CI -0.39 to 0.02, P =
0.077). Removing a high-influence outlier (Rosenheck-USA-NP (C)),
significance returns for the eIect of 'baseline hospital use' (-0.26,
95% CI -0.51 to -0.01, P = 0.046), but not for 'organisation fidelity'.
When combining the two variables within the model ('organisation
fidelity subscore' and 'baseline hospital use'), the pattern of results
did not change for the non-imputed studies.
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D I S C U S S I O N
Summary of main results
1. COMPARISON 1: INTENSIVE CASE MANAGEMENT versus
STANDARD CARE
1.1 Service use
1.1.1 Service use: Average number of days in hospital per month - at
about 24 months
ICM does seem to reduce length of hospitalisation when compared
with standard care (by 0.86 day per month over 24 months).
However, these data were low quality and from a heterogeneous
analysis; when certain studies are removed from the analysis, the
now-homogeneous result suggests that the saving is in the region
of 0.6 days per month. We were unsure which of the two figures was
the most reliable, but in any event trial findings suggest a saving
of time in hospital per person of between about 7 and 10 days in
hospital per year.
What is important, however, is that there was a high duration of
hospital stay for these people in the two previous years (averaging
6 days per month). This was higher than for those in the ICM
versus non-ICM comparison (averaging 3.4 days per month), which
found no diIerence between groups (see Figure 10). The impressive
saving of time in hospital for ICM was greater than that of standard
care, but the saving in standard care was also considerable
(absolute decline for ICM was about 3 days, standard care was 1.8
days). Well-organised standard care, for people with what would
seem to be a history of considerable periods spent in hospital over
the last 24 months, does seem to reduce the time in hospital for the
ensuing two years. However, ICM adds more than an extra day to
that gain.
The meta-regression is a tool of limited power, employed on weak
data. However, the results were in keeping with the results of one
other review (Burns 2007), which suggests that the gain of ICM was
not so much linked with the total fidelity score, the staI subscale, or
the comparison group. It did suggest a link with the organisational
subscore of the Index of Fidelity to Assertive Community Treatment
(IFACT) scale (0.36 day per month out of hospital gained by each
point increase of this subscore). It also suggested that ICM eIect
is linked to length of hospitalisation during the previous two years
(0.2 day per month out of hospital gained by each day increase in
the day in hospital per month during previous two years).
In other words, this means that:
• if the ICM team ratio staI:client is less than 1:20 (calculated
dividing the number of active clients on the caseload by the
number of full-time equivalents of direct service staI on the
team), then it makes no diIerence how much the caseload is
lower than 1:20;• the ICM team size does not matter (calculated as the number of
full-time clinical staI equivalents, as defined earlier);• the availability of a psychiatrist on the team is not pivotal; and/or• the availability of a nurse on the team is not pivotal.
It also suggested that gains in IFACT scores can reduce average
hospital stay. McGrew 1994 and McGrew 1995 suggest that gain can
be mediated by:
• ensuring that the ICM team performed the role of primary
therapist for the client (the primary therapist role designates
the person within the local mental health system with primary
clinical and record keeping (e.g. treatment plans) responsibility
for the client);• the ICM team's oIices being located in a separate building from
the parent agency's main oIices (i.e. usually away from the
hospital site);• the ICM team sharing caseloads (rated as the degree to which
all staI members on the team had contact with all clients on
a regular basis, e.g. through rotation), in contrast to individual
caseloads in which specific staI workers are responsible for
specific clients;• the ICM team meeting as a group each weekday to discuss their
entire caseload;• the ICM team’s supervisor devoting at least half time to client
contacts, either cojointly during supervision of team members,
or individually as part of his or her duties as a member of the
team;• the ICM team providing 24-hour direct access to the team (if
access to the ICM team was triaged through the community
mental health centre emergency 24-hour on-call service,
intermediate score of 0.5 is obtained, therefore the advantage
on decreasing days in hospital per month would be halved (-0.2
days in hospital per month)); and/or• the ICM team serving clients without any expectation of
transferring them to another programme.
1.1.2 Service use: Average number of days in hospital per month – by
follow-up
When the same outcome ‘average number of days in hospital per
month’ was assessed on medium- and long-term follow up, data did
not confirm the eIect of ICM in reducing length of hospitalisation
assessed by 24 months. These data were provided by one large
study (n = 547), where during the follow-up period all participants
received the control intervention (standard care). These data are
suggestive of a loss of eIect on reducing number of days in hospital
over time, if ICM intervention is discontinued.
1.1.3 Service use: Not remaining in contact with psychiatric services
Overall, we found ICM to be better than standard care for retaining
people in psychiatric services (n = 1633, 9 RCTs, RR 0.43, 95% CI
0.30 to 0.61). However, this eIect was not seen for the short-term
analysis (n = 95, 1 RCT, RR 0.54, 95% CI 0.28 to 1.05), although
confidence intervals were compatible with an eIect favouring ICM
(P = 0.07). Medium-term findings did suggest an overall eIect
of ICM being better in reducing loss to follow-up to psychiatric
service contact (n = 1063, 3 RCTs, RR 0.51, 95% CI 0.36 to 0.71).
In the longer term, this same eIect was heterogeneous, due to an
outlying finding of a single study (Herinckx-Oregon). This trial had
a peculiar definition for this outcome, which was diIerent from the
other studies. In Herinckx-Oregon 'not remaining in contact with
psychiatric services' did not include refusing re-interview, moving
out, and death, whereas for the other trials it did. If we exclude
Herinckx-Oregon, and only five long-term trials are retained in the
analysis, then ICM appears to be eIective in preventing loss to
follow-up (n = 475, 5 RCTs, RR 0.27, 95% CI 0.11 to 0.66).
The result of a better retention in care for the ICM group strengthens
the relevance of the result for the first primary outcome (i.e. ICM
decreasing time in hospital). ICM decreases days of hospitalisation
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in a severe mentally ill population where patients are kept in close
contact with services, therefore the ICM eIect on reducing days in
hospital might not be dissipated by a higher rate of loss to follow-
up.
1.1.4 Service use: Use of hospital
We found that ICM reduced the number of people admitted to
hospital more than standard care, at least in the medium term
(n = 1303, 5 RCTs, RR 0.85, 95% CI 0.77 to 0.93). Skewed data
for 'average number of admissions in the medium term' were
in accordance with these first findings, whilst skewed data for
'average number of admissions in the long term' failed to show
any trend in the eIect of intervention. Synthesis of short- and-long
term studies in this outcome produced heterogeneous findings.
The short-term data were from only two studies, and when the most
positive one is removed (Bond-Indiana1), the finding becomes
clearly null. The long-term data was from 11 trials; removing the
three clearly outlying studies, Curtis-New York, Macias-Utah, and
Test-Wisconsin, also restores homogeneity and moves the finding
squarely towards the null. One small study provided inconclusive
data on the unplanned admission to the emergency department,
an outcome describing only one option of psychiatric admission;
for this reason, and because these data come from a single small
study, we considered this finding weak.
Overall, the eIect of ICM on admission to hospital is not strong.
Whereas the time spent in hospital does seem to be less if allocated
ICM - at least for those whose baseline use of hospital was high -
the number of admissions is not greatly changed. Admissions are
shorter, but not by much, if any less frequent.
1.1.5 Service use: Use of services outside of mental health provision
More outcomes were available describing ‘use of services outside
of mental health provision’. Studies did not report a convincing
diIerence in 'use of emergency room', 'rate of use of emergency
room', ‘use of day hospital care’, or ‘rate of outpatient visits’. Only
‘rate of home visits’ was higher for the ICM group. However, we did
not consider these data very robust, as they were based on single
studies providing data per each outcome or on skewed data that
were very diIicult to interpret.
1.2 Adverse event
1.2.1 Death - all cause and suicide
This review did not find any diIerence in mortality either due to
all causes or to suicide in the short, medium, and long term and in
medium- and long-term follow-up. Although death is a rare adverse
event, the duration of the longer studies (˜ 24 months) means that
some deaths would have been expected to occur and did (3.2%
ICM versus 3.8% standard care). This diIerence was not statistically
significant, but is homogeneous, and suggests a trend in terms
of risk reduction (RR 0.84, 95% CI 0.48 to 1.47), partly confirmed
in one large study on medium-term follow-up (RR 0.59, 95% CI
0.22 to 1.61). The same trend was confirmed in the ICM eIect
on mortality due to suicide by long term (suicide rate 1.3% ICM
versus 2% standard care). Again, this diIerence was not statistically
significant, but is homogeneous, and stronger compared to death
due to all causes. If the suicide risk is in actuality so much reduced
(RR 0.68, 95% CI 0.31 to 1.51), this would be a very important
finding, although the quality of the evidence is low (Summary of
findings table 1).
Few things have changed the outcome of death for people with
schizophrenia. If, for this group of people, set in the context of a
standard care with a high baseline risk of admission, ICM could
decrease death, and by so much, this would be a strong argument
in favour of ICM. These data on suicide are the findings of nine
studies with only a total number of participants of 1456 and low-
quality evidence. A single larger trial might be able to confirm this
important suggestion.
1.3 Global state
1.3.1 Global state: Relapse
No data were provided for the important outcome of relapse.
1.3.2 Global state: Leaving the study early
ICM data regarding number of participants lost to follow-up for the
short term were heterogeneous. However, we found ICM to be more
advantageous than standard care in reducing rate of lost to follow-
up both in the medium term (n = 1699, 8 RCTs, RR 0.60, 95% CI
0.51 to 0.70) and long term (n = 1798, 13 RCTs, RR 0.68, 95% CI
0.58 to 0.79, low-quality evidence). The impression remains that
ICM, and again with the proviso that these findings may apply most
specifically to a group with high baseline admission, holds on to
people more tightly across time. This may not significantly lower
admission rate, but loss to follow-up and length of admission may
decrease. Overall, these data were not of high quality (Summary of
findings table 1), but there is a belief that ICM is advantageous over
standard care for the higher-risk groups. For example, in groups
with only 10% loss to follow-up across the long term, only 3 more
people are not lost for every 100 given ICM. However, with more
realistic figures of 50% loss to follow-up, this figure rises to 15 more
people out of every 100 who are kept in care compared with those
allocated standard care.
1.3.3 Global state: Global Assessment of Functioning Scale (GAF)
Short-term studies indicated a better improvement in GAF endpoint
score for participants in the ICM group compared with those
allocated standard care (short term: n = 797, 4 RCTs, MD 2.07, 95%
CI 0.28 to 3.86). This eIect was confirmed by the long-term data (n
= 818, 5 RCTs, MD 3.41, 95% CI 1.66 to 5.16). Whilst this is favourable
for those allocated ICM, we are unsure of the clinical meaning of
these data, as changes of two or three points on a scale that runs to
100 does not seem to be much. We have found no reference to the
clinical meaning of such small changes.
1.3.4 Global state: Not compliant with medication
Only one long-term study provided data on compliance with
medication, and these indicated a higher compliance level in those
allocated to ICM compared with those in the standard care group (n
= 71, 1 RCT, RR 0.35, 95% CI 0.15 to 0.81). Again, this is an important
finding and should be replicated. We are surprised that such easily
recorded data are not reported in more studies.
1.4 Social functioning
1.4.1 Social functioning: Contact with legal system
Studies measuring contact with legal system used diIerent
definitions over varying time periods, which makes interpretation
diIicult. There was no real suggestion that ICM either increases
or decreases the measures of this outcome. The ‘arrested’ and
‘imprisoned’ outcomes were the only ones with some consistency.
They showed no significant diIerence in the intervention eIect
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between groups. The ‘contact with the police’ outcome findings
were from only one study and were not significant in the short term,
but became significantly diIerent in the medium term (favouring
the ICM group). Overall, the legal outcomes were not convincing,
and there is a need for more consistency in approach to this area
of research.
1.4.2 Social functioning: Employment status
This review did not reveal any significant diIerence between
ICM and standard care in employment status, as measured by
diIerent outcomes. Medium-term findings on ‘number of people
not competitively employed’ were based on only one trial. Both
medium- and long-term data reporting ‘not employed’ tended to
favour ICM, although data were heterogeneous, and overall the
quality of the evidence was very low (Summary of findings table
1). Data from one large trial on medium- and long-term follow-up
failed to show any diIerence between interventions. Again, this is
an important outcome for which more data are needed before firm
conclusions can be drawn.
1.4.3 Social functioning: Accommodation status
Data on the outcome 'homelessness' were not convincing by short,
medium, or long term, but were mostly derived from just a few
trials.
The outcome 'not living in stable accommodation' was scarcely
reported, available from only one long-term study.
Regarding the 'not living independently’ outcome, we found that
people allocated to ICM were more likely to live independently
compared with those allocated standard care - in the medium term,
and even more so in the long term. This is another important
finding of this review. If the risk of not living independently is
in actuality substantially reduced by this ICM package (18% ICM
versus 26% standard care, long term), at least for people with high
baseline risk of admission, and if this is a desired outcome for this
particular client group, then, combined with the other moderate
but cumulative advantages, this finding further highlights the
advantage of ICM over standard care.
Only one large study reported the outcome ‘days in supported
house’, assessing it by long term and by medium- and long-term
follow-up. The advantage for standard care reported on medium-
term follow-up was not confirmed on long term or on long-term
follow-up, failing to show a significant trend of eIect.
1.4.4 Social functioning: Substance abuse
Only one study (n = 547) reported usable binary data for alcohol
and drug abuse. A long-term single study failed to show any
advantage for participants treated with ICM compared to standard
care. Skewed data were supplied by Sytema-Netherlands (n = 81),
with Dartmouth Assessment of Lifestyle Interviewscores tending to
favour the ICM group for both drug use and alcohol consumption.
However, we are unsure of the clinical meaning of these scores.
Morse-Missouri3 (n = 103) reported skewed data on days substances
were used per month. There was no indication of any diIerence
between groups. There is currently no compelling evidence that
ICM aIects abuse of substances or alcohol.
1.4.5 Social functioning: Various scales
Few studies reported usable data for social functioning scale, and
outcome data were complicated by the use of diIerent scales
within single studies, making meta-analysis impossible. In this
confusion of evidence, we see no advantage for participants treated
with ICM compared to those treated with standard care in terms
of social functioning measures. This does not seem to concur with
other findings on independent living. It could be that the fine-grain
measures of functioning are picking up subtle parameters of social
function not eIected by the package. It could also be that the
measures are not sensitive enough to broad and important issues
of social function.
1.5 Mental state
Rating of mental state in these trials illustrates the confusion of how
such symptoms are recorded in randomised studies. Timings of use
of the scales diIer, and the findings are so problematic to interpret
from the clinical perspective that we are leP to make safe but bland
conclusions.
No data were provided for the important outcome 'mental state:
not improved to an important extent', and there does not seem to
be any compelling evidence that, in this group of people, set where
the baseline risk of admission is high, ICM in actuality substantially
aIects a person's mental state.
1.6 Behaviour: self harm
Based on findings from the larger of the studies, self harm was not
convincingly reduced by use of the ICM model. The mortality finding
discussed above, however, does seem to suggest that ICM reduced
the risk of death. These findings are a little at odds with each other,
although not entirely, providing all the more reason to continue to
research into this area for these, the simplest of outcomes.
1.7 Quality of life
Few studies reported relevant outcomes. Short- and medium-term
outcome data were complicated by the use of diIerent scales
within single studies, making meta-analysis impossible. We found
that one short-term study (n = 125) showed a better quality of life in
the ICM group on the Lehman's Quality of Life Interview scale, but
more medium- and long-term data failed to show any advantage
for participants treated in the ICM group compared with standard
care. The few skewed data seem to concur with the impression that
for quality of life measures used in trials, ICM confers no advantage
over standard care.
1.8 Participant satisfaction/need
Participants administered ICM were more satisfied with their
treatment compared with those administered standard care in
these trials. These findings were based on data that were quite
strong (short term, n = 61; medium term, n = 500; long term,
n = 423). More satisfaction with care could enhance medication
compliance, the will to keep in services, housing status, and a host
of other variables. We are leP doubting the size and meaning of the
overall finding. We are unsure how encouraged we should be that
these packages of care deliver an average of a two- to three-point
improvement in the Client Satisfaction Questionnaire.
Several of the smaller trials did measure need and unmet need.
These skewed data were diIicult to interpret, but did not seem to
convincingly favour either of the groups.
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1.9 Costs
With respect to cost of inpatient psychiatric care, ICM was
consistently superior to standard care for the outcome 'direct
costs of psychiatric hospital care', suggesting a saving of money
per person of about USD 144 per month (fiscal year 1990). Two
studies taking part in the same multicentre trial provided these
data. Skewed data were contradictory, neither showing a trend
confirming nor disputing these data.
We found no diIerence between groups with respect to direct
healthcare costs (where skewed data were contradictory and
provided by only two small studies). Results on ‘direct costs of all
care’ were inconcludent, as data were skewed and diIerent trials
reported contradictory eIects.
2. COMPARISON 2: INTENSIVE CASE MANAGEMENT versus NON-
INTENSIVE CASE MANAGEMENT
2.1 Service use
2.1.1 Service use: Average number of days in hospital per month - at
about 24 months
Moderate quality evidence from this review showed no significant
advantage of ICM in reducing the average length of hospitalisation
when compared with non-ICM. This could be an important finding,
and we see no good reason not to trust this result. The implications
from this finding could be that if services are already providing
non-ICM, there is no point in investing in further intensiveness.
We currently know of no review comparing non-ICM with standard
care and reporting relevant outcomes. This should be undertaken.
It is possible that there are other features of ICM that may
improve outcome, but we are not stipulating that we should
specifically investigate for these. What was diIerent between the
two sets of comparisons was the baseline risk of admission in
the previous two years (about 6 days per month for Comparison
1 versus about 3.4 days per month for Comparison 2). This was
highlighted by the meta-regression process. This generates further
hypotheses. Baseline hospital risk is linked to service provision,
service culture, severity of illness, and other issues. We do not have
the sophistication of data to investigate these. What we are leP with
is the possibility that in a situation where people with severe mental
illness have a duration in hospital of less than 4 days per month
in the two years preceding the ICM package of care, the increased
intensity of approach may not be justified.
2.1.2 Service use: Average number of days in hospital per month – at
follow-up
Data on medium- and long-term follow-up from one study (n =
237) failed to show a significant advantage of ICM in reducing
the average length of hospitalisation when compared with non-
ICM. During the follow-up period participants could remain in the
originally allocated intervention or be transferred to the control
one. These data on follow-up confirmed the data at 24 months
discussed above.
2.1.3 Service use: Not remaining in contact with psychiatric service
We found ICM to be more eIective in increasing the number
of people retained in contact with psychiatric service in the
medium term, but we did not consider these findings robust as
they were based only on one small trial (n = 73). We found no
diIerence between interventions in the long term, but data were
heterogeneous. Overall, when pooling medium- and long-term
data, we found no advantage for participants treated with ICM
compared to non-ICM for better retention in psychiatric service
but, again, these data were heterogeneous, and we found no
obvious explanation for the heterogeneity (n = 1255, 4 RCTs).
Medium-term (18 months) follow-up data showed a trend favouring
ICM in increasing the number of people retained in contact with
psychiatric service.
2.1.4 Service use: Admissions
We found no diIerence between groups in the risk of being
admitted to hospital in the long term (n = 1132, 3 RCTs, RR 0.91,
95% CI 0.75 to 1.12). These findings were confirmed by data from
one long-term study (n = 678) and one medium-term study (n = 68)
on the average number of admissions, where no advantage was
shown between treatments in reducing number of admissions in
the long term (moderate-quality evidence, Summary of findings 2)
or in the medium- and long-term follow-up. Data on frequency of
admission and on length of hospitalisation therefore consistently
show no eIect of ICM for both outcomes.
2.2 Adverse events
2.2.1 Death due to all causes and to suicide
This review did not find provide strong evidence on mortality rate
either due to all causes or to suicide in the short, medium, and long
term, or in the medium- and long-term follow-up. These data are
quite informative, especially those from long-term studies, where
the study length might balance the rarity of the event in detecting
any diIerence between intervention eIects. Some deaths occurred
in the long-term studies (2.0% ICM versus 2.2% non-ICM) (n = 1634,
5 RCTs, RR 0.90, 95% CI 0.46 to 1.75). This impression was confirmed
for studies reporting suicide only, as shown in Summary of findings
2, where low-quality evidence also showed no diIerence between
groups.
2.3 Global state
2.3.1 Global state: Relapse
No data were provided for this important outcome.
2.3.2 Global state: Leaving the study early
No studies were available for the short-term outcome.
Data showed no diIerence between interventions by the medium
term, but these data were not strong as they came from a small
sample of two studies (n = 225) and were heterogeneous with
inconsistency of eIect.
We found ICM to be more advantageous than non-ICM in reducing
rate of lost to follow-up by the long term.
Overall, pooling studies from subgroups for two time points,
we found heterogeneous data, but substantially confirming
homogeneous data obtained by long term. ICM was confirmed to
be more advantageous than non-ICM in reducing rate of lost to
follow-up (n = 2195, 9 RCTs, RR 0.72, 95% CI 0.52 to 0.99). If we
consider this outcome as proxy of a better retention in care, it
might overcome the inconsistency of data on 'number of people
remaining in contact with psychiatric service' (see Discussion - 2.1.3
Service use: Not remaining in contact with psychiatric service). ICM
therefore seems to positively reduce number of lost to follow-up,
but does not aIect length and frequency of admission. These data
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were of low quality (Summary of findings 2), but it appears that
ICM has an advantage over non-ICM for the higher-risk groups. For
example, in groups with only 10% loss to follow-up across the long
term, only three more people are not lost for every 100 given ICM.
However, with a more realistic figure of 50% loss to follow-up, this
rises to 14 more people out of every 100 are kept in care compared
with those allocated standard care.
2.3.3 Global state: Health of the Nation Outcome Scale (HoNOS)
Not enough studies were available to run a meta-analysis on data
derived from the HoNOS or from any other scales assessing global
state. Considering the comprehensiveness of the scale assessment
of other outcomes, it appears that global state as an outcome is
under-recorded by trialists, despite being informative and relevant
from a clinical point of view.
2.3.4 Global state: Compliance with medication
As for the previous outcome, not enough studies were available
to run a meta-analysis. Again, a very meaningful outcome from a
clinical point of view is neglected.
2.4 Social functioning
2.4.1 Social functioning: Contact with legal system
As for studies included in Comparison 1, studies measuring contact
with legal system used diIerent definitions over a variety of time
periods. This makes interpretation diIicult. In addition, only a
few studies addressed this outcome (three trials overall). There
was no real suggestion that ICM either increases or decreases the
measures of this outcome. The 'imprisoned' outcome was the only
one with some consistency, showing no significant diIerence in the
intervention eIect between groups. The 'contact with the police'
and 'arrested' outcome findings were from only one study each
and were not significant in the short and long term, respectively.
Overall, the legal outcomes were not convincing, and there is a need
for more consistency in approach to this area of research.
2.4.2 Social functioning: Employment status
Data available for this outcome were substantially inconclusive,
reported by only one small trial (n = 73). This trial measured
employment status according to two diIerent definitions: 'spent
more than one day employed' and 'on paid employment'. Both
findings were not significant in the medium term, and overall
quality of evidence was low (Summary of findings 2). One
larger study (n = 214) provided data on long-term follow-up
(8.5 years aPer the randomised allocation was broken), showing
no diIerence between the two groups. These data did not add
much to the understanding of the impact of ICM on employment
status compared to non-ICM. Again, this is an important outcome
underestimated in the current studies, and at this stage more data
are needed before firm conclusions can be drawn.
2.4.3 Social functioning: Accommodation status
Available data on this outcome were surprisingly scarce, as
this outcome was reported in just four studies. Two studies
described this outcome with binary data: one measuring just
'living in supported accommodation' by medium term, the second
measuring 'living in supported accommodation', 'homelessness',
and ‘living independently’ by long term and on follow-up. All data
on diIerent measures at diIerent time periods were based on only
one trial and they were not significant.
Two more studies described this outcome with continuous data
on ‘average days per months in stable accomodation’, again failing
to show any diIerence between the two groups. Findings seemed
to point at a non-significant diIerence in eIects of intervention,
although these findings were inconclusive due to the scarcity of
available data, despite being easily recorded and very relevant from
the perspective of a community-based service.
2.4.4 Social functioning: Substance abuse
Only two studies measured substance abuse, and they described
this outcome as binary and continuous measures, and not
consistently across studies. This makes interpretation diIicult
and findings unconvincing, as a single study entered each
measurement, and we therefore could not carry out any meta-
analysis. As far as we could assess, there was no indication of any
long-term diIerence between groups in 'number of people abusing
alcohol', 'number of people abusing illicit drug', or 'remission from
alcohol use disorder' (defined as Alcohol Use Scale score less
than 3). These findings were confirmed by those continuous data,
assessing the substance abuse with Substance Abuse Treatment
Scale. These data failed to show a significant diIerence between
groups at any time period assessment. As for the first comparison,
currently there is no compelling evidence that ICM aIects abuse of
substances or alcohol.
2.4.5 Social functioning: Scale data
Findings were equivocal on scale data measuring social
functioning, as provided by only one study. We do not think
that future studies should address this outcome by use of
scale measurement. Scales are not sensitive measures of social
functioning. More eIort should be placed on consistent and wide
measurements of the main issues of social functioning (such as
accommodation status, employment status, contact with legal
system, rate of permanent social benefits).
2.5 Mental state: General symptoms and specific symptoms
Again, outcomes measured on scales were substantially
inconclusive, as the data were spread across single studies on
diIerent scales and at diIerent time periods, making meta-analysis
impossible. According to the low-quality data available, there does
not seem to be any compelling evidence that ICM substantially
aIects mental state. No data were available for the significant
outcome of 'important improvement in mental health'.
2.6 Behaviour: Self harm and injury to others
This review did not reveal any long-term significant diIerence
between ICM and non-ICM in risk of committing self harm or injury
to others. These data were based on findings from two studies (n
= 959), one of which is the largest study (UK700-UK 1999), and the
other the only study providing data on medium- and long-term
follow-up (REACT-UK 2002). These findings are consistent with the
mortality findings discussed above, where no significant diIerence
was shown in death rate between groups, either for suicide and
for all causes. Although these data are suggestive of no diIerence
of eIects between interventions, they are still quite weak due to
limited sample size. More trials should address this outcome, one
of the simplest ones to collect.
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2.7 Quality of life
Quality of life rating in these trials illustrates the confusion of how
such symptoms are recorded in randomised studies. The scales
diIer, and the timings of use of the scales also diIer. There was
such an inconsistency in approach to this area of research to make
meta-analysis impossible. None of the available findings showed
any significant diIerence between interventions. There does not
seem to be any compelling evidence that ICM substantially aIects
the quality of life of a person with severe mental illness.
2.8 Participant satisfaction/need
Findings tended to favour the ICM group in being better satisfied
with health services and in reducing need. However, this diIerence
was not significant, and both findings were based on data from the
same trial, the largest one (UK700-UK 1999, n = 585). We therefore
cannot draw any conclusions, but highlight a possible favourable
eIect in the ICM group, which needs to be confirmed.
2.9 Costs
Studies assessed 'direct costs of psychiatric hospital care', 'direct
cost of all care', and ‘total cost of care’. Regarding the first outcome,
findings were based on skewed data, provided by one small trial
(Quinlivan-California 1995, n = 60) and one larger one (Harrison-
Read-UK 2000, n = 193). There did not appear to be any compelling
evidence that ICM substantially aIects 'direct costs of psychiatric
hospital care', either by medium or long term. Also, findings on
long-term 'direct cost of all care' did not show any diIerence
between interventions. Again, findings on ‘total cost of care’ failed
to show any diIerence between ICM and non-ICM.
Overall completeness and applicability of evidence
1. Completeness
1.1 Duration of follow-up
The majority of studies presented long-term data, that is over one
year of follow-up. This is a reasonable length of time to sensibly
assess any diIerence in the intervention eIects.
Two studies, one in the first comparison (ICM versus standard
care) and one in the second comparison (ICM versus non-ICM)
presented long-term follow-up (from 18 months to 8 years),
assessing outcomes aPer the active intervention was discontinued
or aPer participants could chose to which arm they were allocated.
1.2 Coverage of outcomes
As the experimental intervention is a service organisation model, its
realisation involves health policy and research should account for
eIicacy and cost evaluation. The outcomes reported were mainly
service use and social functioning oriented. No studies reported
data on relapse (see Summary of findings for the main comparison,
Summary of findings 2), carer satisfaction and family burden.
Participant satisfaction was scarcely reported and in a fragmented
way, therefore available data are only partially informative on the
eIects of these approaches. Few studies provided cost data.
2. Applicability
2.1 Origin
The origin of the data has changed in the last decade since the
two original reviews (Marshall 2000a; Marshall 2000b). There are
now more included trials from Europe, whereas in the past the
data source was largely North America, with a few trials from
Australia. Thirty per cent of the total sample included in the current
review comprises randomised people from Europe. These studies
add power to the result for the primary outcome, narrowing the
confidence intervals, but otherwise not substantially changing the
findings. As only one study was from China, and all the remaining
included studies were from Europe, North America, and Australia,
the findings of this review still lack applicability to low-income
countries and, more generally, to countries where mental health
systems are not community based.
2.2 People
Studies included people presenting a variability that we feel is
likely to reflect the heterogeneous population a clinician faces
in daily practice when treating people aIected by severe mental
illness. This variability was in terms of diagnosis (where participants
were aIected by a wide diagnostic group including schizophrenic,
aIective, and personality disorder); comorbidity (where four
studies included dually diagnosed participants) (Drake-NHamp
1998; Essock-Connecticut2 2006; Morse-Missouri3 2005; Muller-
Clemm-Canada 1996); and social characteristics (where eight trials
included homeless participants). On average, studies included
people with a long history of illness; only OPUS-Denmark 1999
included participants with a first episode of psychotic illness. This
fits with the concept of severe mental illness, where this label
includes certain criteria relating to length of illness.
2.3 Interventions
Some studies showed a greater applicability because the
experimental intervention was provided by pre-existing team,
therefore closer to the real world and less contaminated by the
experimental setting.
The majority of new included trials from the 2010 update compared
ICM with non-ICM (8 out of 14 trials), and they are all from Europe,
Australia, and North America. This confirms the trend of psychiatric
services in those particular areas to increasingly include some
elements of the original model, but also to dilute and contaminate
them with the current organisation. What we call 'standard care'
is therefore converging toward non-ICM. The two studies newly
included from the 2015 update compare ICM with standard care:
one is from the USA and assesses ICM adapted to the forensic
setting, and the other is from China, where only recently community
care is catching on. For those of us who practice in Europe, the
second of the two comparisons in this review may well be more
applicable to everyday care. Importantly, this comparison did not
illustrate a substantial diIerence between ICM and non-ICM. 
Quality of the evidence
As illustrated in Figure 1, it appears there is an overall unclear
risk of bias in these trials. This would therefore mean there is
a moderate risk of overestimate of positive eIect. Also, making
diIicult judgements about quality has been greatly helped by a
discernable improvement in reporting of methodology.
Potential biases in the review process
There were several potential biases. We have worked mainly
with published reports, and only in few cases with unpublished
material. By doing this we may be perpetuating a reporting and
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publishing bias. It would have been better to have much more
original individual participant data. This review follows from two
past Cochrane reviews (Marshall 2000a; Marshall 2000b), as well as
much work already published in paper format (Burns 2007). The
conduct of these reports has influenced this document, and it is
possible that we have failed to identify systematic biases in the way
we have conducted the reviews across time.
An author of this review is an active pioneer in the development
and implementation of the experimental intervention model across
the scientific community and clinical world (MM), and one included
study is his (Marshall-UK 1995). As a team, we tried to ensure that
decisions were made by rational consensus, and not to have an
expert in the team would have been an inadvisable omission.
In some cases, protocol rules were unclear, and need for
subsequent clarification arose and post hoc decisions had to be
taken (see DiIerences between protocol and review). This could
have aIected the review process in various cases. This has probably
lowered the quality of the data included in the review, but to
not include so much, for example, skewed data, would have
omitted much information. Also, by breaking down studies into
their centres, many fell below the 200-participant cutoI point. We
have included these data in the 'less than 200' category, whereas
in previous versions of the review they would have been in the
'greater than 200' category. Due to the overall eIect of the changes
in protocol, it appears that we have a more inclusive review, with
data that are more heterogeneous and also more favourable for the
experimental interventions than otherwise would have been the
case should we have used a more limited data set. Nevertheless, we
did feel it important to present all of these data for the reader to
consider.
We prespecified what characteristics of studies could be associated
with heterogeneity, and therefore we stated in the protocol what
variables were to be explored in the meta-regression before
inspecting the results of the studies. Despite this prespecification,
we were not blind to what variables were probably more related
to heterogeneity, as we were familiar with some study results
previously published. The undertaken exploration of heterogeneity
might therefore at best lead to generation of hypothesis, but it
cannot provide reliable conclusions.
Agreements and disagreements with other studies or
reviews
This review merges two older Cochrane reviews, fully bringing up
to date how these data should be considered. This version does
not disagree with the older reviews; it simply replaces them with a
more current viewpoint of the data. A major improvement in this
version is data on duration of admission, which were previously
lacking from past reviews. Other research in this area do not provide
a full summary of available evidence on ICM eIects across various
outcomes (Burns 2007). This Cochrane review does not disagree
with the paper version; it is just much more comprehensive.
Regarding the meta-regression, this review substantially confirms
the hypothesis stated elsewhere that baseline hospital use and
fidelity to the model aIects outcome (Burns 2007).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
1. For people with severe mental illnesses
We found ICM to be eIective in ameliorating many outcomes
relevant to people with severe mental illness. Compared to
standard care, ICM may reduce hospitalisation and increase
retention in care. In fact, ICM was shown to reduce hospitalisation,
in terms of less frequent and shorter admission to hospital; increase
retention in care; probably reduce the risk of death and suicide;
and globally improve social functioning in terms of a better
accomodation status, employment status, and showing a trend in
reducing contact with legal system. Although its eIect on mental
state and quality of life remains unclear, ICM seems to significantly
help global state compared with standard care. However, it is
unclear what gain ICM provides on top of a less formal non-ICM
approach. The latter may better suit some people with severe
mental illness than the more intensive full-ICM model. Data on
satisfaction with care for ICM versus non-ICM were very few and
diIicult to interpret.
2. For clinicians
ICM formalises a holistic approach to care of people with
severe mental illness in the era of limiting hospital admissions
and subsequent hospital closure. This review suggests that this
formalising is helpful across several outcomes over and above
standard care, the latter largely based in outpatient departments,
and that this seems acceptable to people with severe mental
illness. However, when the fully formal holistic approach (ICM)
is compared with the less formal, but also holistic non-ICM, the
diIerences are not so clear. This could be seen as encouraging,
as for various reasons many clinicians are unlikely to rigidly apply
full ICM. This does not abrogate the need to know and apply key
components of the model of care within ICM.
3. For policymakers
We know at this juncture that ICM is of value at least to people
with severe mental illness in the subgroup with a high level of
hospitalisation (about 4 days per month in past 2 years). The
intervention should be performed close to the original model,
therefore training should be planned for relevant mental health
workers. Data on costs are still scarce, and we could not draw
conclusions on cost-eIectiveness. Where ICM features are already
available in the community psychiatric service (the non-ICM
intervention), it is unclear if additional full development to the
rigid model of ICM is of value. The results of this review could
guide policies on the introduction of such an ICM service in those
countries where a community psychiatric service is already set up
but ICM is not in use, and in countries where a shiP from hospital-
based care in favour of a more community-focused approach has
still to be developed. Particular consideration should be given to
the setting where ICM is to be developed, as its value was shown
where the level of hospitalisation is high. It is unclear whether the
introduction of some but not all of the ICM features (the non-ICM
intervention) is of value compared with community-based standard
care, as more research is needed to clarify the eIects of non-ICM
versus those of standard care.
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Implications for research
1. General
First, as we have said previously, reporting of research does seem
to have improved across time, and as a result the details of the
practice of modern studies are much easier to understand.
However, this review illustrates how scale measurements are much
more widespread than simple clinical questions for assessing
clinical outcomes. We suggest that binary data are less ambiguous
than continuous. There were many scales for the same outcome,
further complicating matters: we found many studies assessing
the same outcome on diIerent scales and therefore did not feel
justified to run a meta-analysis. For example, there was need for
consistency in approach regarding social functioning outcomes.
Heterogeneous measurements were used to describe the same
outcome. This is not very informative - but this review illustrates
opportunities lost by researchers. As it is possible that the time for
more studies has past, by not having consistency, we will always be
leP in doubt about important eIects of care. Finally, we presume
that the use of scales may discourage any worker committed to
patient care from taking part in an experimental study.
More attention should be placed on patient and family
perspectives, in terms of detecting patient and carer satisfaction,
quality of life, and family burden.
2. Specific
2.1 More reviews
We currently know of no review comparing non-ICM with standard
care and reporting relevant outcomes. This should be undertaken.
In addition, we excluded several good studies from this review
as they evaluated mixed models of care, or models plus other
interventions such as cognitive behavioural therapy. These studies
do merit further attention from reviewers and could help clarify
further ways by which either the ICM model develops or new and
yet more holistic approaches evolve.
2.2 Developing this review
A full data set with all individual participant data would help
in avoiding some biases and allow re-analysis using unified
definitions of outcome. Any relevant studies in this area should
make a provision for prospectively providing data compatible with
this review.
2.3 More trials
We do not think that more trials comparing current ICM with
standard care or non-ICM are justified. We do think that the features
of ICM that may improve outcome should be researched, as it may
be that the model of intervention is eIective only because of some
of its features. This work may involve more observational studies in
order to evolve the ICM model to new and better packages of care.
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Characteristics of included studies [ordered by study ID]
 
Methods Allocation: randomised.
Design: single centre.
Duration: 24 months.
Country: Stockholm, Sweden.
Participants Diagnosis: schizophrenic disorder (DSM-III-R).
N = 40.
Setting: community setting.
Aberg-Wistedt-Sweden 1995 
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Age: 25 to 55 years, mean ˜ 38 years.
Sex: 65% M (26M, 14F).
Ethnicity: not reported.
History: recently admitted to ward or currently in outpatient department.
Interventions 1. ICM: interdisciplinary-team based. Caseload: 1:2.5. N = 20.
2. Standard care: multidisciplinary psychiatric outpatient team, specialised in people with schizophre-
nia. Caseload: ˜ 1:10/15. N = 20.
Outcomes Global state: leaving the study early.
Unable to use -
Service use: average number of days in hospital per month and number of emergency visits (no mean,
no SD).
Quality of life: (no mean, no SD).
Social network size: (measure validated on children only, no mean, no SD).
Burden of care: (no mean, no SD).
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised.
No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: not available.
Secondary outcomes: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service utilisation (emergency and inpatient services): data collected from pa-
tient records. Blinding not reported.
Participant's quality of life, size of social networks, and their relatives' burden
of care self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The study did not address this outcome.
Selective reporting (re-
porting bias)
High risk Most outcomes of interest are reported incompletely.
Other bias Low risk No details. No evidence of the presence of other bias.
Aberg-Wistedt-Sweden 1995  (Continued)
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Methods Allocation: randomised.
Design: single centre.
Duration: 15 months.
Country: London, UK.
Participants Diagnosis: serious mental illness (30% schizophrenia according DSM-III-R).
N = 66.
Setting: psychiatric community services.
Age: 18 to 64 years, median ˜ 37 years.
Sex: 45% M (30M, 36F).
Ethnicity: 26% Afro-Caribbean.
History: mean ˜ 0.2 admissions in last year; completed at least 18 months in ACT programme*.
Excluded: primary addiction, primary organic brain damage.
Interventions 1. ICM: ACT (Stein and Test model).
Caseload: 1:12. N = 33**.
2. Standard care: routine care from psychiatric services, as outpatients or inpatients, or both as neces-
sary, with community support services. N = 33.
Outcomes Service use: average number of days in hospital per month***.
Admitted to hospital.
Average number hospital admissions***.
Death: suicide.
Global state: leaving the study early.
GAF.
Social functioning: SAS, employment status.
Mental state: BPRS 24-item, PSE.
Participant satisfaction: CSQ.
Costs: costs of all care.
Unable to use -
Carer satisfaction: Relative's Satisfaction (scale not peer reviewed, attrition > 50%).
Notes Loss to follow-up: 12.1%
*Participants in this study were recruited from the treatment arm of a trial on ACT 20 to 30 months
long.
**Authors report that "the team became depleted and demoralised" in the course of this trial.
***Variance not reported - data from another study used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised.
No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - Unclear. No details provided.
Audini-UK 1994 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Clinical (mental state) and social function assessed by independent raters.
Blinding not tested.
Participant's and relative's satisfaction self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number and reasons for attrition reported. Missing outcome data balanced
in numbers across intervention groups, with similar reasons for missing data
across groups.
Selective reporting (re-
porting bias)
Low risk All listed outcomes are reported completely.
Other bias Low risk No details. No evidence of the presence of other bias.
Audini-UK 1994  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 36 months.
Country: Lund, Sweden.
Participants Diagnosis*: serious mental illness, according to DSM-III-R.
N = 77.
Setting: community psychiatric service.
Age*: 19 to 55 years, mean ˜ 37 years.
Sex: 36M, 41F.
Ethnicity: not reported.
History: i. serious mental illness for > 2 yrs, ii. impairment due to illness (social-relationship, housing, or
work situation) for more than 2 yrs, iii. no primary diagnosis of substance- or alcohol-related disorders,
iv. informed consent given.
Interventions 1. ICM: Case Management service based on the Strength Model. Caseload: ˜ 1:9. N = 33.
2. Standard care: comprehensive psychiatric service with joint management for outpatient, inpatient,
and day care facilities. N = 44.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services, admitted to hospital.
Death: suicide.
Global state: leaving the study early, GAF.
Social functioning: Strauss-Carpenter Scale, social network (ISSI).
Mental state: general symptoms, SCL-90.
Quality of life: LQoLP.
Participant satisfaction: CAN.
Unable to use -
Client satisfaction: questionnaire by the Swedish Institute for Health Services Development (modified
version, not peer reviewed).
Notes *51.9% schizophrenia-like disorder.
**ICM group significantly older than standard care group (5 yrs older on average).
Bjorkman-Sweden 2002 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised: used a computer random number generator.
Allocation concealment
(selection bias)
Unclear risk Random selection performed by one of the trialist.
No further details.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcomes: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - Unclear.
Interviewers formally blind to participant group allocation. Not tested.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Clinical (mental state) and social function assessed by independent raters.
Blinding not tested.
Service utilisation. Blinding not reported.
Participant's and relative's satisfaction self reported, not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Analysis performed on an ITT basis, but "clients who were not available for or
refused contact at follow-up were excluded from the respective analysis on an
individual basis".
Selective reporting (re-
porting bias)
Low risk All listed outcomes of interest reported.
Other bias Low risk No details. No evidence of the presence of other bias.
Bjorkman-Sweden 2002  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 12 months.
Country: Chicago, Illinois, USA.
Participants Diagnosis*: serious mental illness (schizophrenia, schizoaffective disorder, affective disorder, personal-
ity disorder) according to RDC and SADS.
N = 88.
Setting: private psychiatric rehabilitation agency.
Age: > 18 years, mean ˜ 34 years.
Sex: 56.8% M (50M, 38F).
Ethnicity: non-white 36%.
History**: i. 3 admissions in the last 2 years or total of 5 admissions in life, ii. had no prior contact of
more than 1 month's duration with either study programme, iii. informed consent given.
Interventions 1. ICM***: a large-city adaptation of ACT model according to Stein and Test. Caseload 1:10. N = 45.
2. Standard care***: provided from drop-in centre (day treatment, central meeting place, no require-
ment for frequent contacts). Caseload: 1:≧20. N = 43.
Bond-Chicago1 1990 
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Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services, admitted to hospital, average number of admissions.
Death: all causes, suicide.
Global state: leaving the study early.
Social functioning: police contact, arrested, imprisoned, accomodation status.
Unable to use -
Global functioning: GAS (no SD, no sample size providing data).
Social functioning: Areas of Difficulty Checklist (ADC) (scale not peer reviewed, no SD).
Quality of life: Life Satisfaction Checklist (LSC) (scale not peer reviewed, no SD).
Satisfaction with care: Satisfaction with Services (SWS), author-modified version of CSQ (not peer re-
viewed, no SD).
Cost: no SD, no sample size.
Notes *Schizophrenia ˜ 37%; primary or secondary diagnosis of substance abuse = 26% .
**At the time of study admission, 62% in ICM group and 54% in SC group were in a psychiatric hospital.
***Author reporting: "ACT had been in existence for 6 yrs, SC service for 2 yrs. In both programmes staI
were enthusiastically committed to the respective programme philosophy".
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk Random assignment achieved by individual sealed envelopes (not specified if
opaque), the assignment was carried out by a person unconnected to research
programme.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: most are clinician/participant mediated - rating - Un-
clear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Interviewer was not blind to treatment condition.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Missing outcome data not balanced in numbers across intervention groups,
but similar reasons for missing data across groups.
Selective reporting (re-
porting bias)
High risk Some outcomes of interest are reported incompletely and are not usable (due
to missing SD or sample size providing data).
Other bias Low risk Publicly funded (by the State Department of Mental Health). No further details.
No evidence of the presence of other bias.
Bond-Chicago1 1990  (Continued)
 
 
Methods Methods: see above Bond-Indiana1 1988.
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Participants Participants: see above Bond-Indiana1 1988.
N = 61.
Interventions Interventions: see above Bond-Indiana1 1988.
1. ICM: N = 29.
2. Standard care: N = 32.
Outcomes Service use: average number of days in hospital per month*.
Death: suicide.
Social functioning: contact with the police.
Unable to use -
Costs: total inpatient cost, total treatment cost (no SD).
Notes *Variance not reported - data from another study used.
Bond-Indiana1 (A)  (Continued)
 
 
Methods Methods: see above Bond-Indiana1 1988.
Participants Participants: see above Bond-Indiana1 1988.
N = 64.
Interventions Interventions: see above Bond-Indiana1 1988.
1. ICM: N = 34.
2. Standard care: N = 30.
Outcomes Service use: average number of days in hospital per month*.
Notes *Variance not reported - data from another study used.
Bond-Indiana1 (B) 
 
 
Methods Methods: see above Bond-Indiana1 1988.
Participants Participants: see above Bond-Indiana1 1988.
N = 42.
Interventions Interventions: see above Bond-Indiana1 1988.
1. ICM: N = 21.
2. Standard care: N = 21.
Outcomes Service use: average number of days in hospital per month*.
Notes *Variance not reported - data from another study used.
Bond-Indiana1 (C) 
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Methods Allocation: randomised.
Design: multicentre, 3 centres (3 CMHCs)*.
Duration: 6 months.
Country: Indiana, USA.
Participants Diagnosis**: psychotic disorder (DSM-III).
N = 67.
Setting: CMHCs.
Age: > 17 years, mean ˜ 35 years.
Sex: 61.6% M (103M, 64F).
Ethnicity: black (understood to be African-American) 34%.
History***: high risk of hospitalisation, described as: i. discharged within last year and either rehospi-
talised ≧ 3 times in previous 2 years or determined by mental health services staI to be at high risk for
readmission, ii. committed or awaiting commitment to hospitals, iii. presenting for admission at CMHC
inpatient unit and having ≧ 4 psychiatric hospitalisations in last 2 years.
Interventions 1. ICM: Assertive Case Management, according to the ACT model (Stein and Test), in addition to all other
available mental health programmes. Caseload: 1:8-12. N = 84.
2. Standard care: as provided at CMHCs (including case management services with large caseload). N =
83.
Outcomes Service use: average number of days in hospital per month****, (data available for single centre, see
below); admitted to hospital.
Death: all causes (data from centre A only).
Global state: leaving the study early.
Social functioning: contact with the police (data from centre A only).
Unable to use -
Quality of life: self report instrument (no data, scale not peer reviewed, compiled by the therapist).
Global state: compliance with medication (data not reported).
Costs: available only for centre A (no SD).
Notes *Among client groups at the 3 centres, significant differences were found in: age, gender, race, educa-
tion, employment, diagnosis, and history at baseline.
**Schizophrenia-like disorder: 61%; substance abuse: 39%.
***Average 8.8 lifetime hospitalisation and 1.5 hospitalisation in the previous year.
****Variance not reported - data from another study used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised for single centre. No further details.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: most are clinician/participant mediated - rating - Un-
clear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
Unclear risk No details
Bond-Indiana1 1988 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of lost to follow-up reported, but no reasons for missing data provid-
ed.
Selective reporting (re-
porting bias)
High risk Prespecified outcomes not reported (medication compliance) or reported in-
completely (days in hospital: SD missing).
Other bias Low risk No details. No evidence of the presence of other bias.
Bond-Indiana1 1988  (Continued)
 
 
Methods Allocation: randomised.
Design: single site.
Duration: 12 months.
Country: Atlanta, USA.
Participants Diagnosis*: severe mental illness.
N = 28.
Age: 25 to 56 years.
Sex: 57% M (16M, 12F).
Ethnicity: 50% African-American.
History: high rates of hospital readmissions (2 to 18 previous admissions), difficulty in community liv-
ing.
Interventions 1. ICM: clinical case management, providing intensive support and outreach (according to the Stein and
Test model TCL). N = 14.
2. non-ICM: standard care providing case management at a lower level of intensity and rehabilitation
services. N = 14.
Outcomes Service use: average number of days in hospital per month**.
Death: all causes, suicide.
Unable to use -
Service use: number of hospital admissions (no individual group data); emergency room visits (no indi-
vidual group data).
Global state: compliance: adherence to service and medication plan (incompletely reported data).
Social functioning: appropriate living status (incompletely reported data).
Costs: no individual group data.
Notes *86% schizophrenia.
**Variance not reported - data from another study used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Bush-Georgia 1990 
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All outcomes Secondary outcome: leaving the study early - clinician/participant mediated -
rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use and appropriate living conditions collected from records. Blinding
not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No missing outcome data.
Selective reporting (re-
porting bias)
High risk Outcomes not pre-stated. Most of the reported outcomes are reported incom-
pletely (data not usable).
Other bias Low risk No details. No evidence of the presence of other bias.
Bush-Georgia 1990  (Continued)
 
 
Methods Allocation: randomised.
Design: single site.
Duration: 11 months (5-month intervention period, 6-month follow-up).
Country: Hong Kong.
Participants Diagnosis: chronic schizophrenia.
N = 62.
Setting: recruited from a community mental hospital.
Age: 21 to 65 years.
Sex: 71% female.
Ethnicity: not reported.
History: suffered from schizophrenia for 2 or more years; had 3 or more hospitalisations in the past 24
months before admission; required supervision in living skills; unemployed for 3 or more months; and
unreliable in compliance to treatment.
Interventions 1. ICM: based on the developed case management model, with a community psychiatric nurse case
manager co-ordinating care. Caseload 1:3. N = 31.
2. Standard care: traditional community psychiatric nursing care. Caseload 1:3. N = 31.
Outcomes All of the usable outcomes are provided at the 6 months' follow-up.
Service use: unplanned admission through the Accident and Emergency Department; day hospital care;
outpatient visits; home visits.
Costs: direct healthcare costs.
Unable to use -
SD or equivalent not reported: BPRS; Specific Level of Functioning scale (SLOF); Patient Satisfaction In-
strument (PSI).
Average number of days in hospital per month: it may have been possible to calculate this outcome
(imputing SD), but we decided not to use it as the study reports data only on "unplanned admission",
therefore the available data misses data on overall admission (planned and unplanned).
Chan-Hong Kong 2000 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Patients who met the inclusion criteria and provided consent were ran-
domised to case management or conventional care after recruitment"; no fur-
ther details were provided.
Allocation concealment
(selection bias)
Unclear risk No details on allocation concealment were reported.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details reported.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Details on blinding participants and personnel were not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Details on blinding outcome assessors were not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Analyses were reported as ITT; it was not reported whether any participants
leP early.
Selective reporting (re-
porting bias)
High risk For many of the outcome scales, only items that had a significant difference
between experimental and control groups were reported.
Other bias Low risk The study seems to be free of other bias. The study reports that baseline char-
acteristics were similar, although only age and gender were reported.
Chan-Hong Kong 2000  (Continued)
 
 
Methods Site A: Long Beach.
Methods: see above Chandler-California1 1991.
Participants Participants: see above Chandler-California1 1991.
N = 256.
Interventions Interventions: see above Chandler-California1 1991.
ICM = 127.
SC = 129.
Outcomes Service use: average number of days per month in hospital, not remaining in contact with psychiatric
services, admitted to hospital.
Global state: leaving the study early.
Social functioning: employment status, arrested, imprisoned, accomodation status.
Costs: direct costs of psychiatric hospital care.
Chandler-California1 (A) 
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Notes  
Chandler-California1 (A)  (Continued)
 
 
Methods Site B: Stanislaus County.
Methods: see above Chandler-California1 1991.
Participants Participants: see above Chandler-California1 1991.
N = 260.
Interventions Interventions: see above Chandler-California1 1991.
ICM = 125.
SC = 135.
Outcomes Service use: average number of days per month in hospital, not remaining in contact with psychiatric
services, admitted to hospital.
Global state: leaving the study early.
Social functioning: employment, arrested, imprisoned, accomodation status.
Costs: direct costs of psychiatric hospital care.
Notes  
Chandler-California1 (B) 
 
 
Methods Allocation: randomised.
Design: multicentre, 2 sites*** (site A: Long Beach, urban site; site B: Stanislaus County, rural site).
Duration: 36 months.
Country: California, USA.
Participants Diagnosis: serious and persistent mental illness (DSM-III-R).*
N = 516.
Setting: 1 urban, 1 rural but integrated service agencies.
Age: 30% > 45 years.
Sex: 52% M.
Ethnicity: 26% non-white.
History**: i. functional impairment due to mental disorder, ii. eligibility for public assistance, iii. not a
primary diagnosis of substance abuse, iv. informed consent given.
Interventions 1. ICM***: ACT provided by integrated service agencies, according to Training in Community Living Pro-
gramme (Stein and Test). Caseload: 1:10. N = 252.
2. Standard care: usual mental health service (i.e. outpatients: day treatment, case management; inpa-
tients: minimal rehabilitation services). N = 264.
Outcomes Service use: average number of days in hospital per month
Following outcomes available for single centre.
Service use: not remaining in contact with psychiatric services, admitted to hospital.
Global state: leaving the study early.
Social functioning: employment, arrested, imprisoned, accomodation status.
Costs: cost of psychiatric hospital care.
Unable to use -
Chandler-California1 1991 
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Mental state: general symptoms: Colorado Symptom Index (no data reported).
Self esteem: New York Self Esteem Scale (no data reported).
Quality of life: Lehman's Quality of Life Instrument (no data reported).
Social functioning: level of social activities (scale not peer reviewed).
Family burden: subscales adapted from Tessler's Family Burden Interview (not peer reviewed, attrition
> 50%).
Participant satisfaction: scale for overall satisfaction with mental health services (scale not peer re-
viewed).
Costs: direct costs of health care and of all care (no SD), all mental health care (not listed as review out-
come of interest).
Notes *61% schizophrenia
**28% admitted in previous year
***Intervention programme in 2 sites slightly different: Site A puts more emphasis on employment ser-
vices and social and therapeutic activities. Site B emphasises avoiding hospitalisation through use of
crisis house.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised for single centre. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Employment, arrest, conviction, homelessness, and service use (hospitalisa-
tion) were compiled from state and local databases. Blinding not reported.
For mental state (symptomology), independent research staI conducted inter-
views. Blinding not reported.
Quality of life and personal safety self reported. Not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of lost to follow-up reported, but reasons for missing data not provid-
ed. LOCF for continuous data.
Selective reporting (re-
porting bias)
High risk Listed outcomes of interest not reported (continuous data from scales not re-
ported; days in hospital reported only for site A, no SD).
Other bias Low risk Publicly funded (California Department of Mental Health, NIMH). No details.
No evidence of the presence of other bias.
Chandler-California1 1991  (Continued)
 
 
Methods Allocation: randomised.
Curtis-New York 1992 
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Design: single centre.
Duration: 14 months.
Country: New York, USA.
Follow-up*: range of 18 to 52 months.
Participants Diagnosis**: not stated, DSM-III.
N = 292.
Setting: Harlem Hospital Center (HHC).
Age: age 18 to 54 years, mean ± SD 35.9 ± 12.1 yrs (N = 430).
Sex: 59% F.
Ethnicity: 91% black (understood to be African-American).
History***: i. about to be discharged from hospital, ii. local residents, iii. without a sole diagnosis of
substance abuse or organic mental disorder, iv. inpatients for > 7 days, and not eligible for the "Com-
munity Support System" programme - that is no psychiatric admission of > 6 months duration/3 admis-
sions of > 10 days within the last 2 years, v. informed consent given.
Interventions 1. ICM: intensive outreach case management from a multidisciplinary team at HHC, which implement-
ed a discharge treatment plan and monitored clinical and social problems. The team did not "assume
direct responsibility for care but [...] help[ed] the patient enrol in a day hospital programme, adult men-
tal health clinic, rehabilitation programme, or alcohol treatment programme". Caseload: 1:17. N = 147.
2. Standard care: routine aftercare, within the discharge treatment plan prescribed for each patient by
HHC; "most received at least initial treatment form various divisions of the departments of psychiatry
within the Health and Hospitals Corporation". N = 145.
Outcomes Service use: average number of days in hospital per month, admitted to hospital.
Death: all causes and suicide.
Unable to use -
Use of ambulatory services: this outcome is not listed as an outcome of interest for the review.
Quality of life: measuring instrument written by trialists for this particular trial and was not published in
peer-reviewed journal (EAF - Evaluation Aftercare Form).
Notes *Follow-up period variable, depending on date of participant's entry into the study.
**Schizophrenia 38%; alcohol or drug abuse or dependence 39%.
***Mean number of previous admissions > 1.
Some more severely ill clients not included in this part of study as they were eligible for "Community
Support System" programme group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: some are clinician/participant mediated - rating - Un-
clear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Curtis-New York 1992  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use (rehospitalisations, hospital-based ambulatory services) and mor-
tality derived from the shared medical billings systems. Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Missing data are not addressed.
Selective reporting (re-
porting bias)
Low risk Listed outcomes are reported completely.
Other bias Low risk Funded by public institution (New York City Health and Hospitals Corporation
and foundations). No details. No evidence of the presence of other bias.
Curtis-New York 1992  (Continued)
 
 
Methods Allocation: randomised.
Design: single site.
Duration: 24 months.
Country: USA.
Duration: 2 years.
Participants Diagnosis: DSM-IV axis I major mental disorder.
N = 134.
Setting: Harlem Hospital Center (HHC).
Age: 37 (SD 10) years.
Sex: 59% male.
Ethnicity: 63% Caucasian (understood to be white participants).
History: detained in county prison at enrolment and diagnosed with major mental disorder. Comorbid
substance abuse (66%) or additional mental disorder diagnosis were not excluded. Candidates ever
charged with a serious, violent offence, or "third strike" candidates were excluded.
Interventions 1. ICM: Forensic Assertive Community Treatment (FACT)*, with team-based mental health and sub-
stance abuse services, as well as support for housing, employment assistance, benefits applications,
advocacy, and a full-time peer recovery specialist and a full-time probation officer. Caseload: < 20. N =
72.
2. Standard care: treatment as usual (TAU): services routinely available in the county-operated public
behavioural health system, such as psychiatric assessment, psychiatric medications in both outpatient
and inpatient general hospital settings, outpatient mental health and substance abuse counselling,
and case management. N = 62.
Outcomes Service use: mean number of outpatient visits.
Social functioning: contact with legal system (bookings, jail days, convictions).
Costs: direct costs of psychiatric hospital care; direct costs for outpatient care, jail.
Not used -
Service use: mean number of hospital days (could not be converted to average number of days per
month), crisis contacts.
Notes *With high fidelity to the ACT model, DACTS scores 4.5 and 4.6.
Risk of bias
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation using a random number table, assignment in blocks of 2.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment details were not reported.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details on blinding participants and personnel were reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Results relied on external administrative data.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All analyses were ITT; outcomes were observed regardless of active or contin-
ued participation.
Selective reporting (re-
porting bias)
Low risk Listed outcomes are reported completely.
Other bias Low risk No indication of other bias; baseline characteristics similar between groups,
except, on average, participants in the FACT group were nearly 4.5 years old-
er than participants in the TAU condition. However, after adjusting for age, the
results were essentially the same.
Cusack-North Carolina  (Continued)
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
N = 23.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 11.
2. Standard care: N = 12.
Outcomes Service use: average number of days in hospital per month.
Notes  
Drake-NHamp (A) 
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
Drake-NHamp (B) 
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N = 23.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 10.
2. Standard care: N = 13.
Outcomes Service use: average number of days in hospital per month.
Notes  
Drake-NHamp (B)  (Continued)
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
N = 25.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 14.
2. Standard care: N = 11.
Outcomes Service use: average number of days in hospital per month.
Notes  
Drake-NHamp (C) 
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
N = 60.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 30.
2. Standard care: N = 30.
Outcomes Service use: average number of days in hospital per month.
Notes  
Drake-NHamp (D) 
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
N = 32.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 17.
2. Standard care: N = 15.
Drake-NHamp (E) 
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Outcomes Service use: average days per month in hospital.
Notes  
Drake-NHamp (E)  (Continued)
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
N = 17.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 9.
2. Standard care: N = 8.
Outcomes Service use: average number of days in hospital per month.
Notes  
Drake-NHamp (F) 
 
 
Methods Methods: see above Drake-NHamp 1998.
Participants Participants: see above Drake-NHamp 1998. For this centre, sample providing data:
N = 16.
Interventions Interventions: see above Drake-NHamp 1998. For this centre, sample providing data:
1. ICM: N = 7.
2. Standard care: N = 9.
Outcomes Service use: average number of days in hospital per month.
Notes  
Drake-NHamp (G) 
 
 
Methods Allocation: randomised.
Design: multicentre (7 sites(CHMCs), 2 in urban areaand 5 in rural area).
Duration: 36 months.
Country: New Hampshire, USA.
Participants Diagnosis: schizophrenia, schizoaffective or bipolar disorder (DSM-III-R) and active substance user dis-
order within past 6 months (DSM-III-R)*.
N = 225.
Setting: CHMCs.
Age: 18 to 60 years, mean ˜ 34 years.
Sex: 74.4% M (167M, 58F).
Ethnicity: ethnic minority 3.4%.
History: i. no mental retardation or medical conditions that would prevent participation, ii. written in-
formed consent given.
Drake-NHamp 1998 
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Interventions 1. ICM: ACT teams with special training in substance abuse treatment. Caseload: 1:12. N = 109.
2. Non-ICM: standard non-Intensive Case Management, incorporating most of the ACT principle, but
providing less individual service for substance abuse. Caseload: 1:25. N = 114.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services.
Death: all causes.
Global state: leaving the study early.
Mental state: BPRS-24 item.
Social functioning: average days in stable accomodation, Alcohol Use Scale (AUS), Substance Abuse
Treatment Scale (SATS), alcohol use days (TLFB), remission from alcohol use disorder.
Quality of life: QOLI.
Unable to use -
Substance abuse: drug use scale (DUS), drug use days (TLFB) and not in remission: attrition > 50%, Ad-
diction Severity Index (ASI) (data not reported).
Service use: Service Utilization Interview (data not reported).
Costs: direct costs of psychiatric hospital care (no SD), average total study cost (not listed as outcome
of interest in the review).
Notes *53% schizophrenia, 22% schizoaffective, 24% bipolar disorder, 72.6% alcohol abuse, 41.8% drug
abuse.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: some are clinician/participant mediated - rating - Un-
clear, some are interviewer rated - rating - Unclear. Interviewer blind, not test-
ed.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Independent raters, blind to study condition, separately rated alcohol and
drug use as well as substance abuse treatment. Service use was obtained from
outpatient records and hospital records, blinding not reported. Blinding not
reported for mental state, quality of life, or homelessness.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of lost to follow-up is reported, but reasons for missing data are not
reported for each randomised treatment group (reported overall, information
not usable).
Selective reporting (re-
porting bias)
Low risk Prespecified outcomes of interest are reported.
Other bias Low risk No information available. No evidence of the presence of other bias.
Drake-NHamp 1998  (Continued)
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Methods Allocation: randomised.
Design*: multicentre, 3 sites, all in city area (data for single centre not available).
Duration: 18 months.
Country: Connecticut, USA.
Participants Diagnosis**: major depression, bipolar disorder, schizophrenia, schizoaffective disorder according to
DSM-III-R.
N = 262.
Age: mean ˜ 41 years.
Sex: 64% M.
History***: high level of service use (defined as: i. ≧ 2 psychiatric hospitalisations in last 2 years, ii. 1
psychiatric hospitalisation longer than 180 days in last yr, or iii. ≧ 2 contacts with crisis services in last 2
years) and significant difficulties meeting the demands of everyday life (defined as: 1. homeless in past
year, or ii. requiring extensive supervision or assistance at least weekly to meet personal-care needs),
informed consent given.
Interventions 1. ICM: Assertive Community Treatment teams (Stein and Test model), but having a richer staI and
achieving 24-hour coverage. Caseload: 1:5-7. N = 130****.
2. Non-ICM: generalist model, but providing mobile case managers. Caseload: 1:25-30. N = 132****.
Outcomes Service use: average number of days in hospital per month.
Death: all causes.
Global state: leaving the study early.
Unable to use -
Mental state: modified version of SCL-90 (no peer-reviewed scale, no SD).
Social functioning: accomodation status, number of days homeless (no SD), imprisoned (not reported).
Quality of life: modified version of QOLI (no peer-reviewed scale, no SD).
Carer satisfaction: Family Burden Interview (no SD).
Costs: data reported incompletely.
Notes *Authors state that the same treatments provided in different sites were not identical ("different styles
of providing services were used at different sites"), but single-centre data not available.
**67% schizophrenia or schizoaffective disorder.
***62% participants had lifetime history of substance abuse or dependence and 25% participants were
hospitalised at the study entry.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. Randomisation counterbalanced "so that within each site clients
had 50% likelihood of being assigned to either ICM or non-ICM and counter-
balanced so that clients hospitalised at the time of assignment had 50% likeli-
hood of being assigned to either ICM or non-ICM."
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: leaving the study early - clinician/participant mediated -
rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Essock-Connecticut1 1995 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use (hospitalisation), housing (homelessness, temporary housing):
source of data and blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number and reasons for missing data clearly reported. Missing outcome data
balanced across intervention groups.
Selective reporting (re-
porting bias)
High risk Listed outcome of interest not reported or reported incompletely.
Other bias Low risk Funded by public health institutes and private foundation. No other details
provided. No evidence of the presence of other bias.
Essock-Connecticut1 1995  (Continued)
 
 
Methods Allocation: randomised.
Design: multicentre, 2 urban sites (data for single centre not available).
Duration: 36 months.
Country: Bridgeport, Connecticut, USA.
Participants Diagnosis*: schizophrenia, schizoaffective disorder, depression with psychotic features, bipolar disor-
der according to DSM-III-R.
N** = 198 (randomised to site A: N = 100, to site B: N = 98).
Setting: 2 state-operated outpatient CMHCs.
Age: mean 36.5 years (SD 7.8 years).
Sex: 72% M (143M, 55F).
Ethnicity: African-American 55%; Hispanic 14%.
History: i. active substance use disorder (abuse or dependence on alcohol or other drugs previous 6
months), ii. high service use previous 6 months (≧ 2 between: psychiatric hospitalisation, stays in a
psychiatric crisis or respite programme, emergency department visit, or incarceration), iii. homeless or
unstably housed, iv. poor independent living skills, v. no pending legal charge, vi. no medical condition
or mental retardation, vii. written informed consent given.
Interventions 1. ICM***: Assertive Case Management. Caseload: 1:10-15. N = 99.
2. Non-ICM***: Clinical Case Management provided by clinicians. Caseload: 1:20-30. N = 99.
Outcomes Service use: average number of days in hospital per month.
Unable to use -
Global state: leaving the study early, GAS (N for single intervention group not reported).
Social functioning: days in stable accomodation (N for single intervention group not reported), impris-
oned (days in jail reported with days in hospital).
Social functioning: SATS, AUS, DUS (scales rated by clinicians), days of alcohol/drug use (N for single in-
tervention group not reported).
Mental state: BPRS-24 item (N for single intervention group not reported).
Client satisfaction: General Life Satisfaction (N for single intervention group not reported).
Costs: not reported.
Notes *76% schizophrenia or schizoaffective disorder; 17% mood disorder; 74% alcohol disorder; 81% sub-
stance use disorder.
**Original randomised sample N = 205. 7 participants leP for administrative reason. Authors did not re-
port to which group they were assigned.
***Both interventions addressed substance use disorders.
Risk of bias
Essock-Connecticut2 2006 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using separate computer-generated randomisation stream for
each site.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of missing data (number and reasons for missing data
reported for the total sample, not for each intervention group). 7 randomised
participants were lost due to administrative reason, but their intervention allo-
cation was not reported.
Selective reporting (re-
porting bias)
High risk Listed outcomes of interest are fully reported for each site, but authors did not
provide sample size.
Other bias Low risk Publicly funded. No further details. No evidence of the presence of other bias.
Essock-Connecticut2 2006  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre (multisite study, but randomisation is used in only one site; we have reported data
from this site).
Duration: 18 months.
Country: North Southwark, London, UK.
Participants Diagnosis*: psychotic illness, severely and persistently mentally ill (criteria not reported).
N = 77.
Setting: Centre for Mental Health.
Age: mean ˜ 46 years.
Sex: 47% M.
Ethnicity: 30% ethnic minority.
History: i. either: recent inpatient admission, or impairment in social functioning, or problems in com-
pliance with medication/treatment regimens, or problem in receiving help from multi-agency; ii. no pri-
mary diagnosis of organic psychosis, personality disorder, drug/alcohol abuse, learning difficulty.
Interventions 1. ICM: multidisciplinary team, providing Assertive Community Care not following any specific model of
case management. Caseload: < 15 clients per case manager. ICM provided in addition to standard men-
tal health service. N = 39.
2. Standard care: provided by psychiatric services. N = 38.
Outcomes Service use: average number of days in hospital per month, admitted to hospital.
Death**: all causes and suicide.
Ford-UK 1995 
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Global state: leaving the study early, compliance with medication.
Social functioning: imprisoned.
Mental state: BPRS-18 item.
Quality of life: objective quality of life through QOLI.
Costs: direct costs of psychiatric hospital care, direct costs of all care.
Unable to use -
Social functioning: Life Skill Profile (LSP) (rated by the therapist, not independent rater).
Social support: data not reported due to "high level of missing data".
Notes *Schizophrenia 81%.
**Difference of 1 death (all causes) between 2 reports (3 to 4 deaths reported in ICM group). (Number of
suicide consistent between reports). Reported lowest number of death here.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised. Sequence of random number generated by computer program.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: some are clinician/participant mediated - rating - Un-
clear, some are interviewer rated - rating - Unclear. No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use, costs, convictions/imprisonment, and mortality were collected by
independent researchers. Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Number and reasons for missing dichotomous outcome data reported; im-
balance in numbers and reasons for missing data across intervention groups,
which is not addressed for continuous outcome data.
Selective reporting (re-
porting bias)
Low risk Listed outcome of interest reported, or if not reported, reason is provided (i.e.
social support data are not reported due to high level of missing data).
Other bias Low risk No details. No evidence of the presence of other bias.
Ford-UK 1995  (Continued)
 
 
Methods Site A - Bridge West.
Methods: see above Hampton-Illinois 1992.
Participants Participants: see above Hampton-Illinois 1992.
Site A provided the following information:
Diagnosis: 78% (74/95) primary diagnosis of major mental illness (schizophrenia, affective disorder,
other psychosis), ˜ 13% (12/95) have primary diagnosis of alcohol or substance abuse.
Hampton-Illinois (A) 
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N = 95.
Sex: 80% M (76M, 19F).
Ethnicity: non-white: 50.5% (48/95).
Age: average ˜ 38 years.
History: average age at first psychiatric contact ˜ 23.5 years, average duration of homeless before en-
tering the study ˜ 44.6 months.
Interventions Interventions: see also above Hampton-Illinois 1992.
Site A provided the following information:
1. ICM: N = 48.
2. Standard care: provided by psychiatric services, including traditional office-based outpatient care
and case management. N = 47.
Outcomes Service use: average number of days in hospital per month*, not remaining in contact with psychiatric
services.
Death: all causes.
Global state: leaving the study early.
Social functioning: accomodation status.
Unable to use -
Service use: mean number of admissions (data not reported).
Social functioning: imprisoned (data not reported).
Notes *Variance not reported - data from another study used.
Hampton-Illinois (A)  (Continued)
 
 
Methods Site B - Bridge South.
Methods: see above Hampton-Illinois 1992.
Participants Participants: see above Hampton-Illinois 1992.
Site B provided the following information:
Diagnosis: 54% (38/70) have primary diagnosis of schizophrenia, 27% (19/70) have primary diagnosis of
affective disorder, 1% (1/70) have primary diagnosis of substance abuse.
N = 70.
Sex: 71% M (M59/70).
Age: average ˜ 35 years.
History: average age at first psychiatric contact ˜ 23 years, average homeless before entering the study
˜ 18 months.
Interventions Interventions: see above Hampton-Illinois 1992.
Site B provided the following information:
1. ICM: N = 34.
2. Standard care: N = 36.
Outcomes Service use: average number of days in hospital per month*.
Global state: leaving the study early.
Unable to use** -
Service use: not remaining in contact with psychiatric services.
Death: all causes.
Social functioning: accomodation status, imprisoned.
Notes *Variance not reported - data from another study used.
Hampton-Illinois (B) 
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**Data excluded due to an incomplete report (figures in project report do not add up; > than total N in
study).
Hampton-Illinois (B)  (Continued)
 
 
Methods Allocation: randomised.
Design: multicentre (2 centres: Site A - Bridge West; Site B - Bridge South).
Duration: 12 months.
Country: Chicago, USA.
Participants Diagnosis*: serious mental illness.
N = 165.
Setting: community mental health service.
Age: ≧ 18 years, mean ˜ 37 years.
Sex: 77% M (127M, 38F).
Ethnicity: 55.7% black (understood to be African-American).
History: i. admitted to inpatient units of 2 state hospitals, ii. homeless on admission or at risk of home-
lessness on discharge, iii. informed consent given (site A).
Interventions 1. ICM: Assertive Case Management (Stein and Test model). Caseload: ˜ 1:10. N = 82.
2. Standard care: provided by psychiatric services. N = 83. (Site A included traditional office-based out-
patient care and case management.)
Outcomes Outcomes from different centres are reported separately; we assumed a single-centre randomisation
procedure. See below in Hampton-Illinois (A) and Hampton-Illinois (B).
Notes *Schizophrenia 42%.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Although this was not explicit, we assumed an independent randomisation for
each centre. Authors reported: "Project staI recruited clients on varying days
to reduce bias". We interpreted this as meaning that different days were used
for recruitment to the whole study, and not that group of allocation was deter-
mined by day.
Allocation concealment
(selection bias)
Unclear risk Described as "blinded randomisation".
No further details.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: some clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Hampton-Illinois 1992 
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
114
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition/exclusions to permit judgement.
Selective reporting (re-
porting bias)
High risk In both centres, Hampton-Illinois (A) and Hampton-Illinois (B), some listed out-
comes of interest were not reported or were reported incompletely (i.e. days
spent in hospital: no SD).
Other bias Unclear risk Publicly funded (National Institute of Mental Health). It is unclear whether
the study was interrupted earlier in Hampton-Illinois (B). Authors reported:
"The study sample for Site B was inadequate due to late start, implementation
problems and high dropout rate"; for this reason, they reported data only by 6
months.
Hampton-Illinois 1992  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 24 months.
Country: London, UK.
Participants Diagnosis*: "heavy psychiatric service users", no diagnostic criteria reported.
N = 193.
Setting: community psychiatric services.
Age: 16 to 64 years, mean ˜ 39 years.
Sex: 53% M (102M, 91F).
History: admitted within the last 3 years and had at least 2 admissions in the last 6.5 years.
Excluded: participants who were continuously hospitalised during 8 months' recruitment.
Interventions 1. ICM: enhanced community management on ACT principles (Stein model) provided by dedicated mul-
tiprofessional team. Caseload: 1:8-15. N = 97.
2. Non-ICM: locality-based community psychiatric services using the UK Care Programme Approach.
Caseload: 1 ≧20. N = 96.
Outcomes Service use: average number of days in hospital per month.
Death: all causes, suicide.
Global state: leaving the study early, compliance, Rating of Medication Influences (ROMI).
Social functioning: Social Functioning Questionnaire (SFQ).
Mental state: Krawiecka Scale (KS), Health of the Nation Outcome Scale (HoNOS), Hospital Anxiety and
Depression Scale (HADS).
Participant satisfaction: Camberwell Assessment of Need (CAN).
Costs: direct costs of psychiatric hospital care.
Unable to use -
Mental state: general symptoms, Well-being Questionnaire (W-BQ) (not peer-reviewed scale and modi-
fied from the original).
Notes *Schizophrenia ˜ 65%.
**Median number of 5 admissions over 6.5 years.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence generated by computer program.
Harrison-Read-UK 2000 
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Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: some are interviewer rated - rating - No. Interviewers are
not blind to treatment assignment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Interviewers were not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of lost to follow-up reported, but reasons for attrition not reported.
Number of lost to follow-up balanced between 2 groups. Some participants
were excluded after randomisation, but reasons for exclusion not stated.
Selective reporting (re-
porting bias)
Low risk Listed outcomes of interest are fully reported.
Other bias Low risk Publicly funded (National Health Service). No further details. No evidence of
other bias.
Harrison-Read-UK 2000  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 29 months.
Country: Portland, Oregon, USA.
Participants Diagnosis: schizophrenia, major affective disorder, paranoid disorder, or another severe mental disor-
der; diagnostic criteria not reported.
N = 178.
Setting: community.
Age: > 18 years, mean 36.5 ± 10.3 years (N = 163).
Sex: 61% M (N = 163).
Ethnicity: 18% black (understood to be African-American).
*History: i. chronically mentally ill, ii. history of persistent psychotic symptoms not due to substance
abuse, iii. impaired functioning in > 2 of (i) social role, (ii) daily living, (iii) social acceptability, iv.
no mental retardation. In process of being discharged from hospital or transferring to new service
providers within community.
Interventions 1.ICM**: Assertive Community Treatment from combined teams staIed by consumers (N = 58) and not
staIed by consumers (N = 59). ACT following the Stein and Test model. Caseload: 1:10. N = 117.
2. Standard care***: provided by 1 of 4 CMHCs and a number of smaller, more specialised agencies
(none providing assertive outreach). Average caseload ˜ 1:27. N = 61.
Outcomes Service use: not remaining in contact with psychiatric services****, admitted to hospital, number visits
to emergency room.
Social functioning: accomodation status, arrests.
Unable to use -
Social functioning: employment status, illicit drug use (not reported).
Mental state: general symptoms (not reported).
Herinckx-Oregon 1996 
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Quality of life: measurement instrument not specified (data not reported).
Satisfaction with services: measurement instrument not specified (not reported).
Notes *60% psychotic disorders, 40% affective disorders, 33% severe alcohol or drug use comorbidity, 61% 2+
admissions in last 6 months.
**StaI members were self identified mental health consumers DSM-III-R axis I diagnosis (˜ 50% of staI
had a diagnosis of bipolar disorder).
***In the standard care group: caseload ˜ 1:15 is provided to ˜ 33% participants.
****Disengagement does not include who moved out, who refused to be re-interviewed, death.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. Ratio randomisation between interventions: ICM:SC = 2:1. No fur-
ther details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Source of data not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Missing data are not addressed.
Selective reporting (re-
porting bias)
High risk Not all listed outcomes of interest are reported.
Other bias Low risk No details. No evidence of the presence of other bias.
Herinckx-Oregon 1996  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 18 months.
Country: East Lambeth, London, UK.
Participants Diagnosis*: hospital diagnosis of functional psychosis (no diagnostic criteria stated).
N = 70.
Setting: community psychiatric service.
Age: 16 to 64 years, mean ˜ 35 years.
Sex: 66% M (46M, 24F).
Ethnicity: not available.
Holloway-UK 1996 
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History**: referred by teams as being "hard to treat" (previous non-compliance with treatment, fre-
quent readmission or poor symptomatic response to conventional management), ii. live locally, iii. in-
formed consent given.
Interventions 1. ICM: intensive team-based Case Management. "Continuing care team" providing Assertive Case Man-
agement (according to the Clinical Case Management Model. Caseload: 1:8. N = 35.
2. Standard care: provided by community psychiatric nursing service. N = 35.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services, admitted to hospital.
Death: all causes and suicide.
Global state: leaving the study early.
Social functioning: Disability Assessment Scale (DAS).
Mental state: Comprehensive Psychopathological Rating Scale (CPRS), Schedule for the Assessment of
Negative Symptoms (SANS), depression, Beck Depression inventory (BDI).
Quality of life: Lancashire Quality of Life Profile (LQoLP).
Behaviour: Social Behaviour Scale (SBS).
Unable to use -
Participant satisfaction: satisfaction interview (not peer reviewed, scale developed by the research
team).
Notes *66% schizophrenia/schizoaffective disorder; 26% bipolar disorder.
**All had 1 or more psychiatric admission, years since onset of illness ≃ mean 11 years.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk Randomisation by sealed envelopes (not stated if opaque).
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: most are interviewer rated - rating - No. Interviewers are
not blind to treatment condition.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Source of data and blinding not reported for mortality and service use. Raters
were not blinded for mental state and social functioning outcomes.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk YES - Primary outcomes: average number of days in hospital per month; not
remaining in contact with psychiatric services. No missing data.
NO - Secondary outcomes: imbalance in numbers for missing data across in-
tervention groups.
Selective reporting (re-
porting bias)
Low risk All listed outcomes of interest are fully reported.
Other bias Low risk No details. No evidence of the presence of other bias.
Holloway-UK 1996  (Continued)
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
118
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Methods Allocation: randomised.
Design: single-centre trial.
Duration: 18 months.
Country: South Carolina, USA.
Participants Diagnosis*: psychotic or major affective disorders (DSM-III-R, according to the Computer based Diag-
nostic Interview Schedule Revised (C-DIS-R)).
N = 122.
Age: 18 to 59 years, 55% > 34 years.
Sex: 68M, 54F.
Ethnicity: ˜ 28% non-white.
Setting: large urban mental health service.
History: i. participants were being discharged from the most recent of 2+ inpatient admissions in last
year or subacute care episodes or lengthy residential treatment and repeated emergency psychiatric
visits; ii. 2+ years of poor work history, eligible for public assistance, poor living skills, poor social sup-
port, history of inappropriate behaviour.
Interventions 1. **ICM (1): Programme Assertive Community Treatment (PACT) adaptation. Caseload: 1:15/20. N = 40.
2. **ICM (2): Intensive Broker Case Management Model. Caseload: 1:15/18. N = 42.
3. Standard care: from 1 of 4 multidisciplinary psychiatric teams. Clinical approach according to a gen-
eralist model with supplemental case management provided to ≃ 25% of the most unstable clients.
Caseload: 1:35 to 1:45. N = 40.
Outcomes Service use: average number of days in hospital per month***, average visits to emergency room***.
Social functioning: Social Adjustment Scale-II (SAS-II), Role Functioning Scale (RFS).
Unable to use -
Mental state: not reported with the psychometric measurement instrument.
Social functioning: use of alcohol and drug, legal system involvement (not reported).
Participant satisfaction: satisfaction with service (instrument not stated, data not reported). Satisfac-
tion with Life Scale (SLS) (not reported).
Costs: direct costs of psychiatric inpatient care (no SD).
Notes *Schizophrenia ˜ 75%.
**Both intervention (1) and intervention (2) would fit into the definition of Intensive Case Management
as described in this review, hence they could be considered as a single intervention. But as they were
reported separately in the original study, it was not possible to present data from these two samples
combined (it is not possible to sum up SD data). We decided to present only data from intervention (1)
versus standard care.
***Variance not reported - data from another study used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No information
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - Unclear. No information.
Jerrell-SCarolina1 1991 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Cost-of-care data were based on both public and private mental health ser-
vices. Blinding not reported. Blinding for interviewers for social adjustment,
mental state not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of randomised participants is not stated; only number of randomised
participants completing the study period is reported.
Selective reporting (re-
porting bias)
High risk Listed outcome of interest not reported or reported incompletely (i.e. service
use: no SD).
Other bias Low risk Publicly funded (National Institute of Mental Health). No details. No evidence
of the presence of other bias.
Jerrell-SCarolina1 1991  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 12 months.
Country: Sydney, Australia.
Setting: Eastern Suburb Mental Health Service (ESMHS).
Participants Diagnosis*: schizophrenia, bipolar disorder (diagnostic criteria not reported).
N = 73.
Setting: Eastern Suburb Mental Health Service (ESMHS).
Age: 16 to 70 years, mean ˜ 42 years.
Sex: 56% M (41M, 32F).
History: at least 3 of: i. high relapse rate over previous 2 years, ii. poor compliance, iii. disturbing behav-
iour, iv. frequent changes of accommodation, v. poor budgeting skills, vi. low quality of life, vii. difficul-
ty to manage in existing service. Resident of the ESMHS catchment area. No primary diagnosis of sub-
stance misuse, organic brain disorder, or intellectual disability.
Interventions 1. ICM**: Caseload: 1:8-10. N = 37.
2. Non-ICM: Caseload: 1:20-40. N = 36.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services, admission to hospital.
Death: all causes.
Global state: leaving the study early, compliance with medication.
Social functioning: accomodation status, number living in supported accomodation, employment, par-
ticipants spending at least 1 day employed, participants on paid employment, number of participants
having contact with police or legal system.
Behaviour: number of participants having incident of self harm or harm to others.
Costs: direct costs of all care.
Unable to use -
Service use: number admitted to hospital (not reported), use of general practitioner (not listed as re-
view outcome of interest).
Global state: clinically significant improvement (as Life Skill Profile (LSP) improvement ≧ 18 points/12
months) (scale assessment completed by the therapist, not reported what measurement used).
Social functioning: accomodation changes (not listed as review outcome of interest), LSP (assessment
completed by the therapist).
Johnston-Australia 1998 
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Costs: direct costs of psychiatric hospital care (no SD).
Notes *Schizophrenia 89%.
**Main difference between teams was in ratio of staI to participant. Both are multidisciplinary, co-or-
dinate and provide a variety of services, have access to inpatient, rehabilitation, and 24-hour crisis ser-
vice.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: most are clinician/participant mediated - rating - Un-
clear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use (hospitalisations), social functioning (accomodation status, em-
ployment, police and legal involvement), behaviour (self harm and harm to
others): collected and reported by the case manager. Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk YES - Primary outcomes: average number of days in hospital per month, not
remaining in contact with psychiatric services. Numbers and reasons for miss-
ing data clearly reported and balanced between groups.
NO - Secondary outcomes: imbalance in numbers for missing data across in-
tervention groups.
Selective reporting (re-
porting bias)
Low risk All listed outcomes of interest are fully reported.
Other bias Low risk No details. No evidence of the presence of other bias.
Johnston-Australia 1998  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 12 months.
Country: Baltimore, Maryland, USA.
Participants Diagnosis*: severe mental disorder (schizophrenia, schizoaffective disorder, or any other diagnosis axis
I and extensive prior hospitalisation history, according to the DSM-III-R).
N = 152.
Setting: CMHCs.
Age: 18 to 64 years, mean ˜ 37 years.
Sex: 67% M (102M, 50F).
History**: i. homeless***, ii. severe mental disorder****, iii. written consent given.
Lehman-Maryland1 1994 
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Interventions 1. ICM: Programme of Assertive Community Treatment (Stein and Test model). Caseload: 1:10-12. N =
77.
2. Standard care: care from community mental health centres and emergency facilities, though also a
small amount of non-ICM. N = 75.
Outcomes Service use: average number of days in hospital per month, admitted to hospital, average number of
admissions to emergency room (mean adjusted for race as covariate).
Global state: leaving the study early.
Social functioning: not living independently, days in stable accomodation.
Mental state: Colorado Symptom Index (CSI) (mean adjusted for race as covariate).
Quality of life: Lehman's Quality of Life Index (QOLI), satisfaction with general well-being (mean adjust-
ed for race as covariate).
Costs: direct cost of psychiatric hospital, direct costs of all health care.
Unable to use -
Social functioning: days in prison (reported data are not complete).
Quality of life: specific items reported from Quality of Life Scale (QOLS) (not global assessments).
Social functioning: objective QOLS (no data), days homeless (split reporting of different types of home-
lessness, no SD).
General health: Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) (mean adjusted for
race as covariate) (not listed as outcome of interest for the review).
Notes *Schizophrenia-like disorder: 58%, bipolar disorder 20%, major depression 8%, comorbid for sub-
stance use disorders 71%.
**74% homeless for at least 1 year in total; 34% homeless for ≧ 4 years.
***Homeless defined as: on street or shelter for ≧ 5 days last 45 or ≧ 14 last 180, or in temporary accom-
modation with ≧ 2 residential moves in last 6 months.
****Severe mental disorder: defined as diagnosis of schizophrenia or schizophrenia-like illness or re-
ceiving benefit because of mental disorder or had another axis I disorder and either: > 2 hospitalisa-
tions of > 21 days in past 3 years or a total of > 42 days prior to current hospitalisation or ≧ 90 days in
psychiatric hospital or nursing home in past 3 years or mental disability lasting > 1 year during which
unable to spend > 75% of time in some gainful activity.
Note complex inclusion criteria.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised (stratified random assignment). No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: those interviewer rated - rating - Unclear. No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Source of data not reported for service use (hospitalisations, emergency room
visits, outpatient visits for general medical care), social functioning (homeless-
ness, incarceration). Blinding not reported for mental state.
Quality of life and health survey self reported.
Lehman-Maryland1 1994  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition/exclusion (no reasons for missing data pro-
vided).
Selective reporting (re-
porting bias)
High risk Not all listed outcomes of interest are reported completely.
Other bias Low risk Publicly funded (Center for Mental Health Services, Maryland). No details. No
evidence of the presence of other bias.
Lehman-Maryland1 1994  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 18 months.
Country: Utah, USA.
Participants Diagnosis*: serious and persistent mental disorder.
N = 41.
Setting: mental health centre.
Age: not reported.
Sex: 56% M.
Ethnicity: 100% Caucasian (understood to be white).
History: unclear, no primary diagnosis of mental retardation or substance abuse.
Interventions 1. ICM: psychosocial rehabilitation programme at CMHC + Case Management (CM is modelled as
Strengths CM). Caseload: 1:20. N = 20.
2. Standard care: psychosocial rehabilitation programme** at CMHC. N = 21.
Outcomes Service use: admitted to hospital.
Global state: leaving the study early.
Unable to use -
Mental state: Brief Psychological Well-Being Index (BPWI) (unpublished scales, designed by authors es-
pecially for the population under study).
Global state: Self Report Inventory (SRI) (unpublished scales, designed by authors especially for the
population under study).
Carer satisfaction: Utah Family Burden Scale (unpublished, designed by authors especially for the pop-
ulation under study).
Social functioning: Utah Case Management Consumer Assessment Record (not independently rated, no
summary score, no SD).
Notes *Schizophrenia 46%, major depression 22%.
**Described as "a high quality rehabilitation program that informally provides many services typical of
case management". It is not a specific package of care and does not refer to a specific intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Macias-Utah 1994 
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Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition/exclusion (no reasons for missing data pro-
vided).
Selective reporting (re-
porting bias)
Unclear risk One listed outcome of interest is not reported completely (Utah Case Manage-
ment Consumer Assessment Record: no summary report, no SD).
Other bias Low risk Funded by public institution (NIMH). No details. No evidence of the presence
of other bias.
Macias-Utah 1994  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 14 months.
Country: Oxford, UK.
Participants Diagnosis*: severe persistent psychiatric disorder.
N = 80.
Setting: Oxford Social Service.
Age: 20 to over 60 years, mean ˜ 48 years.
Sex: 85% M (68M, 12F).
Ethnicity: not reported.
History**: i. either homeless, at risk of homelessness, living in supported, temporary or poor-quality
accommodation, experiencing social isolation, or causing disturbances, ii. not already receiving case
management, iii. informed consent given.
Interventions 1. ICM: Case Management from team of social services case managers (case managers are free to
choose how much time to offer each patient, but at minimum provided some intervention). Caseload: ˜
1:10. N = 40.
2. Standard care: provided by CMHTs. N = 40.
Outcomes Service use: average number of days in hospital per month, admitted to hospital.
Death: all causes.
Global state: leaving the study early.
Social functioning: REHAB scale, imprisonment, employment.
Quality of life: Quality of Life Index.
Costs: costs of all care per week (including accomodation).
Unable to use -
Need for care: Medical Research Council (MRC) Needs for Care Schedule (version modified by authors).
Behaviour: Social Integration Questionnaire (not published in peer-reviewed journal).
Social functioning: accomodation status (the definition of "better" and "worse" accommodation status
was not clearly stated), employment (no mean and SD reported).
Marshall-UK 1995 
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
124
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Costs: direct cost of psychiatric hospital care and of health care (no SD).
Notes *Schizophrenia and related disorder 74%.
**40% illness > 1 yr, 85% previous psychiatric admission.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation by permuted block. No further details.
Allocation concealment
(selection bias)
Unclear risk Randomisation by sealed envelopes (not stated if opaque).
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: those interviewer rated - rating - Unclear. No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Data for service use (hospitalisation), costs, social functioning (employment;
accomodation), non-psychiatric health care, psychiatric health care provided
by the respective healthcare providers. Blinding not reported. Mental state and
social functioning (social behaviour measured by REHAB) rated by a trained
observer. Blinding not reported.
Social functioning and quality of life self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition/exclusion (no reasons for missing data pro-
vided). Lost to follow-up reported at 7 months, not at 14 months. Reasons for
attrition reported only for the experimental sample.
Selective reporting (re-
porting bias)
Low risk Listed outcomes reported completely.
Other bias Low risk No details. No evidence of the presence of other bias.
Marshall-UK 1995  (Continued)
 
 
Methods McDonel-Indiana (A) refers to 4 centres grouped together, providing data on service use.
Methods: see above McDonel-Indiana 1997.
Participants Participants: see above McDonel-Indiana 1997.
N = 160.
Interventions Interventions: see above McDonel-Indiana 1997.
1. ICM: N = 80.
2. Non-ICM: N = 80.
Outcomes Service use: average number of days in hospital per month.
McDonel-Indiana (A) 
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
125
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Notes  
McDonel-Indiana (A)  (Continued)
 
 
Methods McDonel-Indiana (B) refers to the 5th centre alone, providing data on service use.
Methods: see above McDonel-Indiana 1997.
Participants Participants: see above McDonel-Indiana 1997.
N = 40.
Interventions Interventions: see above McDonel-Indiana 1997.
1. ICM: N = 20.
2. Control group: N = 20.
Outcomes Service use: average number of days in hospital per month.
Notes  
McDonel-Indiana (B) 
 
 
Methods Allocation: randomised.
Design: multicentre (5 rural sites).
Duration: 24 months.
Country: Indiana, USA.
Participants Diagnosis*: severe mental illness (DSM-III-R coded between 295 and 301.99).
N = 200 (40 participants for each site).
Setting: 5 rural CMHCs.
Age: > 18 years, mean ˜ 38.1 years (SD 11.1).
Sex: 43% M (86M, 114F).
Ethnicity: 98% Caucasian (understood to be white).
History**: i. poor utilisation of community mental health services and frequent use of psychiatric hos-
pital or emergency room, ii. difficulties with the legal system or in maintaining stable housing, iii. more
than 1 episode of intensive psychiatric care lasting > 2 months, iv. impaired role functioning on a con-
tinuing or intermittent basis for at least 2 years.
Interventions 1. ICM: Assertive Community Treatment (1 site had addition of Rhinelander model to ACT). Caseload:
1:10. N = 100.
2. Non-ICM: provided by the mental health services: office-based; subscribed to the tradition of individ-
ual Case Management (including day treatment, partial hospitalisation, outpatient therapy, residential
services). Caseload: 1:30 to 1:60. N = 100.
Outcomes Service use: average number of days in hospital per month (provided for 2 groups of centres, see below
in McDonel-Indiana 1997 A and McDonel-Indiana 1997 B).
Global state: leaving the study early.
Unable to use -
Service use: admission (sample size not reported).
Global functioning: Global Assessment of Functioning (GAF) (rated by the therapist), compliance with
medication on 11-item client-rated checklist (not a peer-reviewed scale).
Social functioning: Indiana Level of Functioning (Indiana LOF) (rated by the therapist), accomodation
quality and employment scale (not a peer-reviewed scale).
McDonel-Indiana 1997 
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Social functioning: days in jail, number of police contacts (sample size not reported).
Mental state: Brief Psychiatric Rating Scale (BPRS) (rated by the therapist).
Quality of life: scale modified by the trialist (not a peer-reviewed scale).
Satisfaction with services: satisfaction with service scale (not peer-reviewed scale).
Notes *Schizophrenia 48%, affective disorder 32%. N = 153.
**Mean lifetime hospitalisation: 8.4 (SD 7.5), mean hospitalisation in the previous years: 1.3 (SD 1.1). N
= 153.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcome: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use (hospitalisation) was obtained from agency records and the state
Department of Mental Health database. Blinding not reported.
Accomodation, legal involvement, and education outcomes were self reported
and verified by case managers. Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition/exclusion (number of missing data is report-
ed, but no reasons provided). Number of participants randomised to each
group not clearly reported (some participants refused to participate and they
were not clearly accounted for in each group).
Selective reporting (re-
porting bias)
High risk Some listed outcomes of interest are reported incompletely (sample size not
reported for social functioning and admission).
Other bias Low risk Publicly funded (NIMH grant). No details. No evidence of the presence of other
bias.
McDonel-Indiana 1997  (Continued)
 
 
Methods Allocation: randomised.
Design: single site.
Duration: 12 months.
Country: Missouri, USA.
Participants Diagnosis*: psychiatric diagnosis (DSM-III-R).
N = 178**
Setting: community (drop-in daytime centres for homeless in St Louis area, mental health clinic operat-
ed by Missouri Department of Mental Health).
Age: mean ˜ 33.7 years.
Morse-Missouri1 1992 
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Sex: 58% M (103M, 75F).
Ethnicity: 52.5% non-white, mostly African-American.
History***: i. serious psychiatric disorder defined as a) previous psychiatric hospitalisation or b) above
90th centile on Global Severity Index or c) above 90th centile on psychoticism, paranoid ideation, or de-
pression subscales of the Brief Symptom Inventory severity index, ii. currently homeless, iii. plans to
stay in the study area for its duration, iv. no serious violent behaviour.
Interventions 1. ICM: clinical case management based on ACT principles (TCL model). Caseload: 1:10. N = 52.
2. Standard care: traditional outpatient treatment provided at local mental health clinic (offered psy-
chotherapy, medication, and assistance in obtaining social services). N = 64.
3. Drop-in centres****: 2 daytime centres made available, 1 exclusively for women. Centre offered
respite when other emergency shelters closed. Provided food, clothing, showers, some recreational ac-
tivity. Social workers available for referrals to other social services, staI-client ratio 1:40. N = 62.
Outcomes Global state: leaving the study early.
Unable to use -
Social functioning: Personality and Social Network Adjustment Scale (N for treatment groups not pre-
sented).
Social functioning: mean number of days spent homeless in past month (N for treatment groups not
presented), monthly quantity and frequency of alcohol consumption based on form developed by the
National Institute on Alcohol Abuse and Alcoholism (N for treatment groups not presented).
Mental state: global severity index of Brief Symptom Inventory (N for treatment groups not presented).
Participant satisfaction: measuring instrument not reported (N for treatment groups not presented).
Self esteem: Rosenberg's Self Esteem Scale (not peer reviewed, N for treatment groups not presented).
Costs: mean monthly income (not described as a review outcome of interest, N for treatment groups
not presented).
Notes *30.1% schizophrenia, 21% major depression, 8% bipolar, 5% other psychotic disorder, 12% alcohol
abuse, 4% other drug abuse, 15% other axis I disorder, 5% no diagnosis. Of those with major axis I dis-
order, 23% had dual diagnosis with substance abuse. N = 155 (as for remaining 23 participants, it was
not possible to assess diagnosis).
**Initially 50 people assigned to each treatment group, but if they were lost to follow-up within the first
month after entering the study, they were replaced by random assignment.
***Mean length of time since last stable address 16.6 months, 71.9% had previous psychiatric hospitali-
sation.
****Data from the drop-in centre arm were not presented as the intervention provided did not fit the in-
clusion criteria for any of the interventions addressed in this review.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details. Participants lost to follow-up within first
month were replaced, replacement was performed through random alloca-
tion.
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: not available.
Secondary outcomes: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Morse-Missouri1 1992  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number and reasons for lost to follow-up incompletely reported.
Selective reporting (re-
porting bias)
High risk All data presented but not usable due to N for treatment groups missing.
Other bias Low risk Publicly funded (grants from National Institute of Mental Health). No further
details. No evidence of the presence of other bias.
Morse-Missouri1 1992  (Continued)
 
 
Methods Allocation: randomised.
Design: single site.
Duration: 24 months.
Country: Missouri, USA.
Participants Diagnosis*: severe mental illness and substance abuse disorder (according to DSM-IV).
N = 196.
Age: 18 to 66 years, mean ˜ 40 years.
Sex: ˜ 80% M.
Ethnic: 73% African-American, 25% Caucasian (understood to be white), 2% other minority.
History**: currently homeless and severely mentally ill, not already enrolled in an Intensive Case Man-
agement programme.
Interventions 1. ICM: clinical team trained to deliver psychiatric care package following ACT principles and practices.
Caseload: 1:10. Treatment of participant's substance abuse via referral to other community providers
for outpatient or individual substance abuse services, 12-step group. N = 46.
2. Standard care: participants shown a list of community agencies that provided mental health and/or
substance abuse treatment***. Team also provided linkage assistance to help participants access these
services. N = 49.
3. Integrated Community Treatment: combination of Integrated Treatment Services and Assertive
Community Treatment (IACT), clinical team trained to deliver psychiatric care package following ACT
principles and practices. Also trained to follow Integrated Treatment principles and practices. Sub-
stance abuse services provided directly via counselling and bi-weekly treatment groups. Substance
abuse specialist part of IACT team. N = 54****.
Outcomes Social functioning: number of days homeless per month, mean number of days used substances.
Costs: inpatient psychiatric costs, healthcare costs, costs of all care.
Unable to use -
Service use: contacts with treatment programme - not clearly defined (not described as a review out-
come of interest).
Global state: leaving the study early (overall loss given, no individual group data).
Mental state: 24-item BPRS (data reported are not likely to be obtained through the stated measure-
ment instrument, as rating scores reported are not consistent with this scale).
Satisfaction: client satisfaction (modified scale used; not peer reviewed).
Social functioning: substance abuse rating score (scale not described or referenced).
Costs: emergency shelter costs (not described as a review outcome of interest).
Morse-Missouri3 2005 
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Notes *48% schizophrenia, 19% schizoaffective disorder, 11% atypical psychotic disorder, 11% bipolar, 9%
major depression-recurrent disorder, 2% delusional disorder.
**Mean 12.5 days homeless in previous month.
***Most agencies specialised in either mental health treatment or substance abuse treatment, but not
both.
****Data from this group not used in final analysis, as ACT plus another treatment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, but no description given.
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: not available.
Secondary outcomes: interviewer rated - rating - Unclear. Not described.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use data were obtained from service agencies, claim records, and par-
ticipant self report. Services provided. Blinding not reported.
Homelessness, income, alcohol consumption self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Attrition described for the total sample and analysed for effect on outcome.
Number and reasons for loss to follow-up not reported for single arm.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.
Other bias Low risk No details. No evidence of the presence of other bias.
Morse-Missouri3 2005  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 18 months.
Country: Greenwich Health District, London, UK.
Participants Diagnosis*: severe mental illness: psychotic disorder (schizophrenia or affective psychosis) (diagnostic
criteria not reported).
N = 82.
Setting: Health District.
Age: 18 to 64 years, mean ˜ 37 years.
Sex: 56% M (46M, 36F).
Race: 23.1% African/Afro-Caribbean.
History**: schizophrenia or affective psychosis lasting > 2 years, ≧ 2 hospital admissions last 2 years,
about to be discharged, no primary organic disorder.
Muijen-UK2 1994 
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Interventions 1. ICM: Case Management approach provided by a Community Support Team (community psychiatric
nurses and team leader). The team acts as advocate, practical assistance with welfare benefits and
housing, no-discharge policy. Caseload: 1:8-11 for the first 15 months (until April 1990), then increased
to caseload: 1:20-25 for the last 3 months, until the end of the trial. N = 41.
2. Standard care: provided by community psychiatric nurses (CPNs) working independently and based
in primary care. N = 41.
Outcomes Service use: average number of days in hospital per month.
Death: all causes and suicide.
Global state: leaving the study early.
Mental state: BPRS 24-item, PSE.
Social functioning scale: GAS, SAS, imprisoned.
Participant satisfaction (by short term).
Costs: direct costs of all care.
Unable to use -
Social functioning: accomodation (authors reported data on "patients using hostel accommodations";
it is unclear what is included in this definition).
Participant satisfaction (by medium and long term).
Client Satisfaction Questionnaire (CSQ) (attrition > 50%).
Carer satisfaction (attrition > 50%).
Costs: other costs (no SD).
Notes *Schizophrenia-like disorder 83%; mania 12%; psychotic depression 0.5%.
**Baseline mean number of admissions: 5.7.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: those interviewer rated - rating - Unclear. No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use, income, and accomodation data were collected using the Client
Service Receipt Interview. Information was also taken from case records on
frequency and duration of input from CPNs. Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number of lost to follow-up is stated, but reason for attrition is reported
generically, referred to the entire sample size and not the single intervention
sample.
Selective reporting (re-
porting bias)
High risk All listed outcomes of interest are fully reported (but some economic out-
comes missing any variance measurement).
Other bias Low risk No details. No evidence of the presence of other bias.
Muijen-UK2 1994  (Continued)
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Methods Allocation: randomised.
Design: multicentre (2 sites: Site A, New West; Site B, Surrey - individual centre data not reported).
Duration: 24 months.
Country: British Columbia, Canada.
Participants Diagnosis*: majority of participants affected by schizophrenic disorder, others any DSM-III axis I or axis
II (including dual diagnosis).
N = 123.
Setting: CMHC.
Ethnicity: data not available.
Age: 19 to 64 years (randomised sample age not reported).
Sex: 49.5% M (61M, 62F).
History: i. serious and persistent mental illness with impaired role functioning, ii. about to be dis-
charged from hospital, iii. high risk of rehospitalisation, iv. no primary diagnosis of substance abuse,
organic brain disease, or developmental disorder, v. no recent history of severe violence, vi. informed
consent to participate.
Interventions 1. ICM: care from a CMHC plus additional Assertive Case Management according to Stein and Test mod-
el. Caseload: ˜ 1:10. N = 63.
2. Standard care: care from a CMHC. N = 60.
Outcomes Service use: average number of days in hospital per month**, number of admissions**.
Death: all causes and suicide.
Global state: leaving the study early.
Unable to use -
Quality of life: scale (not peer reviewed).
Notes *Schizophrenia-like disorder (60.2%).
**Variance not reported - data from another study used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcome: those clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Hospitalisation based on hospital records. Blinding not reported.
Quality of life self reported.
Muller-Clemm-Canada 1996 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number randomised not clearly reported, as authors declared that "Clients
who withdrew from the study within the first 6 months were replaced by other
clients".
Selective reporting (re-
porting bias)
High risk Outcome length of hospitalisation reported incompletely (no SD).
Other bias Low risk No details. No evidence of the presence of other bias.
Muller-Clemm-Canada 1996  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration*: 4 months.
Country: Nashville, Tennessee, USA.
Participants Diagnosis**: mental illness causing significant impairment. No further information provided.
N = 152.
Setting: urban mental health centres.
Age: 18 to 55 years, mean ˜ 36.8 years (SD 9.1).
Sex: 59% M.
Ethnicity: 40% non-white.
History: i. clients of mental health centres, ii. serious mental illness as judged by eligibility for disability
benefits.
Interventions 1. ICM***: employment-oriented case management provided by psychiatric vocational rehabilitation
specialists, supervised by the multidisciplinary team, vocational rehabilitation specialists. Caseload:
1:10. N = 73.
2. Non-ICM: standard case management services from CMHC. Caseload: 1:40 to 90. N = 79.
Outcomes Global state: leaving the study early.
Unable to use -
Service use: admission data (not reported).
Social functioning: employment status (data are reported referring to the full trial length, although in-
tervention was provided for only first 4 months)*.
Costs: insufficient data reported.
Notes  *Variable follow-up period - all received 4 months' intervention and one 3-month follow-up interview,
some participants were followed up for as long as 24 months (intervention duration was 4 months). We
reported data from only 4 months' follow-up.
**Schizophrenia 23%, mood disorder 21%, 33% no current diagnosis according to SCID diagnostic cri-
teria.
***The psychiatric vocational rehabilitation specialist intervention was provided for 4 months. The
project specialist engaged the clients in therapeutic and rehabilitation activities and assisted mental
health workers to obtain services more expeditiously, the psychiatrist was available 24 hours a day for
consultation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Okpaku-Tennessee 1997 
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Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: not available.
Secondary outcome: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Hospitalisation, employment, income, illegal activity self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition/exclusion to permit judgement (number for
missing to follow-up is reported, but reason is not reported).
Selective reporting (re-
porting bias)
High risk More listed outcomes of interest are reported incompletely.
Other bias Low risk Publicly funded (grant from the Social Security Administration). No further de-
tails. No evidence of the presence other bias.
Okpaku-Tennessee 1997  (Continued)
 
 
Methods Allocation: randomised.
Design: multicentre (5 centres, in Copenhagen and Aarhus, data not available for single centres).
Duration: 24 months of active treatments after randomisation.
Follow-up: 5 and 10 years after randomisation (i.e. 3 and 8 years after the active intervention was pro-
vided). Starting from 2 years after randomisation, all participants received standard care (both those
randomised to the experimental intervention and those randomised to standard care).
Country: Copenhagen and Aahrus, Denmark.
Participants Diagnosis*: schizophrenia or schizophrenia-like psychosis (according to ICD-10) (main diagnosis and
comorbidity based on SCAN 2.0 and SCAN 2.1).
N = 547.
Setting: public mental health service.
Age: 18 to 45 years, mean 26.6 years.
Sex: 59% M (323M, 224F).
Ethnicity: not reported.
History**: i. prior treatment of mental disorder has not been adequate (i.e. ≦ 12 weeks of continuous
antipsychotic medication in antipsychotic dosage), ii. absence of learning disability, organic mental
disorder, and psychotic condition due to psychoactive substance use, iii. Danish speaker, iv. written in-
formed consent, v. legal residence in the catchment area, vi. the use of psychoactive drug did not cause
exclusion.
Interventions 1. ICM***: modified Assertive Community Treatment (including individual case manager, recommenda-
tion of antipsychotic medications, psycho-educational family treatment****, and social skill training).
Caseload: 1:15. N = 275.
2. Standard care***: treatment in a CMHC. Caseload: 1:20-30. N = 272.
Outcomes Service use: average number of days in hospital per month; not in contact with service, defined as "an
unplanned break of at least 30 days in treatment or between treatment regimens or status (i.e. from
OPUS-Denmark 1999 
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discharge to outpatient status)"; admitted to hospital (during previous 12 months); proportion not hos-
pitalised; proportion without outpatient contacts; proportion without psychiatric emergency room
contacts.
Death: all causes, suicide.
Global state: leaving the study early.
Social functioning: not working or in education, not living independently, alcohol and drug abuse di-
agnosed with SCAN, contact with the legal system - imprisonment (2-year treatment and 3-year fol-
low-up), number of days in supported housing, number of days in a homeless shelter.
Mental state, specific symptoms: positive symptoms (Scale for Assessment of Positive Symptoms -
SAPS), negative symptoms (Scale for Assessment of Negative Symptoms - SANS), comorbidity with de-
pression.
Participant satisfaction: Client Satisfaction Questionnaire (CSQ).
Behaviour: specific behaviour, self harm (measured by self reporting of suicide attempts).
Unable to use -
Global state: compliance with medications: defined "good compliance" as having taken the prescribed
antipsychotic medications in the recommended doses regularly during previous 3 months (not report-
ed), GAF (reported only subscale data, not global score).
Social functioning: Social Network Size (not published measure instrument), Social Network Schedule
(SNS); various outcomes on accomodation status (as proportion spending at least 1 day in supported
housing or in homeless shelter): not listed as a review outcome of interest.
Mental state, specific symptoms: disorganised dimension (not stated how it is measured) and suicidal
ideation (not listed as a review outcome of interest).
Quality of life: not reported.
Participant satisfaction: Camberwell Assessment of Need (CAN) (not reported).
Relative satisfaction: Client Satisfaction Questionnaire 8-item, adapted version (not reported).
Behaviour: Social Behaviour Assessment Schedule (SBAS) (reported only score on subscale).
Use of coercive measure: not listed as a review outcome of interest.
Assessment of expressed emotion: not listed as a review outcome of interest.
Notes *Schizophrenia 66%; schizotypal disorder ˜ 15%; schizoaffective disorder ˜ 5%.
**Median duration of untreated psychosis ˜ 50 weeks.
***In both interventions use of antipsychotics followed the guidelines from the Danish Psychiatry So-
ciety (recommending a low-dose strategy for patients with first-episode psychosis and the use of sec-
ond-generation drugs as first choice).
****Family treatment followed McFarlane's manual for psychoeducational treatment for multiple-fam-
ily group (18 months' treatment, 1.5 hours twice a week, in a multiple-family group with 2 therapists
and 4 to 6 patients with their families). Focus on problem solving and development of skills to cope
with illness.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised.
In Copenhagen, allocation sequence was computer generated. In Aahrus, a
secretary drew a lot among 5 red and 5 white lots from a black box. Central
randomisation. Randomisation was 1:1, in block of 6, stratified for each of the
5 centres.
Allocation concealment
(selection bias)
Low risk In Copenhagen, randomisation was carried out through centralised telephone
allocation.
In Aahrus, researchers were informed on the randomisation assignment after
they had finished the entry assessment. Block sizes were unknown to investi-
gator.
Blinding (performance
bias and detection bias) 
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
OPUS-Denmark 1999  (Continued)
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All outcomes Secondary outcome: those interviewer rated - rating - No. Reported: "Investi-
gators were not blind to treatment allocation".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use based on official registers, blinding not reported. Interviewers for
mental state unblinded.
Client satisfaction, suicide attempts, and suicidal ideation self reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Numbers and reasons for missing data are clearly reported. Analysis was con-
ducted on an ITT basis.
Selective reporting (re-
porting bias)
High risk Authors reported change of primary outcome stated in the protocol (from "re-
lapse and positive symptoms" to "psychotic and negative symptoms"), as high
attrition occurred in the former outcome measurements. Some listed out-
comes of interest are not reported.
Other bias Low risk Publicly funded. No declaration of interest. No further details. No evidence of
the presence of other bias.
OPUS-Denmark 1999  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 24 months.
Country: San Francisco, USA.
Participants Diagnosis: severe and persistent mental illness (psychiatric disorder as the primary source of disabili-
ty).
N = 37.
Setting: Department of Psychiatry, San Francisco General Hospital.
Age: ≧ 18 years.
Sex: not reported.
Ethnicity: European (understood to be white) or African-American.
History: high user of intensive treatment care who had experienced an unsatisfactory quality of life in
the community, i. recently hospitalised; ii. no primary diagnosis of (a) organic brain disease, (b) sub-
stance abuse disorder with no other psychiatric disorder, or (c) learning disability; iii. no history of vio-
lence not due to treatable psychiatric symptoms; iv. written informed consent.
Interventions 1. ICM: standard care + Assertive Community Treatment according to Stein and Test model, culturally
focused on needs of Afro-American population. Caseload: 1:10. N = 22.
2. Standard care: Caseload: 1:30. N = 15.
Outcomes Global state: leaving the study early.
Unable to use -
Service use: average number of days in hospital per month (not reported).
Global functioning: GAF (attrition 57%).
Costs: reported incompletely (no mean, no SD).
Notes  
Pique-California 1999 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised. Stratified by sex, ethnicity, recruitment centre, assignment to in-
tervention 2:1. Randomisation sequence constructed by independent investi-
gator using a table of random permutation.
Allocation concealment
(selection bias)
Unclear risk Randomisation sequence in sealed, opaque envelopes, unused assignment
envelopes kept in a locked container (available to the recruiter psychiatrists).
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: not available.
Secondary outcome: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use data were obtained from the county database. Costs were ob-
tained from billing records. Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Author did not address this outcome. Reasons for missing outcome data not
reported.
Selective reporting (re-
porting bias)
High risk Listed outcome of interest reported incompletely (costs: no mean, no SD).
Other bias Low risk No details. No evidence of the presence of other bias.
Pique-California 1999  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 24 months.
Country: San Diego, California, USA.
Participants Diagnosis*: major disorder DSM-III-R axis I.
N = 90.
Setting: San Diego County Mental Health Service.
Age: > 18 years, 33% > 40 years, mean ˜ 37 years.
Sex: 44% M (40M, 50F).
Ethnicity: 43% non-white (18% African-American).
History: ≧ 3 hospitalisations last 2.5 years.
Interventions 1. ICM: Assertive Community Treatment according to Stein and Test model. Caseload: 1:15. N = 30.
2. Non-ICM: traditional CM programme, no team approach. Caseload: 1:40-60. N = 30.
3. Standard care: services offered by the public mental health system. N = 30.
Outcomes Service use: average number of days in hospital per month.
Costs: direct costs of psychiatric hospital care.
Unable to use -
Quinlivan-California 1995 
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Service use: other service use than hospital (reported incompletely).
Global state: leaving the study early (not reported).
Costs: direct costs of other psychiatric care (outcomes relevant to this review not directly examined).
Notes *56% schizophrenia; 23% bipolar disorder.
This is a 3-arm study, data from the study are included in both comparisons addressed by the review:
ICM versus non-ICM and ICM versus standard care.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, no further details.
Allocation concealment
(selection bias)
Unclear risk No information
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: - rating - Yes. No information provided, but available
outcomes are not likely to be influenced by lack of blinding.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Hospitalisation data were obtained from the county mental health services di-
vision's management information system. Costs were based on budgeted unit
cost of each service multiplied by the total number of units as reported in the
management information system.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The study did not address this outcome.
Selective reporting (re-
porting bias)
Low risk Listed outcomes of interest are reported completely.
Other bias Low risk No data provided. No evidence of the presence of other bias.
Quinlivan-California 1995  (Continued)
 
 
Methods Allocation: randomised.
Design: multicentre (2 centres, information for single centre not available).
Duration: 18 months. During this period, participants remained allocated in their trial arm.
Follow-up: 36 months and 10 years after randomisation (i.e. 18 months and 8.5 years after the active in-
tervention was provided). During the follow-up period, participants could remain in the originally allo-
cated intervention (ICM) or be transferred to the control one.
Country: London, UK.
Participants Diagnosis*: SMI (schizophrenia, schizoaffective disorder, other chronic psychosis, bipolar affective dis-
order).
N = 251.
Setting: community services in 2 inner London boroughs (Camden and Islington).
REACT-UK 2002 
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Age: mean 39 years (SD 11).
Sex: 58% M.
Ethnicity: African-Caribbean 36%.
History: i. living independently or in low-supported accomodation, ii. under the care of CMHT ≧ 12
months and having difficulty engaging with standard community care, iii. recent high use of inpatient
care (i.e. ≧ 100 consecutive inpatient days or ≧ 5 admissions during previous 2 years, or ≧ 50 consecu-
tive inpatient days or ≧ 3 admissions previous 1 year), iv. substance misuse or personality disorder eli-
gible if these were secondary diagnosis, v. no organic brain damage.
Interventions 1. ICM: Assertive Community Treatment (as described by McGrew 1995). Caseload: 1:12. N = 127.
2. Non-ICM: services offered by CMHT (according to Care Programme Approach). Caseload: 1:35. N =
124.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services (defined as no face-to-face contacts between staI and client in previous 3 months), average
admission, admitted to hospital.
Death: all causes and suicide.
Global state: leaving the study early, Health of the Nation Outcome Scale (HoNOS), Rating of Medica-
tion Influence scale (ROMI).
Social functioning: arrested, imprisoned, number homeless, living independently, living in supported
accomodation, Life Skill Profile (LSP), substance abuse: assessed through various scales (Alcohol Use
Scale - AUS, Drug Use Scale - DUS, Substance Abuse Treatment Scale - SATS), but reported as binary
outcome.
Mental state: Brief Psychiatric Rating Scale (BPRS-24 item).
Behaviour: self harm, injury to others.
Quality of life: Manchester Short Assessment of Quality of Life (MANSA).
Participant satisfaction: Client Satisfaction Questionnaire modified version (CSQ-modified), Camber-
well Assessment Need abbreviated form (CAN).
Unable to use -
Use of Mental Health Act (not listed as review outcome of interest).
Quality of engagement: adapted form of Homeless Engagement Acceptance Scale (HEAS) (not listed as
review outcome of interest).
Notes *53% schizophrenia; 13% schizoaffective; 4% bipolar; 26% illicit drug misuse; 25% alcohol misuse.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised: permuted block randomisation with a block size of 8 ensuring
parity between CMHT in proportions randomised to ICM.
Allocation concealment
(selection bias)
Low risk The interviewer contacted an administrator at the trial centre who opened the
appropriate numbered envelope communicating the outcome of randomisa-
tion. Participants and referrers were informed of the treatment assignment by
letter.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - No. Interviewers were inde-
pendent of clinical care, but not blind.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Source of service use data not reported.
REACT-UK 2002  (Continued)
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Self harm, violence, contact with legal services, quality of life, compliance with
medication, and mental state were obtained from interviews with clients. Oth-
er scales were completed by care co-ordinators. All additional data were col-
lected from case notes. Assessors not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk YES - Primary outcomes: average number of days in hospital per month. No
missing data (except death, balanced in numbers across groups).
YES - Secondary outcomes: number and reasons for missing data are reported.
Analysis carried out on an ITT basis.
Selective reporting (re-
porting bias)
Low risk All of the listed outcomes of interest are completely reported.
Other bias Low risk Publicly funded (Camden and Islington Health Authority; King's Fund; Depart-
ment of Health). Competing interesting declared: none. No further details. No
evidence of the presence of other bias.
REACT-UK 2002  (Continued)
 
 
Methods Allocation: randomised.
Design: multicentre. 10 sites: 6 General Medical and Surgical centres (GMS) and 4 Neuropsychiatric (NP)
centres. Data available both for single centre and for 2 pooled centre groups (GMS and NP). See below.
Duration: 24 months.
Country: Northeastern United States
Participants Diagnosis*: primary psychiatric disorder.
N = 873.
Setting: community-based psychiatric care - Department of Veterans Affairs (VA).
Age: 48% > 45 years, mean 47.6 years.
Sex: 100% M.
Ethnicity: 20% non-white.
History: i. current inpatient in VA psychiatric unit, ii. no primary diagnosis of substance abuse or organ-
ic brain disease, iii. recent high user of psychiatric care (definition varied between GMS and NP centres),
iv. written consent.
Interventions 1. ICM: Intensive Psychiatric Community Care programme, providing ACT intervention according to
Stein and Test model. Caseload: average 1:7-15. N = 454.
2. Standard care**: routine care from psychiatric services provided by Veterans Affairs, including inpa-
tient and outpatient psychiatric treatment, psychopharmacological treatment, and rehabilitation ser-
vice. N = 419.
Outcomes Service use: average number of days in hospital per month (both pooled data for GMS and NP centres
and data for single centre available; see below)***.
Global state: GAS (authors reported results pooled for GMS and NP centres; see below).
Mental state: BPRS-18 item, BSI (authors reported results pooled for GMS and NP centres; see below).
Costs: total healthcare cost (authors reported results pooled for GMS and NP centres; see below).
Unable to use -
Global state: self reported measure (not published, not peer reviewed).
Participant satisfaction: satisfaction with service (measurement instrument not published, not peer re-
viewed).
Social functioning: Addiction Severity Index (ASI) (reported only a subscale, not the overall score).
Costs: non-healthcare costs (not listed as an outcome of interest in the review).
Notes *Schizophrenia 50.5%, dual diagnosis 28%, bipolar disorder 10%.
**Standard care provided by both types of centre did not differ programme wise.
Rosenheck-USA 1993 
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***Pooled data for GMS and NP entered the meta-analysis; data for single centre entered in meta-re-
gression.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised through coin tossing.
Allocation concealment
(selection bias)
Unclear risk No details (reported only that the assignment by coin tossing was performed
by an independent researcher).
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - Unclear. Authors report that
interviewers are independent, but it is not stated whether they are blind to
participant assignment.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Service use (hospital and nursing home service use) was derived from the VA's
national computerised workload monitoring systems. Blinding not reported.
Costs were determined using VA's standardised Cost Distribution Report.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The study did not address this outcome.
Selective reporting (re-
porting bias)
High risk Some listed outcomes of interest are not reported completely (i.e. substance
abuse, which is reported only as a subscale score and not general score).
Other bias Low risk No details. No evidence of the presence of other bias.
Rosenheck-USA 1993  (Continued)
 
 
Methods Rosenheck-USA-GMS refers to 6 General Medical and Surgical centres (GMS) pooled together (centre A,
B, D, F, I, J).
Methods: see above Rosenheck-USA 1993.
Participants Participants: see above Rosenheck-USA 1993.
Following data are specific for Rosenheck-USA-GMS:
N = 528.
Setting: Department of Veterans Affairs (VA) - 6 GMS centres enrolled in the Intensive Psychiatric Com-
munity Care programme. GMS centres are located in urban centres, provide shorter-term, crisis-orient-
ed, inpatient care.
History: i. current inpatient in VA psychiatric unit, ii. no primary diagnosis of substance abuse or organ-
ic brain disease, iii. recent high user of psychiatric care (defined as i. ≧ 40 days in hospital or ii. ≧ 2 ad-
missions in the previous year), iv. written consent.
Interventions 1. ICM*: Intensive Psychiatric Community Care programme, providing ACT intervention according to
Stein and Test model. Caseload: average 1:7-15. N = 271.
Rosenheck-USA-GMS 
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2. Standard care: routine care from psychiatric services provided by Veterans Affairs, including inpa-
tient and outpatient psychiatric treatment, psychopharmacological treatment, and rehabilitation ser-
vice. N = 257.
Outcomes Service use: average number of days in hospital per month**.
Global state: GAS.
Mental state: BPRS-18 item, BSI.
Costs: costs of health care.
Notes *Centre J: caseload 1:44.
**Entered in the meta-analysis.
Rosenheck-USA-GMS  (Continued)
 
 
Methods Rosenheck-USA-GMS (A) is a GMS centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
N = 79.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
1. ICM: N = 44.
2. Standard care: N = 35.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-GMS (A) 
 
 
Methods Rosenheck-USA-GMS (B) is a GMS centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
N = 94.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
1. ICM: N = 47.
2. Standard care: N = 47.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-GMS (B) 
 
 
Methods Rosenheck-USA-GMS (D) is a GMS centre.
Rosenheck-USA-GMS (D) 
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Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
N = 102.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
1. ICM: N = 49.
2. Standard care: N = 53.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-GMS (D)  (Continued)
 
 
Methods Rosenheck-USA-GMS (F) is a GMS centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
N = 78.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
1. ICM: N = 43.
2. Standard care: N = 35.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-GMS (F) 
 
 
Methods Rosenheck-USA-GMS (I) is a GMS centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
N = 88.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-GMS.
1. ICM: N = 44.
2. Standard care: N = 44.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-GMS (I) 
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Methods Rosenheck-USA-NP refers to 4 Neuropsychiatric centres (NP) pooled together (centre C, E, G, H).
Methods: see above Rosenheck-USA 1993.
Participants Participants: see above Rosenheck-USA 1993.
Following data are specific for Rosenheck-USA-NP:
N = 345.
Setting: Department of Veterans Affairs (VA) - 4 NP centres enrolled in the Intensive Psychiatric Commu-
nity Care programme. NP centres are large facilities providing long-term mental health care in subur-
ban or rural settings.
History*: i. current inpatient in VA psychiatric unit, ii. no primary diagnosis of substance abuse or or-
ganic brain disease, iii. recent high user of psychiatric care (defined as i. ≧ 180 days in hospital or ii. ≧ 4
admissions in the previous year), iv. written consent.
Interventions 1. ICM: Intensive Psychiatric Community Care programme, providing ACT intervention according to
Stein and Test model. Caseload: average 1:7-15. N = 183.
2. Standard care: routine care from psychiatric services provided by Veterans Affairs, including inpa-
tient and outpatient psychiatric treatment, psychopharmacological treatment, and rehabilitation ser-
vice. N = 162.
Outcomes Service use: average number of days in hospital per month**.
Global state: GAS.
Mental state: BPRS-18 item, BSI.
Costs: direct costs of health care.
Notes *Characteristic at baseline differs between NP sites regarding inpatient days before programme en-
try. Difference was attributable to site C. To compensate for this imbalance, the authors made an ad-
justment. The adjusted value was used in all the calculations, but the results they yielded did not differ
substantially from those obtained with unadjusted value.
**Entered in the meta-analysis.
Rosenheck-USA-NP 
 
 
Methods Rosenheck-USA-NP (C) is a NP centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
N = 93.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
1. ICM: N = 50.
2. Standard care: N = 43.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-NP (C) 
 
 
Methods Rosenheck-USA-NP (E) is a NP centre.
Rosenheck-USA-NP (E) 
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Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
N = 67.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
1. ICM: N = 34.
2. Standard care: N = 33.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-NP (E)  (Continued)
 
 
Methods Rosenheck-USA-NP (G) is a NP centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
N = 71
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
1. ICM: N = 40.
2. Standard care: N = 31.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-NP (G) 
 
 
Methods Rosenheck-USA-NP (H) is a NP centre.
Methods: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
Participants Participants: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
N = 114.
Interventions Interventions: see above Rosenheck-USA 1993 and Rosenheck-USA-NP.
1. ICM: N = 59.
2. Standard care: N = 55.
Outcomes Service use: average number of days in hospital per month*.
Notes *Entered in the meta-regression.
Rosenheck-USA-NP (H) 
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Methods Allocation: randomised.
Design: single centre.
Duration: 18 months.
Country: Charleston, South Carolina, USA.
Participants Diagnosis*: schizophrenia, schizoaffective disorder, bipolar disorder or other psychotic disorder (DSM-
III-R).
N = 173.
Setting: Charleston and Darchester CMHCs.
Age: 18 to 65 years, mean ≃ 35.5 yrs.
Sex: 54.8% M. (N = 114).
Ethnicity: 62.5% non-white. (N = 114).
History: i. history or high risk for high services use patterns (i.e. long-term or multiple hospitalisation),
ii. difficulty with treatment compliance, independent living, or activities of daily living, iii. no primary
diagnosis of personality disorder or substance abuse or organic brain syndrome, iv. no need for 24-hour
supervision, v. no assault behaviour in the previous year not associated with psychosis.
Interventions 1. ICM**: Programme of Assertive Community Treatment (PACT) provided by 2 different locations
(treatment based in CMHC and treatment run by nonprofit organisation located near CMHC). Caseload:
ranging during the trial duration from 1:6.5 to 1:13. N = 104.
2. Non-ICM: standard care from CMHC, providing primarily office-based case management programme.
Caseload: decreased during the trial duration from 1:68 to 1:34. N = 69.
Outcomes Service use: average number of days in hospital per month***; admitted to hospital.
Global state: leaving the study early.
Unable to use -
Costs: direct costs of psychiatric hospital care (no SD).
Notes *N = 114, 81.5% schizophrenia or schizoaffective disorder, 50.8% secondary diagnosis of substance
abuse disorder.
**PACT provided by the 2 sites did not differ.
***Variance not reported - data from another study used.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details
Salkever-SCarolina 1999 
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Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of missing data (number for missing data is provided,
but reason is provided for the whole sample, is not stated for single interven-
tion group).
Selective reporting (re-
porting bias)
High risk Listed outcomes of interest are fully reported, but any variance measurements
are missing.
Other bias Low risk Publicly funded (by NIMH and grant from universities and university centres
for research). No further details. No evidence of the presence of other bias.
Salkever-SCarolina 1999  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 24 months.
Country: New York, USA.
Participants Diagnosis*: severe mental illness causing severe disability (definition not clearly reported).
N = 168.
Setting: community services.
Age: ≧ 18 years, mean ˜ 40 years, range 21 to 66 years.
Sex: 76% M (128M, 40F).
Ethnicity: 61% black (understood to be African-American).
History: i. homeless for 7 of last 14 nights, ii. no primary diagnosis of substance abuse or learning dis-
ability, iii. not considered dangerous to self or others, iv. informed consent given.
Interventions 1. ICM: from the CHOICE programme, which aims to develop "housing readiness" (i.e. compliance with
psychiatric treatment and period of sobriety). The main features are: i. drop-in centre, ii. Case Manage-
ment intervention modelled according to main principles of the ACT model. Caseload: ˜ 1:13. N = 91.
2. Standard care**: homelessness and specialty mental health services provided from a variety of agen-
cies (including drop-in centres, outreach services, mental health and health services, soup kitchen,
shelters). It could involve non-ICM. N = 77.
Outcomes Social functioning: not living in stable accomodation.
Mental state: Colorado Symptom Index.
Quality of Life: Lehman's Quality of life Index (QOLI).
Unable to use -
Service use: hospital use (data partially reported).
Social functioning: police contact - imprisoned, arrested (data partially reported), change in proportion
of time spent in residential setting (incompletely reported).
Self esteem: Rosenberg's Self Esteem Scale (not peer reviewed).
Coping: Pearlin and Schooler's Mastery Scale (not listed as a review outcome of interest).
Participant satisfaction: unmet needs (measurement instrument not described).
Notes *˜ 9% no major mental illness.
**People randomised to standard care were just "provided informations by the research interviewers
about local homelessness service programmes". No attempts were made to arrange the first contact to
available local services.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. No further details.
Shern-USA1 2000 
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Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
High risk Primary outcome: not provided.
Secondary outcomes: interviewer mediated - rating - No. Not clearly stated,
but it is implicitly not blind.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Service use and housing status were assessed in face-to face interviews, proto-
cols were used. Interviewers not blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Authors declared "using alternative techniques for accommodate missing ob-
servations". Our main concern was regarding the high attrition rate the au-
thors declared, but was not clearly reported as presented data were already
transformed through statistician techniques accounting for missing observa-
tion.
Selective reporting (re-
porting bias)
High risk Some listed outcomes of interest are not usable due to incomplete reporting
(service use, social functioning, quality of life outcomes).
Other bias Low risk Publicly funded (NIMH). No further details. No evidence of the presence of oth-
er bias.
Shern-USA1 2000  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: 12 months.
Country: Philadelphia, Pennsylvania, USA.
Not entering meta-regression.
Participants Diagnosis*: seriously mentally ill (schizophrenia, affective or personality disorder according to DSM-III-
R).
N = 200.
Setting: CMHC.
Age: mean 35.2 years (SD 9.4).
Sex: 86.5% M.
Ethnicity: Afro-American 81%
History: i. about to be released from prison, ii. homeless (i.e. situational, episodically, or chronically
without a domicile or if jail detention resulted in the loss of a stable housing situation), iii. state hospi-
talisation ≧ 60 days in previous 2 years or a significant amount of outpatient treatment, iv. GAF ≦ 40 or
GAF ≦ 60 if age ≦ 35 years, v. written informed consent.
Interventions 1**. ICM: Assertive Community Treatment according to the Stein and Test model. Caseload: 1:8-12. N =
60.
2**. ICM: Intensive Case Management provided from an individual forensic case manager who worked
at CMHC, but as individual rather than as part of a treatment team. Caseload: not available. N = 60.
3. Standard care: from local CMHC (2 clients received ICM services at times during the year in the study).
N = 80.
Outcomes Global state: leaving the study early.
Solomon-Pennsylvania 1994 
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
148
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Social functioning: imprisonment***.
Unable to use -
Service use: days in hospital, hospitalisation (data not available); drug and alcohol use Addiction Sever-
ity Index (data not available); accomodation, employment, arrest (data not available), Pattison Psy-
chosocial Network Inventory (data not available).
Mental state: BPRS (data not available).
Quality of life: Lehman's Quality of Life Interview (objective and subjective components).
Notes *Schizophrenia 82.5%, major affective disorder 10%, other (unspecified psychotic disorder and person-
ality disorder) 3%, substance abuse disorder 52%. N = 200.
**We considered both arms as a single intervention.
***Attrition in the control group > 50%.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised. Authors reported that "slightly higher number of clients were
assigned to the control treatment", but it is not clear if it was a stratified ran-
domisation. No further details provided.
Allocation concealment
(selection bias)
Unclear risk No details
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: not available.
Secondary outcome: clinician/participant mediated - rating - Unclear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Participants and personnel not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Incomplete reporting of missing data (number of missing data is reported, but
reasons not provided).
Selective reporting (re-
porting bias)
High risk Some listed outcomes of interest are not reported (i.e. service use, quality of
life, etc.).
Other bias Low risk No evidence of the presence of other bias.
Solomon-Pennsylvania 1994  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration*: follow-up variable (minimum 12 months, maximum 24 months).
Country: Netherlands.
Participants Diagnosis**: severe mental illness (diagnostic criteria not reported).
N = 118***.
Setting: rural catchment area, community mental health service.
Sytema-Netherlands 1999 
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Age: mean ˜ 41.5 yrs (SD ˜ 11 years).
Sex: 68.6% M.
Ethnicity: not reported.
History: Health of the Nation Outcome Scale (HoNOS) ≧ 15.
Interventions 1. ICM: ACT model according to a fidelity scale (DACTS). Caseload: 1:10. N = 59.
2. Standard care: provided by CMHT. Caseload: 1:40. N = 59.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services (defined by authors as "not having any registered contact with the mental health services dur-
ing the last 12 months of observation"), average number of admissions per month.
Death: all causes, suicide.
Social functioning: homeless at the end of the trial, average days per month in sheltered houses, Dart-
mouth Assessment of Lifestyle Interview (DALI).
Mental state: BPRS-24 item.
Participant satisfaction: Client Satisfaction Questionnaire (CSQ), Camberwell Assessment of Needs
Short Appraisal Schedule (CANSAS).
Unable to use -
Social functioning: Social Functioning Scale (SFS) (data not clearly reported).
Notes *Participant inclusion in the study started April 2004 and was closed at 1 June 2005. All participants
were followed up until August 2006.
**Schizophrenia 51.7%, major depression 13.5%, bipolar 3%.
***The number of participants randomised was 119, but 1 participant was excluded from sample be-
cause he or she moved to another area directly after randomisation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised, based on block design (block size of 5).
Allocation concealment
(selection bias)
Low risk Participant included in the study received ID number from service administra-
tion. The new ID number was emailed to a researcher who had a pre-arranged
list of ID numbers randomised.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - No. Open-label.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk YES - Primary outcomes: service use data. No missing data (but 1 participant
excluded from sample because he or she moved to another area directly after
randomisation).
UNCLEAR - Secondary outcomes: number of missing data is provided, but rea-
sons not stated.
Sytema-Netherlands 1999  (Continued)
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Selective reporting (re-
porting bias)
Low risk All listed outcomes of interest are completely reported.
Other bias Low risk Publicly funded (grant from The Netherlands Organisation for Health Research
and Development). No further details. No evidence of the presence of other
bias.
Sytema-Netherlands 1999  (Continued)
 
 
Methods Allocation: randomised.
Design: single centre.
Duration: total duration of the trial 12 years, participants were followed at least 5 years, extended to 12
years for those who first entered the study. Some data available at 4 years, some at 24 months.
Country: Dane County, Wisconsin, USA.
Participants Diagnosis*: schizophrenia or schizoaffective disorder (according to RDC), or schizotypal personality (ac-
cording to DSM-III).
N = 122.
Setting: CMHS.
Age: 18 to 30 years.
Sex: 67.2% M (82M, 40F).
Ethnicity: white 95.9%.
History**: i. resident of Dane County, ii. < 12 months total prior time spent in psychiatric and penal in-
stitutions, iii. no primary diagnosis of mental retardation, organic brain syndrome, or alcoholism, iv. in-
formed consent.
Interventions 1. ICM: Assertive Community Treatment according to Stein and Test model. Caseload: ˜1:9. N = 75.
2. Standard care: routine care from Dane County psychiatric services - included an unspecified degree
of case management. N = 47.
Outcomes Service use: average number of days in hospital per month, not remaining in contact with psychiatric
services, admitted to hospital.
Death: all causes, suicide.
Global state: leaving the study early.
Social functioning: number homeless or living in sheltered accomodation (at least 1 day), not living in-
dependently, imprisoned.
Unable to use -
Mental state: BPRS, BSI (no data).
Social functioning: days homeless (no SD), days in jail (no SD), Community Adjustment Form (scale not
peer reviewed, no data).
Quality of life: Satisfaction with Life Scale (scale not peer reviewed, no data).
Notes *Schizophrenia 73.8%; schizoaffective disorder ˜ 23%.
**Average age first contact with mental health system: 19.02 yrs.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised (randomised assignment to experimental and control interven-
tion on a ratio 6:4), no further details.
Allocation concealment
(selection bias)
Unclear risk No details
Test-Wisconsin 1985 
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Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: most are clinician/participant mediated - rating - Un-
clear.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Problematic to blind participants and those providing the intervention in stud-
ies comparing ICM intervention with standard care.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Number and reasons for missing data are not clearly reported.
Selective reporting (re-
porting bias)
High risk Listed outcomes of interest not reported or reported incompletely, BPRS and
BSI (not reported), days in jail and days in hospital (no SD).
Other bias Low risk Publicly funded (grant by NIMH). No further details. No evidence of the pres-
ence of other bias.
Test-Wisconsin 1985  (Continued)
 
 
Methods Centre: St. George's - London.
Methods: see above UK700-UK 1999.
Participants Participants: see above UK700-UK 1999.
N = 196.
Interventions Methods: see above UK700-UK 1999. Sample size providing data:
1. ICM: N = 96.
2. Non-ICM: N = 99.
Outcomes Service use: average number of days in hospital per month.
Notes  
UK700-UK (A) 
 
 
Methods Centre: King's - London.
Methods: see above UK700-UK 1999.
Participants Participants: see above UK700-UK 1999.
N = 153.
Interventions Methods: see above UK700-UK 1999. Sample size providing data:
1. ICM: N = 77.
UK700-UK (B) 
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2. Non-ICM: N = 74.
Outcomes Service use: average number of days in hospital per month.
Notes  
UK700-UK (B)  (Continued)
 
 
Methods Centre: Manchester.
Methods: see above UK700-UK 1999.
Participants Participants: see above UK700-UK 1999.
N = 158.
Interventions Methods: see above UK700-UK 1999.
1. ICM: N = 79.
2. Non-ICM: N = 79.
Outcomes Service use: average number of days in hospital per month.
Notes  
UK700-UK (C) 
 
 
Methods Centre: St. Mary's* - London.
Methods: see above UK700-UK 1999.
Participants Participants: see above UK700-UK 1999.
N = 201.
Interventions Methods: see above UK700-UK 1999. Sample size providing data:
1. ICM: N = 99.
2. Non-ICM: N = 101.
Outcomes Service use: average number of days in hospital per month.
Notes *In St. Mary's centre staI were randomly assigned to ICM or non-ICM position.
UK700-UK (D) 
 
 
Methods Allocation: randomised.
Design: multicentre (4 sites, 3 in London and 1 in Manchester).
Duration: 24 months.
Country: UK.
Participants Diagnosis*: psychotic illness (diagnosed through OPCRIT).
N = 708.
UK700-UK 1999 
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Setting: inner-city mental health services.
Age: 18 to 65 years, mean ˜ 37.3 years.
Sex: 57% M (404M, 304F).
Ethnicity: Afro-Caribbean 28%.
History: i. psychotic illness for at least 2 years, ii. ≧ 2 previous hospital admissions, 1 within past 2 years,
iii. no organic brain disease or primary diagnosis of substance misuse, iv. written informed consent.
Interventions 1. ICM**: Caseload: 1:10-15. N = 353.
2. Non-ICM: Caseload: 1:30-35. N = 355.
Outcomes Service use: average number of days in hospital per month (available for single centre, see below), not
remaining in contact with psychiatric services (reported as not remaining in contact with case manag-
er), admitted to hospital, mean number of admissions.
Death: all causes and suicide.
Global state: leaving the study early.
Social functioning: time in independent living accomodation (reported as time spent in stable accomo-
dation), imprisoned, Camberwell Assessment of Need (CAN).
Mental state: general symptoms CPRS, negative symptoms (SANS).
Behaviour: self harm, harm to others.
Quality of life: Lancashire Quality of Life Profile (LQoLP).
Participant satisfaction: Patients' satisfaction with health services questionnaire.
Costs: direct costs of all care.
Unable to use -
Social functioning: DAS (scale adapted by the trialist, not peer reviewed).
Mental state: subscale of CPRS for depression (Montgomery–Åsberg Depression Rating Scale) and for
psychotic symptoms (no SD), for anxiety and for behavioural disturbance (no SD, not peer-reviewed
scale).
Carer satisfaction: Experience of Caregiving Inventory, 12-Item General Health Questionnaire (attrition
83.6%).
Costs: direct costs of health care and of psychiatric hospital care (no SD).
Adverse drug effects: Abnormal Involuntary Movement Scale (not listed as outcome of interest of the
review).
Notes *Schizophrenia 38%, schizoaffective 49%, mania or bipolar 5%.
**The team organisation varied slightly across centres.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, randomisation stratified by centre. No further details.
Allocation concealment
(selection bias)
Low risk Randomised allocation assigned by telephone or fax by an independent statis-
tical centre.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Primary outcome: clinician/participant mediated - rating - Unclear.
Secondary outcomes: interviewer rated - rating - No. (Researchers were not
masked to treatment allocation.)
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Blinding not reported.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Blinding not reported.
UK700-UK 1999  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Number and reasons for attrition stated. Analysis performed on an ITT basis.
Selective reporting (re-
porting bias)
Unclear risk Most of the listed outcomes are reported completely (the only exception is for
CPRS subscale: SD missing).
Other bias Low risk Publicly funded (grants from the UK Department of Health and NHS research
and development programme). No further details. No evidence of the pres-
ence of other bias.
UK700-UK 1999  (Continued)
ACT - Assertive Community Treatment
CM - Case Management
CMHC - Community Mental Health Center
CMHT - Community Mental Health Team
CPA - Care Programme Approach: the CPA is a combination of non-Intensive Case Management and care from a CMHT, introduced in
England in the mid-1990s and becoming standard care thereaPer
CPNS - Community Psychiatric Nursing Service
DSM-III-R - Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised (APA 1987)
DSM IV - Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (APA 1994)
F - female
ICD-10 - International Statistical Classification of Diseases and Related Health Problems 10th Revision (WHO 1992)
ICM - Intensive Case Management
ITT - intention to treat
LOCF - last observation carried forward
M - male
N - number
NIMH - National Institute of Mental Health (USA)
non-ICM - non-Intensive Case Management
OPCRIT - Operational Criteria (McGuIin 1991)
OPD - outpatient department
PACT - Programme of Assertive Community Treatment
P/T - part time
RDC - Research Diagnostic Criteria (Spitzer 1978)
SADS - Schedule for AIective Disorders and Schizophrenia interview (Endicott 1978)
SC - standard care
SCAN 2.0 - 2.1: Schedule for Clinical Assessment in Neuropsychiatry (SCAN 2.0 in 1998, SCAN 2.1 since 1999) (WHO 1998)
SCID - Structured Clinical Interview for DSM-IV (First 1997)
SD - standard deviation
SMI - severe mental illness
TCL - Training in Community Living
VA - Veterans administration
Yrs - years
Scales
ACL - Adjective Checklists
ASI - Addiction Severity Index
AUS - Alcohol Use Scale
BDI - Beck Depression Inventory
BPRS - Brief Psychiatric Rating Scale
BSI - Brief Symptom Inventory
CAN - Camberwell Assessment of Need Interview
CANSAS - Camberwell Assessment of Need Short Appraisal Schedule
CPRS - Comprehensive Psychopathological Rating Scale
C-DIS-R - Computer-based Diagnostic Interview Schedule Revised
CSI - Colorado Symptom Index
CSQ - Client Satisfaction Questionnaire
CSRI - Client Service Receipt Inventory
DALI - Dartmouth Assessment of Lifestyle Interview
DACTS - Dartmouth Assertive Community Treatment Scale
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DAS - Disability Assessment Scale
DUS - Drug Use Scale
GAF - Global Assessment of Functioning Scale
GAS - Global Assessment Scale
GSI - Global Severity Index
HADS - Hospital Anxiety and Depression Scale
HEAS - Homeless Engagement Acceptance Scale
HoNOS - Health of the Nation Outcome Scale
IMPS - Inpatient Multidimensional Psychiatric Scale
Indiana LOF - Indiana Level of Functioning
ISSI: Interview Schedule for Social Interaction
KS - Krawiecka Scale
LQoLP - Lancashire Quality of Life Profile
LSP - Life Skill Profile
MANSA - Manchester Short Assessment of Quality of Life
PANSS - Positive and Negative Syndrome Scale
PSE - Present State Examination
PSNAS - Personality and Social Network Adjustment Scale
QOLI - Lehman's Quality of Life Interview
REHAB - a scale of social functioning (REHAB GB: general behaviour); (REHAB DB: deviant behaviour)
ROMI - Rating of Medication Influences
RSES - Rosenberg Self Esteem Scale
SAI - Scale for the Assessment of Insight
SAI-E - Scale for the Assessment of Insight-expanded
SANS - Scale for the Assessment of Negative Symptoms
SAPS - Scale for the Assessment of Positive Symptoms
SAS - Social Adjustment Scale
SATS - Substance Abuse Treatment Scale
SBS - Social Behaviour Scale
SCL-90: Hopkins Symptoms Check List-90
SCRS - Short Clinical Rating Scale
SFQ - Social Functioning Questionnaire
SLS - Satisfaction with Life Scale
TLFB - Timeline Followback
W-BQ - Well-being Questionnaire
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Agius-Croatia 2007 Allocation: not randomised (cohort study).
An 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Community-based follow-up interventions.
2. Care as usual.
Not ICM.
An Qi 2013 Allocation: randomised.
Participants: primary schizophrenia.
Interventions: 1. Family intervention.
2. Care as usual.
Not ICM.
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Study Reason for exclusion
Bao 2012 Allocation: unclear.
Not RCT.
Bao-China 2005 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: 1. Family intervention, community based. Not ICM.
2. Standard care.
Barbic 2009 Allocation: randomised.
Participants: people who met DSM-IV diagnostic criteria for schizophrenia, schizoaffective disorder,
schizophreniform disorder, delusional disorder, or bipolar disorder.
Intervention: No relevant comparison: ACT vs ACT + Recovery Workbook.
Barekatain-Iran 2014 Allocation: randomised.
Participants: age 18 to 65 years. DSM-IV diagnosis of bipolar I disorder (mania or mixed), schizo-
phrenia, or schizoaffective disorder.
Intervention:
1. Psychoeducation program for families, explicity operationalised, provided within a package of
care close to the ICM model (caseload 1:12).
2. Standard care: routine psychiatric treatments. Caseload not reported. N = 62.
Bigelow-Oregon 1991 Allocation: not randomised, quasi-experimental design.
Bond-Chicago2 1989 Allocation: not randomised, matched-groups design.
Interventions: 2 types of crisis housing.
Bond-Indiana2 1991 Allocation: not randomised, allocation to ACT and reference group was not random in 1 of the 3
participating centres. The study could be included if separate data can be obtained from the 2 cen-
tres where randomisation took place.
Borland-Washington 1989 Allocation: not randomised.
Borras 2009 Allocation: randomised.
Participants: all meeting ICD-10 criteria for a diagnosis of schizophrenia or other non- affective psy-
choses.
Interventions: no relevant comparison: traditional psychiatric outpatient care or case management
vs traditional psychiatric outpatient care or case management + self esteem module.
Botha 2014 Allocation: randomised.
Participants: adults with severe mental illness.
Intervention: 1. Modified assertive intervention.
2. Standard care.
Caseload > 20.
Burns 2013 Allocation: randomised.
Participants: adult patients diagnosed with psychosis.
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Study Reason for exclusion
Interventions: 1. Community treatment orders (CTOs): program for patient who needs supervision
after a period of involuntary hospital treatment and who, without it, is highly likely to relapse and
be readmitted involuntarily. Not ICM.
2. Section 17 leave: a well-established rehabilitation practice, used for brief periods to assess the
stability of a patient’s recovery after or during a period of involuntary hospital treatment.
Burns-UK 1993 Allocation: randomised.
Participants: people who were (a) aged between 18 and 74 years, (b) from the appropriate catch-
ment area of Psychiatric Service, (c) not in treatment during the preceding 12 months, (d) able to
be interviewed in English.
Intervention: multidisciplinary team home treatment, not ICM.
Champney-Ohio 1992 Allocation: randomised.
Participants: adults with severe mental disabilities.
Intervention: all 4 comparison groups received some form of case management, no ACT. Neither
standard care nor non-ICM in the comparison group.
Chandler 1999 Allocation: randomised.
Participants: volunteers randomly assigned to ACT.
Not exclusively community setting.
Chandler 2000 Allocation: randomised.
Participants: not clear, described as "high cost inpatient users".
Intervention: no relevant comparison: ACT + social skills training vs ACT.
Chandler-California2 2006 Allocation: randomised.
Participants: current serious mental illness and substance use disorder.
Intervention: 1. In-custody standard care + brief aftercare + Integrated Dual Disorders Treatment.
Postcustody treatment includes ICM and specific intervention addressing substance abuse disor-
der. Not exclusively community setting; not only ICM.
2. Service as usual: in-custody standard care + usual postcustody services + 60 days of postrelease
case management and housing assistance. Not exclusively community setting.
Chang 2013 Allocation: randomised.
Participants: 18 to 35 years with a diagnosis of schizophrenia, non-affective psychosis, affective dis-
orders with psychotic features, or delusional disorder.
Intervention: 1. Community-based case management (n = 79).
2. Standard care: general psychiatric care with all auxiliary care options unchanged (n = 77).
All participants had been enrolled in the Early Assessment Service for Young People with Early Psy-
chosis (EASY) for 2 years before starting this trial.
Not ICM, caseload 1:80.
Chatterjee 2014 Allocation: randomised.
Participants: patients aged 16 to 60 years with a primary diagnosis of schizophrenia according to
the ICD-10 Diagnostic Criteria for Research (DCR).
Intervention: 1. Collaborative community-based care plus facility-based care.
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Study Reason for exclusion
2. Facility-based care alone. Not ICM.
Chen XZ 2012 Allocation: randomised.
Participants: schizophrenia.
Interventions:
1. Home visit.
2. Education.
Not ICM.
Chen-China 2007 Allocation: randomised.
Participants: adults with schizophrenia (non-acute).
Intervention:
1. Antipsychotic + Digital Network + Community Support Network.
2. Antipsychotic + Community Support Network.
Digital Network involves providing online consultation to patients, emailing them periodically, pro-
viding online health education. Community Support Network involves providing physical, psycho-
logical, and rehabilitation treatment to non-acute patients. Not ICM.
COAST-UK 2004 Allocation: randomised.
Participants: those with any functional psychosis.
Interventions: 1. ICM: Assertive Outreach Team model; caseload: 1:12. Also includes individual ther-
apy for residual positive symptoms of psychosis (CBT) and family intervention, if appropriate. Not
only ICM.
2. Non-ICM: usual services available to a local multidisciplinary team (according to Care Pro-
gramme Approach); caseload: 1:35. Does not include any specialised psychological interventions.
COMO-UK 2003 Allocation: cluster randomisation.
Participants: case manager providing care to patients with psychosis and comorbid substance mis-
use ("dual diagnosis").
Interventions: 1. Training in dual-diagnosis intervention (i.e. i. treatment manual; ii. 5-day training
course in assessment and management of dual diagnosis; iii. subsequent monthly supervision).
Not ICM.
2. CMHT management as usual.
Cook 2013 Allocation: randomised.
Participants: patients with serious mental illness as defined by federal Public Law 102–321 specify-
ing diagnosis, duration, and level of disability (schizophrenia, schizoaffective, bipolar, depressive,
other); age ≥ 18 years.
Interventions: 1. Wellness Recovery Action Planning: an evidence-based practice that consisted of
9, 2.5-hour group sessions that were facilitated free of charge by 2 trained and certified instructors
in recovery from mental illness, with backup instructors available as needed. Not ICM.
2. Choosing Wellness: Healthy Eating Curriculum: a nutrition education intervention holistically fo-
cused on wellness.
CORE 2014 Allocation: randomised.
Participants: patients diagnosed with bipolar disorder, anxiety disorder, major depressive disorder,
schizophrenia, personality disorder, panic disorder, age 16 to 64 years.
Intervention: 1. Co-design technique to optimise psychosocial recovery. Not ICM.
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2. Waiting list.
Cosden-California 2005 Allocation: randomised.
Participants: offenders with serious mental illness.
Interventions: 1. ICM + non-adversarial court proceeding.
2. Non-ICM + adversarial court proceeding.
2 arms are provided with different intervention between groups in addition to ICM and non-ICM.
CRIMSON-UK 2008 Allocation: randomised.
Participants: diagnosis of psychotic illness; ≧ 1 admission to a psychiatric inpatient service during
previous 2 yrs.
Interventions: 1. Joint Crisis Plan: aims to empower the client and to facilitate early detection and
treatment of relapse. Plan contains client's treatment preferences for any future psychiatric emer-
gency, when the client may be too unwell to express clear views. Not ICM. 2. Standard treatment: as
provided by CMHT.
Cui 2012 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Case management.
2. Outpatient visits.
Not ICM.
De Cangas-Canada 1994 Allocation: randomised.
Intervention: hospital-based care for those in control group, not community-based ICM.
Dean-UK1 1990 Allocation: not randomised.
Dean-UK2 1993 Allocation: not randomised, quasi-experimental study.
Dekker-Netherlands 2002 Allocation: randomised, but randomisation is compromised because after initial randomisation
control group were combined with control group from another study that experienced problems.
Participants: chronic psychiatric patients with a history of several admissions.
Interventions: 1. ACT; caseload: 1:30. Not ICM. 2. Standard care.
Deng-China 2006 Allocation: quasi-randomised (randomisation according to hospital admission number).
Participants: admitted to hospital for a first-onset schizophrenia.
Interventions: hospital based, not community based.
Dharwadkar-Victoria 1994 Allocation: not randomised, before-and-after design.
Dinitz 1965 Allocation: randomised.
Participants: acutely mentally ill patients in a hospital setting.
Er 2013 Allocation: randomised.
Participants: chronic schizophrenia.
Interventions: 1. Antipsychotics + family education, and rehabilitation instruction
2. Care as usual.
Not ICM.
Fenton-Canada 1978 Allocation: randomised.
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Participants: people with schizophrenia, acutely ill, requiring immediate hospital admission.
Intervention: home-care community-based treatment vs hospital care. Not ICM in the experimental
group; comparison group not community based.
Franklin-Texas 1987 Allocation: randomised.
Participants: people who at least had 2 discharges from mental hospital.
Intervention: Assertive Community Treatment caseload over 30. Not ICM.
Gao 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Hospital-community-family integrated management. 2. Care as usual.
Caseload not reported.
Gaughran 2013 Allocation: randomised.
Participants: patients with a ICD-10 diagnosis of psychotic disorder (F20-29, F31.2, F31.5).
Intervention: 1. Improving physical health and reducing substance use in psychosis (IM-
PACT)-Health Promotion Intervention. Not ICM.
2. Standard care.
Glick-New York 1986 Allocation: randomised.
Intervention: day hospital care vs outpatient group therapy, not ICM.
Godley-Illinois 1994 Allocation: randomised.
Participants: major psychiatric and substance abuse diagnosis.
Intervention: 1. ICM: specialised case management. Caseload ˜ 1:15. 2. Standard care.
Outcome: incomplete data reporting. Not providing usable outcomes.
Goering-Canada 1988 Allocation: not randomised, used historical controls.
Gold-SCarolina 2006 Allocation: randomised.
Participants: adults with severe mental illness.
Intervention: ACT + Individual Placement and Support (integrated supported employment pro-
gramme). Not only ICM.
2. Traditional programme: providing mental health and brokered case management services in
parallel to vocational services. Not only standard-care services.
2 arms are provided with different interventions between groups in addition to ACT and standard
care.
Gong 2014 Allocation: randomised.
Participants: adults with severe mental illness.
Interventions: 1. Case management provided by village doctors.
2. Usual care. Not ICM.
Grawe-Norway 2005 Allocation: randomised.
Participants: people with recent-onset schizophrenia.
Interventions: 1. Integrated treatment: package of care provided by a multidisciplinary team with
management caseload ˜ 1:10; cognitive-behavioural family treatment and home-based crisis man-
agement. Not only ICM.
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2. Standard treatment: clinical-based case management caseload ˜ 1:10 and crisis inpatient treat-
ment.
Gu-China 2010 Allocation: randomised (multicentre trial; 4 centres).
Participants: patients suffering from schizophrenia.
1. Integrated training: the intervention includes life skill training, occupational skill training, com-
munication training, psycho-education, and family visiting. Delivered by nurses. Caseload is proba-
bly 1<20.
2. Standard care. Routine training, no more details.
Not ICM in the intervention.
Han SH 2012 Allocation: randomised.
Participants: primary schizophrenia.
Interventions: 1. Antipsychotics, psycho-education, family visit, and instruction.
2. Antipsychotics and psycho-education.
Not ICM.
Hargreaves-California Allocation: not randomised.
Havassy-California 2000 Allocation: randomised.
Participants: seriously mentally ill adults with and without substance dependence.
Interventions: 1. Intensive Clinical Case Management community-based.
2. Expanded brokerage case management program (data on caseload not available; it could be ei-
ther ICM or non-ICM), hospital based, providing intensive support during the initial postdischarge
period, with a maximum of 60 days.
Outcome: poor reporting data results, not usable.
2 reasons for exclusion: intervention (not clear if the comparison intervention is ICM or non–ICM)
and not providing usable data (comparison is between the 2 subgroups “with or without substance
dependence”, not between the 2 interventions).
He-China 2004 Allocation: quasi-randomised (randomised allocation according to register number).
Hornstra-Kansas 1993 Allocation: not randomised, historical controls.
Hoult-Australia 1981 Allocation: randomised.
Participants: people with schizophrenia, acutely ill, requiring immediate hospital admission.
Interventions: ICM vs acute admission to a psychiatric hospital.
Huang 2012 Allocation: unclear.
Not RCT.
Huang 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Community nursing intervention and rehabilitation training.
2. Treatment as usual.
Not ICM.
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Hui 2014 Allocation: randomised.
Participants: patients diagnosed with schizophrenia, schizophreniform disorder, schizoaffective
disorder, delusional disorder, brief psychotic disorder, psychotic disorder not otherwise specified,
or manic episodes with psychotic features (DSM-IV); age 22 to 55 years.
Interventions: 1. Early Intervention Program: specialised and individualised case management as
well as community-based group programmes. Caseload > 20.
2. Standard care.
Hurlburt-California 1996 Allocation: randomised.
Participants: severe mental illness.
Interventions:
1. Non-ICM: comprehensive case management; caseload 1:22. Not ICM.
2. Non-ICM: traditional case management; caseload 1:40. Not ICM.
3. Non-ICM: comprehensive case management; caseload 1:22 + high-level access to independent
housing. Not ICM.
4. Non-ICM: traditional case management; caseload 1:40 + high-level access to independent hous-
ing. Not ICM.
ISRCTN73683215 Allocation: randomised.
Participants: adults with severe mental illness who received mental health care in clinical settings.
Interventions: Not ICM. Boston Psychiatric Rehabilitation Approach versus treatment as usual.
Jerrell-California 1989 Allocation: randomised. Randomisation is compromised because number of people excluded after
randomisation is not reported (patients were excluded if they refused to participate after randomi-
sation or if they had not been discharged from hospital within 6 months of entering the study).
Participants: severe mental illness.
Intervention: 1. ICM, according to the ACT Stein and Test model. 2. Standard care: provided in the
community setting.
Jerrell-SCarolina2 1994 Allocation: randomised.
Interventions: ACT vs 12-step recovery programme and behavioural skills training + standard care.
Not standard care only in the comparison group.
Jiang 2012 Allocation: randomised.
Participants: primary schizophrenia
Interventions: 1. Family intervention plus antipsychotics.
2. Antipsychotics alone.
Not ICM.
Jiang 2013 Allocation: randomised.
Participants: chronic schizophrenia.
Interventions: 1. Intergrated community-based intervention.
2. Care as usual.
Not ICM.
Jorgensen 2012 Allocation: randomised.
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Participants: patients meeting the criteria for schizophrenia according to ICD10 F.20.09 or schizoaf-
fective disorder according to ICD10 F.25.09; age 18to 70 years.
Interventions: 1. Guided Self Determination: 21 worksheets designed to guide patient and men-
tal health professionals through autonomy-supportive problem solving. The worksheets are filled
in by the patient before and between conversations with their community nurse over 10 sessions,
each approximately 1 hour. Not ICM.
2. Waiting list
*Trial status: ongoing (trial registration form only).
Kane-Virginia 2004 Not randomised.
Kilbourne 2014 Allocation: randomised.
Participants: Adult Veterans Administration (VA) Center patients diagnosed with an ICD-9 diagnosis
of schizophrenia or related disorder or bipolar disorder who was lost to care.
Interventions: 1: Re-Engage: a national VA outreach program consisting of risk assessment (i.e.
identifying the patient's current status, including clinical care needs and current disposition) and
outreach services (i.e. attempting to contact patients and invite them back to receive health ser-
vices). Not ICM.
2. Standard care.
Klotz-California 2001 Wrote to author for further information. Received email from D. Innes-Gomberg on 4 January 2016
stating that there is no data. Consequently, this study is excluded.
Knight-California 1990 Allocation: not randomised, quasi-experimental design.
Kuldau-California 1977 Allocation: randomised.
Interventions: rapid discharge vs hospital care, not ICM.
Lafave-Canada 1996 Allocation: randomised.
Intervention: hospital-based care for control group, not community-based care. Neither standard
care nor non-ICM in the comparison group.
Langley 2009 Allocation: randomised
Participants: diagnosed with a DSM-IV axis 1 disorder.
Interventions: ACT vs ICM. No relevant comparison: both interventions types of ICM.
Langsley-Colorado 1968 Allocation: randomised.
Interventions: outpatient family crisis management vs hospital admission. Not ICM.
Lehman-Maryland2 1993 Allocation: randomised.
Participants: dually diagnosed people.
Interventions: 1. ICM + experimental group treatment Being Sober Group (addressing the specific
problems of dually diagnosed adults). 2. Non-ICM. In the experimental group: not only ICM.
LEO-UK 1994 Allocation: randomised.
Participants: people with non-affective psychosis.
Interventions: 1. ICM: Assertive Outreach model; caseload ˜ 1:7. Including also: i. CBT based on
manualised protocol; ii. family counselling and vocational strategies based on established proto-
cols. Not only ICM.
2. Non-ICM: delivered by the sector community mental health teams (according to Care Pro-
gramme Approach). No CBT, no family counselling and vocational strategies.
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Li 2011 Study design: randomised.
Participants: inpatients with schizophrenia (Chinese Classification of Mental Disorders (CCMD-3)).
Interventions: hospital-based intervention, not community based.
Assessed by Sai Zhao.
Li 2012 Allocation: randomised.
Participants: primary schizophrenia.
Interventions: 1. Community comprehensive intervention.
2. Care as usual.
Not ICM.
Li 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Care package involving family intervention, psycho-education, and drug therapy.
2. Care as usual.
Not ICM.
Li JX 2013 Allocation: randomised.
Participants: primary schizophrenia.
Interventions: 1. Individulised rehabilitation training.
2. Care as usual.
Not ICM.
Li MD 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Family intervention plus usual care.
2. Care as usual.
Not ICM.
Li Ning 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Community-based comprehensive intervention.
2. Standard community intervention.
Caseload not reported.
Li WX 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Community-based interventions.
2. Long-term hospitalisation.
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Not ICM.
Li-China 2004 Not community setting: hospital setting. In Chinese. Assessment by Tao Yuan Li Jun and Chunbo
Lee.
Liang 2009 Allocation: not randomised. The author randomly selected 188 participants and divided them into
2 groups.
Participants: schizophrenia.
Interventions: talking therapy and instruction for medication.
Assessed by Sai Zhao.
Liang 2012 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Family intervention and antipsychotic medication.
2. Antipsychotics alone.
Not ICM.
Liao 2010 Study design: RCT.
Participants: inpatients with schizophrenia.
Interventions: hospital-based intervention included psycho-education, social skills training, family
education, etc.
Assessed by Sai Zhao.
Lichtenberg-Israel 2008 Allocation: randomised.
Participants: people with at least 3 psychiatric admissions during the previous 2 yrs. Diagnosis is
not stated.
Interventions: 1. Non-ICM; caseload 1:30. Not ICM.
2. Standard care: provided by the mental healthcare centres.
Lin-China 1998 Allocation: not randomised.
Liu 2010 Study design: RCT.
Participants: inpatients with schizophrenia.
Interventions: hospital-based group psycho-education.
Assessed by Sai Zhao.
Lloyd 2000 Allocation: not randomised.
Lu 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Hospital-community integrated management model.
2. Care as usual.
Caseload not reported.
Malm-Sweden 2003 Allocation: randomised.
Participants: diagnosed according to DSM-IV schizophrenia, schizophreniform, schizoaffective, or
delusion disorders.
Intervention: 1. "Integrated Care" vs 2. "Rational Rehabilitation".
Both of the compared treatment programmes were delivered in the context of clinical case man-
agement by CMHTs. They actively incorporated some key features of ACT; caseloads ˜ 1:40.
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
166
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
The additional component in the Integrated Care programme was the continuous social network
resource group for each patient. Not ICM.
Martin-Delaware 1993 Allocation: not randomised.
Martin-UK 2005 Allocation: randomised.
Participants: people with intellectual disability and mental illness.
Marx-Wisconsin 1973 Allocation: randomised.
Interventions: hospital-based care for control group, not community-based care. Neither standard
care nor non-ICM in the comparison group.
McDonell 2013 Allocation: randomised.
Participants: patients meeting Mini International Neuropsychiatric Interview criteria for schizo-
phrenia, schizoaffective disorder, bipolar I or II disorder, or recurrent major depressive disorder
and methamphetamine, amphetamine, or cocaine dependence who had used stimulants during
the past 30 days.
Intervention: 1. Contingency management for stimulant abstinence. Not ICM.
2. Treatment as usual.
McFarlane-New York 1992 Allocation: unclear if randomised.
Interventions: ACT vs Family-Aided Assertive Community Treatment (FACT). Neither standard care
nor non-ICM in the comparison group.
McGowan-California 1995 Allocation: unclear if randomised; control and treatment groups were "randomly selected" from a
population already receiving ACT or standard care.
McGrew-Indiana 1994 Allocation: not randomised (study was a before-and-after design examining the effects of imple-
menting ACT teams in 6 sites in Indiana).
McHugo-Washington DC 2004 Allocation: randomised.
Participants: adults with severe mental illness at high risk for homelessness.
Intervention: 1. Parallel housing services programme: including ICM - caseload 1:15, implemented
by mobile ACT team, and housing by routine community-based landlords. Not only ICM.
2. Integrated housing services programme: including ICM - caseload 1:15; case management and
housing services were provided by teams within a single agency and were closely co-ordinated.
Neither standard care nor non-ICM in the comparison group.
MECCA-Europe 2002 Allocation: cluster randomisation.
Participants: people with functional psychosis.
Intervention: 1. Treatment as usual + "outcome management". The latter is an innovative treat-
ment where every 2 months a key-worker assesses patient's subjective quality of life, treatment
satisfaction, and wishes for additional/different support using a questionnaire (MECCA). It is ex-
pected that the results will directly feed into the therapeutic dialogue and be discussed by the pa-
tient and key-worker together. Not ICM.
2. Treatment as usual.
Meneghelli-Italy 2000 Allocation: not randomised.
Merson-UK 1992 Allocation: randomised.
Interventions: multidisciplinary team home treatment vs emergency assessment at hospital. Nei-
ther standard care nor non-ICM in the comparison group.
Modcrin-Kansas 1988 Allocation: randomised.
Participants: chronically mentally ill.
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Interventions: strengths model of case management versus standard case management. As case-
load is not reported for either group, it is unclear if experimental intervention could be considered
ICM and comparison group could be considered standard care or non-ICM. The study could be in-
cluded if more data can be obtained on caseload.
Morse-Missouri2 1997 Allocation: randomised.
Participants: homeless people with severe mental illness.
Interventions: 1. ICM: ACT, caseload 1:10; vs 2. Non-ICM: Brokered Case Management, caseload
1:85; vs 3. ACT plus community worker support, caseload 1:10.
Outcomes: unable to use data, numbers for treatment groups not presented.
Morthorst 2012 Allocation: randomised.
Participants: patients admitted after a suicide attempt to acute emergency units, intensive care
units, paediatric units, and psychiatric emergency rooms: age: ≥ 12 (subgroup analysis according
to age reported). Excluded patients who had been diagnosed with severe mental illness (i.e. schizo-
phrenia spectrum disorders, severe depression, severe bipolar disorder).
Mosher-California 1975 Allocation: not randomised, alternative assignment.
Muijen-UK1 1992 Allocation: randomised.
Participants: those with severe mental illness requiring immediate emergency admission.
Interventions: ICM vs acute admission to a psychiatric hospital.
Mulder-Missouri 1985 Allocation: randomised, but data from randomised and non-randomised patients not reported sep-
arately.
Participants: people with schizophrenia, acutely ill, presenting for psychiatric hospital admission.
Interventions: 1. ICM: modelled according to the PACT model (as an alternative to current hospitali-
sation).
2. Standard care: usual hospital admission procedure, and at discharge the usual aftercare case
management services.
NCT00781079 Allocation: randomised.
Participants: must have serious mental illness and must be working with Veterans Affairs ICM team.
Interventions: No relevant comparison: ICM + peer specialists vs ICM only.
NCT01597141 Allocation: randomised.
Participants: aged 12 to 35 years, with prodromal schizophrenia, psychotic disorders, severe bipo-
lar disorder with psychotic features, or severe major depression with psychotic features.
Interventions:
1. Family-Aided Assertive Community Treatment (FACT) (a combination of family psycho-educa-
tion, ACT, supported education/employment, and psychotropic medication).
2. Enhanced standard treatment: the participants will receive the same psychotropic drugs, but
will receive individual case management, family education, and crisis intervention.
Not ICM vs standard care or ICM vs non-ICM.
Nieves 2002 Allocation: not a randomised study: "quasi-experimental design with a matched-groups compari-
son of outcomes achieved by patients in two community mental health centers in the South Bronx
area of New York City".
Odom 2005 Allocation: non-randomised, post-hoc analysis of RCT.
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Pai-India 1982 Allocation: not randomised, alternative assignment.
Pioli 2006 Allocation: randomised.
Participants: aged between 18 and 65 years; affected by severe mental illness.
Intervention: generic rehabilitation interventions, not ICM.
Setting: conducted partially in residential rehabilitation centre.
Polak-Colorado 1976 Allocation: randomised.
Participants: not clearly specified.
Interventions: admission to small "community-based therapeutic environments" vs standard hos-
pital care. Not ICM.
PRiSM-UK 1998 Allocation: not randomised.
Ren-China 2004 Allocation: not clearly stated if randomised.
Participants: people with chronic schizophrenia, admitted to rehabilitation hospital.
Interventions: rehabilitation hospital based, not community based.
Roldan-Merino 2012 Allocation: randomised
Participants: patients diagnosed with schizophrenia with an evolution of 2 or more years since the
moment of the diagnosis.
Interventions: 1. Personalised in-home nursing care plan: periodic home visits, with maximum in-
tervals of 21 days between visits. Not ICM.
2. Standard care.
Rossler-Germany1 1992 Allocation: not randomised, case control study.
Rossler-Germany2 1995 Allocation: not randomised, case control study.
Rutter-UK Allocation: randomised.
Participants. severe mental illness.
Interventions: 1. ICM: case management provided by a case manager internal to the CMHT; case-
load 1:15.
2. ICM: case management provided by a case manager outside the CMHT; caseload 1:15. The com-
parison group was neither standard care nor non-ICM.
Salyers 2010 Allocation: randomised.
Participants: adults with severe mental illness.
Interventions: Not ICM. Illness Management and Recovery (IMR) vs intensive problem solving. IMR:
psycho-education, cognitive behavioural approaches, relapse prevention, social skills training, and
coping skills training.
Salyers 2014 Allocation: randomised.
Participants: patients diagnosed with schizophrenia or schizoaffective disorder, currently receiv-
ing (or newly admitted to) mental health services at a Veterans Administration (VA) or community
mental health centre; age 18 or older.
Interventions: 1. Group-based Illness Management and Recovery (IMR) program: developed to in-
corporate effective strategies including psycho-education, cognitive behavioural approaches to
medication adherence, relapse prevention, social skills training, and coping skills training.
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2. Equally intensive problem-solving (PS) control group.
Not ICM and irrelevant comparison.
Santiago-Arizona 1985 Allocation: randomised.
Participants: those with serious mental illnesses, recently admitted to hospital and ready for dis-
charge.
Intervention: 1. Treatment Network Team provided both in community- and hospital-based set-
ting. Caseload not stated. Not ICM.
2. Standard care.
Unable to use all outcomes.
Sato 2012 Allocation: randomised.
Participants: hospitalised patients.
Schmidt 2005 Not randomised: retrospective cohort design using an approximation of random assignment.
Segal 2010 Allocation: randomised.
Participants: adults with severe mental illness.
Interventions: 1. Community Mental Health Agencies (CMHA) treatment vs 2. CMHA treatment and
Self-Help Agencies.
Not ICM.
Segal 2011 Allocation: randomised.
Participants: adults with serious mental illness (schizophrenia or schizoaffective disorder, major af-
fective disorder).
Interventions: 1. CMHA outpatient treatment. Not ICM.
2. A combination of CMHA outpatient treatment and consumer-operated service programs (COSP).
Sha 2010 Allocation: randomised.
Participants: inpatients with schizophrenia (Chinese Classification of Mental Disorders (CCMD-3)).
Interventions: hospital-based intervention, not community based.
Assessed by Sai Zhao.
Shen WW 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Hospital-community-family integrated management.
2. Care as usual.
Caseload not reported.
Shern-USA2 Allocation: randomised.
Participants: serious and persistent mental health disorder + homelessness.
Interventions: 1. Pathways to Housing: supporting housing programme, providing permanent, in-
dependent housing + ACT (according to Stein and Test model); caseload 1:10. Not only ICM.
2. Standard care: provided by social agencies (i.e. outreach teams, drop-in centres). If participant
has no current affiliation to service providers, information was given about where services could be
obtained. No active engagement.
Shern-USA3 Allocation: randomised.
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Participants: severe mental illness, co-occurring addiction and homelessness.
Interventions: 1. Housing First programme: providing permanent, independent housing without
prerequisites for sobriety and treatment + ACT; vs 2. Standard care. Not only ACT.
Shern-USA4 Allocation: randomised.
Participants: homeless mentally ill population.
Interventions: 1. Pathways to Housing: supporting-housing programme, providing permanent, in-
dependent housing; vs 2. Standard residential treatment. Not ICM.
Solomon 2014 Intervention: Not ICM: Transitional Care Model is a time-limited (90 days), transitional intervention
from release from acute hospitalisation to full engagement with community mental health care
1. Transitional Care with case management: nurse practitioner managing risk factors to prevent
further cognitive or emotional decline, managing problem behaviours, assessing and managing
physical symptoms, preventing functional decline; promoting adherence to therapies, assuring
proper medical management and continuity of care, and helping case managers understand the in-
tegrated mental and physical care approach.
2. Usual case management: a case manager was assigned to the participant and a psychiatrist pro-
vided medication management.
Solomon-Pennsylvania1 Allocation: randomised.
Intervention: 1 type of case management vs another. Neither standard care nor non-ICM in the
comparison group.
Somers 2013 Allocation: randomised
Participants: homelessness or precarious housing participants with current mental disorder status
meeting Mini-International Neuropsychiatric Interview criteria for major depressive episode, manic
or hypomanic episode, post-traumatic stress disorder, mood disorder with psychotic features, and
psychotic disorder.
Interventions: 1. Housing First + ICM. Not ICM alone.
2. Usual care.
Song 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Family psychological care plus social skills training and antipsychotics.
2. Antipsychotics alone.
Not ICM.
Stein 1974 Allocation: randomised
Participants: adults with severe mental illness; age 18 to 62 years.
Interventions: 1. Training in community living.
2. Hospital care.
Control group not in community.
Stein-Wisconsin Allocation: randomised.
Participants: those with severe mental illness requiring immediate emergency admission.
Intervention: ICM (according to the ACT model) vs acute admission to a psychiatric hospital.
Stultz 2014 Allocation: randomised
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Participants: patients in need for acute psychiatric inpatient care
Intervention: 1. Community treatment (not specified).
2. Hospital admission and inpatient treatment. Control group not community treated.
*Trial status: ongoing (trial registration form only).
Sungur 2011 Allocation: randomised.
Participants: between the ages of 18 and 45 years; a DSM-IV diagnosis of schizophrenia confirmed
by Structured Clinical Interview for DSM-IV (SCID-IV) interviews; duration of illness of less than 10
years; living with a family member the year prior to admission; a resident of Ankara; completed
written informed consent approved by the ethics committee (caregivers were also required to pro-
vide written informed consent.
Intervention: 1. Optimal case management. Caseload: 4:50.
2. Routine case management. Caseload: 4:50.
Supereden 2012 Allocation: randomised
Participants: patients with nonaffective psychosis who had been with Early Intervention Service
(EIS) between 1 and 2 years and who showed a low level of structured activity after at least 1 year of
treatment (defined as 30 hours or less per week).
Interventions:1. Social recovery-oriented cognitive behavioural therapy + standard care. Not ICM.
2. Standard care.
Susser-New York 1997 Allocation: randomised.
Participants: severe mental illness.
Interventions: 1. "Critical time intervention": a time-limited approach aimed at stabilising the pa-
tient's social support network, designed for transitions from various institutions to the community;
the goal is to enhance continuity of care, strengthening the individual's long-term ties to services.
Not ICM.
2. Standard care: community-based services.
Tang 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Carers-provided home-based rehabilitation intervention.
2. Professional-provided home visit.
Not ICM.
Tao-China 2004 Allocation: randomised.
Participants: people with schizophrenia, admitted to hospital.
Intervention: provided pre-discharging. Hospital, not community, based.
Teague-New Hampshire 1995 Allocation: not randomised.
Thornicroft-Maryland 1991 Allocation: not randomised.
Tomita 2011 Allocation: randomised.
Participants: 150 previously homeless individuals with severe and persistent mental illness after
discharge from inpatient treatment.
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Study Reason for exclusion
Intervention: Critical Time Intervention (primarily designed to prevent homelessness) is not ICM; it
is transitional care from hospital to full engagement with community mental health services.
Toro-New York 1997 Allocation: randomised.
Participants: a minority of the participants suffered from severe mental illness; around 80% were
simply homeless.
Tyrer-UK 1995 Allocation: randomised
Participants: psychotic illness.
Intervention: 1. ICM. 2. Standard treatment: provided by social and psychiatric services. The case
managers for the treatment group were also the case managers for the control group (see Excluded
studies section).
van Meijel 2003 Allocation: randomised
Participants: adults with severe mental illness.
Interventions: 1. Relapse Prevention Plan: includes detecting the early signs of difficulty and ac-
tions that could be taken when psychotic relapse threatens (not ICM).
2. Usual care.
Vesterager 2011 Allocation: randomised, parallel-group clinical trial.
Participants: outpatients, aged 18 to 35 years, diagnosed with first-episode psychosis or schizotyp-
al disorder within F2 spectrum in ICD-10. Participants were in a postacute phase of illness, had suf-
ficient comprehension of Danish (i.e. did not need an interpreter), and provided written informed
consent.
Intervention: 1. OPUS + cognitive training vs 2. OPUS only.
OPUS consists of affiliation with a primary contact person, involvement of family, possibility of psy-
cho-education and social skills training. Depending on individual needs, patients are can take part
in group therapy, either social skills training or cognitive behavioural therapy.
No relevant comparison.
Vincent-Ohio 1977 Allocation: not randomised, alternative assignment.
Wang 2008a Not randomised.
Wang F 2012 Allocation: randomised.
Participants: chronic schizophrenia.
Interventions: 1. Family rehabilitation intervention.
2. Care as usual.
Not ICM.
Wang FY 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Family rehabilitation intervention.
2. Care as usual.
Not ICM.
Wang YL 2012 Allocation: randomised.
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Study Reason for exclusion
Participants: schizophrenia.
Interventions: 1. Family nursing intervention.
2. Care as usual.
Not ICM.
Wang YQ 2010a Allocation: randomised.
Participants: inpatients with schizophrenia.
Interventions: hospital-based intervention.
Assessed by Sai Zhao.
Wang Z 2012 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Family intervention plus antipsychotics.
2. Antipsychotics alone.
Not ICM.
Wen 2010 Allocation: randomised.
Participants: schizophrenia.
Interventions: family interventions; the nurses made an individualised treatment plan for each par-
ticipant, then implemented intervention according to the plan. The effects of the intervention on
outcomes were evaluated and treatments revised according to specific problems of the partici-
pant.
Assessed by Sai Zhao.
Wirshing 2006 Allocation: randomised.
Participants: all with a diagnosis of DSM-IV schizophrenia or schizoaffective disorder.
Interventions: not ICM (Community Re-Entry Program), not outpatient/community setting (deliv-
ered during brief hospitalisations).
Wood-New Zealand 1994 Allocation: not randomised, case control study.
Wu 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Group psychotherapy combined with family intervention.
2. Care as usual.
Not ICM.
Wunderink 2015 Allocation: randomised.
Participants: severely mentally ill patients.
Interventions: 1. Enhanced Assertive Community Treatment: ACT enhanced with evidence-based
interventions.
2. Standard care.
*Trial status is ongoing (trial registration form only).
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Study Reason for exclusion
Xing 2013 Allocation: randomised.
Participants: chronic schizophrenia.
Interventions: 1. Rehabilitation training.
2. Control group.
Not ICM.
Yang 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Rehabilitation training.
2. Treatment as usual.
Not ICM.
Yao 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Case management model.
2. No case management.
Not ICM.
Yao 2014 Allocation: randomised.
Participants: chronic schizophrenia.
Interventions: 1. Day nursing care in community.
2. Care as usual.
Not ICM.
Yu 2011 Study design: not randomised. Allocation based on admission sequences.
Assessed by Sai Zhao.
Yuan 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Case management model.
2. Conventional community management model.
Caseload not reported.
Zhang SY 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Enhanced family nursing intervention.
2. Conventional family intervention.
Not ICM.
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Study Reason for exclusion
Zhang YF 2012 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Community visit and antipsychotics.
2. Antipsychotics alone.
Not ICM.
Zhang YM 2013 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Comprehensive intervention (family visit, medicine compliance intervention, fam-
ily intervention, crisis intervention).
2. Telephone follow-up.
Not ICM.
Zhao HM 2013 Allocation: randomisation.
Participants: schizophrenia.
Intervention: 1. Comprehensive community rehabilitation intervention.
2. Standard drug therapy.
Caseload not reported.
Zhu 2009 Allocation: not randomised. Allocation based on admission sequences.
Assessed by Sai Zhao.
Zhu DP 2012 Allocation: randomised.
Participants: schizophrenia.
Interventions: 1. Family intervention plus antipsychotics.
2. Antipsychotics alone.
Not ICM.
ACT - Assertive Community Treatment
CBT - cognitive behavioural therapy
CMHA - Community Mental Health Agencies
CMHT: Community Mental Health Team
CPA - Care Programme Approach: the CPA is a combination of non-ICM and care from a CMHT, introduced in England in the mid-1990s and
becoming standard care thereaPer
DSM - Diagnostic and Statistical Manual of Mental Disorders
ICD-10 - 10th revision of the International Statistical Classification of Diseases and Related Health Problems
ICM - Intensive Case Management
non-ICM - non-Intensive Case Management
PACT - Programme of Assertive Community Treatment
RCT - randomised controlled trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
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Methods Allocation: randomised.
Participants Aged 18 to 65 years, following psychiatric hospitalisation.
Interventions 1. Transitional Case Management.
2. Standard care.
Outcomes Adherence to outpatient care; working alliance; number of readmissions; degree of psychiatric
symptoms (SCL-90 R); etc.
Notes ClinicalTrials.gov (clinicaltrials.gov/ct2/show/NCT02258737): "This study has been completed."; no
results posted or publication announced.
Written to investigator for clarification.
Bonsack-Switzerland 
 
 
Methods Allocation: randomised.
Participants Adults with severe mental illness.
Interventions 1. Assertive Community Treatment.
2. Standard community service.
Outcomes  
Notes Insufficient information in trial registry entry to determine inclusion/exclusion.
Written to investigator for clarification.
ChiCTR-TRC-13003407 
 
 
Methods Allocation: randomised.
Participants People with chronic functional psychosis.
Interventions Community rehabilitation programme.
Outcomes  
Notes Not available as full report, written to investigator for clarification, awaiting response.
Dick-UK 2000 
 
 
Methods Allocation: randomised, no further details.
Participants Participants: people with schizophrenia (CCMD-3), living in the community.
Interventions Intervention: community-based.
Guo-China 2003 
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1. Experimental intervention: provided by team composed by nurses, social worker; caseload 1:10.
Providing: i. Expressed Emotion intervention; ii. psycho-education (how to prevent relapse, how to
deal with adverse effects); iii. daily living activity.
2. Standard care. Awaiting further information on comparison treatment.
Outcomes Outcomes: awaiting for data extraction.
Notes In Chinese.
Written to investigator for clarification.
Guo-China 2003  (Continued)
 
 
Methods Allocation: randomised; multicentre.
Participants People with mental health problems who have attempted suicide.
Interventions 1. Assertive case management
2. Enhanced usual care.
Outcomes  
Notes Caseload not reported.
Written to investigator for clarification.
Kawanishi-Japan 2014 
 
 
Methods Allocation: randomised.
Participants People with chronic psychoses, mostly schizophrenia; N = 107.
Interventions 1. Mobile community teams.
2. Traditional psychiatric care.
Outcomes  
Notes To be assessed, in Polish.
Kossobudzka-Poland 2001 
 
 
Methods Allocation: randomised.
Participants People with chronic schizophrenia.
Interventions Interventions: community-based integrated intervention includes supportive psychosocial thera-
py, family therapy, rehabilitation training, and antipsychotics.
Caseload: the author did not state the caseload.
Li 2010 
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Outcomes  
Notes In Chinese. Assessed by Sai Zhao. (Li 2010).
Insufficient information to determine inclusion or exclusion; written to investigator.
Li 2010  (Continued)
 
 
Methods Allocation: randomised.
Participants Young patients with recent-onset psychosis.
Interventions  
Outcomes  
Notes Not enough information in the published conference abstracts to determine intervention or age of
participants (described as "young").
Written to authors for more published reports.
Linszen-Netherlands 2002 
 
 
Methods  
Participants  
Interventions  
Outcomes  
Notes To be assessed. PDF not yet retrieved.
Manuel 2009 
 
 
Methods Allocation: randomised.
Participants Clients with schizophrenia and bipolar disorder, 18 to 65 years of age, referred for case manage-
ment by community health services.
Interventions 1. Standard case management.
2. Client-focused case management.
3. Client-focused case management plus consumer advocacy.
Outcomes  
Notes Written to authors asking for caseload.
O'Donnell-Australia 1999 
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Methods Allocation: randomised.
Participants 203 clients with severe and persistent mental illness.
Interventions ICM vs peer-enhanced ICM vs clinic-based ICM.
Outcomes  
Notes Written to authors asking for caseload.
Rivera-New York 2007 
 
 
Methods Allocation: randomised.
Participants Adults with severe mental illness.
Interventions 1. Multi-element psychosocial intervention.
2. Standard care.
Outcomes  
Notes Caseloads not reported. Unclear whether intervention is ICM.
Written to authors for clarification.
Ruggeri-Italy 
 
 
Methods Allocation: randomised.
Design: multicentre (2 cities in Connecticut, not stated which ones).
Duration: 12 months.
Country: Connecticut, USA.
Not entering meta-regression.
Participants Diagnosis*: severe mental illness (schizophrenia spectrum disorder, major mood disorder, or both).
N = 137.
Setting: public mental health centres, urban site.
Age: 20 to 63 years, mean 41 yrs (SD 9 years).
Sex: 61% M.
Ethnicity: African-American 28.5%.
History: i. treatment disengagement, ii. informed consent provided.
Interventions 1. ICM**: Case management services from peer providers partnered with ACT teams. Peer case
manager. Caseload: 1:10-12. N = 68.
2. Non-ICM***: regular case management from regular providers. Caseload: ˜ 1:20-24. N = 69.
Outcomes Unable to use -
Service use: 26-item self reported measure of service use (not peer reviewed).
Level of engagement: rated using 1 item of Level of Care Utilization System (subscale not validat-
ed).
Social functioning: subscale from Addiction Severity Index (ASI) (subscale not peer reviewed, data
not reported).
Sells-Connecticut 2006 
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
180
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Client-counsellor relationship: modified version of Barrett-Lennard Relationship Inventory (BLRI)
(not peer reviewed, modified by authors).
Notes *61% psychiatric disorder; 63% major mood disorder; 72% substance abuse disorder; 70% co-oc-
curring disorder (psychotic disorder, mood disorder, or both plus substance abuse disorder).
**All peer staI had publicly disclosed histories of severe mental illness and some of co-occurring
drug use disorder. They received broad-based training concerning the provision of case manage-
ment service.
***Regular providers worked alongside peer providers on the same treatment teams.
1 additional paper requested.
Sells-Connecticut 2006  (Continued)
 
 
Methods Allocation: randomised.
Participants People with severe mental disorders. N = 120.
Interventions 1. Home aftercare service: home visits by multidisciplinary teams, including general practitioners,
nurses, and social workers supervised by psychiatrists.
2. Treatment as usual.
Outcomes  
Notes Conference abstract, not enough information to determine inclusion/exclusion.
Written to authors for clarification.
Sharifi-Iran 2009 
 
 
Methods Allocation: randomised.
Participants People with schizophrenia.
Interventions Interventions: community-based integrated intervention includes rehabilitation consultant, devel-
op individualised rehabilitation plan, telephone follow-up, and family psycho-education.
Caseload: the author did not state the caseload.
Outcomes  
Notes In Chinese. To be assessed.
Su-China 2008 
 
 
Methods Allocation: randomised, no further details.
Participants Diagnosis: schizophrenia.
Interventions 1. Experimental intervention: provided by team, caseload not reported. Providing: i. antipsychotic
drug treatment; ii. family intervention; iii. occupational intervention; iv. rehabilitation intervention.
Tan-China 2005 
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2. Control intervention: no details provided.
Outcomes Awaiting further information from author about experimental intervention caseload.
Notes In Chinese. To be assessed.
Tan-China 2005  (Continued)
 
 
Methods Allocation: unclear.
Participants People with first-episode psychosis, 18 to 35 years of age.
Interventions 1. ACT with different modalities.
2. Care as usual.
Outcomes  
Notes Unclear if this is a randomised study (caseload is also unclear). Main paper in Dutch to be assessed.
Written to authors for clarification.
Verhaegh-Netherlands 2006 
 
 
Methods Allocation: randomised.
Participants People with schizophrenia.
Interventions Interventions: community-based integrated intervention includes psycho-education, direction on
use of medication, social rehabilitation training, psychological intervention, and crisis intervention.
Caseload: the author did not state the caseload.
Outcomes  
Notes In Chinese. Asessed by Sai Zhao. (Wang 2009).
Insufficient information to determine inclusion or exclusion; written to investigator.
Wang 2009 
 
 
Methods Allocation: randomised.
Participants People with schizophrenia.
Interventions Interventions: community-based integrated intervention includes psycho-education, life skill train-
ing, and cognitive therapy.
Caseload: the author did not state the caseload.
Outcomes  
Notes In Chinese. Assessed by Sai Zhao. (Zhang 2009).
Zhang 2009 
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Insufficient information to determine inclusion or exclusion; written to investigator.
Zhang 2009  (Continued)
 
 
Methods Allocation: randomised.
Participants Homeless patients with severe mental illness.
Interventions 1. ACT.
2. Case management.
Outcomes  
Notes Trial completed, but no results or publication found. Caseload unclear.
Written to investigator for clarification.
Zoeteman-Netherlands 
ACT - Assertive Community Treatment
CCMD-3 - Chinese Classification of Mental Disorders
ICM - Intensive Case Management
SD - standard deviation
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study
protocol for a randomised controlled trial.
Methods Allocation: randomised.
Blinding: Only assessors blinded.
Participants People who received a diagnosis of F2 or F3 (ICD-10), with psychotic symptoms.
Interventions 1. Comprehensive community-based care.
2. Standard care.
N = expected 150.
Age: 15 to 35 years.
Outcomes Primary outcome: Global Assessment of Functioning (GAF-F) scores at the first endpoint.
Secondary outcomes: GAF-F at the second and last endpoints, symptom domain of Global Assess-
ment of Functioning (GAF-S), PANSS, the World Health Organization Quality of Life 26-item version
(WHOQOL-BREF), Brief Evaluation of Medication Influences and Beliefs (BEMIB), care satisfaction of
participants and their families, educational and vocational recovery rates, remission rate, readmis-
sion rate, lost to follow-up rate, self harm and suicide attempt rate, suicide rate, engagement be-
haviour, and direct and indirect costs at each endpoint.
Starting date March 2011.
Contact information skoike-tky@umin.ac.jp; nishida-at@igakuken.or.jp
Koike-Japan 
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Notes The University Hospital Medical Information Network Clinical Trials Registry (No. UMIN000005092).
Expected completion date: September 2017.
Koike-Japan  (Continued)
 
 
Trial name or title A five-year randomized parallel and blinded clinical trial of an extended specialized early interven-
tion vs. regular care in the early phase of psychotic disorders.
Methods Allocation: randomised.
Participants People with first-episode psychosis.
Interventions 1. Extended Specialized Early Intervention: modified assertive case management; psycho-educa-
tion for families; multiple-family intervention; cognitive behavioural therapy; and substance abuse
treatment and monitoring.
2. Regular care.
Outcomes Primary outcomes: proportion of participants in complete remission and mean length of remission
achieved.
Secondary outcomes: relapse, functioning, quality of life.
Starting date  
Contact information Danyael Lutgens: Danyael.Lutgens@douglas.mcgill.ca
Notes  
Lutgens 2015 
 
 
Trial name or title Extending specialized early intervention service from 2 to 5 years: a randomised controlled trial.
Methods Allocation: randomised.
Participants Adults with severe mental illness.
Interventions 1. Extended Specialized Early Intervention.
2. Usual care.
Outcomes Rates of sustained engagement, length of remission, health economic indices.
Starting date  
Contact information Ashok Malla: ashok.malla@mcgill.ca
Notes Conference abstracts with brief interim results only.
Malla-Canada 
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Trial name or title Forensic Assertive Community Treatment: an emerging model of service delivery (FACT).
Methods Allocation: randomised, open, and parallel.
Participants Individuals diagnosed with any psychotic disorder such as schizophrenia, schizoaffective disorder,
bipolar disorder with psychotic features, depressive disorder with psychotic features, and psychot-
ic disorder, not otherwise specified, who currently face misdemeanor or violation charges and have
not yet been sentenced; N = 53.
Interventions 1. Forensic Assertive Community Treatment (FACT): services of an Assertive Community Treatment
team and close supervision of a judge trained in the FACT model.
2. Enhanced treatment as usual: expedited appointment at a clinic specialising in the treatment of
psychotic disorders; services of a therapist, psychiatrist, and case manager.
Outcomes Jail recidivism; mental health service utilisation.
Starting date May 2008.
Contact information Steven Lamberti, University of Rochester.
Notes Completed, no results posted, no publications found.
Written to author for further information. Received email from S. Lamberti on 30 December 2015
stating that they are unable to share the results at this time as they are being prepared for publica-
tion. Awaiting publication.
NCT01313052 
 
 
Trial name or title RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia).
Methods Cluster randomised trial.
Participants Adults with a diagnosis of schizophrenia spectrum disorder (schizophrenia, schizoaffective disor-
der, or schizophreniform disorder) using (DSM-IV) criteria.
Interventions 1. Communitybased rehabilitation: delivered to participants and their caregivers at their home,
comprising psycho-education, adherence support, rehabilitation (including self care and social
skills), family support groups, and accessing existing community organisations. The intervention
also involves community awareness raising and education and mobilisation of community leaders;
antipsychotic medication prescribed by a nurse or clinical officer in a health centre; and basic psy-
cho-education.
2. Facility-based usual care: antipsychotic medication prescribed by a nurse or clinical officer in a
health centre and basic psycho-education.
Outcomes Disability, symptom severity, Clinical Global Impression, relapse, functioning, economic activity of
participant (employment, income, and household work), medication adherence, engagement with
facility-based care, proportion with human rights problems, nutritional status (BMI), serious ad-
verse events, etc.
Starting date September 2015.
Contact information Mary De Silva, PhD MSc, London School of Hygiene and Tropical Medicine.
Abebaw Fekadu, Addis Ababa University Department of Psychiatry.
RISE - Ethiopia 
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Notes Currently recruiting.
RISE - Ethiopia  (Continued)
 
 
Trial name or title Specialized Treatment Early in Psychosis (STEP).
Methods Allocation: randomised.
Blinding: open label.
Participants Diagnosis: schizophrenia spectrum psychosis or affective psychosis (DSM-IV, SCID).
N = expected 200.
Age: 16 to 45 years.
History: ≦ 8 weeks of received antipsychotic treatment lifetime, informed consent, no psychosis
believed due to substance use.
Interventions 1. Specialised early treatment: including individual case management, antipsychotic prescription,
multifamily group therapy, group cognitive behavioural therapy, and cognitive remediation.
2. Standard care: usual referral to CMHC.
Outcomes Primary outcomes: service use: rehospitalisation (measured every 6 months for 5 yrs).
Secondary outcomes: relapse, overall functioning, quality of life, education and employment sta-
tus, treatment satisfaction, adherence, substance use, adverse effects (including self harm and vio-
lence), medication side effect, economic measures.
Starting date March 2006.
Contact information barbara.walsh@yale.edu; vinod.srihari@yale.edu
Notes ClinicalTrials.gov identifier: NCT00309452
Expected completion: September 2011.
NOTE: Results are available in Srihari VH, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJ, Pollard
J, Ozkan B, Saksa J, Walsh BC, Woods SW. First-episode services for psychotic disorders in the U.S.
public sector: a pragmatic randomized controlled trial. Psychiatric Services 2015 Jul;66(7):705-12.
Walsh-Connecticut 
BMI - body mass index
CMHC - Community Mental Health Centre
DSM - Diagnostic and Statistical Manual of Mental Disorders
ICD-10 - International Statistical Classification of Diseases and Related Health Problems 10th Revision
PANSS - Positive and Negative Syndrome Scale
SCID - Structured Clinical Interview for DSM-IV (First 1997)
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Intensive Case Management versus standard care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Service use: 1. Average number of days in
hospital per month - by about 24 months
24 3595 Mean Difference (IV, Random, 95%
CI)
-0.86 [-1.37, -0.34]
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
186
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.1 skewed data (sample size ≧ 200) 5 1812 Mean Difference (IV, Random, 95%
CI)
-0.46 [-0.95, 0.03]
1.2 skewed data (sample size < 200) 19 1783 Mean Difference (IV, Random, 95%
CI)
-1.01 [-1.74, -0.28]
2 Service use: 1a. Number of days in hos-
pital - by follow-up (skewed data, sample
size ≧ 200)
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
2.1 by medium term FUP (3 years) (previ-
ous year)
1 547 Mean Difference (IV, Random, 95%
CI)
0.10 [-10.26, 10.46]
2.2 by long term FUP (8 years) (previous
year)
1 547 Mean Difference (IV, Random, 95%
CI)
4.30 [-4.63, 13.23]
3 Service use: 2. Not remaining in contact
with psychiatric services
9 1633 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.30, 0.61]
3.1 by short term 1 95 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.28, 1.05]
3.2 by medium term 3 1063 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.36, 0.71]
3.3 by long term 5 475 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.11, 0.66]
4 Service use: 3a. Admitted to hospital 16   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 by short term 2 244 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.22, 1.69]
4.2 by medium term 5 1303 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.77, 0.93]
4.3 by long term 11 1516 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.74, 1.23]
4.4 by long term- during previous 12
months
1 547 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.52, 0.86]
4.5 by short term FUP - unplanned admis-
sion through Emergency Department
1 62 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 15.28]
5 Service use: 3b. Average number of ad-
missions per month (skewed data)
    Other data No numeric data
5.1 by medium term     Other data No numeric data
5.2 by long term     Other data No numeric data
6 Service use: 4a. Admitted to ER - by long
term
1 178 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.72, 1.76]
7 Service use: 4b. Average number of ad-
missions to ER (skewed data) - by medium
term
    Other data No numeric data
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
8 Service use: 5a. Received day hospital
care - by short term FUP
1 62 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.19, 20.93]
9 Service use: 5b. Outpatient visits - by
short term FUP (6 months)
1 62 Mean Difference (IV, Random, 95%
CI)
0.29 [-0.14, 0.72]
10 Service use: 5c. Outpatient visits - by
medium term (skewed data)
    Other data No numeric data
11 Service use: 5d. Received home visits -
by short term FUP
1 62 Mean Difference (IV, Random, 95%
CI)
4.32 [3.42, 5.22]
12 Adverse event: 1a. Death - any cause 14   Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 by short term 2 161 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.16, 6.91]
12.2 by medium term 6 901 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.23, 2.62]
12.3 by long term 9 1456 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.48, 1.47]
12.4 by medium term FUP (3 years) 1 547 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.22, 1.61]
12.5 by long term FUP (8 years) 1 547 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.45, 1.88]
13 Adverse event: 1b. Death - suicide 12   Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 by short term 2 127 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.27]
13.2 by medium term 4 819 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.17, 5.60]
13.3 by long term 9 1456 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.31, 1.51]
13.4 by medium term FUP (3 years) 1 547 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.17, 3.28]
14 Global state: 1. Leaving the study early 21   Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 by short term 5 598 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.44, 1.41]
14.2 by medium term 8 1699 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.51, 0.70]
14.3 by long term 13 1798 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.58, 0.79]
14.4 by medium term FUP (3 years) 1 547 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.84, 1.21]
14.5 by long term FUP (8 years) 1 547 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.70, 1.09]
15 Global state: 2. Average endpoint score
(GAF, high = good)
5   Mean Difference (IV, Random, 95%
CI)
Subtotals only
15.1 by short term 4 797 Mean Difference (IV, Random, 95%
CI)
2.07 [0.28, 3.86]
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15.2 by medium term 3 722 Mean Difference (IV, Random, 95%
CI)
0.09 [-3.11, 3.28]
15.3 by long term 5 818 Mean Difference (IV, Random, 95%
CI)
3.41 [1.66, 5.16]
16 Global state: 3. Not compliant with med-
ication - by long term
1 71 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.15, 0.81]
17 Social functioning: 1a. Contact with le-
gal system (various measurements)
11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 by short term - contact with the police 1 61 Risk Ratio (M-H, Random, 95% CI) 2.57 [0.73, 9.04]
17.2 by medium term - arrested 3 604 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.61, 1.90]
17.3 by medium term - contact with the po-
lice
1 88 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.09, 0.55]
17.4 by medium term - imprisoned 4 804 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.39, 1.64]
17.5 by long term - arrested 1 178 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.32, 1.37]
17.6 by long term - imprisoned 5 908 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.45, 1.65]
18 Social functioning: 1b. Mean contacts
with legal system (skewed data) - by medi-
um term
    Other data No numeric data
18.1 Bookings     Other data No numeric data
18.2 Jail days     Other data No numeric data
18.3 Convictions     Other data No numeric data
19 Social functioning: 2. Employment sta-
tus (various measurements)
6   Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 by medium term - not competitively
employed at the end of the trial
1 88 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.91, 1.10]
19.2 by medium term - not employed at the
end of the trial
4 1136 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.00]
19.3 by long term - not employed at the
end of the trial
4 1129 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.49, 1.00]
19.4 by long term - not working/studying in
the previous year
1 547 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.74, 0.99]
19.5 by medium term FUP (3 years) - not
working/studying in the previous year
1 547 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.90, 1.16]
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19.6 by long term FUP (8 years) - not work-
ing/studying in the previous year
1 547 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.88, 1.11]
20 Social functioning: 3a. Accommodation
status (various measurements)
10   Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 by short term - homelessness 1 95 Risk Ratio (M-H, Random, 95% CI) 0.04 [0.00, 0.70]
20.2 by medium term - homelessness 1 88 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.03, 2.95]
20.3 by medium term - not living indepen-
dently
5 1303 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.66, 0.97]
20.4 by long term - homelessness 3 418 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.34, 1.82]
20.5 by long term - not living independent-
ly
4 1185 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.49, 0.88]
20.6 by long term - not living in stable ac-
commodation
1 168 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.65, 0.98]
21 Social functioning: 3b. Accomodation
status: mean number of days in supported
house (skewed data, sample size ≧ 200)
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
21.1 by long term (previous year) 1 547 Mean Difference (IV, Random, 95%
CI)
0.30 [-13.98, 14.58]
21.2 by medium term FUP (3 years) (previ-
ous year)
1 547 Mean Difference (IV, Random, 95%
CI)
-22.20 [-38.47, -5.93]
21.3 by long term FUP (8 years) (previous
year)
1 547 Mean Difference (IV, Random, 95%
CI)
-6.70 [-19.35, 5.95]
22 Social functioning: 3c. Accommodation
status (various measurements, skewed da-
ta)
    Other data No numeric data
22.1 by medium term - average days per
month in stable accommodation
    Other data No numeric data
22.2 by long term - average days per month
in sheltered homes
    Other data No numeric data
23 Social functioning: 4a. Substance abuse 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
23.1 alcohol abuse - by long term 1 547 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.26, 1.17]
23.2 illicit drug abuse - by long term 1 547 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.63, 1.47]
23.3 substance abuse - by medium term
FUP (3 years)
1 547 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.67, 1.24]
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24 Social functioning: 4b. Substance abuse
(DALI, skewness not detectable) - by medi-
um term
    Other data No numeric data
24.1 alcohol abuse (DALI, -4 to + 6, high =
worse)
    Other data No numeric data
24.2 drug abuse (DALI, - 4 to + 4, high =
worse)
    Other data No numeric data
25 Social functioning: 4c. Substance abuse
- days used per month (skewed data)
    Other data No numeric data
25.1 by medium term     Other data No numeric data
25.2 by long term     Other data No numeric data
26 Social functioning: 5a. Average end-
point score (various scales)
3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
26.1 by short term (RFS, low = poor) 1 80 Mean Difference (IV, Random, 95%
CI)
-0.62 [-2.23, 0.99]
26.2 by short term (SAS-adapted version,
low = poor)
1 80 Mean Difference (IV, Random, 95%
CI)
-3.34 [-7.55, 0.87]
26.3 by medium term - social role perfor-
mance (DAS, high = poor)
1 55 Mean Difference (IV, Random, 95%
CI)
0.10 [-0.40, 0.60]
26.4 by medium term (RFS, low = poor) 1 80 Mean Difference (IV, Random, 95%
CI)
-0.86 [-2.72, 1.00]
26.5 by medium term (SAS-adapted ver-
sion, low = poor)
1 80 Mean Difference (IV, Random, 95%
CI)
-3.30 [-7.83, 1.23]
26.6 by long term - social role performance
(DAS, high = poor)
1 58 Mean Difference (IV, Random, 95%
CI)
-0.20 [-0.67, 0.27]
26.7 by long term (ISSI, low = poor) 1 62 Mean Difference (IV, Random, 95%
CI)
3.20 [0.11, 6.29]
26.8 by long term (RFS, low = poor) 1 80 Mean Difference (IV, Random, 95%
CI)
-2.35 [-4.05, -0.65]
26.9 by long term (SAS-adapted version,
low = poor)
1 80 Mean Difference (IV, Random, 95%
CI)
-2.75 [-7.13, 1.63]
26.10 by long term (Strauss-Carpenter
Scale, low = poor)
1 60 Mean Difference (IV, Random, 95%
CI)
0.10 [-1.17, 1.37]
27 Social functioning: 5b. Average end-
point score (various scales, skewed data)
    Other data No numeric data
27.1 by short term (SAS, high = poor)     Other data No numeric data
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27.2 by medium term (SAS, high = poor)     Other data No numeric data
27.3 by long term (SAS, high = poor)     Other data No numeric data
27.4 by long term (REHAB, high = poor)     Other data No numeric data
28 Mental state: 1a. General symptoms -
average endpoint score (various scales)
4   Mean Difference (IV, Random, 95%
CI)
Subtotals only
28.1 by short term (BPRS-18 items, high =
poor)
2 668 Mean Difference (IV, Random, 95%
CI)
-1.56 [-6.85, 3.73]
28.2 by short term (BSI, high = poor) 2 668 Mean Difference (IV, Random, 95%
CI)
-0.06 [-0.19, 0.06]
28.3 by short term (CSI, low = poor) 1 125 Mean Difference (IV, Random, 95%
CI)
-0.56 [-0.84, -0.28]
28.4 by medium term (BPRS-18 items, high
= poor)
2 662 Mean Difference (IV, Random, 95%
CI)
-0.96 [-2.42, 0.51]
28.5 by medium term (BSI, high = poor) 2 662 Mean Difference (IV, Random, 95%
CI)
-0.02 [-0.15, 0.10]
28.6 medium term (CSI, low = poor) 1 125 Mean Difference (IV, Random, 95%
CI)
-0.35 [-0.65, -0.05]
28.7 by long term (BPRS-18 items, high =
poor)
3 777 Mean Difference (IV, Random, 95%
CI)
-1.48 [-3.69, 0.74]
28.8 by long term (BSI, high = poor) 2 647 Mean Difference (IV, Random, 95%
CI)
-0.18 [-0.31, -0.06]
29 Mental state: 1b. General symptoms
- mean change from baseline (CSI, low =
poor ) - by long term
1 168 Mean Difference (IV, Random, 95%
CI)
-0.32 [-0.53, -0.11]
30 Mental state: 1c. General symptoms -
average endpoint score (various scales,
skewed data)
    Other data No numeric data
30.1 by short term (BPRS-24 items, high =
poor)
    Other data No numeric data
30.2 by short term (PSE, high = poor)     Other data No numeric data
30.4 by medium term (BPRS-24 items, high
= poor)
    Other data No numeric data
30.5 by medium term (CPRS, high = poor)     Other data No numeric data
30.6 by medium term (PSE, high = poor)     Other data No numeric data
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30.8 by long term (BPRS-18 items, high =
poor)
    Other data No numeric data
30.9 by long term (BPRS-24 items, high =
poor)
    Other data No numeric data
30.10 by long term (CPRS, high = poor)     Other data No numeric data
30.11 by long term (PSE, high = poor)     Other data No numeric data
30.12 by long term (SCL-90, high = poor)     Other data No numeric data
31 Mental state: 2a. Specific symptoms -
depression at follow up interview
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
31.1 by medium term 1 547 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.04]
31.2 by long term 1 547 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.57, 1.21]
31.3 by medium term FUP (3 years) 1 547 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.91, 1.72]
32 Mental state: 2b. Specific symptoms -
average endpoint score (various scales,
skewed data, sample size ≧ 200)
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
32.1 by long term - positive symptoms
(SAPS, high = poor)
1 547 Mean Difference (IV, Random, 95%
CI)
-0.22 [-0.45, 0.01]
32.2 by long term - negative symptoms
(SANS, high = poor)
1 547 Mean Difference (IV, Random, 95%
CI)
-0.42 [-0.62, -0.22]
32.3 by medium term FUP (3 years) - posi-
tive symptoms (SAPS, high = poor)
1 547 Mean Difference (IV, Random, 95%
CI)
0.12 [-0.15, 0.39]
32.4 by medium term FUP (3 years) - nega-
tive symptoms (SANS, high = poor)
1 547 Mean Difference (IV, Random, 95%
CI)
-0.10 [-0.33, 0.13]
32.5 by long term FUP (8 years) - positive
symptoms (SAPS, high = poor)
1 547 Mean Difference (IV, Random, 95%
CI)
0.03 [-0.21, 0.27]
32.6 by long term FUP (8 years) - negative
symptoms (SANS, high = poor)
1 547 Mean Difference (IV, Random, 95%
CI)
0.06 [-0.13, 0.25]
33 Mental state: 2c. Specific symptoms -
average endpoint score (various scales,
skewed data)
    Other data No numeric data
33.3 by medium term - depression symp-
toms (BDI, high = poor)
    Other data No numeric data
33.4 by medium term - negative symptoms
(SANS, high = poor)
    Other data No numeric data
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33.7 by long term - depression symptoms
(BDI, high = poor)
    Other data No numeric data
33.11 by long term - negative symptoms
(SANS, high = poor)
    Other data No numeric data
34 Behaviour: 1. Specific behaviour - self-
harm
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
34.1 by medium term 2 620 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.61, 1.59]
34.2 by long term 1 123 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.14, 6.55]
34.3 attempted suicide - by long term (dur-
ing last 12 months)
1 547 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.47, 1.38]
34.4 attempted suicide - by medium term
FUP (3 years) (during last 3 years)
1 547 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.56, 1.62]
35 Behaviour: 2. Social behaviour - average
endpoint score (SBS, high = poor)
    Other data No numeric data
35.1 by medium term     Other data No numeric data
35.2 by long term     Other data No numeric data
36 Quality of life: 1a. Average endpoint
score (various scales)
7   Mean Difference (IV, Random, 95%
CI)
Subtotals only
36.1 by short term - general well-being
(QOLI, high = better)
1 125 Mean Difference (IV, Random, 95%
CI)
0.53 [0.09, 0.97]
36.2 by medium term (LQoLP, high = better) 1 52 Mean Difference (IV, Random, 95%
CI)
0.09 [-0.60, 0.78]
36.3 by medium term (MANSA - range 1-7,
high = better)
1 81 Mean Difference (IV, Random, 95%
CI)
0.20 [-0.29, 0.69]
36.4 by long term (LQoLP, high = better) 3 274 Mean Difference (IV, Random, 95%
CI)
-0.13 [-0.38, 0.12]
36.5 by long term (QOLI, high = better) 2 132 Mean Difference (IV, Random, 95%
CI)
0.09 [-0.24, 0.42]
37 Quality of life: 1b. Mean change from
baseline (QOLI, high = better, skewed data)
- by long term
    Other data No numeric data
38 Participant satisfaction: 1a. Average
endpoint score (CSQ, high = better)
3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
38.1 by short term 1 61 Mean Difference (IV, Random, 95%
CI)
6.20 [2.60, 9.80]
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38.2 by medium term 2 500 Mean Difference (IV, Random, 95%
CI)
1.93 [0.86, 3.01]
38.3 by long term 2 423 Mean Difference (IV, Random, 95%
CI)
3.23 [2.31, 4.14]
39 Participants satisfaction: 1b. Average
endpoint score (CSQ, high = better, skewed
data) - by short term
    Other data No numeric data
40 Participants need: 1. Average endpoint
score (various scales, skewed data)
    Other data No numeric data
40.1 by medium term - met needs
(CANSAS, high = better)
    Other data No numeric data
40.2 by medium term - unmet needs
(CANSAS, high = poor)
    Other data No numeric data
40.4 by long term (CAN, high = poor)     Other data No numeric data
41 Costs: 1a. Direct costs of psychiatric hos-
pital care - by medium term (Unit cost =
USD, fiscal year 1990)
2 426 Mean Difference (IV, Random, 95%
CI)
-143.74 [-272.40,
-15.08]
42 Costs: 1b. Direct costs of psychiatric
hospital care - skewed data
    Other data No numeric data
42.1 by medium term     Other data No numeric data
42.2 by long term     Other data No numeric data
43 Costs: 2a. Direct healthcare costs - by
long term (Unit cost = USD, fiscal year
1988)
2 873 Mean Difference (IV, Random, 95%
CI)
-529.24 [-2143.59,
1085.10]
44 Costs: 2b. Direct healthcare costs -
skewed data
    Other data No numeric data
44.1 by medium term     Other data No numeric data
44.2 by short term FUP     Other data No numeric data
45 Costs: 3. Direct costs - other data -
skewed data
    Other data No numeric data
45.1 all care - by short term     Other data No numeric data
45.2 all care - by medium term     Other data No numeric data
45.3 all care - by long term     Other data No numeric data
45.4 specific - outpatient care - by medium
term
    Other data No numeric data
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
195
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
45.5 specific - prison - by medium term     Other data No numeric data
 
 
Analysis 1.1.   Comparison 1 Intensive Case Management versus standard care, Outcome
1 Service use: 1. Average number of days in hospital per month - by about 24 months.
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.1.1 skewed data (sample size ≧ 200)  
Chandler-California1 (A) 102 0.5 (2.3) 101 0.8 (1.8) 6.82% -0.31[-0.89,0.27]
Chandler-California1 (B) 115 0.7 (2.6) 114 1 (2.1) 6.77% -0.29[-0.89,0.31]
OPUS-Denmark 1999 263 5.1 (7.7) 244 6.6 (8.7) 4.72% -1.46[-2.9,-0.02]
Rosenheck-USA-GMS 271 4 (4.1) 257 4.2 (4.6) 6.46% -0.13[-0.87,0.61]
Rosenheck-USA-NP 183 8.9 (10.5) 162 11.7 (12.4) 2.79% -2.75[-5.19,-0.31]
Subtotal *** 934   878   27.56% -0.46[-0.95,0.03]
Heterogeneity: Tau2=0.11; Chi2=6.36, df=4(P=0.17); I2=37.08%  
Test for overall effect: Z=1.85(P=0.06)  
   
1.1.2 skewed data (sample size < 200)  
Audini-UK 1994 33 1 (2.8) 33 0.9 (2) 5.34% 0.02[-1.17,1.21]
Bjorkman-Sweden 2002 33 0.8 (3.1) 44 2.2 (4.1) 4.29% -1.32[-2.94,0.3]
Bond-Chicago1 1990 42 3.2 (4.6) 40 5.3 (5.4) 3.21% -2.08[-4.25,0.09]
Bond-Indiana1 (A) 29 1.3 (3.2) 32 7.7 (9) 1.82% -6.44[-9.76,-3.12]
Bond-Indiana1 (B) 34 2.7 (4.5) 30 3.6 (5.2) 2.83% -0.9[-3.32,1.52]
Bond-Indiana1 (C) 21 0.1 (1.9) 21 3.4 (5) 3.04% -3.33[-5.61,-1.05]
Curtis-New York 1992 146 1.8 (1.8) 143 1 (1.2) 7.21% 0.75[0.4,1.1]
Ford-UK 1995 39 3.1 (6.9) 38 1.8 (3.7) 2.77% 1.31[-1.15,3.77]
Hampton-Illinois (A) 48 1.8 (3.6) 47 4.8 (6.5) 3.3% -3.08[-5.2,-0.96]
Hampton-Illinois (B) 34 3.3 (5) 36 3.4 (5) 2.93% -0.17[-2.52,2.18]
Holloway-UK 1996 34 2.4 (5.1) 26 1.2 (3) 3.4% 1.2[-0.87,3.27]
Jerrell-SCarolina1 1991 40 0.5 (2.4) 40 0.8 (1.9) 5.97% -0.27[-1.21,0.67]
Lehman-Maryland1 1994 77 3 (5.2) 75 5.4 (7) 3.59% -2.37[-4.33,-0.41]
Marshall-UK 1995 40 1 (2.2) 40 1.6 (4.5) 4.49% -0.52[-2.06,1.02]
Muijen-UK2 1994 41 2.5 (5.6) 41 2.5 (5.8) 2.76% 0.08[-2.38,2.54]
Muller-Clemm-Canada 1996 61 1.7 (3.6) 57 1.6 (2.9) 5.38% 0.05[-1.12,1.22]
Quinlivan-California 1995 30 1.1 (2.7) 30 5.5 (8.7) 1.89% -4.44[-7.68,-1.2]
Sytema-Netherlands 1999 58 3.4 (5.4) 57 4.3 (7.3) 2.93% -0.9[-3.25,1.45]
Test-Wisconsin 1985 72 0.4 (2.3) 41 2.1 (3.5) 5.3% -1.71[-2.92,-0.5]
Subtotal *** 912   871   72.44% -1.01[-1.74,-0.28]
Heterogeneity: Tau2=1.67; Chi2=79.27, df=18(P<0.0001); I2=77.29%  
Test for overall effect: Z=2.7(P=0.01)  
   
Total *** 1846   1749   100% -0.86[-1.37,-0.34]
Heterogeneity: Tau2=0.93; Chi2=89.43, df=23(P<0.0001); I2=74.28%  
Test for overall effect: Z=3.26(P=0)  
Test for subgroup differences: Chi2=1.5, df=1 (P=0.22), I2=33.21%  
Favours treatment 2010-20 -10 0 Favours control
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Analysis 1.2.   Comparison 1 Intensive Case Management versus standard care, Outcome 2
Service use: 1a. Number of days in hospital - by follow-up (skewed data, sample size ≧ 200).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.2.1 by medium term FUP (3 years) (previous year)  
OPUS-Denmark 1999 275 20.5 (62.7) 272 20.4 (60.9) 100% 0.1[-10.26,10.46]
Subtotal *** 275   272   100% 0.1[-10.26,10.46]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
   
1.2.2 by long term FUP (8 years) (previous year)  
OPUS-Denmark 1999 275 17.6 (59.7) 272 13.3 (46) 100% 4.3[-4.63,13.23]
Subtotal *** 275   272   100% 4.3[-4.63,13.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
Test for subgroup differences: Chi2=0.36, df=1 (P=0.55), I2=0%  
INTENSIVE CASE MANAGEMENT 10050-100 -50 0 STANDARD CARE
 
 
Analysis 1.3.   Comparison 1 Intensive Case Management versus standard care,
Outcome 3 Service use: 2. Not remaining in contact with psychiatric services.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 by short term  
Hampton-Illinois (A) 10/48 18/47 14.25% 0.54[0.28,1.05]
Subtotal (95% CI) 48 47 14.25% 0.54[0.28,1.05]
Total events: 10 (INTENSIVE CASE MANAGEMENT), 18 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.81(P=0.07)  
   
1.3.2 by medium term  
Chandler-California1 (A) 30/127 46/129 21% 0.66[0.45,0.98]
Chandler-California1 (B) 14/125 39/135 16.53% 0.39[0.22,0.68]
OPUS-Denmark 1999 21/275 47/272 18.4% 0.44[0.27,0.72]
Subtotal (95% CI) 527 536 55.93% 0.51[0.36,0.71]
Total events: 65 (INTENSIVE CASE MANAGEMENT), 132 (STANDARD CARE)  
Heterogeneity: Tau2=0.03; Chi2=3.02, df=2(P=0.22); I2=33.79%  
Test for overall effect: Z=3.99(P<0.0001)  
   
1.3.3 by long term  
Bjorkman-Sweden 2002 0/33 3/44 1.4% 0.19[0.01,3.54]
Bond-Chicago1 1990 11/45 40/43 17.53% 0.26[0.16,0.44]
Holloway-UK 1996 1/35 9/35 2.8% 0.11[0.01,0.83]
Sytema-Netherlands 1999 0/59 13/59 1.52% 0.04[0,0.61]
Test-Wisconsin 1985 6/75 4/47 6.58% 0.94[0.28,3.16]
Subtotal (95% CI) 247 228 29.82% 0.27[0.11,0.66]
Total events: 18 (INTENSIVE CASE MANAGEMENT), 69 (STANDARD CARE)  
Heterogeneity: Tau2=0.43; Chi2=7.19, df=4(P=0.13); I2=44.33%  
Favours experimental 200.05 50.2 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=2.86(P=0)  
   
Total (95% CI) 822 811 100% 0.43[0.3,0.61]
Total events: 93 (INTENSIVE CASE MANAGEMENT), 219 (STANDARD CARE)  
Heterogeneity: Tau2=0.12; Chi2=15.57, df=8(P=0.05); I2=48.61%  
Test for overall effect: Z=4.71(P<0.0001)  
Test for subgroup differences: Chi2=1.85, df=1 (P=0.4), I2=0%  
Favours experimental 200.05 50.2 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Intensive Case Management versus
standard care, Outcome 4 Service use: 3a. Admitted to hospital.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 by short term  
Bond-Indiana1 1988 20/84 52/83 55.19% 0.38[0.25,0.58]
Ford-UK 1995 10/39 9/38 44.81% 1.08[0.5,2.37]
Subtotal (95% CI) 123 121 100% 0.61[0.22,1.69]
Total events: 30 (INTENSIVE CASE MANAGEMENT), 61 (STANDARD CARE)  
Heterogeneity: Tau2=0.45; Chi2=5.36, df=1(P=0.02); I2=81.36%  
Test for overall effect: Z=0.96(P=0.34)  
   
1.4.2 by medium term  
Bond-Chicago1 1990 34/45 37/43 21.18% 0.88[0.72,1.08]
Chandler-California1 (A) 27/127 28/129 4.06% 0.98[0.61,1.56]
Chandler-California1 (B) 29/125 44/135 5.55% 0.71[0.48,1.06]
Lehman-Maryland1 1994 42/77 45/75 11.78% 0.91[0.69,1.2]
OPUS-Denmark 1999 162/275 193/272 57.43% 0.83[0.73,0.94]
Subtotal (95% CI) 649 654 100% 0.85[0.77,0.93]
Total events: 294 (INTENSIVE CASE MANAGEMENT), 347 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=1.58, df=4(P=0.81); I2=0%  
Test for overall effect: Z=3.43(P=0)  
   
1.4.3 by long term  
Audini-UK 1994 9/33 9/33 6.15% 1[0.45,2.2]
Bjorkman-Sweden 2002 15/33 27/44 10.3% 0.74[0.48,1.15]
Chandler-California1 (A) 42/127 39/129 11.48% 1.09[0.76,1.57]
Chandler-California1 (B) 50/125 61/135 12.58% 0.89[0.67,1.18]
Curtis-New York 1992 75/146 51/143 12.75% 1.44[1.1,1.89]
Ford-UK 1995 16/39 14/38 8.65% 1.11[0.64,1.95]
Herinckx-Oregon 1996 54/117 25/61 11.5% 1.13[0.79,1.61]
Holloway-UK 1996 15/35 15/35 8.92% 1[0.58,1.72]
Macias-Utah 1994 0/20 8/21 0.79% 0.06[0,1]
Marshall-UK 1995 17/40 10/40 7.61% 1.7[0.89,3.25]
Test-Wisconsin 1985 15/75 27/47 9.26% 0.35[0.21,0.58]
Subtotal (95% CI) 790 726 100% 0.96[0.74,1.23]
  100.1 50.2 20.5 1  
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 308 (INTENSIVE CASE MANAGEMENT), 286 (STANDARD CARE)  
Heterogeneity: Tau2=0.11; Chi2=32.88, df=10(P=0); I2=69.59%  
Test for overall effect: Z=0.35(P=0.72)  
   
1.4.4 by long term- during previous 12 months  
OPUS-Denmark 1999 72/275 106/272 100% 0.67[0.52,0.86]
Subtotal (95% CI) 275 272 100% 0.67[0.52,0.86]
Total events: 72 (INTENSIVE CASE MANAGEMENT), 106 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.14(P=0)  
   
1.4.5 by short term FUP - unplanned admission through Emergency
Department
 
Chan-Hong Kong 2000 1/31 1/31 100% 1[0.07,15.28]
Subtotal (95% CI) 31 31 100% 1[0.07,15.28]
Total events: 1 (INTENSIVE CASE MANAGEMENT), 1 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
  100.1 50.2 20.5 1  
 
 
Analysis 1.5.   Comparison 1 Intensive Case Management versus standard care,
Outcome 5 Service use: 3b. Average number of admissions per month (skewed data).
Service use: 3b. Average number of admissions per month (skewed data)
Study Intervention Mean SD Total Note
by medium term
Bond-Chicago1 1990 1. ICM 0.16 0.15 42  
Bond-Chicago1 1990 2. Standard care 0.26 0.23 40  
by long term
Audini-UK 1994 1. ICM 0.02 0.05* 33  
Audini-UK 1994 2. Standard care 0.03 0.06* 33 * Carried over from
Sytema-Netherlands.
Muller-Clemm-Canada
1996
1. ICM 0.09 0.05* 61  
Muller-Clemm-Canada
1996
2. Standard care 0.08 0.06* 57 * Carried over from
Sytema-Netherlands.
Sytema-Netherlands
1999
1. ICM 0.05 0.05 58  
Sytema-Netherlands
1999
2. Standard care 0.05 0.06 57  
 
 
Analysis 1.6.   Comparison 1 Intensive Case Management versus
standard care, Outcome 6 Service use: 4a. Admitted to ER - by long term.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Herinckx-Oregon 1996 41/117 19/61 100% 1.13[0.72,1.76]
Favours experimental 1000.01 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
Total (95% CI) 117 61 100% 1.13[0.72,1.76]
Total events: 41 (INTENSIVE CASE MANAGEMENT), 19 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.52(P=0.61)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 1.7.   Comparison 1 Intensive Case Management versus standard care, Outcome
7 Service use: 4b. Average number of admissions to ER (skewed data) - by medium term.
Service use: 4b. Average number of admissions to ER (skewed data) - by medium term
Study Intervention Mean SD Total Note
Jerrell-SCarolina1 1991 1. ICM 0.85 1.7* 40  
Jerrell-SCarolina1 1991 2. Standard care 0.73 3.3* 40 * Carried over from
Lehman-Maryland1.
Lehman-Maryland1 1994 1. ICM 0.9 1.7 77  
Lehman-Maryland1 1994 2. Standard care 2 3.3 75  
 
 
Analysis 1.8.   Comparison 1 Intensive Case Management versus standard care,
Outcome 8 Service use: 5a. Received day hospital care - by short term FUP.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chan-Hong Kong 2000 2/31 1/31 100% 2[0.19,20.93]
   
Total (95% CI) 31 31 100% 2[0.19,20.93]
Total events: 2 (INTENSIVE CASE MANAGEMENT), 1 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Favours ICM 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.9.   Comparison 1 Intensive Case Management versus standard care,
Outcome 9 Service use: 5b. Outpatient visits - by short term FUP (6 months).
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chan-Hong Kong 2000 31 4.5 (0.8) 31 4.2 (0.9) 100% 0.29[-0.14,0.72]
   
Total *** 31   31   100% 0.29[-0.14,0.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
Favours experimental 42-4 -2 0 Favours control
 
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
200
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
Analysis 1.10.   Comparison 1 Intensive Case Management versus standard care,
Outcome 10 Service use: 5c. Outpatient visits - by medium term (skewed data).
Service use: 5c. Outpatient visits - by medium term (skewed data)
Study Intervention Mean SD Total Note
Cusack-North Carolina ICM 95.9 57.1 72 -
Cusack-North Carolina Standard care 43.3 47.9 62 -
 
 
Analysis 1.11.   Comparison 1 Intensive Case Management versus standard
care, Outcome 11 Service use: 5d. Received home visits - by short term FUP.
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chan-Hong Kong 2000 31 9.3 (1.7) 31 4.9 (1.9) 100% 4.32[3.42,5.22]
   
Total *** 31   31   100% 4.32[3.42,5.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=9.41(P<0.0001)  
Favours standard care 10050-100 -50 0 Favours ICM
 
 
Analysis 1.12.   Comparison 1 Intensive Case Management versus
standard care, Outcome 12 Adverse event: 1a. Death - any cause.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.12.1 by short term  
Audini-UK 1994 0/33 1/33 35.86% 0.33[0.01,7.9]
Hampton-Illinois (A) 2/48 1/47 64.14% 1.96[0.18,20.88]
Subtotal (95% CI) 81 80 100% 1.04[0.16,6.91]
Total events: 2 (INTENSIVE CASE MANAGEMENT), 2 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=0.77, df=1(P=0.38); I2=0%  
Test for overall effect: Z=0.04(P=0.97)  
   
1.12.2 by medium term  
Audini-UK 1994 0/33 1/33 14.6% 0.33[0.01,7.9]
Bond-Chicago1 1990 1/45 0/43 14.52% 2.87[0.12,68.58]
Johnston-Australia 1998 0/1 0/1   Not estimable
Marshall-UK 1995 2/40 0/40 16.19% 5[0.25,100.97]
OPUS-Denmark 1999 1/275 3/272 28.71% 0.33[0.03,3.15]
Sytema-Netherlands 1999 1/59 2/59 25.97% 0.5[0.05,5.37]
Subtotal (95% CI) 453 448 100% 0.78[0.23,2.62]
Total events: 5 (INTENSIVE CASE MANAGEMENT), 6 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=3.11, df=4(P=0.54); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
1.12.3 by long term  
Audini-UK 1994 0/33 1/33 3.12% 0.33[0.01,7.9]
Favours treatment 1000.01 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bjorkman-Sweden 2002 0/33 1/44 3.11% 0.44[0.02,10.5]
Curtis-New York 1992 11/147 10/145 45.96% 1.09[0.48,2.48]
Ford-UK 1995 3/39 0/38 3.64% 6.83[0.36,127.84]
Holloway-UK 1996 1/35 2/35 5.64% 0.5[0.05,5.27]
Muijen-UK2 1994 0/41 0/41   Not estimable
Muller-Clemm-Canada 1996 2/63 3/60 10.17% 0.63[0.11,3.67]
OPUS-Denmark 1999 1/275 6/272 7.03% 0.16[0.02,1.36]
Test-Wisconsin 1985 6/75 4/47 21.32% 0.94[0.28,3.16]
Subtotal (95% CI) 741 715 100% 0.84[0.48,1.47]
Total events: 24 (INTENSIVE CASE MANAGEMENT), 27 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=5.43, df=7(P=0.61); I2=0%  
Test for overall effect: Z=0.62(P=0.53)  
   
1.12.4 by medium term FUP (3 years)  
OPUS-Denmark 1999 6/275 10/272 100% 0.59[0.22,1.61]
Subtotal (95% CI) 275 272 100% 0.59[0.22,1.61]
Total events: 6 (INTENSIVE CASE MANAGEMENT), 10 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.02(P=0.31)  
   
1.12.5 by long term FUP (8 years)  
OPUS-Denmark 1999 14/275 15/272 100% 0.92[0.45,1.88]
Subtotal (95% CI) 275 272 100% 0.92[0.45,1.88]
Total events: 14 (INTENSIVE CASE MANAGEMENT), 15 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.83)  
Favours treatment 1000.01 100.1 1 Favours control
 
 
Analysis 1.13.   Comparison 1 Intensive Case Management versus
standard care, Outcome 13 Adverse event: 1b. Death - suicide.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.13.1 by short term  
Audini-UK 1994 0/33 1/33 49.95% 0.33[0.01,7.9]
Bond-Indiana1 (A) 0/29 1/32 50.05% 0.37[0.02,8.66]
Subtotal (95% CI) 62 65 100% 0.35[0.04,3.27]
Total events: 0 (INTENSIVE CASE MANAGEMENT), 2 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=0.92(P=0.36)  
   
1.13.2 by medium term  
Audini-UK 1994 0/33 1/33 30.27% 0.33[0.01,7.9]
Bond-Chicago1 1990 1/45 0/43 30.11% 2.87[0.12,68.58]
OPUS-Denmark 1999 1/275 1/272 39.62% 0.99[0.06,15.73]
Sytema-Netherlands 1999 0/59 0/59   Not estimable
Favours experimental 10000.001 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 412 407 100% 0.98[0.17,5.6]
Total events: 2 (INTENSIVE CASE MANAGEMENT), 2 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=0.89, df=2(P=0.64); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
   
1.13.3 by long term  
Audini-UK 1994 0/33 1/33 6.34% 0.33[0.01,7.9]
Bjorkman-Sweden 2002 0/33 1/44 6.32% 0.44[0.02,10.5]
Curtis-New York 1992 1/147 2/145 11.13% 0.49[0.05,5.38]
Ford-UK 1995 1/39 0/38 6.32% 2.93[0.12,69.64]
Holloway-UK 1996 0/35 1/35 6.33% 0.33[0.01,7.91]
Muijen-UK2 1994 0/41 0/41   Not estimable
Muller-Clemm-Canada 1996 2/63 2/60 17.09% 0.95[0.14,6.55]
OPUS-Denmark 1999 1/275 4/272 13.31% 0.25[0.03,2.2]
Test-Wisconsin 1985 5/75 3/47 33.16% 1.04[0.26,4.17]
Subtotal (95% CI) 741 715 100% 0.68[0.31,1.51]
Total events: 10 (INTENSIVE CASE MANAGEMENT), 14 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=2.67, df=7(P=0.91); I2=0%  
Test for overall effect: Z=0.94(P=0.35)  
   
1.13.4 by medium term FUP (3 years)  
OPUS-Denmark 1999 3/275 4/272 100% 0.74[0.17,3.28]
Subtotal (95% CI) 275 272 100% 0.74[0.17,3.28]
Total events: 3 (INTENSIVE CASE MANAGEMENT), 4 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.69)  
Favours experimental 10000.001 100.1 1 Favours control
 
 
Analysis 1.14.   Comparison 1 Intensive Case Management versus
standard care, Outcome 14 Global state: 1. Leaving the study early.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.14.1 by short term  
Audini-UK 1994 2/33 5/33 8.75% 0.4[0.08,1.92]
Bond-Indiana1 1988 18/84 25/83 20.4% 0.71[0.42,1.2]
Hampton-Illinois (A) 38/48 29/47 23.3% 1.28[0.98,1.68]
Hampton-Illinois (B) 34/34 36/36 24.47% 1[0.95,1.06]
Solomon-Pennsylvania 1994 42/120 52/80 23.08% 0.54[0.4,0.72]
Subtotal (95% CI) 319 279 100% 0.79[0.44,1.41]
Total events: 134 (INTENSIVE CASE MANAGEMENT), 147 (STANDARD CARE)  
Heterogeneity: Tau2=0.35; Chi2=80.24, df=4(P<0.0001); I2=95.01%  
Test for overall effect: Z=0.8(P=0.43)  
   
1.14.2 by medium term  
Bond-Chicago1 1990 11/45 19/43 6.48% 0.55[0.3,1.02]
Favours treatment 10000.001 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chandler-California1 (A) 25/127 28/129 10.58% 0.91[0.56,1.47]
Chandler-California1 (B) 10/125 27/135 5.23% 0.4[0.2,0.79]
Lehman-Maryland1 1994 10/77 17/75 4.8% 0.57[0.28,1.17]
Marshall-UK 1995 6/40 5/40 2.01% 1.2[0.4,3.62]
Morse-Missouri1 1992 15/52 29/64 9.59% 0.64[0.38,1.05]
OPUS-Denmark 1999 48/275 80/272 24.43% 0.59[0.43,0.81]
Solomon-Pennsylvania 1994 48/120 58/80 36.88% 0.55[0.43,0.71]
Subtotal (95% CI) 861 838 100% 0.6[0.51,0.7]
Total events: 173 (INTENSIVE CASE MANAGEMENT), 263 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=6.28, df=7(P=0.51); I2=0%  
Test for overall effect: Z=6.39(P<0.0001)  
   
1.14.3 by long term  
Aberg-Wistedt-Sweden 1995 0/20 0/20   Not estimable
Audini-UK 1994 3/33 5/33 1.33% 0.6[0.16,2.31]
Bjorkman-Sweden 2002 5/33 8/44 2.3% 0.83[0.3,2.32]
Chandler-California1 (A) 44/127 60/129 24.7% 0.74[0.55,1.01]
Chandler-California1 (B) 33/125 63/135 19.38% 0.57[0.4,0.8]
Ford-UK 1995 4/39 9/38 2.02% 0.43[0.15,1.29]
Holloway-UK 1996 1/35 9/35 0.6% 0.11[0.01,0.83]
Macias-Utah 1994 2/20 5/21 1.04% 0.42[0.09,1.92]
Muijen-UK2 1994 10/41 14/41 5.06% 0.71[0.36,1.42]
Muller-Clemm-Canada 1996 2/63 3/60 0.78% 0.63[0.11,3.67]
OPUS-Denmark 1999 70/275 108/272 35.08% 0.64[0.5,0.82]
Pique-California 1999 14/22 7/15 6.06% 1.36[0.73,2.55]
Test-Wisconsin 1985 6/75 4/47 1.64% 0.94[0.28,3.16]
Subtotal (95% CI) 908 890 100% 0.68[0.58,0.79]
Total events: 194 (INTENSIVE CASE MANAGEMENT), 295 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=11.22, df=11(P=0.42); I2=1.97%  
Test for overall effect: Z=4.94(P<0.0001)  
   
1.14.4 by medium term FUP (3 years)  
OPUS-Denmark 1999 124/275 122/272 100% 1.01[0.84,1.21]
Subtotal (95% CI) 275 272 100% 1.01[0.84,1.21]
Total events: 124 (INTENSIVE CASE MANAGEMENT), 122 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.96)  
   
1.14.5 by long term FUP (8 years)  
OPUS-Denmark 1999 94/275 106/272 100% 0.88[0.7,1.09]
Subtotal (95% CI) 275 272 100% 0.88[0.7,1.09]
Total events: 94 (INTENSIVE CASE MANAGEMENT), 106 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.25)  
Favours treatment 10000.001 100.1 1 Favours control
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Analysis 1.15.   Comparison 1 Intensive Case Management versus standard
care, Outcome 15 Global state: 2. Average endpoint score (GAF, high = good).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.15.1 by short term  
Audini-UK 1994 31 66.4 (14.5) 30 66.6 (17.5) 4.93% -0.2[-8.28,7.88]
Muijen-UK2 1994 36 45.7 (15.6) 32 45.8 (14.7) 6.19% -0.1[-7.3,7.1]
Rosenheck-USA-GMS 233 49.5 (12.9) 177 47.9 (11.9) 55.36% 1.63[-0.78,4.04]
Rosenheck-USA-NP 137 43.5 (12.7) 121 39.9 (12.6) 33.52% 3.53[0.43,6.63]
Subtotal *** 437   360   100% 2.07[0.28,3.86]
Heterogeneity: Tau2=0; Chi2=1.63, df=3(P=0.65); I2=0%  
Test for overall effect: Z=2.26(P=0.02)  
   
1.15.2 by medium term  
Muijen-UK2 1994 33 41.8 (13.7) 27 46.7 (14.5) 15.03% -4.9[-12.09,2.29]
Rosenheck-USA-GMS 239 49.2 (13.4) 181 49.6 (12.2) 46.12% -0.44[-2.9,2.02]
Rosenheck-USA-NP 132 43.5 (13.7) 110 40.9 (11.6) 38.85% 2.64[-0.55,5.83]
Subtotal *** 404   318   100% 0.09[-3.11,3.28]
Heterogeneity: Tau2=4.18; Chi2=4.42, df=2(P=0.11); I2=54.74%  
Test for overall effect: Z=0.05(P=0.96)  
   
1.15.3 by long term  
Audini-UK 1994 30 62 (22) 28 61.5 (20.6) 2.55% 0.5[-10.46,11.46]
Bjorkman-Sweden 2002 22 52.3 (14.6) 33 55.3 (17) 4.32% -3[-11.42,5.42]
Muijen-UK2 1994 31 42.6 (13.3) 27 39.3 (14.5) 5.91% 3.3[-3.9,10.5]
Rosenheck-USA-GMS 221 52.8 (11.3) 189 48.8 (11.7) 61.43% 3.98[1.75,6.21]
Rosenheck-USA-NP 129 45.3 (14.7) 108 41.9 (12.4) 25.79% 3.44[-0.01,6.89]
Subtotal *** 433   385   100% 3.41[1.66,5.16]
Heterogeneity: Tau2=0; Chi2=2.75, df=4(P=0.6); I2=0%  
Test for overall effect: Z=3.82(P=0)  
Favours control 2010-20 -10 0 Favours experimental
 
 
Analysis 1.16.   Comparison 1 Intensive Case Management versus standard care,
Outcome 16 Global state: 3. Not compliant with medication - by long term.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ford-UK 1995 6/39 14/32 100% 0.35[0.15,0.81]
   
Total (95% CI) 39 32 100% 0.35[0.15,0.81]
Total events: 6 (INTENSIVE CASE MANAGEMENT), 14 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.46(P=0.01)  
  100.1 50.2 20.5 1  
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Analysis 1.17.   Comparison 1 Intensive Case Management versus standard care,
Outcome 17 Social functioning: 1a. Contact with legal system (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.17.1 by short term - contact with the police  
Bond-Indiana1 (A) 7/29 3/32 100% 2.57[0.73,9.04]
Subtotal (95% CI) 29 32 100% 2.57[0.73,9.04]
Total events: 7 (INTENSIVE CASE MANAGEMENT), 3 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
   
1.17.2 by medium term - arrested  
Bond-Chicago1 1990 4/45 2/43 11.93% 1.91[0.37,9.9]
Chandler-California1 (A) 10/127 9/129 43.01% 1.13[0.47,2.68]
Chandler-California1 (B) 9/125 11/135 45.06% 0.88[0.38,2.06]
Subtotal (95% CI) 297 307 100% 1.08[0.61,1.9]
Total events: 23 (INTENSIVE CASE MANAGEMENT), 22 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=0.69, df=2(P=0.71); I2=0%  
Test for overall effect: Z=0.25(P=0.8)  
   
1.17.3 by medium term - contact with the police  
Bond-Chicago1 1990 5/45 21/43 100% 0.23[0.09,0.55]
Subtotal (95% CI) 45 43 100% 0.23[0.09,0.55]
Total events: 5 (INTENSIVE CASE MANAGEMENT), 21 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.29(P=0)  
   
1.17.4 by medium term - imprisoned  
Bond-Chicago1 1990 1/45 4/43 9.2% 0.24[0.03,2.05]
Chandler-California1 (A) 5/127 9/129 24.1% 0.56[0.19,1.64]
Chandler-California1 (B) 4/125 7/135 21.03% 0.62[0.19,2.06]
Solomon-Pennsylvania 1994 60/120 29/80 45.68% 1.38[0.98,1.94]
Subtotal (95% CI) 417 387 100% 0.8[0.39,1.64]
Total events: 70 (INTENSIVE CASE MANAGEMENT), 49 (STANDARD CARE)  
Heterogeneity: Tau2=0.27; Chi2=6.21, df=3(P=0.1); I2=51.66%  
Test for overall effect: Z=0.61(P=0.54)  
   
1.17.5 by long term - arrested  
Herinckx-Oregon 1996 14/117 11/61 100% 0.66[0.32,1.37]
Subtotal (95% CI) 117 61 100% 0.66[0.32,1.37]
Total events: 14 (INTENSIVE CASE MANAGEMENT), 11 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.11(P=0.27)  
   
1.17.6 by long term - imprisoned  
Ford-UK 1995 0/39 0/38   Not estimable
Marshall-UK 1995 0/40 0/40   Not estimable
Muijen-UK2 1994 1/41 4/41 8.87% 0.25[0.03,2.14]
OPUS-Denmark 1999 4/275 2/272 13.97% 1.98[0.37,10.71]
Test-Wisconsin 1985 19/75 14/47 77.16% 0.85[0.47,1.53]
Subtotal (95% CI) 470 438 100% 0.86[0.45,1.65]
Total events: 24 (INTENSIVE CASE MANAGEMENT), 20 (STANDARD CARE)  
  2000.005 100.1 1  
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.05; Chi2=2.21, df=2(P=0.33); I2=9.48%  
Test for overall effect: Z=0.46(P=0.65)  
  2000.005 100.1 1  
 
 
Analysis 1.18.   Comparison 1 Intensive Case Management versus standard care, Outcome
18 Social functioning: 1b. Mean contacts with legal system (skewed data) - by medium term.
Social functioning: 1b. Mean contacts with legal system (skewed data) - by medium term
Study Intervention Mean SD Total
Bookings
Cusack-North Carolina 1. ICM 0.64 1.2 72
Cusack-North Carolina 2. Standard care 1.42 1.86 62
Jail days
Cusack-North Carolina 1. ICM 18.5 45.3 72
Cusack-North Carolina 2. Standard care 35.3 56.9 62
Convictions
Cusack-North Carolina 1. ICM 0.75 0.77 72
Cusack-North Carolina 2. Standard care 0.85 1.03 62
 
 
Analysis 1.19.   Comparison 1 Intensive Case Management versus standard care,
Outcome 19 Social functioning: 2. Employment status (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.19.1 by medium term - not competitively employed at the end of the
trial
 
Bond-Chicago1 1990 43/45 41/43 100% 1[0.91,1.1]
Subtotal (95% CI) 45 43 100% 1[0.91,1.1]
Total events: 43 (INTENSIVE CASE MANAGEMENT), 41 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
   
1.19.2 by medium term - not employed at the end of the trial  
Chandler-California1 (A) 81/127 111/129 21.49% 0.74[0.64,0.86]
Chandler-California1 (B) 103/125 128/135 27.95% 0.87[0.79,0.95]
Johnston-Australia 1998 35/37 34/36 25.68% 1[0.9,1.12]
OPUS-Denmark 1999 179/275 188/272 24.89% 0.94[0.84,1.06]
Subtotal (95% CI) 564 572 100% 0.89[0.79,1]
Total events: 398 (INTENSIVE CASE MANAGEMENT), 461 (STANDARD CARE)  
Heterogeneity: Tau2=0.01; Chi2=11.86, df=3(P=0.01); I2=74.71%  
Test for overall effect: Z=2.04(P=0.04)  
   
1.19.3 by long term - not employed at the end of the trial  
Audini-UK 1994 23/33 24/33 23.03% 0.96[0.7,1.3]
Chandler-California1 (A) 35/127 110/129 23.44% 0.32[0.24,0.43]
Favours treatment 50.2 20.5 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chandler-California1 (B) 89/125 120/135 26.76% 0.8[0.71,0.91]
OPUS-Denmark 1999 168/275 182/272 26.77% 0.91[0.8,1.04]
Subtotal (95% CI) 560 569 100% 0.7[0.49,1]
Total events: 315 (INTENSIVE CASE MANAGEMENT), 436 (STANDARD CARE)  
Heterogeneity: Tau2=0.12; Chi2=46.48, df=3(P<0.0001); I2=93.55%  
Test for overall effect: Z=1.95(P=0.05)  
   
1.19.4 by long term - not working/studying in the previous year  
OPUS-Denmark 1999 147/275 170/272 100% 0.86[0.74,0.99]
Subtotal (95% CI) 275 272 100% 0.86[0.74,0.99]
Total events: 147 (INTENSIVE CASE MANAGEMENT), 170 (STANDARD CARE)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.13(P=0.03)  
   
1.19.5 by medium term FUP (3 years) - not working/studying in the
previous year
 
OPUS-Denmark 1999 176/275 170/272 100% 1.02[0.9,1.16]
Subtotal (95% CI) 275 272 100% 1.02[0.9,1.16]
Total events: 176 (INTENSIVE CASE MANAGEMENT), 170 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
1.19.6 by long term FUP (8 years) - not working/studying in the previ-
ous year
 
OPUS-Denmark 1999 185/275 185/272 100% 0.99[0.88,1.11]
Subtotal (95% CI) 275 272 100% 0.99[0.88,1.11]
Total events: 185 (INTENSIVE CASE MANAGEMENT), 185 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Favours treatment 50.2 20.5 1 Favours control
 
 
Analysis 1.20.   Comparison 1 Intensive Case Management versus standard care,
Outcome 20 Social functioning: 3a. Accommodation status (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.20.1 by short term - homelessness  
Hampton-Illinois (A) 0/48 11/47 100% 0.04[0,0.7]
Subtotal (95% CI) 48 47 100% 0.04[0,0.7]
Total events: 0 (INTENSIVE CASE MANAGEMENT), 11 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.21(P=0.03)  
   
1.20.2 by medium term - homelessness  
Bond-Chicago1 1990 1/45 3/43 100% 0.32[0.03,2.95]
Subtotal (95% CI) 45 43 100% 0.32[0.03,2.95]
Total events: 1 (INTENSIVE CASE MANAGEMENT), 3 (STANDARD CARE)  
Favours treatment 2000.005 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
   
1.20.3 by medium term - not living independently  
Bond-Chicago1 1990 32/45 37/43 35.71% 0.83[0.66,1.03]
Chandler-California1 (A) 20/127 31/129 12.28% 0.66[0.4,1.09]
Chandler-California1 (B) 53/125 56/135 27.43% 1.02[0.77,1.36]
Lehman-Maryland1 1994 15/77 20/75 9.52% 0.73[0.41,1.32]
OPUS-Denmark 1999 27/275 46/272 15.06% 0.58[0.37,0.91]
Subtotal (95% CI) 649 654 100% 0.8[0.66,0.97]
Total events: 147 (INTENSIVE CASE MANAGEMENT), 190 (STANDARD CARE)  
Heterogeneity: Tau2=0.02; Chi2=5.81, df=4(P=0.21); I2=31.17%  
Test for overall effect: Z=2.25(P=0.02)  
   
1.20.4 by long term - homelessness  
Herinckx-Oregon 1996 26/117 11/61 55.61% 1.23[0.65,2.32]
Sytema-Netherlands 1999 1/59 5/59 13.25% 0.2[0.02,1.66]
Test-Wisconsin 1985 5/75 5/47 31.14% 0.63[0.19,2.05]
Subtotal (95% CI) 251 167 100% 0.78[0.34,1.82]
Total events: 32 (INTENSIVE CASE MANAGEMENT), 21 (STANDARD CARE)  
Heterogeneity: Tau2=0.23; Chi2=3.27, df=2(P=0.19); I2=38.87%  
Test for overall effect: Z=0.56(P=0.57)  
   
1.20.5 by long term - not living independently  
Chandler-California1 (A) 14/127 30/129 17.37% 0.47[0.26,0.85]
Chandler-California1 (B) 38/125 58/135 33.12% 0.71[0.51,0.98]
OPUS-Denmark 1999 36/275 38/272 25.94% 0.94[0.61,1.43]
Test-Wisconsin 1985 20/75 25/47 23.57% 0.5[0.32,0.8]
Subtotal (95% CI) 602 583 100% 0.65[0.49,0.88]
Total events: 108 (INTENSIVE CASE MANAGEMENT), 151 (STANDARD CARE)  
Heterogeneity: Tau2=0.04; Chi2=5.39, df=3(P=0.15); I2=44.3%  
Test for overall effect: Z=2.84(P=0)  
   
1.20.6 by long term - not living in stable accommodation  
Shern-USA1 2000 56/91 59/77 100% 0.8[0.65,0.98]
Subtotal (95% CI) 91 77 100% 0.8[0.65,0.98]
Total events: 56 (INTENSIVE CASE MANAGEMENT), 59 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.11(P=0.04)  
Favours treatment 2000.005 100.1 1 Favours control
 
 
Analysis 1.21.   Comparison 1 Intensive Case Management versus standard care, Outcome 21 Social functioning:
3b. Accomodation status: mean number of days in supported house (skewed data, sample size ≧ 200).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.21.1 by long term (previous year)  
Favours control 10050-100 -50 0 Favours treatment
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Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
OPUS-Denmark 1999 275 27 (84) 272 26.7 (86.4) 100% 0.3[-13.98,14.58]
Subtotal *** 275   272   100% 0.3[-13.98,14.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
1.21.2 by medium term FUP (3 years) (previous year)  
OPUS-Denmark 1999 275 20.1 (78.4) 272 42.3 (112.5) 100% -22.2[-38.47,-5.93]
Subtotal *** 275   272   100% -22.2[-38.47,-5.93]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.67(P=0.01)  
   
1.21.3 by long term FUP (8 years) (previous year)  
OPUS-Denmark 1999 275 14.1 (66.5) 272 20.8 (83.4) 100% -6.7[-19.35,5.95]
Subtotal *** 275   272   100% -6.7[-19.35,5.95]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
Test for subgroup differences: Chi2=4.26, df=1 (P=0.12), I2=53.04%  
Favours control 10050-100 -50 0 Favours treatment
 
 
Analysis 1.22.   Comparison 1 Intensive Case Management versus standard care, Outcome
22 Social functioning: 3c. Accommodation status (various measurements, skewed data).
Social functioning: 3c. Accommodation status (various measurements, skewed data)
Study Intervention Mean SD Total
by medium term - average days per month in stable accommodation
Lehman-Maryland1 1994 1. ICM 17.5 9 77
Lehman-Maryland1 1994 2. Standard care 13.34 9 75
Morse-Missouri3 2005 1. ICM 5.77 7.42 54
Morse-Missouri3 2005 2. Standard care 5.02 8.62 49
by long term - average days per month in sheltered homes
Morse-Missouri3 2005 1. ICM 17.78 12.68 54
Morse-Missouri3 2005 2. Standard care 12.59 13.27 49
Sytema-Netherlands 1999 1. ICM 2.8 7.4 58
Sytema-Netherlands 1999 2. Standard care 3.6 9.2 57
 
 
Analysis 1.23.   Comparison 1 Intensive Case Management versus
standard care, Outcome 23 Social functioning: 4a. Substance abuse.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.23.1 alcohol abuse - by long term  
OPUS-Denmark 1999 10/275 18/272 100% 0.55[0.26,1.17]
Subtotal (95% CI) 275 272 100% 0.55[0.26,1.17]
Total events: 10 (INTENSIVE CASE MANAGEMENT), 18 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.56(P=0.12)  
Favours experimental 1000.01 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
1.23.2 illicit drug abuse - by long term  
OPUS-Denmark 1999 37/275 38/272 100% 0.96[0.63,1.47]
Subtotal (95% CI) 275 272 100% 0.96[0.63,1.47]
Total events: 37 (INTENSIVE CASE MANAGEMENT), 38 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.18(P=0.86)  
   
1.23.3 substance abuse - by medium term FUP (3 years)  
OPUS-Denmark 1999 60/275 65/272 100% 0.91[0.67,1.24]
Subtotal (95% CI) 275 272 100% 0.91[0.67,1.24]
Total events: 60 (INTENSIVE CASE MANAGEMENT), 65 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 1.24.   Comparison 1 Intensive Case Management versus standard care, Outcome 24
Social functioning: 4b. Substance abuse (DALI, skewness not detectable) - by medium term.
Social functioning: 4b. Substance abuse (DALI, skewness not detectable) - by medium term
Study Intervention Mean SD Total
alcohol abuse (DALI, -4 to + 6, high = worse)
Sytema-Netherlands 1999 1. ICM -0.8 2.7 45
Sytema-Netherlands 1999 2. Standard Care -1.2 2.4 36
drug abuse (DALI, - 4 to + 4, high = worse)
Sytema-Netherlands 1999 1. ICM -1.4 1.3 45
Sytema-Netherlands 1999 2. Standard Care -1.8 1.3 36
 
 
Analysis 1.25.   Comparison 1 Intensive Case Management versus standard care, Outcome
25 Social functioning: 4c. Substance abuse - days used per month (skewed data).
Social functioning: 4c. Substance abuse - days used per month (skewed data)
Study Intervention Mean SD Total
by medium term
Morse-Missouri3 2005 1. ICM 6.25 7.84 54
Morse-Missouri3 2005 2. Standard care 6.34 7.52 49
by long term
Morse-Missouri3 2005 1. ICM 6.77 8.86 54
Morse-Missouri3 2005 2. Standard care 6.42 7.84 49
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Analysis 1.26.   Comparison 1 Intensive Case Management versus standard care,
Outcome 26 Social functioning: 5a. Average endpoint score (various scales).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.26.1 by short term (RFS, low = poor)  
Jerrell-SCarolina1 1991 40 -11.4 (3.4) 40 -10.7 (3.9) 100% -0.62[-2.23,0.99]
Subtotal *** 40   40   100% -0.62[-2.23,0.99]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
   
1.26.2 by short term (SAS-adapted version, low = poor)  
Jerrell-SCarolina1 1991 40 -81.2 (10.1) 40 -77.8 (9.1) 100% -3.34[-7.55,0.87]
Subtotal *** 40   40   100% -3.34[-7.55,0.87]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.56(P=0.12)  
   
1.26.3 by medium term - social role performance (DAS, high = poor)  
Holloway-UK 1996 27 1 (1) 28 0.9 (0.9) 100% 0.1[-0.4,0.6]
Subtotal *** 27   28   100% 0.1[-0.4,0.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.7)  
   
1.26.4 by medium term (RFS, low = poor)  
Jerrell-SCarolina1 1991 40 -12.1 (4.2) 40 -11.2 (4.3) 100% -0.86[-2.72,1]
Subtotal *** 40   40   100% -0.86[-2.72,1]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
   
1.26.5 by medium term (SAS-adapted version, low = poor)  
Jerrell-SCarolina1 1991 40 -80.8 (10.7) 40 -77.5 (10) 100% -3.3[-7.83,1.23]
Subtotal *** 40   40   100% -3.3[-7.83,1.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
   
1.26.6 by long term - social role performance (DAS, high = poor)  
Holloway-UK 1996 32 0.8 (0.8) 26 1 (1) 100% -0.2[-0.67,0.27]
Subtotal *** 32   26   100% -0.2[-0.67,0.27]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
   
1.26.7 by long term (ISSI, low = poor)  
Bjorkman-Sweden 2002 28 -14.3 (6.4) 34 -17.5 (5.9) 100% 3.2[0.11,6.29]
Subtotal *** 28   34   100% 3.2[0.11,6.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.03(P=0.04)  
   
1.26.8 by long term (RFS, low = poor)  
Jerrell-SCarolina1 1991 40 -13.4 (3.7) 40 -11 (4) 100% -2.35[-4.05,-0.65]
Subtotal *** 40   40   100% -2.35[-4.05,-0.65]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.7(P=0.01)  
   
Favours experimental 52.5-5 -2.5 0 Favours control
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Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.26.9 by long term (SAS-adapted version, low = poor)  
Jerrell-SCarolina1 1991 40 -81.6 (8.4) 40 -78.8 (11.3) 100% -2.75[-7.13,1.63]
Subtotal *** 40   40   100% -2.75[-7.13,1.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
   
1.26.10 by long term (Strauss-Carpenter Scale, low = poor)  
Bjorkman-Sweden 2002 28 -11.4 (2.5) 32 -11.5 (2.5) 100% 0.1[-1.17,1.37]
Subtotal *** 28   32   100% 0.1[-1.17,1.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours experimental 52.5-5 -2.5 0 Favours control
 
 
Analysis 1.27.   Comparison 1 Intensive Case Management versus standard care, Outcome
27 Social functioning: 5b. Average endpoint score (various scales, skewed data).
Social functioning: 5b. Average endpoint score (various scales, skewed data)
Study Intervention Mean SD Total
by short term (SAS, high = poor)
Muijen-UK2 1994 1. ICM 3.9 1.1 35
Muijen-UK2 1994 2. Standard care 3.9 1.6 29
by medium term (SAS, high = poor)
Muijen-UK2 1994 1. ICM 4.3 1.6 29
Muijen-UK2 1994 2. Standard care 3.7 1.5 25
by long term (SAS, high = poor)
Audini-UK 1994 1. ICM 3.0 1.6 30
Audini-UK 1994 2. Standard care 2.9 1.1 28
Muijen-UK2 1994 1. ICM 3.6 1.4 24
Muijen-UK2 1994 2. Standard care 4.2 1.4 22
by long term (REHAB, high = poor)
Marshall-UK 1995 1. ICM 31.7 29.3 31
Marshall-UK 1995 2. Standard care 40.83 19.65 30
 
 
Analysis 1.28.   Comparison 1 Intensive Case Management versus standard care, Outcome
28 Mental state: 1a. General symptoms - average endpoint score (various scales).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.28.1 by short term (BPRS-18 items, high = poor)  
Rosenheck-USA-GMS 233 14.5 (8.8) 177 13.5 (7) 51.9% 1.04[-0.48,2.56]
Rosenheck-USA-NP 137 19 (9.5) 121 23.4 (11.3) 48.1% -4.36[-6.93,-1.79]
Subtotal *** 370   298   100% -1.56[-6.85,3.73]
Heterogeneity: Tau2=13.42; Chi2=12.58, df=1(P=0); I2=92.05%  
Test for overall effect: Z=0.58(P=0.56)  
   
1.28.2 by short term (BSI, high = poor)  
Rosenheck-USA-GMS 233 1.2 (0.9) 177 1.3 (0.9) 54.13% -0.07[-0.24,0.1]
Favours experimental 10.5-1 -0.5 0 Favours control
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Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Rosenheck-USA-NP 137 0.8 (0.7) 121 0.9 (0.8) 45.87% -0.05[-0.24,0.14]
Subtotal *** 370   298   100% -0.06[-0.19,0.06]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%  
Test for overall effect: Z=0.95(P=0.34)  
   
1.28.3 by short term (CSI, low = poor)  
Lehman-Maryland1 1994 67 -4.2 (0.8) 58 -3.7 (0.8) 100% -0.56[-0.84,-0.28]
Subtotal *** 67   58   100% -0.56[-0.84,-0.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.96(P<0.0001)  
   
1.28.4 by medium term (BPRS-18 items, high = poor)  
Rosenheck-USA-GMS 239 14 (9.3) 181 14.4 (9.3) 66.66% -0.46[-2.25,1.33]
Rosenheck-USA-NP 132 19 (9.8) 110 20.9 (10.2) 33.34% -1.95[-4.49,0.59]
Subtotal *** 371   291   100% -0.96[-2.42,0.51]
Heterogeneity: Tau2=0; Chi2=0.88, df=1(P=0.35); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
   
1.28.5 by medium term (BSI, high = poor)  
Rosenheck-USA-GMS 239 1.2 (0.9) 181 1.2 (0.9) 55.19% -0.01[-0.18,0.16]
Rosenheck-USA-NP 132 0.7 (0.7) 110 0.8 (0.8) 44.81% -0.04[-0.23,0.15]
Subtotal *** 371   291   100% -0.02[-0.15,0.1]
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.81); I2=0%  
Test for overall effect: Z=0.37(P=0.71)  
   
1.28.6 medium term (CSI, low = poor)  
Lehman-Maryland1 1994 67 -4.1 (0.9) 58 -3.8 (0.8) 100% -0.35[-0.65,-0.05]
Subtotal *** 67   58   100% -0.35[-0.65,-0.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.26(P=0.02)  
   
1.28.7 by long term (BPRS-18 items, high = poor)  
Morse-Missouri3 2005 65 2 (0.5) 65 2 (0.6) 41.06% 0.02[-0.18,0.22]
Rosenheck-USA-GMS 221 11.4 (8.3) 189 14.3 (9.6) 32.81% -2.96[-4.71,-1.21]
Rosenheck-USA-NP 129 15.6 (9.2) 108 17.6 (11.1) 26.13% -1.96[-4.58,0.66]
Subtotal *** 415   362   100% -1.48[-3.69,0.74]
Heterogeneity: Tau2=3.11; Chi2=13.13, df=2(P=0); I2=84.77%  
Test for overall effect: Z=1.3(P=0.19)  
   
1.28.8 by long term (BSI, high = poor)  
Rosenheck-USA-GMS 221 1.1 (0.8) 189 1.3 (0.9) 51.84% -0.23[-0.4,-0.06]
Rosenheck-USA-NP 129 0.6 (0.6) 108 0.7 (0.8) 48.16% -0.13[-0.31,0.05]
Subtotal *** 350   297   100% -0.18[-0.31,-0.06]
Heterogeneity: Tau2=0; Chi2=0.63, df=1(P=0.43); I2=0%  
Test for overall effect: Z=2.88(P=0)  
Favours experimental 10.5-1 -0.5 0 Favours control
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Analysis 1.29.   Comparison 1 Intensive Case Management versus standard care, Outcome 29
Mental state: 1b. General symptoms - mean change from baseline (CSI, low = poor ) - by long term.
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Shern-USA1 2000 91 -0.3 (0.7) 77 0 (0.7) 100% -0.32[-0.53,-0.11]
   
Total *** 91   77   100% -0.32[-0.53,-0.11]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.93(P=0)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 1.30.   Comparison 1 Intensive Case Management versus standard care, Outcome 30
Mental state: 1c. General symptoms - average endpoint score (various scales, skewed data).
Mental state: 1c. General symptoms - average endpoint score (various scales, skewed data)
Study Intervention Mean SD Total
by short term (BPRS-24 items, high = poor)
Audini-UK 1994 1. ICM 39.1 10.0 31
Audini-UK 1994 2. Standard Care 39.5 12.0 30
Muijen-UK2 1994 1. ICM 42.4 16.8 36
Muijen-UK2 1994 2. Standard Care 43.1 15.2 32
by short term (PSE, high = poor)
Audini-UK 1994 1. ICM 7.2 7.2 31
Audini-UK 1994 2. Standard Care 8.4 9.3 30
Muijen-UK2 1994 1. ICM 19.9 19.5 35
Muijen-UK2 1994 2. Standard Care 17.3 15.8 32
by medium term (BPRS-24 items, high = poor)
Audini-UK 1994 1. ICM 42.3 14.8 30
Audini-UK 1994 2. Standard Care 41.4 12.2 28
Muijen-UK2 1994 1. ICM 45.7 15.2 32
Muijen-UK2 1994 2. Standard Care 43.1 12.7 26
Sytema-Netherlands 1999 1. ICM 38 10 45
Sytema-Netherlands 1999 2. Standard Care 42 11 36
by medium term (CPRS, high = poor)
Holloway-UK 1996 1. ICM 20.6 12.1 22
Holloway-UK 1996 2. Standard Care 21.3 14.0 22
by medium term (PSE, high = poor)
Muijen-UK2 1994 1. ICM 18.7 15.9 35
Muijen-UK2 1994 2. Standard Care 14.4 15 27
by long term (BPRS-18 items, high = poor)
Ford-UK 1995 1. ICM 12.8 9.6 36
Ford-UK 1995 2. Standard Care 13.5 11.9 32
by long term (BPRS-24 items, high = poor)
Muijen-UK2 1994 1. ICM 44.4 13.3 31
Muijen-UK2 1994 2. Standard Care 51.8 18.8 26
by long term (CPRS, high = poor)
Holloway-UK 1996 1. ICM 21.6 12.9 21
Holloway-UK 1996 2. Standard Care 22.4 14.5 19
by long term (PSE, high = poor)
Audini-UK 1994 1. ICM 7.6 8.2 30
Audini-UK 1994 2. Standard Care 10.6 12.2 28
Muijen-UK2 1994 1. ICM 20.3 13.7 28
Muijen-UK2 1994 2. Standard Care 27.6 23.5 25
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Mental state: 1c. General symptoms - average endpoint score (various scales, skewed data)
Study Intervention Mean SD Total
by long term (SCL-90, high = poor)
Bjorkman-Sweden 2002 1. ICM 102 68.5 27
Bjorkman-Sweden 2002 2. Standard Care 81.4 55.1 33
 
 
Analysis 1.31.   Comparison 1 Intensive Case Management versus standard care,
Outcome 31 Mental state: 2a. Specific symptoms - depression at follow up interview.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.31.1 by medium term  
OPUS-Denmark 1999 55/275 71/272 100% 0.77[0.56,1.04]
Subtotal (95% CI) 275 272 100% 0.77[0.56,1.04]
Total events: 55 (INTENSIVE CASE MANAGEMENT), 71 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.69(P=0.09)  
   
1.31.2 by long term  
OPUS-Denmark 1999 41/275 49/272 100% 0.83[0.57,1.21]
Subtotal (95% CI) 275 272 100% 0.83[0.57,1.21]
Total events: 41 (INTENSIVE CASE MANAGEMENT), 49 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
   
1.31.3 by medium term FUP (3 years)  
OPUS-Denmark 1999 67/275 53/272 100% 1.25[0.91,1.72]
Subtotal (95% CI) 275 272 100% 1.25[0.91,1.72]
Total events: 67 (INTENSIVE CASE MANAGEMENT), 53 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.37(P=0.17)  
Favours experimental 50.2 20.5 1 Favours control
 
 
Analysis 1.32.   Comparison 1 Intensive Case Management versus standard care, Outcome 32 Mental
state: 2b. Specific symptoms - average endpoint score (various scales, skewed data, sample size ≧ 200).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.32.1 by long term - positive symptoms (SAPS, high = poor)  
OPUS-Denmark 1999 275 1.1 (1.3) 272 1.3 (1.4) 100% -0.22[-0.45,0.01]
Subtotal *** 275   272   100% -0.22[-0.45,0.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
   
1.32.2 by long term - negative symptoms (SANS, high = poor)  
OPUS-Denmark 1999 275 1.4 (1.2) 272 1.8 (1.3) 100% -0.42[-0.62,-0.22]
Subtotal *** 275   272   100% -0.42[-0.62,-0.22]
Heterogeneity: Not applicable  
Favours experimental 10.5-1 -0.5 0 Favours control
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Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=4.07(P<0.0001)  
   
1.32.3 by medium term FUP (3 years) - positive symptoms (SAPS, high = poor)  
OPUS-Denmark 1999 275 1.4 (1.6) 272 1.3 (1.6) 100% 0.12[-0.15,0.39]
Subtotal *** 275   272   100% 0.12[-0.15,0.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.38)  
   
1.32.4 by medium term FUP (3 years) - negative symptoms (SANS, high = poor)  
OPUS-Denmark 1999 275 1.7 (1.3) 272 1.8 (1.5) 100% -0.1[-0.33,0.13]
Subtotal *** 275   272   100% -0.1[-0.33,0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.4)  
   
1.32.5 by long term FUP (8 years) - positive symptoms (SAPS, high = poor)  
OPUS-Denmark 1999 275 1.2 (1.4) 272 1.2 (1.4) 100% 0.03[-0.21,0.27]
Subtotal *** 275   272   100% 0.03[-0.21,0.27]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.81)  
   
1.32.6 by long term FUP (8 years) - negative symptoms (SANS, high = poor)  
OPUS-Denmark 1999 275 1.5 (1.1) 272 1.4 (1.1) 100% 0.06[-0.13,0.25]
Subtotal *** 275   272   100% 0.06[-0.13,0.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Test for subgroup differences: Chi2=17.17, df=1 (P=0), I2=70.88%  
Favours experimental 10.5-1 -0.5 0 Favours control
 
 
Analysis 1.33.   Comparison 1 Intensive Case Management versus standard care, Outcome 33
Mental state: 2c. Specific symptoms - average endpoint score (various scales, skewed data).
Mental state: 2c. Specific symptoms - average endpoint score (various scales, skewed data)
Study Intervention Mean SD Total
by medium term - depression symptoms (BDI, high = poor)
Holloway-UK 1996 1. ICM 11.5 8.9 23
Holloway-UK 1996 2. Standard care 18.5 13.9 19
by medium term - negative symptoms (SANS, high = poor)
Holloway-UK 1996 1. ICM 7.3 4 26
Holloway-UK 1996 2. Standard care 6.3 4.4 22
by long term - depression symptoms (BDI, high = poor)
Holloway-UK 1996 1. ICM 12.8 8.1 25
Holloway-UK 1996 2. Standard care 14.8 11.5 17
by long term - negative symptoms (SANS, high = poor)
Holloway-UK 1996 1. ICM 7.3 3.7 26
Holloway-UK 1996 2. Standard care 7.1 4.1 20
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Analysis 1.34.   Comparison 1 Intensive Case Management versus
standard care, Outcome 34 Behaviour: 1. Specific behaviour - self-harm.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
STAN-
DARD CARE
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.34.1 by medium term  
Johnston-Australia 1998 0/37 0/36   Not estimable
OPUS-Denmark 1999 30/275 30/272 100% 0.99[0.61,1.59]
Subtotal (95% CI) 312 308 100% 0.99[0.61,1.59]
Total events: 30 (INTENSIVE CASE MANAGEMENT), 30 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
   
1.34.2 by long term  
Muller-Clemm-Canada 1996 2/63 2/60 100% 0.95[0.14,6.55]
Subtotal (95% CI) 63 60 100% 0.95[0.14,6.55]
Total events: 2 (INTENSIVE CASE MANAGEMENT), 2 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
   
1.34.3 attempted suicide - by long term (during last 12 months)  
OPUS-Denmark 1999 22/275 27/272 100% 0.81[0.47,1.38]
Subtotal (95% CI) 275 272 100% 0.81[0.47,1.38]
Total events: 22 (INTENSIVE CASE MANAGEMENT), 27 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
   
1.34.4 attempted suicide - by medium term FUP (3 years) (during last
3 years)
 
OPUS-Denmark 1999 24/275 25/272 100% 0.95[0.56,1.62]
Subtotal (95% CI) 275 272 100% 0.95[0.56,1.62]
Total events: 24 (INTENSIVE CASE MANAGEMENT), 25 (STANDARD CARE)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
Favours treatment 200.05 50.2 1 Favours control
 
 
Analysis 1.35.   Comparison 1 Intensive Case Management versus standard care,
Outcome 35 Behaviour: 2. Social behaviour - average endpoint score (SBS, high = poor).
Behaviour: 2. Social behaviour - average endpoint score (SBS, high = poor)
Study Intervention Mean SD Total
by medium term
Holloway-UK 1996 1. ICM 3.2 2.8 33
Holloway-UK 1996 2. Standard Care 2.4 2.9 30
by long term
Holloway-UK 1996 1. ICM 3.3 2.8 34
Holloway-UK 1996 2. Standard Care 2.7 2.2 26
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Analysis 1.36.   Comparison 1 Intensive Case Management versus standard
care, Outcome 36 Quality of life: 1a. Average endpoint score (various scales).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.36.1 by short term - general well-being (QOLI, high = better)  
Lehman-Maryland1 1994 67 4.7 (1.3) 58 4.2 (1.2) 100% 0.53[0.09,0.97]
Subtotal *** 67   58   100% 0.53[0.09,0.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.35(P=0.02)  
   
1.36.2 by medium term (LQoLP, high = better)  
Holloway-UK 1996 26 4.3 (1.4) 26 4.2 (1.2) 100% 0.09[-0.6,0.78]
Subtotal *** 26   26   100% 0.09[-0.6,0.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
   
1.36.3 by medium term (MANSA - range 1-7, high = better)  
Sytema-Netherlands 1999 45 4.5 (1) 36 4.3 (1.2) 100% 0.2[-0.29,0.69]
Subtotal *** 45   36   100% 0.2[-0.29,0.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.8(P=0.42)  
   
1.36.4 by long term (LQoLP, high = better)  
Bjorkman-Sweden 2002 29 4.6 (0.7) 34 4.9 (0.7) 51.38% -0.3[-0.65,0.05]
Holloway-UK 1996 25 4.5 (1.6) 25 4.5 (1.1) 10.51% 0.09[-0.68,0.86]
OPUS-Denmark 1999 88 4.7 (1.3) 73 4.7 (1.3) 38.12% 0.03[-0.37,0.43]
Subtotal *** 142   132   100% -0.13[-0.38,0.12]
Heterogeneity: Tau2=0; Chi2=1.85, df=2(P=0.4); I2=0%  
Test for overall effect: Z=1.05(P=0.29)  
   
1.36.5 by long term (QOLI, high = better)  
Ford-UK 1995 36 3.2 (0.6) 38 3 (1.2) 56.64% 0.2[-0.23,0.63]
Marshall-UK 1995 31 4.9 (1) 27 5 (0.9) 43.36% -0.05[-0.55,0.45]
Subtotal *** 67   65   100% 0.09[-0.24,0.42]
Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.55(P=0.58)  
Favours control 21-2 -1 0 Favours treatment
 
 
Analysis 1.37.   Comparison 1 Intensive Case Management versus standard care, Outcome 37
Quality of life: 1b. Mean change from baseline (QOLI, high = better, skewed data) - by long term.
Quality of life: 1b. Mean change from baseline (QOLI, high = better, skewed data) - by long term
Study Intervention Mean SD Total
Shern-USA1 2000 1. ICM 1.19 1.99 91
Shern-USA1 2000 2. Standard Care -0.02 1.65 77
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Analysis 1.38.   Comparison 1 Intensive Case Management versus standard care,
Outcome 38 Participant satisfaction: 1a. Average endpoint score (CSQ, high = better).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.38.1 by short term  
Audini-UK 1994 31 27.6 (3.9) 30 21.4 (9.3) 100% 6.2[2.6,9.8]
Subtotal *** 31   30   100% 6.2[2.6,9.8]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.38(P=0)  
   
1.38.2 by medium term  
OPUS-Denmark 1999 227 24.9 (4.5) 192 23 (7.2) 84.03% 1.9[0.73,3.07]
Sytema-Netherlands 1999 45 22.6 (4.5) 36 20.5 (7.2) 15.97% 2.1[-0.59,4.79]
Subtotal *** 272   228   100% 1.93[0.86,3.01]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=3.52(P=0)  
   
1.38.3 by long term  
Audini-UK 1994 28 26.6 (4.8) 26 22.9 (8.7) 5.84% 3.7[-0.09,7.49]
OPUS-Denmark 1999 205 26.1 (3.7) 164 22.9 (5.2) 94.16% 3.2[2.26,4.14]
Subtotal *** 233   190   100% 3.23[2.31,4.14]
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%  
Test for overall effect: Z=6.91(P<0.0001)  
Favours control 105-10 -5 0 Favours experimental
 
 
Analysis 1.39.   Comparison 1 Intensive Case Management versus standard care, Outcome 39
Participants satisfaction: 1b. Average endpoint score (CSQ, high = better, skewed data) - by short term.
Participants satisfaction: 1b. Average endpoint score (CSQ, high = better, skewed data) - by short term
Study Intervention Mean SD Total Note
Muijen-UK2 1994 1. ICM 26 5.4 30  
Muijen-UK2 1994 2. Standard Care* 22 7.5 13 * Attrition >50%.
 
 
Analysis 1.40.   Comparison 1 Intensive Case Management versus standard care,
Outcome 40 Participants need: 1. Average endpoint score (various scales, skewed data).
Participants need: 1. Average endpoint score (various scales, skewed data)
Study Intervention Mean SD Total Note
by medium term - met needs (CANSAS, high = better)
Sytema-Netherlands
1999
1. ICM 8.5 4.5 45  
Sytema-Netherlands
1999
2. Standard Care 8.6 4.7 36  
by medium term - unmet needs (CANSAS, high = poor)
Sytema-Netherlands
1999
1. ICM 1.4 1.9 45  
Sytema-Netherlands
1999
2. Standard Care 1.6 1.7 36  
by long term (CAN, high = poor)
Bjorkman-Sweden 2002 1. ICM 3.2 1.8 28  
Bjorkman-Sweden 2002 2. Standard Care 4.6 3.8 36  
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Analysis 1.41.   Comparison 1 Intensive Case Management versus standard care, Outcome 41 Costs:
1a. Direct costs of psychiatric hospital care - by medium term (Unit cost = USD, fiscal year 1990).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Chandler-California1 (A) 102 90.1 (316.7) 101 258.5
(824.3)
55.89% -168.4[-340.51,3.71]
Chandler-California1 (B) 115 190.7
(703.3)
108 303.2
(768.4)
44.11% -112.5[-306.21,81.21]
   
Total *** 217   209   100% -143.74[-272.4,-15.08]
Heterogeneity: Tau2=0; Chi2=0.18, df=1(P=0.67); I2=0%  
Test for overall effect: Z=2.19(P=0.03)  
Favours experimental 1000500-1000 -500 0 Favours control
 
 
Analysis 1.42.   Comparison 1 Intensive Case Management versus standard care,
Outcome 42 Costs: 1b. Direct costs of psychiatric hospital care - skewed data.
Costs: 1b. Direct costs of psychiatric hospital care - skewed data
Study Intervention Mean SD Total Note
by medium term
Cusack-North Carolina 1. ICM* 5,530 12,414 72 * Unit cost US $, Inpa-
tient costs
Time period: 12 months.
Cusack-North Carolina 2. Standard care* 8,827 19,289 62 * Unit cost US $, Inpa-
tient costs
Time period: 12 months.
Lehman-Maryland1 1994 1. ICM* 2,619 4,440 77  
Lehman-Maryland1 1994 2. Standard care* 4,662 6,034 75 * Unit cost US $, fiscal
year 1994.
t-value=2.34
Time period: 12 months.
Morse-Missouri3 2005 1. ICM* 624 2,314 54  
Morse-Missouri3 2005 2. Standard care* 439 1,596 49 * Unit cost US $, fiscal
year 2001.
"No main effect of
of treatment condi-
tion for inpatient cost-
s,F(2, 146)=0.10, p=0.9,
ɧ2=0.01."
Time period: 6 months.
by long term
Ford-UK 1995 1. ICM* 378 846 39  
Ford-UK 1995 2. Standard care* 237 492 38 * Unit cost £, fiscal year
not reported, study base
year 1990.
** No statistical analysis
available from the paper.
Time period: 18 months.
Morse-Missouri3 2005 1. ICM* 855 2,356 54  
Morse-Missouri3 2005 2. Standard care* 455 1,065 49 * Unit cost US $, fiscal
year 2001.
** "No main effect
of treatment condi-
tion for inpatient cost-
s,F(2, 146)=0.10, p=0.9,
ɧ2=0.01."
Time period: 6 months.
Quinlivan-California
1995
1. ICM* 301 397 30  
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Costs: 1b. Direct costs of psychiatric hospital care - skewed data
Study Intervention Mean SD Total Note
Quinlivan-California
1995
2. Standard care* 1,636 2,593 30 * Unit cost US $, fiscal
year not reported, but
study was carried on
from April 1990 to March
1992.
** "Costs significant-
ly lower for the ICM
group (F=4.32, df=2.87,
p=0.02.)"
Time period: 24 months.
 
 
Analysis 1.43.   Comparison 1 Intensive Case Management versus standard care, Outcome
43 Costs: 2a. Direct healthcare costs - by long term (Unit cost = USD, fiscal year 1988).
Study or subgroup INTENSIVE CASE
MANAGEMENT
STANDARD CARE Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Rosenheck-USA-GMS 271 1972.8
(1663.2)
257 1711.4
(1639)
52.04% 261.4[-20.32,543.12]
Rosenheck-USA-NP 183 3353.6
(2957.9)
162 4740.9
(3688.7)
47.96% -1387.3[-2098.85,-675.75]
   
Total *** 454   419   100% -529.24[-2143.59,1085.1]
Heterogeneity: Tau2=1.28287555E6; Chi2=17.83, df=1(P<0.0001); I2=94.39%  
Test for overall effect: Z=0.64(P=0.52)  
Favours experimental 1000500-1000 -500 0 Favours control
 
 
Analysis 1.44.   Comparison 1 Intensive Case Management versus standard
care, Outcome 44 Costs: 2b. Direct healthcare costs - skewed data.
Costs: 2b. Direct healthcare costs - skewed data
Study Intervention Mean SD Total Note
by medium term
Lehman-Maryland1 1994 1. ICM* 4,229 5,058 77  
Lehman-Maryland1 1994 2. Standard care* 5,540 6,368 75 * Unit cost US $, fiscal
year 1994.
** 'Total per-case cost
did not reach statistical
significance (p = 0.07).
Transformation of to-
tal costs per case to ac-
count for non-normal-
ity (square root of to-
tal costs, t-test=0.77,
df=1,134, NS) and non-
parametric analysis
(Wilcoxon test for ranks,
Z=0.146, NS) also were
non-significant.'
Time period 12 months.
by short term FUP
Chan-Hong Kong 2000 1. ICM 14,833 1,539 31 HK $ (HK$8=US$1, at
time of study publica-
tion, 2000).
Statistically significant
difference (P = 0.017).
Chan-Hong Kong 2000 2. Standard care 11,230 7,979 31  
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Analysis 1.45.   Comparison 1 Intensive Case Management versus standard
care, Outcome 45 Costs: 3. Direct costs - other data - skewed data.
Costs: 3. Direct costs - other data - skewed data
Study Intervention Mean SD Total Note
all care - by short term
Audini-UK 1994 1.ICM* 4,264 1,768 33  
Audini-UK 1994 2. Standard care* 7,202 5,564 29 * Unit cost £, fiscal year
1996/7.
** 'Bivariate cost com-
parisons (after log trans-
formation) revealed sig-
nificant advantage for
ICM group (p=0.001)'.
***Time period: miss-
ing (it is not the monthly
cost per patient).
all care - by medium term
Marshall-UK 1995 1. ICM* 1,044 425.3 31  
Marshall-UK 1995 2. Standard care* 1,108 530.4 30 * Unit cost £, fiscal year
1994.
** 'No significant dif-
ferences between two
groups were found.'
***Time period: mean
weekly cost.
Morse-Missouri3 2005 1. ICM* 2,946.8 3,219.3 54  
Morse-Missouri3 2005 2. Standard care* 1,899.5 3,629.6 49 * Unit cost US $, fiscal
year 2001.
** 'There was a main ef-
fect of treatment con-
dition on total costs,
F(2, 146)=4.00, p=0.02,
ɧ2=0.05. Standard care
condition had signifi-
cantly lower costs than
ICM.'
***Time period: 6
months
all care - by long term
Audini-UK 1994 1. ICM* 10,192 3,900 32  
Audini-UK 1994 2. Standard care* 15,288 17,160 28 * Unit cost £, fiscal year
1996/7.
** 'Bivariate cost com-
parisons (after log trans-
formation) did not re-
vealed significant ad-
vantage for ICM group
(p=0.09)'.
***Time period: miss-
ing (it is not the monthly
cost per patient).
Ford-UK 1995 1. ICM* 1,813 1,347 39  
Ford-UK 1995 2. Standard care* 717 768 38 * Unit cost £, fiscal year
not reported, study base
year 1990.
** 'ANOVA analysis car-
ried on, revealing signif-
icant advantage for ICM
group (p<0.05).'
***Time period: 12
months.
Marshall-UK 1995 1. ICM* 996 398 31  
Marshall-UK 1995 2. Standard care* 1,088 562.4 30 * Unit cost £, fiscal year
1994.
** 'No significant dif-
ferences between two
groups were found.'
***Time period: mean
weekly cost.
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Costs: 3. Direct costs - other data - skewed data
Study Intervention Mean SD Total Note
Morse-Missouri3 2005 1. ICM* 3,190 3,441 54  
Morse-Missouri3 2005 2. Standard care* 1,467 2,173 49 * Unit cost US $, fiscal
year 2001.
** 'There was a main ef-
fect of treatment con-
dition on total costs,
F(2, 146)=4.00, p=0.02,
ɧ2=0.05. Standard care
condition had signifi-
cantly lower costs than
ICM.'
***Time period: 6
months.
OPUS-Denmark 1999 1. ICM* 111,924 100,862 151  
OPUS-Denmark 1999 2. Standard Care* 137,638 147,570 150 *Unit cost Euro €, fiscal
year 2009.
**No significant dif-
ference between the
groups.
***Time period: FUP 3
years.
specific - outpatient care - by medium term
Cusack-North Carolina 1. ICM* 13,481 9,547 72 * Unit cost US $.
**Time period: 12
months.
Cusack-North Carolina 2. Standard care* 5,118 6,184 62 * Unit cost US $.
**Time period: 12
months.
specific - prison - by medium term
Cusack-North Carolina 1. ICM* 1,848 4,533 72 * Unit cost US $.
**Time period: 12
months.
Cusack-North Carolina 2. Standard care* 3,530 5,690 62 * Unit cost US $.
**Time period: 12
months.
 
 
Comparison 2.   Intensive Case Management versus non-Intensive Case Management
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Service use: 1. Average number of days in
hospital per month - by about 24 months
21 2220 Mean Difference (IV, Random, 95%
CI)
-0.08 [-0.37, 0.21]
1.1 skewed data (sample size ≧ 200) 3 694 Mean Difference (IV, Random, 95%
CI)
-0.58 [-1.93, 0.76]
1.2 skewed data (sample size < 200) 18 1526 Mean Difference (IV, Random, 95%
CI)
-0.03 [-0.33, 0.28]
2 Service use: 1a. Average number of days in
hospital per month - by medium/long term
follow up (skewed data, sample size ≧ 200)
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
2.1 by medium term FUP (18 months) 1 237 Mean Difference (IV, Random, 95%
CI)
0.60 [-1.25, 2.45]
2.2 by long term FUP (8.5 years) 1 203 Mean Difference (IV, Random, 95%
CI)
0.80 [-1.47, 3.07]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Service use: 2. Not remaining in contact
with psychiatric services
4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 by medium term 1 73 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.08, 0.87]
3.2 by long term 3 1182 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.34, 1.98]
3.3 by medium term FUP (18 months) 1 251 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.17, 1.05]
4 Service use: 3a. Admitted to hospital - by
long term
3 1132 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.12]
5 Service use: 3b. Average number of admis-
sions (skewed data -sample size ≧ 200)
2   Mean Difference (IV, Random, 95%
CI)
Subtotals only
5.1 - by long term (24 months) 1 678 Mean Difference (IV, Random, 95%
CI)
-0.18 [-0.41, 0.05]
5.2 by medium term FUP (18 months) 1 237 Mean Difference (IV, Random, 95%
CI)
-0.10 [-0.60, 0.40]
5.3 by long term FUP (8.5 years) 1 203 Mean Difference (IV, Random, 95%
CI)
1.0 [-0.25, 2.25]
6 Service use: 3c. Average number of admis-
sions (skewed data) - by medium term
    Other data No numeric data
7 Adverse event: 1a. Death - any cause 7   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 by short term 1 193 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 by medium term 3 294 Risk Ratio (M-H, Random, 95% CI) 2.92 [0.12, 69.43]
7.3 by long term 5 1637 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.46, 1.75]
7.4 by medium term FUP (18 months) 1 251 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.32, 2.95]
7.5 by long term FUP (8.5 years) 1 251 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.63, 2.09]
8 Adverse event: 1b. Death - suicide 8   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 by short term 1 193 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 by medium term 6 929 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.26, 9.85]
8.3 by long term 3 1152 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.27, 2.84]
8.4 by medium term FUP (18 months) 1 251 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.09]
9 Global state: 1. Leaving the study early 9 2195 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.52, 0.99]
9.1 by medium term 2 225 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.13, 3.07]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
9.2 by long term 7 1970 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.52, 0.95]
10 Global state: 2a. Average endpoint score
(HoNOS, high = poor) - by long term
1 239 Mean Difference (IV, Random, 95%
CI)
-0.40 [-1.77, 0.97]
11 Global state: 2b. Average endpoint score
(HoNOS, high = poor) - skewed data
    Other data No numeric data
11.1 medium term     Other data No numeric data
11.2 long term     Other data No numeric data
12 Global state: 3a. Not compliant with med-
ication - by medium term
1 73 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.42, 3.05]
13 Global state: 3b. Compliance with med-
ication - average endpoint sub-scale score
(ROMI) - by long term
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
13.1 compliance sub-scale (high = good) 1 239 Mean Difference (IV, Random, 95%
CI)
0.60 [-0.05, 1.25]
13.2 non-compliance sub-scale (high = poor) 1 239 Mean Difference (IV, Random, 95%
CI)
-0.60 [-1.63, 0.43]
14 Global state: 3c. Compliance with med-
ication - average endpoint sub-scale score
(ROMI, score 1-3, skewed data)
    Other data No numeric data
14.1 medium term - compliance sub-scale
(high = good)
    Other data No numeric data
14.2 medium term - non-compliance sub-
scale (high = poor)
    Other data No numeric data
14.3 long term - compliance sub-scale (high
= good)
    Other data No numeric data
14.4 long term - non-compliance sub-scale
(high = poor)
    Other data No numeric data
15 Social functioning: 1. Contact with legal
system (various measurements)
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 by medium term - contact with the po-
lice
1 73 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.04, 2.97]
15.2 by long term - imprisoned 2 959 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.64, 2.08]
15.3 by long term - arrested 1 251 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.53, 1.42]
15.4 by medium term FUP (18 months) - im-
prisoned
1 251 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.47, 2.44]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
15.5 by long term FUP (8.5 years) - impris-
oned
1 214 Risk Ratio (M-H, Random, 95% CI) 0.7 [0.43, 1.14]
16 Social functioning 2. Employment status
(various measurements)
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 spent >1 day employed - by medium
term
1 73 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.45, 4.74]
16.2 on paid employment - by medium term 1 73 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.14, 6.54]
16.3 unemployed - by long term FUP (8.5
years)
1 214 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.91, 1.34]
17 Social functioning: 3a. Accommodation
status (various measurements)
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 by medium term - living in supported
accommodation
1 73 Risk Ratio (M-H, Random, 95% CI) 2.59 [0.75, 9.01]
17.2 by long term - homelessness 1 251 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.34, 1.38]
17.3 by medium term FUP (18 months) - liv-
ing independently
1 251 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.13]
17.4 by medium term FUP (18 months) - liv-
ing in supported accomodation
1 251 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.38, 1.77]
17.5 by medium term FUP (18 months) -
homelessness
1 251 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.47, 1.49]
17.6 by long term FUP (8.5 years) - living in
supported accomodation
1 214 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.75, 1.48]
17.7 by long term FUP (8.5 years) - home-
lessness
1 214 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.55, 1.53]
18 Social functioning: 3b. Accommodation
status - average days per month in stable ac-
commodation
2   Mean Difference (IV, Random, 95%
CI)
Subtotals only
18.1 by short term 1 203 Mean Difference (IV, Random, 95%
CI)
-0.20 [-2.48, 2.08]
18.2 by medium term 1 203 Mean Difference (IV, Random, 95%
CI)
0.10 [-2.15, 2.35]
18.3 by long term 2 901 Mean Difference (IV, Random, 95%
CI)
-0.19 [-1.37, 1.00]
19 Social functioning: 4a. Substance abuse -
by long term
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 alcohol abuse 1 251 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.67, 1.83]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
19.2 illicit drug abuse 1 251 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.69, 1.71]
19.3 alcohol - remission from alcohol use
disorder (AUS score < 3)
1 223 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.65, 1.14]
20 Social functioning: 4b. Substance abuse -
average endpoint score (SATS, low = poor)
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
20.1 by short term 1 203 Mean Difference (IV, Random, 95%
CI)
0.07 [-0.28, 0.42]
20.2 by medium term 1 203 Mean Difference (IV, Random, 95%
CI)
-0.11 [-0.55, 0.33]
20.3 by long term 1 203 Mean Difference (IV, Random, 95%
CI)
0.11 [-0.41, 0.63]
21 Social functioning: 4c. Alcohol - abuse
(various measurements, skewed data)
    Other data No numeric data
21.1 short term - days using alcohol during
previous 6 months (TLFB)
    Other data No numeric data
21.2 short term - average endpoint score
(AUS, high = poor)
    Other data No numeric data
21.3 medium term - days using alcohol dur-
ing previous 6 months (TLFB)
    Other data No numeric data
21.4 medium term - average endpoint score
(AUS, high = poor)
    Other data No numeric data
21.5 long term - days using alcohol during
previous 6 months (TLFB)
    Other data No numeric data
21.6 long term - average endpoint score
(AUS, high = poor)
    Other data No numeric data
22 Social functioning: 5a. Average endpoint
score (LSP, high = poor) - by long term
1 239 Mean Difference (IV, Random, 95%
CI)
4.0 [-0.61, 8.61]
23 Social functioning: 5b. Average endpoint
score (SFQ, high = poor) - skewed data
    Other data No numeric data
23.1 by medium term     Other data No numeric data
23.2 by long term     Other data No numeric data
24 Mental state: 1a. General symptoms - av-
erage endpoint score (various scales)
2   Mean Difference (IV, Random, 95%
CI)
Subtotals only
24.1 by short term (BPRS-24 items, high =
poor)
1 203 Mean Difference (IV, Random, 95%
CI)
-0.65 [-3.99, 2.69]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
24.2 by medium term (BPRS-24 items, high =
poor)
1 203 Mean Difference (IV, Random, 95%
CI)
-1.62 [-4.76, 1.52]
24.3 by long term (BPRS-24 items, high =
poor)
1 203 Mean Difference (IV, Random, 95%
CI)
-0.22 [-3.32, 2.88]
24.4 by long term (CPRS, high = poor) 1 595 Mean Difference (IV, Random, 95%
CI)
0.40 [-1.83, 2.63]
25 Mental state: 1b. General symptoms -
average endpoint scores (various scales,
skewed data)
    Other data No numeric data
25.1 by medium term (Krawiecka Scale, high
= poor)
    Other data No numeric data
25.2 by long term (Krawiecka Scale, high =
poor)
    Other data No numeric data
25.3 by long term (BPRS 24-items, high =
good)
    Other data No numeric data
26 Mental state: 2a. Specific symptoms: neg-
ative symptoms - average endpoint score
(SANS, high = poor) - by long term
1 593 Mean Difference (IV, Random, 95%
CI)
0.20 [-2.32, 2.72]
27 Mental state: 2b. Specific symptoms -
average endpoint scores (various scales,
skewed data)
    Other data No numeric data
27.1 medium term - anxiety (HADS, high =
poor)
    Other data No numeric data
27.2 medium term - depression (HADS, high
= poor)
    Other data No numeric data
27.3 long term - anxiety (HADS, high = poor)     Other data No numeric data
27.5 long term - depression (HADS, high =
poor)
    Other data No numeric data
28 Behaviour: 1. Specific behaviour (various
measurements)
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
28.1 by medium term - harm to self or others 1 73 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.40, 1.90]
28.2 by long term - self-harm 2 959 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.69, 1.46]
28.3 by long term - injury/assault to others 2 959 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.85, 1.40]
28.4 by medium term FUP (18 months) - self
harm
1 251 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.44, 1.67]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
28.5 by medium term FUP (18 months) - in-
jury/assualt to others
1 251 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.87, 2.10]
28.6 by long term FUP (8.5 years) - self harm 1 214 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.51, 1.27]
28.7 by long term FUP (8.5 years) - injury/as-
sault to others
1 214 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.83, 1.09]
29 Quality of life: 1. Average endpoint score
(various scales)
3   Mean Difference (IV, Random, 95%
CI)
Subtotals only
29.1 by short term - overall life satisfaction
(QOLI, high = better)
1 203 Mean Difference (IV, Random, 95%
CI)
-0.02 [-0.43, 0.39]
29.2 by medium term - overall life satisfac-
tion (QOLI, high = better)
1 203 Mean Difference (IV, Random, 95%
CI)
-0.04 [-0.43, 0.35]
29.3 by long term (LQoLP, high = better) 1 526 Mean Difference (IV, Random, 95%
CI)
0.03 [-0.10, 0.16]
29.4 by long term (MANSA, range 1-7, high =
better)
1 166 Mean Difference (IV, Random, 95%
CI)
0.10 [-0.19, 0.39]
29.5 by long term - overall life satisfaction
(QOLI, high = better)
1 203 Mean Difference (IV, Random, 95%
CI)
0.10 [-0.25, 0.45]
30 Participant satisfaction/need: 1. Aver-
age endpoint scores (various scale) - by long
term
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
30.1 Patient need: CAN (high = poor) 1 585 Mean Difference (IV, Random, 95%
CI)
-0.29 [-0.69, 0.11]
30.2 Patient Satisfaction with Health Ser-
vices (high = poor)
1 490 Mean Difference (IV, Random, 95%
CI)
-0.40 [-1.25, 0.45]
31 Participants need: 1. Average endpoint
scores (various scales, skewed data)
    Other data No numeric data
31.1 by medium term (CAN, high = poor)     Other data No numeric data
31.2 by long term (CAN, high = poor)     Other data No numeric data
31.3 by long term (CANSAS, high = poor)     Other data No numeric data
32 Participant satisfaction: 1. Average end-
point scores (CSQ-modified, high = better,
skewed data) - by long term
    Other data No numeric data
33 Costs: 1. Direct costs of psychiatric hospi-
tal care (skewed data)
    Other data No numeric data
33.3 by medium term     Other data No numeric data
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
33.4 by long term     Other data No numeric data
34 Costs: 2a. Direct costs of all care - by long
term (2 years). Unit cost GBP, fiscal year
1997/98
1   Mean Difference (IV, Random, 95%
CI)
Subtotals only
35 Costs: 2b. Direct costs of all care - by
medium term (skewed data)
    Other data No numeric data
36 Costs: 3. Total costs of care per patient -
Unit cost GBP
2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
36.1 by 24 months, fiscal year 1997/98 1 667 Mean Difference (IV, Fixed, 95% CI) 1849.0 [-1598.23,
5296.23]
36.2 by 18 months, fiscal year 2003/2004
( GBP 1 = USD 1.58)
1 243 Mean Difference (IV, Fixed, 95% CI) 4031.00 [-2724.13,
10786.13]
 
 
Analysis 2.1.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 1 Service use: 1. Average number of days in hospital per month - by about 24 months.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.1.1 skewed data (sample size ≧ 200)  
Essock-Connecticut1 1995 130 2.9 (7.8) 132 4.3 (9.5) 1.89% -1.43[-3.54,0.68]
REACT-UK 2002 124 9 (8.9) 119 8 (7.8) 1.9% 1[-1.1,3.1]
UK700-UK (D) 91 2.7 (4.7) 98 3.8 (5.2) 4.21% -1.05[-2.46,0.36]
Subtotal *** 345   349   8.01% -0.58[-1.93,0.76]
Heterogeneity: Tau2=0.54; Chi2=3.2, df=2(P=0.2); I2=37.52%  
Test for overall effect: Z=0.85(P=0.39)  
   
2.1.2 skewed data (sample size < 200)  
Bush-Georgia 1990 14 1.6 (3.5) 14 2.4 (3.9) 1.14% -0.81[-3.52,1.9]
Drake-NHamp (A) 7 0.5 (0.9) 9 2.2 (3.2) 1.72% -1.67[-3.88,0.54]
Drake-NHamp (B) 16 0.9 (1.4) 14 1.4 (2.1) 5.08% -0.56[-1.85,0.73]
Drake-NHamp (C) 10 2.3 (3.2) 12 1.7 (3.8) 0.97% 0.61[-2.33,3.55]
Drake-NHamp (D) 13 1 (2.4) 11 0.6 (0.9) 4.11% 0.41[-1.02,1.84]
Drake-NHamp (E) 30 1.1 (4.2) 27 1.4 (2.4) 2.81% -0.31[-2.04,1.42]
Drake-NHamp (F) 10 1.7 (4.5) 13 0.8 (2.3) 0.9% 0.82[-2.24,3.88]
Drake-NHamp (G) 9 2.1 (3.1) 8 0.9 (0.9) 1.91% 1.18[-0.92,3.28]
Essock-Connecticut2 2006 99 0.6 (1.9) 99 0.7 (1.3) 40.91% -0.08[-0.53,0.37]
Harrison-Read-UK 2000 97 2.9 (5.7) 96 3.8 (5.8) 3.16% -0.82[-2.45,0.81]
Johnston-Australia 1998 35 4 (5.8) 33 3.1 (4.3) 1.46% 0.92[-1.48,3.32]
McDonel-Indiana (A) 61 3.2 (7.1) 64 1.4 (2.9) 2.28% 1.72[-0.2,3.64]
McDonel-Indiana (B) 14 1.2 (3.7) 17 0.6 (1.3) 2.08% 0.64[-1.37,2.65]
Quinlivan-California 1995 30 1.1 (2.7) 30 2.8 (4.7) 2.23% -1.71[-3.65,0.23]
Salkever-SCarolina 1999 91 1.1 (3) 53 1.3 (2.5) 10.03% -0.18[-1.1,0.74]
UK700-UK (A) 94 3.1 (5.8) 95 2.6 (3.5) 4.54% 0.44[-0.92,1.8]
Favours experimental 105-10 -5 0 Favours control
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Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
UK700-UK (B) 77 3.2 (4.8) 73 3.2 (5) 3.44% 0.04[-1.52,1.6]
UK700-UK (C) 76 3.3 (5.4) 75 2.5 (4.7) 3.22% 0.81[-0.81,2.43]
Subtotal *** 783   743   91.99% -0.03[-0.33,0.28]
Heterogeneity: Tau2=0; Chi2=14.95, df=17(P=0.6); I2=0%  
Test for overall effect: Z=0.17(P=0.87)  
   
Total *** 1128   1092   100% -0.08[-0.37,0.21]
Heterogeneity: Tau2=0; Chi2=19.47, df=20(P=0.49); I2=0%  
Test for overall effect: Z=0.51(P=0.61)  
Test for subgroup differences: Chi2=0.63, df=1 (P=0.43), I2=0%  
Favours experimental 105-10 -5 0 Favours control
 
 
Analysis 2.2.   Comparison 2 Intensive Case Management versus non-Intensive
Case Management, Outcome 2 Service use: 1a. Average number of days in hospital
per month - by medium/long term follow up (skewed data, sample size ≧ 200).
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.2.1 by medium term FUP (18 months)  
REACT-UK 2002 120 8 (7.8) 117 7.4 (6.7) 100% 0.6[-1.25,2.45]
Subtotal *** 120   117   100% 0.6[-1.25,2.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.52)  
   
2.2.2 by long term FUP (8.5 years)  
REACT-UK 2002 99 8.7 (8.6) 104 7.9 (7.9) 100% 0.8[-1.47,3.07]
Subtotal *** 99   104   100% 0.8[-1.47,3.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 2.3.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 3 Service use: 2. Not remaining in contact with psychiatric services.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 by medium term  
Johnston-Australia 1998 3/37 11/36 100% 0.27[0.08,0.87]
Subtotal (95% CI) 37 36 100% 0.27[0.08,0.87]
Total events: 3 (INTENSIVE CASE MANAGEMENT), 11 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=2.18(P=0.03)  
Favours experimental 500.02 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
2.3.2 by long term  
Drake-NHamp 1998 22/109 28/114 39.67% 0.82[0.5,1.35]
REACT-UK 2002 2/127 11/124 19.87% 0.18[0.04,0.78]
UK700-UK 1999 46/353 27/355 40.46% 1.71[1.09,2.69]
Subtotal (95% CI) 589 593 100% 0.82[0.34,1.98]
Total events: 70 (INTENSIVE CASE MANAGEMENT), 66 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0.45; Chi2=10.86, df=2(P=0); I2=81.59%  
Test for overall effect: Z=0.45(P=0.65)  
   
2.3.3 by medium term FUP (18 months)  
REACT-UK 2002 6/127 14/124 100% 0.42[0.17,1.05]
Subtotal (95% CI) 127 124 100% 0.42[0.17,1.05]
Total events: 6 (INTENSIVE CASE MANAGEMENT), 14 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
Favours experimental 500.02 100.1 1 Favours control
 
 
Analysis 2.4.   Comparison 2 Intensive Case Management versus non-Intensive
Case Management, Outcome 4 Service use: 3a. Admitted to hospital - by long term.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
REACT-UK 2002 75/127 68/124 34.05% 1.08[0.87,1.34]
Salkever-SCarolina 1999 31/104 32/69 18.15% 0.64[0.44,0.95]
UK700-UK 1999 219/353 237/355 47.8% 0.93[0.83,1.04]
   
Total (95% CI) 584 548 100% 0.91[0.75,1.12]
Total events: 325 (INTENSIVE CASE MANAGEMENT), 337 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0.02; Chi2=5.26, df=2(P=0.07); I2=62.01%  
Test for overall effect: Z=0.87(P=0.38)  
Favours experimental 50.2 20.5 1 Favours control
 
 
Analysis 2.5.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 5 Service use: 3b. Average number of admissions (skewed data -sample size ≧ 200).
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.5.1 - by long term (24 months)  
UK700-UK 1999 338 1 (1.5) 340 1.2 (1.6) 100% -0.18[-0.41,0.05]
Subtotal *** 338   340   100% -0.18[-0.41,0.05]
Favours experimental 52.5-5 -2.5 0 Favours control
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Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.52(P=0.13)  
   
2.5.2 by medium term FUP (18 months)  
REACT-UK 2002 120 2 (1.8) 117 2.1 (2.1) 100% -0.1[-0.6,0.4]
Subtotal *** 120   117   100% -0.1[-0.6,0.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.69)  
   
2.5.3 by long term FUP (8.5 years)  
REACT-UK 2002 99 6 (5) 104 5 (4) 100% 1[-0.25,2.25]
Subtotal *** 99   104   100% 1[-0.25,2.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.57(P=0.12)  
Test for subgroup differences: Chi2=3.33, df=1 (P=0.19), I2=40.01%  
Favours experimental 52.5-5 -2.5 0 Favours control
 
 
Analysis 2.6.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 6 Service use: 3c. Average number of admissions (skewed data) - by medium term.
Service use: 3c. Average number of admissions (skewed data) - by medium term
Study Intervention Mean SD Total
Johnston-Australia 1998 1. ICM 1.6 2 35
Johnston-Australia 1998 2. non-ICM 1.9 2.4 33
 
 
Analysis 2.7.   Comparison 2 Intensive Case Management versus non-
Intensive Case Management, Outcome 7 Adverse event: 1a. Death - any cause.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.7.1 by short term  
Harrison-Read-UK 2000 0/97 0/96   Not estimable
Subtotal (95% CI) 97 96 Not estimable
Total events: 0 (INTENSIVE CASE MANAGEMENT), 0 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.7.2 by medium term  
Bush-Georgia 1990 0/14 0/14   Not estimable
Harrison-Read-UK 2000 0/97 0/96   Not estimable
Johnston-Australia 1998 1/37 0/36 100% 2.92[0.12,69.43]
Subtotal (95% CI) 148 146 100% 2.92[0.12,69.43]
Total events: 1 (INTENSIVE CASE MANAGEMENT), 0 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Favours experimental 10000.001 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.66(P=0.51)  
   
2.7.3 by long term  
Drake-NHamp 1998 3/109 4/114 20.47% 0.78[0.18,3.42]
Essock-Connecticut1 1995 2/130 2/132 11.75% 1.02[0.15,7.1]
Harrison-Read-UK 2000 0/97 0/96   Not estimable
REACT-UK 2002 3/127 4/124 20.4% 0.73[0.17,3.21]
UK700-UK 1999 8/353 8/355 47.37% 1.01[0.38,2.65]
Subtotal (95% CI) 816 821 100% 0.9[0.46,1.75]
Total events: 16 (INTENSIVE CASE MANAGEMENT), 18 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0; Chi2=0.17, df=3(P=0.98); I2=0%  
Test for overall effect: Z=0.32(P=0.75)  
   
2.7.4 by medium term FUP (18 months)  
REACT-UK 2002 6/127 6/124 100% 0.98[0.32,2.95]
Subtotal (95% CI) 127 124 100% 0.98[0.32,2.95]
Total events: 6 (INTENSIVE CASE MANAGEMENT), 6 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
2.7.5 by long term FUP (8.5 years)  
REACT-UK 2002 20/127 17/124 100% 1.15[0.63,2.09]
Subtotal (95% CI) 127 124 100% 1.15[0.63,2.09]
Total events: 20 (INTENSIVE CASE MANAGEMENT), 17 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.45(P=0.65)  
Favours experimental 10000.001 100.1 1 Favours control
 
 
Analysis 2.8.   Comparison 2 Intensive Case Management versus non-
Intensive Case Management, Outcome 8 Adverse event: 1b. Death - suicide.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.8.1 by short term  
Harrison-Read-UK 2000 0/97 0/96   Not estimable
Subtotal (95% CI) 97 96 Not estimable
Total events: 0 (INTENSIVE CASE MANAGEMENT), 0 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.8.2 by medium term  
Bush-Georgia 1990 0/14 0/14   Not estimable
Harrison-Read-UK 2000 0/97 0/96   Not estimable
UK700-UK (A) 0/97 2/99 28.3% 0.2[0.01,4.2]
Favours experimental 2000.005 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
UK700-UK (B) 0/77 0/76   Not estimable
UK700-UK (C) 1/79 0/79 26.04% 3[0.12,72.54]
UK700-UK (D) 4/100 1/101 45.66% 4.04[0.46,35.52]
Subtotal (95% CI) 464 465 100% 1.61[0.26,9.85]
Total events: 5 (INTENSIVE CASE MANAGEMENT), 3 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Tau2=0.64; Chi2=2.65, df=2(P=0.27); I2=24.43%  
Test for overall effect: Z=0.51(P=0.61)  
   
2.8.3 by long term  
Harrison-Read-UK 2000 0/97 0/96   Not estimable
REACT-UK 2002 1/127 3/124 26.24% 0.33[0.03,3.09]
UK700-UK 1999 5/353 4/355 73.76% 1.26[0.34,4.64]
Subtotal (95% CI) 577 575 100% 0.88[0.27,2.84]
Total events: 6 (INTENSIVE CASE MANAGEMENT), 7 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Tau2=0.04; Chi2=1.04, df=1(P=0.31); I2=4.09%  
Test for overall effect: Z=0.21(P=0.83)  
   
2.8.4 by medium term FUP (18 months)  
REACT-UK 2002 1/127 3/124 100% 0.33[0.03,3.09]
Subtotal (95% CI) 127 124 100% 0.33[0.03,3.09]
Total events: 1 (INTENSIVE CASE MANAGEMENT), 3 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
Favours experimental 2000.005 100.1 1 Favours control
 
 
Analysis 2.9.   Comparison 2 Intensive Case Management versus non-Intensive
Case Management, Outcome 9 Global state: 1. Leaving the study early.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.9.1 by medium term  
Johnston-Australia 1998 3/37 11/36 5.5% 0.27[0.08,0.87]
Okpaku-Tennessee 1997 34/73 29/79 16.88% 1.27[0.87,1.85]
Subtotal (95% CI) 110 115 22.38% 0.64[0.13,3.07]
Total events: 37 (INTENSIVE CASE MANAGEMENT), 40 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=1.1; Chi2=6.38, df=1(P=0.01); I2=84.34%  
Test for overall effect: Z=0.56(P=0.58)  
   
2.9.2 by long term  
Drake-NHamp 1998 4/109 16/114 6.49% 0.26[0.09,0.76]
Essock-Connecticut1 1995 2/130 6/132 3.5% 0.34[0.07,1.65]
Harrison-Read-UK 2000 34/97 34/96 16.82% 0.99[0.68,1.45]
McDonel-Indiana 1997 11/80 19/80 11.22% 0.58[0.29,1.14]
REACT-UK 2002 36/127 49/124 17.45% 0.72[0.5,1.02]
Favours experimental 2000.005 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Salkever-SCarolina 1999 13/104 16/69 11.37% 0.54[0.28,1.05]
UK700-UK 1999 16/353 14/355 10.78% 1.15[0.57,2.32]
Subtotal (95% CI) 1000 970 77.62% 0.7[0.52,0.95]
Total events: 116 (INTENSIVE CASE MANAGEMENT), 154 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0.06; Chi2=9.88, df=6(P=0.13); I2=39.25%  
Test for overall effect: Z=2.3(P=0.02)  
   
Total (95% CI) 1110 1085 100% 0.72[0.52,0.99]
Total events: 153 (INTENSIVE CASE MANAGEMENT), 194 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0.12; Chi2=19.58, df=8(P=0.01); I2=59.13%  
Test for overall effect: Z=2.03(P=0.04)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.91), I2=0%  
Favours experimental 2000.005 100.1 1 Favours control
 
 
Analysis 2.10.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 10 Global state: 2a. Average endpoint score (HoNOS, high = poor) - by long term.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
REACT-UK 2002 124 8.6 (4.8) 115 9 (5.9) 100% -0.4[-1.77,0.97]
   
Total *** 124   115   100% -0.4[-1.77,0.97]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours experimental 42-4 -2 0 Favours control
 
 
Analysis 2.11.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 11 Global state: 2b. Average endpoint score (HoNOS, high = poor) - skewed data.
Global state: 2b. Average endpoint score (HoNOS, high = poor) - skewed data
Study Intervention Mean SD Total
medium term
Harrison-Read-UK 2000 1. ICM 12 6.8 54
Harrison-Read-UK 2000 2. non-ICM 11.4 6.4 64
long term
Harrison-Read-UK 2000 1. ICM 11.9 5.9 60
Harrison-Read-UK 2000 2. non-ICM 10.4 6.4 59
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Analysis 2.12.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 12 Global state: 3a. Not compliant with medication - by medium term.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Johnston-Australia 1998 7/37 6/36 100% 1.14[0.42,3.05]
   
Total (95% CI) 37 36 100% 1.14[0.42,3.05]
Total events: 7 (INTENSIVE CASE MANAGEMENT), 6 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 2.13.   Comparison 2 Intensive Case Management versus non-Intensive Case Management, Outcome
13 Global state: 3b. Compliance with medication - average endpoint sub-scale score (ROMI) - by long term.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.13.1 compliance sub-scale (high = good)  
REACT-UK 2002 124 6.7 (2.6) 115 6.1 (2.5) 100% 0.6[-0.05,1.25]
Subtotal *** 124   115   100% 0.6[-0.05,1.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
   
2.13.2 non-compliance sub-scale (high = poor)  
REACT-UK 2002 124 10.8 (4.3) 115 11.4 (3.8) 100% -0.6[-1.63,0.43]
Subtotal *** 124   115   100% -0.6[-1.63,0.43]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.14(P=0.25)  
Favours experimental 42-4 -2 0 Favours control
 
 
Analysis 2.14.   Comparison 2 Intensive Case Management versus non-Intensive Case Management, Outcome 14
Global state: 3c. Compliance with medication - average endpoint sub-scale score (ROMI, score 1-3, skewed data).
Global state: 3c. Compliance with medication - average endpoint sub-scale score (ROMI, score 1-3, skewed data)
Study Intervention Mean SD Total
medium term - compliance sub-scale (high = good)
Harrison-Read-UK 2000 1. ICM 1.8 0.4 49
Harrison-Read-UK 2000 2. non-ICM 2.0 0.5 61
medium term - non-compliance sub-scale (high = poor)
Harrison-Read-UK 2000 1. ICM 1.3 0.3 49
Harrison-Read-UK 2000 2. non-ICM 1.2 0.3 61
long term - compliance sub-scale (high = good)
Harrison-Read-UK 2000 1. ICM 1.8 0.4 62
Harrison-Read-UK 2000 2. non-ICM 1.9 0.5 60
long term - non-compliance sub-scale (high = poor)
Harrison-Read-UK 2000 1. ICM 1.2 0.3 63
Harrison-Read-UK 2000 2. non-ICM 1.2 0.3 61
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Analysis 2.15.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 15 Social functioning: 1. Contact with legal system (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.15.1 by medium term - contact with the police  
Johnston-Australia 1998 1/37 3/36 100% 0.32[0.04,2.97]
Subtotal (95% CI) 37 36 100% 0.32[0.04,2.97]
Total events: 1 (INTENSIVE CASE MANAGEMENT), 3 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
   
2.15.2 by long term - imprisoned  
REACT-UK 2002 3/127 4/124 15.85% 0.73[0.17,3.21]
UK700-UK 1999 20/353 16/355 84.15% 1.26[0.66,2.39]
Subtotal (95% CI) 480 479 100% 1.15[0.64,2.08]
Total events: 23 (INTENSIVE CASE MANAGEMENT), 20 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.48(P=0.63)  
   
2.15.3 by long term - arrested  
REACT-UK 2002 24/127 27/124 100% 0.87[0.53,1.42]
Subtotal (95% CI) 127 124 100% 0.87[0.53,1.42]
Total events: 24 (INTENSIVE CASE MANAGEMENT), 27 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
   
2.15.4 by medium term FUP (18 months) - imprisoned  
REACT-UK 2002 11/127 10/124 100% 1.07[0.47,2.44]
Subtotal (95% CI) 127 124 100% 1.07[0.47,2.44]
Total events: 11 (INTENSIVE CASE MANAGEMENT), 10 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.86)  
   
2.15.5 by long term FUP (8.5 years) - imprisoned  
REACT-UK 2002 21/107 30/107 100% 0.7[0.43,1.14]
Subtotal (95% CI) 107 107 100% 0.7[0.43,1.14]
Total events: 21 (INTENSIVE CASE MANAGEMENT), 30 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
Test for subgroup differences: Chi2=2.66, df=1 (P=0.62), I2=0%  
Favours treatment 5000.002 100.1 1 Favours control
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Analysis 2.16.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 16 Social functioning 2. Employment status (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.16.1 spent >1 day employed - by medium term  
Johnston-Australia 1998 6/37 4/36 100% 1.46[0.45,4.74]
Subtotal (95% CI) 37 36 100% 1.46[0.45,4.74]
Total events: 6 (INTENSIVE CASE MANAGEMENT), 4 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
   
2.16.2 on paid employment - by medium term  
Johnston-Australia 1998 2/37 2/36 100% 0.97[0.14,6.54]
Subtotal (95% CI) 37 36 100% 0.97[0.14,6.54]
Total events: 2 (INTENSIVE CASE MANAGEMENT), 2 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.03(P=0.98)  
   
2.16.3 unemployed - by long term FUP (8.5 years)  
REACT-UK 2002 74/107 67/107 100% 1.1[0.91,1.34]
Subtotal (95% CI) 107 107 100% 1.1[0.91,1.34]
Total events: 74 (INTENSIVE CASE MANAGEMENT), 67 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 2.17.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 17 Social functioning: 3a. Accommodation status (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.17.1 by medium term - living in supported accommodation  
Johnston-Australia 1998 8/37 3/36 100% 2.59[0.75,9.01]
Subtotal (95% CI) 37 36 100% 2.59[0.75,9.01]
Total events: 8 (INTENSIVE CASE MANAGEMENT), 3 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
   
2.17.2 by long term - homelessness  
REACT-UK 2002 12/127 17/124 100% 0.69[0.34,1.38]
Subtotal (95% CI) 127 124 100% 0.69[0.34,1.38]
Total events: 12 (INTENSIVE CASE MANAGEMENT), 17 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
   
Favours experimental 1000.01 100.1 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.17.3 by medium term FUP (18 months) - living independently  
REACT-UK 2002 93/127 93/124 100% 0.98[0.84,1.13]
Subtotal (95% CI) 127 124 100% 0.98[0.84,1.13]
Total events: 93 (INTENSIVE CASE MANAGEMENT), 93 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
   
2.17.4 by medium term FUP (18 months) - living in supported accomo-
dation
 
REACT-UK 2002 11/127 13/124 100% 0.83[0.38,1.77]
Subtotal (95% CI) 127 124 100% 0.83[0.38,1.77]
Total events: 11 (INTENSIVE CASE MANAGEMENT), 13 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.49(P=0.62)  
   
2.17.5 by medium term FUP (18 months) - homelessness  
REACT-UK 2002 18/127 21/124 100% 0.84[0.47,1.49]
Subtotal (95% CI) 127 124 100% 0.84[0.47,1.49]
Total events: 18 (INTENSIVE CASE MANAGEMENT), 21 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.6(P=0.55)  
   
2.17.6 by long term FUP (8.5 years) - living in supported accomodation  
REACT-UK 2002 42/107 40/107 100% 1.05[0.75,1.48]
Subtotal (95% CI) 107 107 100% 1.05[0.75,1.48]
Total events: 42 (INTENSIVE CASE MANAGEMENT), 40 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.28(P=0.78)  
   
2.17.7 by long term FUP (8.5 years) - homelessness  
REACT-UK 2002 22/107 24/107 100% 0.92[0.55,1.53]
Subtotal (95% CI) 107 107 100% 0.92[0.55,1.53]
Total events: 22 (INTENSIVE CASE MANAGEMENT), 24 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Analysis 2.18.   Comparison 2 Intensive Case Management versus non-Intensive Case Management, Outcome
18 Social functioning: 3b. Accommodation status - average days per month in stable accommodation.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.18.1 by short term  
Drake-NHamp 1998 105 25.8 (7.5) 98 26 (9) 100% -0.2[-2.48,2.08]
Favours experimental 10050-100 -50 0 Favours control
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Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 105   98   100% -0.2[-2.48,2.08]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.86)  
   
2.18.2 by medium term  
Drake-NHamp 1998 105 25.3 (7.2) 98 25.2 (9) 100% 0.1[-2.15,2.35]
Subtotal *** 105   98   100% 0.1[-2.15,2.35]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.09(P=0.93)  
   
2.18.3 by long term  
Drake-NHamp 1998 105 28.6 (8.8) 98 28 (9.7) 21.48% 0.6[-1.95,3.15]
UK700-UK 1999 349 14.9 (9.2) 349 15.3 (8.8) 78.52% -0.4[-1.74,0.94]
Subtotal *** 454   447   100% -0.19[-1.37,1]
Heterogeneity: Tau2=0; Chi2=0.46, df=1(P=0.5); I2=0%  
Test for overall effect: Z=0.31(P=0.76)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 2.19.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 19 Social functioning: 4a. Substance abuse - by long term.
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.19.1 alcohol abuse  
REACT-UK 2002 26/127 23/124 100% 1.1[0.67,1.83]
Subtotal (95% CI) 127 124 100% 1.1[0.67,1.83]
Total events: 26 (INTENSIVE CASE MANAGEMENT), 23 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
   
2.19.2 illicit drug abuse  
REACT-UK 2002 30/127 27/124 100% 1.08[0.69,1.71]
Subtotal (95% CI) 127 124 100% 1.08[0.69,1.71]
Total events: 30 (INTENSIVE CASE MANAGEMENT), 27 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
   
2.19.3 alcohol - remission from alcohol use disorder (AUS score < 3)  
Drake-NHamp 1998 47/109 57/114 100% 0.86[0.65,1.14]
Subtotal (95% CI) 109 114 100% 0.86[0.65,1.14]
Total events: 47 (INTENSIVE CASE MANAGEMENT), 57 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.02(P=0.31)  
Favours experimental 200.05 50.2 1 Favours control
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Analysis 2.20.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 20 Social functioning: 4b. Substance abuse - average endpoint score (SATS, low = poor).
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.20.1 by short term  
Drake-NHamp 1998 105 3.7 (1.3) 98 3.6 (1.2) 100% 0.07[-0.28,0.42]
Subtotal *** 105   98   100% 0.07[-0.28,0.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
   
2.20.2 by medium term  
Drake-NHamp 1998 105 4 (1.6) 98 4.1 (1.6) 100% -0.11[-0.55,0.33]
Subtotal *** 105   98   100% -0.11[-0.55,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
   
2.20.3 by long term  
Drake-NHamp 1998 105 5 (1.9) 98 4.9 (1.9) 100% 0.11[-0.41,0.63]
Subtotal *** 105   98   100% 0.11[-0.41,0.63]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.41(P=0.68)  
Favours experimental 21-2 -1 0 Favours control
 
 
Analysis 2.21.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 21 Social functioning: 4c. Alcohol - abuse (various measurements, skewed data).
Social functioning: 4c. Alcohol - abuse (various measurements, skewed data)
Study Intervention Mean SD Total
short term - days using alcohol during previous 6 months (TLFB)
Drake-NHamp 1998 1. ICM 56.8 56.4 75
Drake-NHamp 1998 2. non-ICM 47.5 58.4 68
short term - average endpoint score (AUS, high = poor)
Drake-NHamp 1998 1. ICM 3.09 1.02 83
Drake-NHamp 1998 2. non-ICM 2.91 1.08 73
medium term - days using alcohol during previous 6 months (TLFB)
Drake-NHamp 1998 1. ICM 59.1 53.3 75
Drake-NHamp 1998 2. non-ICM 42.8 52.9 68
medium term - average endpoint score (AUS, high = poor)
Drake-NHamp 1998 1. ICM 3.11 1.05 83
Drake-NHamp 1998 2. non-ICM 2.8 1.13 73
long term - days using alcohol during previous 6 months (TLFB)
Drake-NHamp 1998 1. ICM 46.4 53.6 75
Drake-NHamp 1998 2. non-ICM 43.6 57.3 68
long term - average endpoint score (AUS, high = poor)
Drake-NHamp 1998 1. ICM 2.64 1.12 83
Drake-NHamp 1998 2. non-ICM 2.77 1.18 73
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Analysis 2.22.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 22 Social functioning: 5a. Average endpoint score (LSP, high = poor) - by long term.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
REACT-UK 2002 124 119 (16.4) 115 115 (19.7) 100% 4[-0.61,8.61]
   
Total *** 124   115   100% 4[-0.61,8.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.7(P=0.09)  
Favours experimental 2010-20 -10 0 Favours control
 
 
Analysis 2.23.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 23 Social functioning: 5b. Average endpoint score (SFQ, high = poor) - skewed data.
Social functioning: 5b. Average endpoint score (SFQ, high = poor) - skewed data
Study Intervention Mean SD Tot
by medium term
Harrison-Read-UK 2000 1. ICM 7.3 5.3 49
Harrison-Read-UK 2000 2. non-ICM 7.5 5.1 62
by long term
Harrison-Read-UK 2000 1. ICM 8.9 4.9 57
Harrison-Read-UK 2000 2. non-ICM 7.9 4.9 58
 
 
Analysis 2.24.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 24 Mental state: 1a. General symptoms - average endpoint score (various scales).
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.24.1 by short term (BPRS-24 items, high = poor)  
Drake-NHamp 1998 105 42.2 (12.2) 98 42.9 (12.1) 100% -0.65[-3.99,2.69]
Subtotal *** 105   98   100% -0.65[-3.99,2.69]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
   
2.24.2 by medium term (BPRS-24 items, high = poor)  
Drake-NHamp 1998 105 41.6 (10.8) 98 43.2 (12) 100% -1.62[-4.76,1.52]
Subtotal *** 105   98   100% -1.62[-4.76,1.52]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
   
2.24.3 by long term (BPRS-24 items, high = poor)  
Drake-NHamp 1998 105 40.9 (10.8) 98 41.1 (11.7) 100% -0.22[-3.32,2.88]
Subtotal *** 105   98   100% -0.22[-3.32,2.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
   
2.24.4 by long term (CPRS, high = poor)  
UK700-UK 1999 311 18.5 (13.8) 284 18.1 (13.9) 100% 0.4[-1.83,2.63]
  2010-20 -10 0  
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Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 311   284   100% 0.4[-1.83,2.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.72)  
  2010-20 -10 0  
 
 
Analysis 2.25.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 25 Mental state: 1b. General symptoms - average endpoint scores (various scales, skewed data).
Mental state: 1b. General symptoms - average endpoint scores (various scales, skewed data)
Study Intervention Mean SD Total
by medium term (Krawiecka Scale, high = poor)
Harrison-Read-UK 2000 1. ICM 8.8 5.6 57
Harrison-Read-UK 2000 2. non-ICM 8 4.5 65
by long term (Krawiecka Scale, high = poor)
Harrison-Read-UK 2000 1. ICM 9.2 5.5 47
Harrison-Read-UK 2000 2. non-ICM 7.9 4.5 57
by long term (BPRS 24-items, high = good)
REACT-UK 2002 1. ICM 32.9 9 91
REACT-UK 2002 2. non-ICM 33.5 8.6 75
 
 
Analysis 2.26.   Comparison 2 Intensive Case Management versus non-
Intensive Case Management, Outcome 26 Mental state: 2a. Specific symptoms:
negative symptoms - average endpoint score (SANS, high = poor) - by long term.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
UK700-UK 1999 306 22.1 (15.5) 287 21.9 (15.8) 100% 0.2[-2.32,2.72]
   
Total *** 306   287   100% 0.2[-2.32,2.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.88)  
Favours experimental 105-10 -5 0 Favours control
 
 
Analysis 2.27.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 27 Mental state: 2b. Specific symptoms - average endpoint scores (various scales, skewed data).
Mental state: 2b. Specific symptoms - average endpoint scores (various scales, skewed data)
Study Intervention Mean SD Total
medium term - anxiety (HADS, high = poor)
Harrison-Read-UK 2000 1. ICM 6.5 4.9 52
Harrison-Read-UK 2000 2. non-ICM 6.7 4.6 61
medium term - depression (HADS, high = poor)
Harrison-Read-UK 2000 1. ICM 6.4 5.4 52
Harrison-Read-UK 2000 2. non-ICM 6.6 4.9 61
long term - anxiety (HADS, high = poor)
Harrison-Read-UK 2000 1. ICM 7.5 5.3 56
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
245
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Mental state: 2b. Specific symptoms - average endpoint scores (various scales, skewed data)
Study Intervention Mean SD Total
Harrison-Read-UK 2000 2. non-ICM 6.4 4.6 58
long term - depression (HADS, high = poor)
Harrison-Read-UK 2000 1. ICM 7.3 5.4 56
Harrison-Read-UK 2000 2. non-ICM 6.8 5.6 58
 
 
Analysis 2.28.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 28 Behaviour: 1. Specific behaviour (various measurements).
Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.28.1 by medium term - harm to self or others  
Johnston-Australia 1998 9/37 10/36 100% 0.88[0.4,1.9]
Subtotal (95% CI) 37 36 100% 0.88[0.4,1.9]
Total events: 9 (INTENSIVE CASE MANAGEMENT), 10 (NON-INTENSIVE CASE
MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.34(P=0.74)  
   
2.28.2 by long term - self-harm  
REACT-UK 2002 9/127 11/124 19.71% 0.8[0.34,1.86]
UK700-UK 1999 40/353 38/355 80.29% 1.06[0.7,1.61]
Subtotal (95% CI) 480 479 100% 1[0.69,1.46]
Total events: 49 (INTENSIVE CASE MANAGEMENT), 49 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0; Chi2=0.34, df=1(P=0.56); I2=0%  
Test for overall effect: Z=0.01(P=0.99)  
   
2.28.3 by long term - injury/assault to others  
REACT-UK 2002 21/127 15/124 16.56% 1.37[0.74,2.53]
UK700-UK 1999 81/353 78/355 83.44% 1.04[0.79,1.37]
Subtotal (95% CI) 480 479 100% 1.09[0.85,1.4]
Total events: 102 (INTENSIVE CASE MANAGEMENT), 93 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Tau2=0; Chi2=0.62, df=1(P=0.43); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
   
2.28.4 by medium term FUP (18 months) - self harm  
REACT-UK 2002 14/127 16/124 100% 0.85[0.44,1.67]
Subtotal (95% CI) 127 124 100% 0.85[0.44,1.67]
Total events: 14 (INTENSIVE CASE MANAGEMENT), 16 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.46(P=0.65)  
   
2.28.5 by medium term FUP (18 months) - injury/assualt to others  
REACT-UK 2002 36/127 26/124 100% 1.35[0.87,2.1]
Subtotal (95% CI) 127 124 100% 1.35[0.87,2.1]
Total events: 36 (INTENSIVE CASE MANAGEMENT), 26 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
Favours experimental 50.2 20.5 1 Favours control
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Study or subgroup INTENSIVE
CASE MAN-
AGEMENT
NON-IN-
TENSIVE CASE
MANAGEMENT
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
2.28.6 by long term FUP (8.5 years) - self harm  
REACT-UK 2002 25/107 31/107 100% 0.81[0.51,1.27]
Subtotal (95% CI) 107 107 100% 0.81[0.51,1.27]
Total events: 25 (INTENSIVE CASE MANAGEMENT), 31 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
   
2.28.7 by long term FUP (8.5 years) - injury/assault to others  
REACT-UK 2002 83/107 87/107 100% 0.95[0.83,1.09]
Subtotal (95% CI) 107 107 100% 0.95[0.83,1.09]
Total events: 83 (INTENSIVE CASE MANAGEMENT), 87 (NON-INTENSIVE
CASE MANAGEMENT)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
Favours experimental 50.2 20.5 1 Favours control
 
 
Analysis 2.29.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 29 Quality of life: 1. Average endpoint score (various scales).
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.29.1 by short term - overall life satisfaction (QOLI, high = better)  
Drake-NHamp 1998 105 4.3 (1.6) 98 4.3 (1.4) 100% -0.02[-0.43,0.39]
Subtotal *** 105   98   100% -0.02[-0.43,0.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.92)  
   
2.29.2 by medium term - overall life satisfaction (QOLI, high = better)  
Drake-NHamp 1998 105 4.3 (1.5) 98 4.3 (1.4) 100% -0.04[-0.43,0.35]
Subtotal *** 105   98   100% -0.04[-0.43,0.35]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.2(P=0.84)  
   
2.29.3 by long term (LQoLP, high = better)  
UK700-UK 1999 274 4.6 (0.7) 252 4.6 (0.8) 100% 0.03[-0.1,0.16]
Subtotal *** 274   252   100% 0.03[-0.1,0.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
2.29.4 by long term (MANSA, range 1-7, high = better)  
REACT-UK 2002 91 4.5 (1) 75 4.4 (0.9) 100% 0.1[-0.19,0.39]
Subtotal *** 91   75   100% 0.1[-0.19,0.39]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.68(P=0.5)  
   
2.29.5 by long term - overall life satisfaction (QOLI, high = better)  
Favours control 10.5-1 -0.5 0 Favours experimental
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Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Drake-NHamp 1998 105 4.6 (1.2) 98 4.5 (1.3) 100% 0.1[-0.25,0.45]
Subtotal *** 105   98   100% 0.1[-0.25,0.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.56(P=0.57)  
Favours control 10.5-1 -0.5 0 Favours experimental
 
 
Analysis 2.30.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 30 Participant satisfaction/need: 1. Average endpoint scores (various scale) - by long term.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.30.1 Patient need: CAN (high = poor)  
UK700-UK 1999 306 1.8 (2.2) 279 2.1 (2.7) 100% -0.29[-0.69,0.11]
Subtotal *** 306   279   100% -0.29[-0.69,0.11]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
   
2.30.2 Patient Satisfaction with Health Services (high = poor)  
UK700-UK 1999 258 16.7 (4.9) 232 17.1 (4.7) 100% -0.4[-1.25,0.45]
Subtotal *** 258   232   100% -0.4[-1.25,0.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
Favours experimental 21-2 -1 0 Favours control
 
 
Analysis 2.31.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 31 Participants need: 1. Average endpoint scores (various scales, skewed data).
Participants need: 1. Average endpoint scores (various scales, skewed data)
Study Intervention Mean SD Total
by medium term (CAN, high = poor)
Harrison-Read-UK 2000 1. ICM 7.3 3.7 49
Harrison-Read-UK 2000 2. non-ICM 6.1 4 60
by long term (CAN, high = poor)
Harrison-Read-UK 2000 1. ICM 6.6 3.6 54
Harrison-Read-UK 2000 2. non-ICM 5.6 3.8 59
by long term (CANSAS, high = poor)
REACT-UK 2002 1. ICM 3.3 2.7 91
REACT-UK 2002 2. non-ICM 3.4 2.9 75
 
 
Analysis 2.32.   Comparison 2 Intensive Case Management versus non-Intensive Case Management, Outcome 32
Participant satisfaction: 1. Average endpoint scores (CSQ-modified, high = better, skewed data) - by long term.
Participant satisfaction: 1. Average endpoint scores (CSQ-modified, high = better, skewed data) - by long term
Study Intervention Mean SD Total
REACT-UK 2002 1. ICM 77.2 20 91
REACT-UK 2002 2. non-ICM 70 20.6 75
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Analysis 2.33.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 33 Costs: 1. Direct costs of psychiatric hospital care (skewed data).
Costs: 1. Direct costs of psychiatric hospital care (skewed data)
Study Intervention Mean SD Total Note
by medium term
Harrison-Read-UK 2000 1. ICM* 501 967.4 97  
Harrison-Read-UK 2000 2. Low ICM* 527 753 96 * Unit cost £, fiscal year
1995/6.
** 'No significant differ-
ence between groups.
Statistical analysis on
non-parametric data
were performed using
bootstrap methods'.
***Time period: 12
months.
by long term
Harrison-Read-UK 2000 1. ICM* 414 777.8 97  
Harrison-Read-UK 2000 2. Low ICM* 478 890 96 * Unit cost £, fiscal year
1995/6.
** 'No significant differ-
ence between groups.
Statistical analysis on
non-parametric data
were performed using
bootstrap methods'.
***Time period: 12
months.
Quinlivan-California
1995
1. ICM* 301 396.6 30  
Quinlivan-California
1995
2. Low ICM* 959 1,572.7 30 * Unit cost US $, fiscal
year not reported, but
study was carried on
from April 1990 to March
1992.
** 'Costs significant-
ly lower for the ICM
group (F=4.32, df=2.87,
p=0.02.)'
***Time period: 24
months
 
 
Analysis 2.34.   Comparison 2 Intensive Case Management versus non-Intensive Case Management,
Outcome 34 Costs: 2a. Direct costs of all care - by long term (2 years). Unit cost GBP, fiscal year 1997/98.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
UK700-UK 1999 335 1023
(975.3)
332 946 (916.7) 0% 77[-66.63,220.63]
Favours experimental 1000500-1000 -500 0 Favours control
 
 
Analysis 2.35.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 35 Costs: 2b. Direct costs of all care - by medium term (skewed data).
Costs: 2b. Direct costs of all care - by medium term (skewed data)
Study Intervention Mean SD Total Note
Johnston-Australia 1998 1. ICM*  2,408 2,581.4 33  
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Costs: 2b. Direct costs of all care - by medium term (skewed data)
Study Intervention Mean SD Total Note
Johnston-Australia 1998 2. Non-ICM* 1,762 1,872 25 * Unit cost Aus $, fiscal
year 1991/2.
** 'The significance test
on the cost of care per
patient was performed
on transformed means.
No significant differ-
ences were found be-
tween groups'.
***Time period: 12
months.
 
 
Analysis 2.36.   Comparison 2 Intensive Case Management versus non-Intensive Case
Management, Outcome 36 Costs: 3. Total costs of care per patient - Unit cost GBP.
Study or subgroup INTENSIVE CASE
MANAGEMENT
NON-INTENSIVE
CASE MANAGEMENT
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.36.1 by 24 months, fiscal year 1997/98  
UK700-UK 1999 335 24553
(23408)
332 22704
(22000)
100% 1849[-1598.23,5296.23]
Subtotal *** 335   332   100% 1849[-1598.23,5296.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
   
2.36.2 by 18 months, fiscal year 2003/2004 ( GBP 1 = USD 1.58)  
REACT-UK 2002 124 34572
(28810)
119 30541
(24840)
100% 4031[-2724.13,10786.13]
Subtotal *** 124   119   100% 4031[-2724.13,10786.13]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.17(P=0.24)  
Test for subgroup differences: Chi2=0.32, df=1 (P=0.57), I2=0%  
Favours [ICM] 1000500-1000 -500 0 Favours [NON- ICM]
 
 
A D D I T I O N A L   T A B L E S
 
1. Case Management (CM)
The key principle of case management is that a single person - the 'case manager' - takes primary responsibility for a defined group of
patients in the community. The case manager is responsible for (Holloway 1991):
• assessing the patient's needs;• developing a care plan;• arranging suitable care from community services;• keeping contact with the patient.
Initially, in its simplest form (referred to as 'brokerage'), case managers were not mental health professionals, did not provide any di-
rect care, and worked independently.
2. Assertive Community Treatment (ACT)
Assertive Community Treatment should be practiced according to a defined and validated model (Stein 1980), based on the consen-
sus of an international panel of ACT experts (McGrew 1994; McGrew 1995). A key aspect of ACT is that it is a team-based approach,
Table 1.   Case Management and Assertive Community Treatment 
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characteristically a multidisciplinary team including social workers, nurses, and psychiatrists, caring exclusively for a defined group
of patients (McGrew 1995; Olfson 1990). Team members share responsibility for their clients, so it is common for several team mem-
bers to work together in treating the same patient. Other characteristics of ACT are (Stein 1980):
• provide all necessary care themselves, rather than arranging for it to be provided by other services;• provide care at home or in workplaces;• carry low caseloads (usually 10 to 15 patients per member);• practice 'assertive outreach', meaning that they persist in attempts to engage unco-operative clients;• place particular emphasis on medication compliance;• provide 24-hour emergency cover.
Table 1.   Case Management and Assertive Community Treatment 
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Intensive Case Management versus standard care ICM ICM ICM SC SC SC
Study ID Mean SD Total Mean SD Total
Note
Audini-UK 1994 0.95 2.84* 33 0.93 2.03* 33 *SD imput-
ed
Bjorkman-Sweden 2002 0.83 3.13 33 2.15 4.13 44  
Bond-Chicago1 1990 3.22 4.55 42 5.3 5.42 40  
Bond-Indiana1 (A) 1.28 3.17* 29 7.72 8.99* 32 *SD imput-
ed
Bond-Indiana1 (B) 2.72 4.54* 34 3.62 5.24* 30 *SD imput-
ed
Bond-Indiana1 (C) 0.05 1.89* 21 3.38 4.98* 21 *SD imput-
ed
Chandler-California1 (A) 0.47 2.34* 102 0.78 1.84* 101 *SD imput-
ed
Chandler-California1 (B) 0.67 2.55* 115 0.96 2.07* 114 *SD imput-
ed
Curtis-New York 1992 1.77 1.79 146 1.02 1.18 143  
Ford-UK 1995 3.07 6.9 39 1.76 3.67 38  
Hampton-Illinois (A) 1.75 3.63* 48 4.83 6.49* 47 *SD imput-
ed
Hampton-Illinois (B) 3.25 5.01* 34 3.42 5.02* 36 *SD imput-
ed
Holloway-UK 1996 2.4 5.1 34 1.2 3 26  
Jerrell-SCarolina1 1991 0.53 2.40* 40 0.8 1.86* 40 *SD imput-
ed
Lehman-Maryland1 1994 3.04 5.15 77 5.41 7 75  
Table 2.   Average number of days in hospital per month - at about 24 months - entering meta-regression 
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Marshall-UK 1995 1.04 2.18 40 1.56 4.45 40  
Muijen-UK2 1994 2.53 5.55 41 2.45 5.83 41  
Muller-Clemm-Canada 1996 1.68 3.56* 61 1.63 2.93* 57 *SD imput-
ed
OPUS-Denmark 1999 5.11 7.7 263 6.57 8.73 244  
Quinlivan-California 1995 1.09 2.65 30 5.53 8.65 30  
Rosenheck-USA-GMS (A) 3.63 3.89 44 3.71 2.76 35  
Rosenheck-USA-GMS (B) 6.99 4.85 47 4.23 5.18 47  
Rosenheck-USA-NP (C) 18.52 11.16 50 19.16 12.19 43  
Rosenheck-USA-GMS (D) 2.8 3.31 49 3.26 3.98 53  
Rosenheck-USA-NP (E) 4.13 5.24 34 3.05 4.61 33  
Rosenheck-USA-GMS (F) 2.39 3.16 43 2.58 2.45 35  
Rosenheck-USA-NP (G) 7.68 7.72 40 12.2 10.65 31  
Rosenheck-USA-NP (H) 4.63 8.58 59 11.21 13.38 55  
Rosenheck-USA-GMS (I) 5.62 4.67 44 7.8 6.63 44  
Sytema-Netherlands 1999 3.4 5.4 58 4.3 7.3 57  
Test-Wisconsin 1985 0.42 2.29* 72 2.13 3.54* 41 *SD imput-
ed
Intensive Case Management versus non-Intensive Case
Management
ICM ICM ICM Non-ICM Non-ICM Non-ICM
Study ID Mean SD Total Mean SD Total
Note
Bush-Georgia 1990 1.58 3.46* 14 2.39 3.85* 14 *SD imput-
ed
Table 2.   Average number of days in hospital per month - at about 24 months - entering meta-regression  (Continued)
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Drake-NHamp (A) 0.5 0.94 7 2.17 3.21 9  
Drake-NHamp (B) 0.85 1.43 16 1.41 2.06 14  
Drake-NHamp (C) 2.28 3.2 10 1.67 3.84 12  
Drake-NHamp (D) 1.04 2.44 13 0.63 0.91 11  
Drake-NHamp (E) 1.08 4.15 30 1.39 2.36 27  
Drake-NHamp (F) 1.66 4.49 10 0.84 2.33 13  
Drake-NHamp 1998 G 2.05 3.06 9 0.87 0.92 8  
Essock-Connecticut1 1995 2.87 7.82 130 4.3 9.52 132  
Essock-Connecticut2 2006 0.64 1.9 99 0.72 1.3 99  
Harrison-Read-UK 2000 2.94 5.74 97 3.76 5.83 96  
Johnston-Australia 1998 4.0 5.75 35 3.08 4.3 33  
McDonel-Indiana (A) 3.15 7.1 61 1.43 2.91 64  
McDonel-Indiana (B) 1.22 3.66 14 0.58 1.29 17  
Quinlivan-California 1995 1.09 2.65 30 2.8 4.74 30  
REACT-UK 2002 9.0 8.9 124 8.0 7.8 119  
Salkever-SCarolina 1999 1.12 3.01* 91 1.3 2.51* 53 *SD imput-
ed
UK700-UK (A) 3.08 5.77 94 2.64 3.49 95  
UK700-UK (B) 3.2 4.79 77 3.16 4.97 73  
UK700-UK (C) 3.29 5.41 76 2.48 4.71 75  
UK700-UK (D) 2.74 4.69 91 3.79 5.22 98  
Table 2.   Average number of days in hospital per month - at about 24 months - entering meta-regression  (Continued)
ICM: Intensive Case Management
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SC: standard care
SD: standard deviation
Study ID: Study identification name
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Intensive Case Management versus standard
care
Baseline
hospital use
Baseline
hospital
use
IFACT IFACT IFACT
Study ID Mean Total Total
score
Organ-
isation
subscale
score
Sta; sub-
scale
score
Note
Audini-UK 1994 1.08 66 6.7 3.5 3.2  
Bjorkman-Sweden 2002 5.63 77 7 4.5 2.5  
Bond-Chicago1 1990 7.83 88 6 4 2  
Bond-Indiana1 (A) 14.17 61 9.2 7 2.2  
Bond-Indiana1 (B) 4.95 64 2.2 1 1.2  
Bond-Indiana1 (C) 10.86 42 7.4 5 2.4  
Chandler-California1 (A) 0.5 203 8.5 5 3.5  
Chandler-California1 (B) 1.14 229 6.6 5 1.6  
Curtis-New York 1992 0.95* 289 5.8 3.5 2.3 *Mean im-
puted
Ford-UK 1995 2.61 77 4.8 2 2.8  
Hampton-Illinois (A) 5.6 95 6 4 2  
Hampton-Illinois (B) 5.2 70 5 3 2  
Holloway-UK 1996 7.37 70 9.3 6 3.3  
Jerrell-SCarolina1 1991 2.85 80 8.8 5.5 3.3  
Lehman-Maryland1 1994 4.94* 152 11 7 4 *Mean im-
puted
Marshall-UK 1995 3.31* 80 4.9 4 0.9 *Mean im-
puted
Muijen-UK2 1994 8.43* 82 5.4 3 2.4 *Mean im-
puted
Muller-Clemm-Canada 1996 4.07 123 6.2 4 2.2  
OPUS-Denmark 1999 NA 547 8 4 4 *Baseline
hospital
use: not
applica-
ble as first
episode
Table 3.   Covariates entering meta-regression 
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Quinlivan-California 1995 4.50* 60 6.4 4 2.4 *Mean im-
puted
Rosenheck-USA-GMS (A) 3.96 79 6 2 4  
Rosenheck-USA-GMS (B) 5.83 94 3.8 2 1.8  
Rosenheck-USA-NP (C) 19.8 93 7.7 5 2.7  
Rosenheck-USA-GMS (D) 4.19 102 7 3 4  
Rosenheck-USA-NP (E) 5.33 67 6.4 3.5 2.9  
Rosenheck-USA-GMS (F) 3.22 78 6.6 3 3.6  
Rosenheck-USA-NP (G) 11.42 71 8.4 5 3.4  
Rosenheck-USA-NP (H) 11.4 114 6.4 4 2.4  
Rosenheck-USA-GMS (I) 8.28 88 5.8 2 3.8  
Sytema-Netherlands 1999 12.17* 118 7.6* 5.1* 2.5* *Mean
and IFACT
score im-
puted
Test-Wisconsin 1985 2.33 122 8.5 5.5 3  
Intensive Case Management versus non-In-
tensive Case Management
Baseline
hospital use
Baseline
hospital
use
IFACT IFACT IFACT
Study ID Mean Total Total
score
Organ-
isation
subscale
score
Sta; sub-
scale
score
Note
Bush-Georgia 1990 3.99 28 3.1 2 1.1  
Drake-NHamp (A) 2.88 19 8 5 3  
Drake-NHamp (B) 1.72 33 3.8 3 0.8  
Drake-NHamp (C) 3.02 25 8.8 5.5 3.3  
Drake-NHamp (D) 1.78 26 7.8 4.5 3.3  
Drake-NHamp (E) 2.76 66 8.5 4.5 4  
Drake-NHamp (F) 2.34 22 3.5 3 0.5  
Drake-NHamp 1998 (G) 4.1 19 5 2 3  
Essock-Connecticut1 1995 2.81* 262 8.5 4.5 4 *Mean im-
puted
Table 3.   Covariates entering meta-regression  (Continued)
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Essock-Connecticut2 2006 1.08* 198 10* 7* 3* *Mean
and IFACT
score im-
puted
Harrison-Read-UK 2000 4.11 193 7.6 4 3.6  
Johnston-Australia 1998 3.66 71 7.3 3.5 3.8  
McDonel-Indiana (A) 4.2 152 4.2 3 1.2  
McDonel-Indiana (B) 1.16 39 4.4 3 1.4  
Quinlivan-California 1995 2.96* 60 6.4 4 2.4 *Mean im-
puted
REACT-UK 2002 7.3 251 10.3 6.5 3.8  
Salkever-SCarolina 1999 3.06 144 7 5 2  
UK700-UK (A) 4.55 196 8.8 5 3.8  
UK700-UK (B) 4.66 153 4.5 3 1.5  
UK700-UK (C) 4.33 158 4.2 2 2.2  
UK700-UK (D) 4.59 200 8.5 5 3.5  
Table 3.   Covariates entering meta-regression  (Continued)
Baseline hospital use: average number of days per month in hospital for all participants in the two years before the study began
IFACT: Index of Fidelity to Assertive Community Treatment
NA: not applicable
Study ID: Study identification name
 
 
1. ICM: "Intensive outreach case management" from a multidisciplinary team at Harlem Hospital Center. This team implemented a
discharge treatment plan and monitored clinical and social problems. The team did not "assume direct responsibility for care but [...]
help[ed] the patient enrol in a day hospital programme, adult mental health clinic, rehabilitation programme, or alcohol treatment
programme". Caseload: 1:17. N = 147.
2. Standard care: routine aftercare, within the discharge treatment plan prescribed for each patient from Harlem Hospital Center;
"most received at least initial treatment from various divisions of the departments of psychiatry within the Health and Hospitals Cor-
poration". N = 145.
Table 4.   Interventions in Curtis-New York 
 
 
A P P E N D I C E S
Appendix 1. Previous searches
1 Search method Assertive Community Treatment Review
1.1 Electronic searches
1.1.1 CINAHL (January 1982 to May 1997)
It was searched using the CSG's terms for randomised controlled trials and the CSG's terms for schizophrenia combined with the phrase:
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[and ((case or care) near management) or CPA or (Care near1 Programme near1 Approach) or (Assertive near1 Community near1 Treatment)
or PACT or TCL or (Training near (community near1 living)) or (Madison near4 model)]
1.1.2 The Cochrane Schizophrenia Group's Register (1997)
It was searched using the phrase:
[and ((case or care) and management) or CPA or (Care and Programme and Approach) or (Assertive and Community and Treatment) or
PACT or TCL or (Training and (community and living)) or (Madison and model)]
1.1.3 EMBASE (January 1980 to May 1997)
It was searched using the CSG's terms for randomised controlled trials and the CSG's terms for schizophrenia combined with the phrase:
[and ((case or care) near management) or CPA or (Care near1 Programme near1 Approach) or (Assertive near1 Community near1 Treatment)
or PACT or TCL or (Training near (community near1 living)) or (Madison near4 model)]
1.1.4 MEDLINE (January 1966 to May 1997)
It was searched using the CSG's terms for randomised controlled trials and the CSG's terms for schizophrenia combined with the phrase:
[and ((case or care) near management) or CPA or (Care near1 Programme near1 Approach) or (Assertive near1 Community near1 Treatment)
or PACT or TCL or (Training near (community near1 living)) or (Madison near4 model)]
1.1.5 PsycLIT (January 1974 to May 1997)
It was searched using the CSG's terms for randomised controlled trials and the CSG's terms for schizophrenia combined with the phrase:
[and ((case or care) near management) or CPA or (Care near1 Programme near1 Approach) or (Assertive near1 Community near1 Treatment)
or PACT or TCL or (Training near (community near1 living)) or (Madison near4 model)]
1.2. Searching other resources
1.2.1 Reference searching
Each of the randomised controlled trial identified was sought as a citation on the SCISEARCH database. Reports of articles that had cited
these studies were inspected in order to identify further trials. Reference lists of all included trials and identified reviews were scanned for
evidence of trials missed by the computerised search.
It should be noted that in electronic searches the phrase 'ACT' is not feasible as this common word generates a very large number of false
positives.
2 Search method Case Management Review
2.1. Electronic searches
The Cochrane Schizophrenia Group's Register (1997), EMBASE (January 1980 to May 1995), MEDLINE (January 1966 to May 1995), PsycLIT
(January 1974 to May 1995) and CINAHL were all searched for any text containing the following phrases:
[((case or care) and (management)) or CPA or (Care Programme Approach) or (Assertive Community Treatment) or (PACT) or (TCL) or
(Training near2 community living) or (Madison near model)]
Each randomised controlled trial identified by the search was sought as a citation on the SCISEARCH database.
2.2. Searching other resources
2.2.1 Hand searching
Reports of articles that had cited these studies were inspected in order to identify further trials.
Citation lists of all included trials and identified reviews were scanned for evidence of trials missed by the computerised search.
3 Search method 2009, 2012 versions ICM Review
3.1. Cochrane Schizophrenia Group Trials Register (February 2009)
The register was searched using the phrase:
(*ca?e management* OR *cpa* OR *community treatment* OR *community team* OR *community cent* OR *community care approach*
OR *madison model* OR *outreach* OR *hostel* OR *aPercare* OR *residential* OR *housing* OR *transitional* OR *posthospital* OR
*partial hospitali?ation* OR *Foster* OR *Guardianship* OR *daily living programme* OR *crisis intervention* OR *early intervention* OR
*Ambulatory treatment* OR *Ambulatory care* OR *community living* OR *social support* OR *patient care team* OR *community mental
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health* OR *patient participation* OR *assertive outreach* OR *drop-in hospital* OR *drop-in care* OR *drop-in treatment* OR *drop-
in cent* OR *drop-in unit* OR *drop in hospital* OR *drop in care* OR *drop in treatment* OR *drop in cent* OR *drop in unit* OR *day
hospital* OR *day care* OR *day treatment* OR *day cent* OR *day unit* OR *Intensive care* OR *Intensive interven* OR *Intensive treat*
OR *Intensive therap* OR *Intensive management* OR *Intensive model* OR *Intensive programmem* OR *Intensive team* OR *Intensive
service* OR *mobile care* OR *mobile interven* OR *mobile treat* OR *mobile therap* OR *mobile management* OR *mobile model*
OR *mobile programmem* OR *mobile team* OR *mobile service* OR *outreach care* OR *outreach interven* OR *outreach treat* OR
*outreach therap* OR *outreach management* OR *outreach model* OR *outreach programmem* OR *outreach team* OR *outreach
service* OR *community care* OR *community interven* OR *community treat* OR *community therap* OR *community management*
OR *community model* OR *community programmem* OR *community team* OR *community service* OR *community base* OR *home
care* OR *home interven* OR *home treat* OR *home therap* OR *home management* OR *home model* OR *home programmem* OR
*home team* OR *home service* OR *home base* OR *aggressive outreach* OR *broker* OR *programme* OR *care programme approach*
OR *care programme* in title, abstract, index terms of REFERENCE and in interventions of STUDY) OR (*Pact* OR *tcl* In title) OR(Pact* OR
tcl* in abstract and index terms of REFERENCEand in interventions of STUDY)
This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group’s Module -
Specialised Register).
3.2. Cochrane Schizophrenia Group Trials Register (August) 2012
The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group’s Trials Register (August 2012)
(*ca?e management* OR *cpa* OR *community treatment* OR *community team* OR *community cent* OR *community care approach*
OR *madison model* OR *outreach* OR *hostel* OR *aPercare* OR *residential* OR *housing* OR *transitional* OR *posthospital* OR
*partial hospitali?ation* OR *Foster* OR *Guardianship* OR *daily living programme* OR *crisis intervention* OR *early intervention* OR
*Ambulatory treatment* OR *Ambulatory care* OR *community living* OR *social support* OR *patient care team* OR *community mental
health* OR *patient participation* OR *assertive outreach* OR *drop-in hospital* OR *drop-in care* OR *drop-in treatment* OR *drop-
in cent* OR *drop-in unit* OR *drop in hospital* OR *drop in care* OR *drop in treatment* OR *drop in cent* OR *drop in unit* OR *day
hospital* OR *day care* OR *day treatment* OR *day cent* OR *day unit* OR *Intensive care* OR *Intensive interven* OR *Intensive treat*
OR *Intensive therap* OR *Intensive management* OR *Intensive model* OR *Intensive programmem* OR *Intensive team* OR *Intensive
service* OR *mobile care* OR *mobile interven* OR *mobile treat* OR *mobile therap* OR *mobile management* OR *mobile model*
OR *mobile programmem* OR *mobile team* OR *mobile service* OR *outreach care* OR *outreach interven* OR *outreach treat* OR
*outreach therap* OR *outreach management* OR *outreach model* OR *outreach programmem* OR *outreach team* OR *outreach
service* OR *community care* OR *community interven* OR *community treat* OR *community therap* OR *community management*
OR *community model* OR *community programmem* OR *community team* OR *community service* OR *community base* OR *home
care* OR *home interven* OR *home treat* OR *home therap* OR *home management* OR *home model* OR *home programmem* OR
*home team* OR *home service* OR *home base* OR *aggressive outreach* OR *broker* OR *programme* OR *care programme approach*
OR *care programme* or *Pact* OR *tcl* iin title, abstract, index terms of REFERENCE)
The Cochrane Schizophrenia Group’s Trials Register is compiled by systematic searches of major databases, handsearches and conference
proceedings (see Group’s Module). Incoming trials are assigned to existing or new review titles.
Appendix 2. Previous data collection and analyses methods
Selection of studies
The principal reviewer (MD) inspected all abstracts of studies identified as above and identified potentially relevant reports. In addition,
to ensure reliability, CBI inspected a random sample of these abstracts, comprising 10% of the total. Where disagreement occurred this
was resolved by discussion, or where there was still doubt, the full article was acquired for further inspection. The full articles of relevant
reports were acquired for reassessment and carefully inspected for a final decision on inclusion (see Criteria for considering studies for
this review). Once the full articles were obtained, in turn MD and CBI inspected all full reports and independently decided whether they
met inclusion criteria. MD and CBI were not blinded to the names of the authors, institutions or journal of publication. Where diIiculties
or disputes arose, we asked author MM for help and if it was impossible to decide, these studies were added to those awaiting assessment
and the authors of the papers contacted for clarification.
Data extraction and management
1. Extraction
1.1 Data regarding criteria and outcomes
The principal reviewer (MD) extracted data from all included studies. In addition, to ensure reliability, CBI independently extracted data
from a random sample of these studies, comprising 10% of the total. Again, any disagreement was discussed, decisions documented and, if
necessary, authors of studies were contacted for clarification. With remaining problems MM helped clarify issues and those final decisions
were documented. Data presented only in graphs and figures were extracted whenever possible, but were included only if two reviewers
independently had the same result. Attempts were made to contact authors through an open-ended request in order to obtain missing
information or for clarification whenever necessary. Where possible, we extracted data relevant to each component centre of multi-centre
studies separately.
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1.2 Additional data
1.2.1 Fidelity
This rating related to the Intensive Case Management intervention. This rated fidelity of the intervention to assertive community treatment
on the 'team membership' and 'team structure and organisation' sub-scales of the Index of Fidelity to Assertive Community Treatment
(IFACT) (McGrew 1994).
This index was derived from a survey of 20 clinical experts in assertive community treatment and validated in a survey of 18 programmes.
a. The 'team membership' sub-scale comprises four items:
- ratio of patients to staI
- total size of team
- extent of psychiatric input
- extent of nursing input to the team
b. The 'structure and organisation' sub-scale comprises seven items, whether the team is:
- the primary source of care for its patients
- is situated away from the hospital
- meets daily
- shares responsibility for caseloads
- is available 24 hours a day
- has a team leader who is also a case manager
- oIers unlimited time for its services
We chose IFACT because the sub-scales are brief and are possible to be completed from published or unpublished text. For each item on
the index, a score of one indicates high fidelity to the model. Score ranges from 0 to 11, where the maximum score available on 'team
membership' sub-scale is 4, and on 'structure and organisation' sub-scale is 7, with higher scores indicating higher fidelity to the model.
We obtained fidelity data from published and unpublished trial reports, direct contact with trialists, and data previously obtained directly
from trialists by previous reviews (Burns 2001, Catty 2002, Burns 2007). Two raters (MD and CBI) independently combined these data into
a single fidelity score. Multicentre trials of Intensive Case Management oPen struggle to implement a uniform approach, with centres
operating at diIerent degrees of fidelity. Where possible, we rated each component centre separately.
1.2.2 Baseline hospital use
The average number of days per month in hospital for all participants in the two years before the study began.
We obtained this data from published and unpublished trial reports and from direct contact with trialists.
1.2.3 Service use: hospitalisation
We obtained the primary outcome mean number of days per month in hospital for the included studies from published and unpublished
trial reports, direct contact with trialists and data previously obtained directly from trialists reported by a previous review (Burns 2007).
2. Management
2.1 Forms
Data were extracted onto standard, simple forms.
2.2 Data from multi-centre trials
Where possible MD and CBI verified independently calculated centre data against original trial reports.
3. Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument was not written or modified by one of the trialists for that particular trial; and
c. the measuring instrument is either i. a self-report or ii. completed by an independent rater or relative (not the therapist).
4. Endpoint versus change data
We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view.
Change data are oPen not ordinal and are very problematic to interpret. If endpoint data were unavailable, we used change data.
5. Skewed data
5.1 General
Continuous data on clinical and social outcomes are oPen not normally distributed. To avoid the pitfall of applying parametric tests to non-
parametric data, we aim to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the
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paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two,
is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (Altman 1996); c) if
a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified
to take the scale starting point into account. In these cases skew is present if 2SD>(S-S min), where S is the mean score and S min is the
minimum score. Endpoint scores on scales oPen have a finite start and end point and these rules can be applied. When continuous data
are presented on a scale which includes a possibility of negative values (such as change data), it is diIicult to tell whether data are skewed
or not. Skewed data from studies of less than 200 participants were entered in additional tables rather than into an analysis. Skewed data
pose less of a problem when looking at means if the sample size is large and were entered into syntheses.
5.2 Specific - mean number of days in hospital
We implemented one exception to the above rule (5.1) in order to present more data, recognising that this is a 'post hoc' decision, but
also that the rules as regards management of skewed data and how robust skewed data are within meta-analysis is unclear (Higgins 2011).
Where mean number of days in hospital data were skewed, and they were provided by studies of less than 200 participants, we nevertheless
entered those data into a sub-group of the overall analysis. We also presented the overall eIect from all data pooled.
6. Common measure
To facilitate comparison between trials, we intended to convert variables that can be reported in diIerent metrics, such as days in hospital
(mean days per year, per week or per month) to a common metric (e.g. mean days per month).
7. Conversion of continuous to binary
Where possible, eIorts were made to convert outcome measures to dichotomous data. This could be done by identifying cut-oI points on
rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if
there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the Positive and
Negative Syndrome Scale (PANSS, Kay 1986), this could be considered as a clinically significant response ( Leucht 2005a, Leucht 2005b). If
data based on these thresholds were not available, we used the primary cut-oI point presented by the original authors.
8. Direction of graphs
Where possible, we entered data in such a way that the area to the leP of the line of no eIect indicates a favourable outcome for Intensive
Case Management.
Assessment of risk of bias in included studies
Again working independently, the principal reviewer (MD) assessed risk of bias of all included studies and the second reviewer (CBI)
assessed risk of bias from a random sample of these studies, comprising 10% of the total. MD and CBI assessed risk of bias using the
tool described in the Cochrane Collaboration Handbook (Higgins 2011). This tool encourages consideration of how the sequence was
generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and
other biases. We would have excluded studies where allocation was clearly not concealed.
Trials with high risk of bias (defined as at least three out of five domains categorised as 'No') were not included in the meta-analysis. If the
raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate
details of randomisation and other characteristics of trials are provided, authors of the studies were contacted in order to obtain further
information. Non-concurrence in quality assessment was reported.
Measures of treatment e;ect
1. Binary data
For binary outcomes we calculated a standard estimation of the random-eIects risk ratio (RR) and its 95% confidence interval (CI). It
has been shown that RR is more intuitive (Boissel 1999) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). For statistically significant results we had planned to calculate the number needed to treat to provide benefit /to induce
harm statistic (NNTB/H), and its 95% confidence interval (CI) using Visual Rx (http://www.nntonline.net/) taking account of the event rate
in the control group. This, however, was superseded by Summary of findings table 1 and the calculations therein.
2. Continuous data
2.1 Summary statistic
For continuous outcomes we estimated a random-eIects mean diIerence (MD) between groups. We preferred not to calculate eIect size
measures (standardised mean diIerence SMD). However, in the case of where scales were of such similarity to allow presuming there was
a small diIerence in measurement, we calculated it and, whenever possible, we transformed the eIect back to the units of one or more
of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered
data poses problems. Firstly, authors oPen fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis'
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error (Divine 1992) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated.
This causes type I errors (Bland 1997, Gulliford 1999).
Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a
probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class
correlation coeIicients for their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Where clustering had
been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted for
the clustering eIect.
We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design eIect'.
This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coeIicient (ICC) [Design eIect =
1+(m-1)*ICC] (Donner 2002). If the ICC was not reported it was assumed to be 0.1 (Ukoumunne 1999).
If cluster studies has been appropriately analysed taking into account intra-class correlation coeIicients and relevant data documented
in the report, synthesis with other studies would have been possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over eIect. It occurs if an eIect (e.g. pharmacological, physiological or psychological)
of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants
can diIer systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the
condition of interest is unstable (Elbourne 2002). As both eIects are very likely in severe mental illness, we only used data of the first phase
of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where
the additional treatment arms were not relevant, these data were not reproduced.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia 2007). For any particular outcome should more than 50% of data be
unaccounted for, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study
were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias.
2. Binary
In the case where attrition for a binary outcome is between 0 and 50% and where these data were not clearly described, data were
presented on a 'once-randomised-always-analyse' basis (an intention to treat analysis). Those leaving the study early were all assumed to
have the same rates of negative outcome as those who completed, with the exception of the outcome of death. A sensitivity analysis was
undertaken testing how prone the primary outcomes were to change when data from only those who completed the study were compared
with intention to treat data using the assumption outlined above.
In the case were number of death was more than 10% of the sample overall, the above statement was applied but attrition due to death
was not imputed.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0 and 50% and data from only those who completed the study are reported,
we have reproduced these.
3.2 Standard deviations
3.2.1 General
Where there are missing measures of variance for continuous data, but exact standard errors or confidence intervals for group means, or
either ‘p’ or 't' values for diIerences in means, we calculated standard deviation value according to method described in Section 7.7.3 of
the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). If standard deviations were not reported and could not
be calculated from available data, we asked authors to supply the data. In the absence of data from authors, we used the mean standard
deviation from other studies.
3.2.2 Standard deviation mean number of days per month in hospital
For the primary outcome, mean number of days per month in hospital, if standard deviations were not reported and could not be calculated
from available data, we asked authors for additional information. In the absence of data from authors, we imputed the missing standard
deviations using a regression analysis of SD against mean from those trials that provided both. We documented in Table 2 in what studies
we imputed SDs according to the above technique.
3.3 Last observation carried forward
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We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report.
As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results. Therefore,
where LOCF data has been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that
they are the product of LOCF assumptions.
3.4 Incomplete data for meta-regression
In some cases we anticipated that IFACT score variables would not all be available. If IFACT score could not be calculated from available
data, we imputed it by multiple imputation using the mi library in R (R 2008). As explained above, we only made these assumptions if
we were able to directly rate over 50% of the data. We documented in Table 3 in what studies we calculated IFACT score according to the
above technique.
In some cases we anticipated that baseline hospital use data would not all be available. Missing data was imputed as for the IFACT scores.
As explained above, we only make these assumptions if we were able to directly rate over 50% of the data. We documented for which
studies we calculated baseline hospital use data according to the above technique (Table 3).
A sensitivity analysis was undertaken testing how prone the results from meta-regression were to change when data from only those who
completed the studies were compared with the imputed data using the assumption outlined above.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies
for clearly outlying situations or people, which we had not predicted would arise. When such situations or participant groups arose, these
were fully discussed.
In addition two potential sources of heterogeneity were specified a priori (fidelity and baseline level of hospital use (Data extraction and
management). These data were extracted as described above.
2. Methodological heterogeneity
We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected
all studies for clearly outlying methods which we had not predicted would arise. Should such methodological outliers arise these will be
fully discussed.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of statistical heterogeneity.
3.2 Employing the I2statistic
Heterogeneity between studies was investigated by considering the I2 method alongside the Chi2 'p' value. The I2 provides an estimate
of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I2 depends on i.
magnitude and direction of eIects and ii. strength of evidence for heterogeneity (e.g. 'p' value from Chi2 test, or a confidence interval for I2).
I2 estimate greater than or equal to 50% accompanied by a statistically significant Chi2 statistic, was interpreted as evidence of substantial
levels of heterogeneity (Section 9.5.2 - Higgins 2011). When substantial levels of heterogeneity were found in the primary outcome, we
explored reasons for heterogeneity (Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These
are described in Section 10 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We are aware that funnel
plots may be useful in investigating reporting biases but are of limited power to detect small-study eIects. We did not use funnel plots for
outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible,
we sought statistical advice in their interpretation.
Data synthesis
Where possible we employed a random-eIects model for analyses. We understand that there is no closed argument for preference for use
of fixed or random-eIects models. The random-eIects method incorporates an assumption that diIerent studies are estimating diIerent,
yet related, intervention eIects. According to our hypothesis of an existing variation across studies, to be explored further in the meta-
regression analysis despite being cautious that random-eIects methods does put added weight onto the smaller of the studies - we
favoured using random-eIects model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
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We anticipate two sub-group analyses. For the first version of the protocol for this review we did not anticipate any sub-group analyses.
On further consideration we now realise that analysis at separate time periods could be thought of as sub-groups. The second sub-group
is within the primary outcome and relates to skewed and non-skewed data. This has been introduced late into this protocol and could
be considered post hoc. However, we are also conscious that our original rule for management of these data could be considered overly
cautious and result in some important data not being presented (Higgins 2011).
2. Investigation of heterogeneity
2.1 Anticipated heterogeneity - outcome of mean days per month in hospital
Investigation of heterogeneityformed part of the secondary objectives of the review. We hypothesised that the eIect of Intensive Case
Management on one of our primary outcomes (mean number of days per month in hospital) diIers according to fidelity of intervention to
the assertive community treatment model and the baseline level of hospital use.
The association of the IFACT score and the baseline number of days in hospital with the treatment eIect was examined by performing
random-eIects meta-regression analysis in R (R 2008). The script we used to perform meta-regression analyses is reported in Appendix
3. Meta-regression was also carried out using both variables within the same model. The relationship between the treatment eIect and
the two variables was also examined using a thin plate spline. If possible data from multi-centre studies were to be entered in the meta-
regression disaggregated into the component centre with outcome and fidelity data for each.
Meta-regression was performed:
a) only if at least ten studies per comparison are available (Higgins 2011)
b) all included studies were entered into the meta-regression. Comparison type was also tested as an additional regressor in the model.
2.2 Unanticipated heterogeneity - other outcomes
2.2.1 For outcomes other than the second primary outcome (not remaining in contact with psychiatric services)
If inconsistency was high this was reported and no exploration undertaken.
2.2.2 For outcome 'not remaining in contact with psychiatric services'
If inconsistency was high this was reported. First we investigated whether data had been entered correctly. Second, if data had been correct,
the graph was visually inspected and studies outside of the company of the rest were successively removed to see if heterogeneity was
restored. Should this occur with no more than 10% of the data being excluded, data were presented. If not, data were not pooled.
Should unanticipated clinical or methodological heterogeneity be obvious we simply stated hypotheses regarding these for future reviews
or versions of this review. We did not anticipate undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they are described in some way as to imply randomisation. For the primary outcomes
we included these studies and if there was no substantive diIerence when the implied randomised studies were added to those with better
description of randomisation, then all data were employed from these studies.
2. Standard care caseload
If data were available, a sensitivity analysis was undertaken testing how prone the primary outcomes were to change when trials comparing
Intensive Case Management to standard community care caseload ≦ 20 were compared with trials comparing Intensive Case Management
to standard community care caseload >20. If there was a substantial diIerence, we reported results and discussed them but continued
to pool the data.
3. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to follow-up (see Dealing with missing data) we compared the findings of the
primary outcomes when we used our assumption compared with completer data only. If there was a substantial diIerence, we reported
results and discussed them but continued to employ our assumption.
4. Assumptions for incomplete data for meta-regression
Where assumptions had to be made regarding missing SDs data in studies entering meta-regression (see Dealing with missing data), we
compared the findings of the meta-regression on our primary outcome when we used our assumption compared with data taken from only
those who completed the studies. A sensitivity analysis was undertaken testing how prone results from meta-regression were to change
when data from those who completed were compared with imputed data using the assumption outlined above. If there was a substantial
diIerence, we reported results and discussed them but continued to employ our assumption.
Appendix 3. R script used to impute data and perform meta-regression analysis
AOIP <- read.csv('META-REG_2010_fmi.csv')
AOIP <- AOIP[1:52,]
names(AOIP)
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AOIPM <- AOIP
# initially replace missing SD's by simple regression model on means
exp <- lm(AOIP$Exp_SD ˜ poly(AOIP$Exp_MEAN,2))
exp2 <- predict(exp, as.data.frame(AOIP$Exp_MEAN), type = 'response')
# plot(AOIP$Exp_SD, AOIP$Exp_MEAN, xlim = c(0,15))
# points(exp2, AOIP$Exp_MEAN, col = 'red')
exp3 <- AOIP$Exp_SD
exp3[is.na(exp3)] <- exp2[is.na(exp3)]
AOIP$Exp_SD <- exp3
exp <- lm(AOIP$Con_SD ˜ poly(AOIP$Con_MEAN,2))
exp2 <- predict(exp, as.data.frame(AOIP$Con_MEAN), type = 'response')
# plot(AOIP$Con_SD, AOIP$Con_MEAN, xlim = c(0,15))
# points(exp2, AOIP$Con_MEAN, col = 'red')
exp3 <- AOIP$Con_SD
exp3[is.na(exp3)] <- exp2[is.na(exp3)]
AOIP$Con_SD <- exp3
library(mi)
AOIP2 <- cbind(AOIP[,18], AOIP[,5:11], AOIP[,13], AOIP[,16:17])
names(AOIP2)[1] <- names(AOIP)[18]
names(AOIP2)[9] <- names(AOIP)[13]
info.aoip <- mi.info(AOIP2)
# info.aoip <- update(info.aoip, "include",
# list(trial_no="FALSE",cent.no="FALSE",trial_id="FALSE",centre_id="FALSE" ))
imp.aoip <- mi(AOIP2, info.aoip, n.iter = 30)
AOIP2 <- mi.data.frame(imp.aoip)
AOIP2 <- cbind(AOIP[,1:4],AOIP2)
# recreate Fideltot
Fideltot <- AOIP2$Fid.Org + AOIP2$FidstaI
AOIP2 <- cbind(AOIP2, Fideltot)
# set OPUS baseline mean to missing
is.na(AOIP2[,13]) <- 19
AOIP2.mi <- AOIP2
AOIP <- AOIPM
# write.csv(AOIP2, 'metaregdataset_imputed2010.csv')
# meta analysis
library(meta)
AO1 <- metacont(AOIP$Exp_N, AOIP$Exp_MEAN, AOIP$Exp_SD, AOIP$Con_N, AOIP$Con_MEAN,
AOIP$Con_SD, AOIP$centre_id)
AO2 <- metacont(AOIP2$Exp_N, AOIP2$Exp_MEAN, AOIP2$Exp_SD, AOIP2$Con_N, AOIP2$Con_MEAN,
AOIP2$Con_SD, AOIP2$centre_id)
AO3 <- metacont(AOIP2$Exp_N, AOIP2$Exp_MEAN, AOIP2$Exp_SD, AOIP2$Con_N, AOIP2$Con_MEAN,
AOIP2$Con_SD, AOIP2$centre_id, subset = (AOIP2$SCvsLICM == 1))
AO4 <- metacont(AOIP2$Exp_N, AOIP2$Exp_MEAN, AOIP2$Exp_SD, AOIP2$Con_N, AOIP2$Con_MEAN,
AOIP2$Con_SD, AOIP2$centre_id, subset = (AOIP2$SCvsLICM == 2))
summary(AO1)
summary(AO2)
# metaregression
# Control type
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AO2rct <- lm(AO2$TE ˜ AOIP2$SCvsLICM, weights = AO2$w.random)
summary(AO2rct)
# Total fidelity score
AO2r1 <- lm(AO2$TE ˜ AOIP2$Fideltot, weights = AO2$w.random)
summary(AO2r1)
plot(AO2$TE ˜ AOIP2$Fideltot)
abline(lm(AO2$TE ˜ AOIP2$Fideltot, weights = AO2$w.random))
# Interaction
AO2rint <- lm(AO2$TE ˜ AOIP2$Fideltot * AOIP2$SCvsLICM, weights = AO2$w.random)
summary(AO2rint)
plot(AO2$TE ˜ AOIP2$Fideltot)
abline(lm(AO2$TE ˜ AOIP2$Fideltot, weights = AO2$w.random))
# Organizational fidelity score
AO2r2 <- lm(AO2$TE ˜ AOIP2$Fid.Org, weights = AO2$w.random)
summary(AO2r2)
plot(AO2$TE ˜ AOIP2$Fid.Org)
abline(lm(AO2$TE ˜ AOIP2$Fid.Org, weights = AO2$w.random))
# more fancy plot
plot(AO1$TE ˜ AOIP$Fid.Org, pch = 21, bg = 'blue', cex = AO1$w.random*6,
ylab = 'Treatment EIect (Days)', xlab = 'Organizational Fidelity Score')
abline(lm(AO2$TE ˜ AOIP2$Fid.Org, weights = AO2$w.random))
# against baseline
AO2r4 <- lm(AO2$TE ˜ AOIP2$Baseline_Mean, weights = AO2$w.random)
summary(AO2r4)
plot(AO2$TE ˜ AOIP2$Baseline_Mean)
abline(lm(AO2$TE ˜ AOIP2$Baseline_Mean, weights = AO2$w.random))
# fancy plot
plot(AO1$TE ˜ AOIP$Baseline_Mean, pch = 21, bg = 'blue', cex = AO1$w.random*6,
ylab = 'Treatment EIect (Days)', xlab = 'Baseline Days in Hospital')
abline(lm(AO2$TE ˜ AOIP2$Baseline_Mean, weights = AO2$w.random))
# multivariate model
AO2r5 <- lm(AO2$TE ˜ AOIP2$Baseline_Mean + AOIP2$SCvsLICM + AOIP2$Fid.Org, weights = AO2$w.random)
summary(AO2r5)
# Thin plate spline
library(fields)
x <- cbind(AOIP2$Baseline_Mean[-19], AOIP2$Fid.Org[-19])
fit <- Tps( x, AO2$TE[-19], weights = AO2$w.random[-19], df = 10)
par(mfrow=c(2,1))
surface(fit)
plot(x, pch = 21, bg = 'red', cex = AO2$w.random[-19]*4)
Appendix 4. Results of searches from previous versions of this review
1. Selection of studies (see Selection of studies).
When CBI inspected a random sample of study abstracts identified as above (see Search methods for identification of studies) comprising
10% of total abstracts the principal reviewer (MD) had inspected, disagreement did occur. Full articles were therefore acquired for further
inspection. At this next stage MD and CBI had full agreement on the total sample of reports selected for further inspection.
When MD and CBI in turn inspected all full articles of relevant reports and independently decided whether they met inclusion criteria (see
Criteria for considering studies for this review), they fully agreed and no diIiculties or disputes arose on any report. It was not necessary
contact third reviewer (MM) for clarifying issues.
2. Data extraction (see Data extraction and management)
When CBI independently extracted data from a random sample of included studies (10% of total) disagreements were discussed. MD and
CBI reached full agreement on final decisions.
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3. Original Cochrane reviews (Marshall 2000a, Marshall 2000b)
3.1 ACT (Marshall 2000b)
Fourteen trials had met inclusion for the ACT versus standard care comparison. The trials included were Aberg-Wistedt-Sweden 1995,
Audini-UK 1994, Bond-Chicago1 1990, Bond-Indiana1 1988, Chandler-California1 1991, Hampton-Illinois 1992, Herinckx-Oregon 1996,
Jerrell-SCarolina1 1991, Lehman-Maryland1 1994, Morse-Missouri1 1992, Quinlivan-California 1995, Rosenheck-USA 1993, Solomon-
Pennsylvania 1994 and Test-Wisconsin 1985. All trials were included in the current review in the comparison ICM versus standard care.
For the ACT versus hospital-based rehabilitation comparison, three trials had been eligible for inclusion (De Cangas-Canada 1994, Lafave-
Canada 1996, Marx-Wisconsin 1973). All three have been excluded from the current update as they did not met inclusion criteria.
Six trials were included in the ACT versus case management comparison (Bush-Georgia 1990, Essock-Connecticut1 1995, Jerrell-SCarolina1
1991, Morse-Missouri2 1997, Quinlivan-California 1995, Solomon-Pennsylvania 1994). Of the original six studies described above, two
were included in the ICM versus standard care comparison as both are three arm studies comparing ICM (in two arms) versus standard
care (Jerrell-SCarolina1 1991, Solomon-Pennsylvania 1994). Three trials were included in the ICM versus non-ICM comparison (Bush-
Georgia 1990, Essock-Connecticut1 1995, Quinlivan-California 1995). Quinlivan-California 1995 was included in both comparisons ICM
versus standard care and ICM versus non-ICM, as it had three arms comparing three diIerentiated interventions (ICM, non-ICM and standard
care). The sixth trial, Morse-Missouri2 1997, although previously included, was excluded from the current update because it contained no
usable data, as number for treatment groups were not presented.
3.2 Case Management (Marshall 2000a)
Ten randomised controlled trials were included in the comparison of case management versus standard care (Curtis-New York 1992, Ford-
UK 1995, Franklin-Texas 1987, Jerrell-SCarolina1 1991, Macias-Utah 1994, Marshall-UK 1995, Muijen-UK2 1994, Quinlivan-California 1995,
Solomon-Pennsylvania 1994, Tyrer-UK 1995). Of these eight are now included (Curtis-New York 1992, Ford-UK 1995, Jerrell-SCarolina1
1991, Macias-Utah 1994, Marshall-UK 1995, Muijen-UK2 1994, Quinlivan-California 1995, Solomon-Pennsylvania 1994). Franklin-Texas 1987
and Tyrer-UK 1995 had to be excluded as they did not meet inclusion criteria on type of intervention.
4. 2009 update
The February 2009 update search of Cochrane Schizophrenia Group’s Register of trials yielded 2565 references. We selected 55 for
further inspection. Of these 14 trials met the inclusion criteria and were included (Bjorkman-Sweden 2002, Drake-NHamp 1998,
Essock-Connecticut2 2006, Harrison-Read-UK 2000, Johnston-Australia 1998, Morse-Missouri3 2005, Muller-Clemm-Canada 1996, Okpaku-
Tennessee 1997, OPUS-Denmark 1999, Pique-California 1999, REACT-UK 2002, Sytema-Netherlands 1999, Salkever-SCarolina 1999, UK700-
UK 1999). Thirty one trials were excluded.
We added ten English language trials and five Chinese trials to those awaiting assessment and sought further information. Three trials
which had been previously been awaiting assessment were able to be included as more reports had become available (Fekete 1998 now
included as McDonel-Indiana 1997, Holloway-UK 1996, Shern-USA1 2000).
Appendix 5. Dealing with missing data - standard deviation mean number of days per month in hospital (Intensive
Case Management Protocol)
3.2.2 Standard deviation mean number of days per month in hospital
For the primary outcome, mean number of days per month in hospital, if standard deviations were not reported and could not be calculated
from available data, we asked authors for additional information. In the absence of data from authors, we calculated missing standard
deviations using a regression analysis of standard deviation against mean, based on data from studies which did report these data. If the
standard deviations calculated according to the above technique were available from a previous review (published and unpublished data)
(Burns 2007), we used these data.
Appendix 6. Dealing with missing data - incomplete data for meta-regression (Intensive Case Management Protocol)
3.4 Incomplete data for meta-regression
In some cases we anticipate that IFACT score variables will not all be available. Where these missing data are from multi-centre studies
from which we do have relevant data we assumed the missing variable score to be the mode of the available data from the other centres
that we used as a reference. Where there was no clear reference centres, we tried to match the study to another we felt to be closest and
used those scores. As explained above, we will only make these assumptions if we are able to directly rate over 50% of the data within
each multi-centre study and overall.
In some cases we anticipate that baseline hospital use data will not all be available. Where these missing data are from multi-centre studies
from which we do have relevant data we assumed the missing information to be the mean of the available data from the other centres
that we used as a reference. Where there was no clear reference centres, we tried to match the study to another we felt to be closest and
used those means. As explained above, we will only make these assumptions if we are able to directly rate over 50% of the data within
each multi-centre study and overall.
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W H A T ' S   N E W
 
Date Event Description
23 August 2016 New search has been performed Results of 2012 and 2015 update searches added to the review.
Two new studies added to included studies.
23 August 2016 New citation required but conclusions
have not changed
Data from two new studies did not substantially alter results or
change overall conclusions.
10 April 2015 Amended Search updated, and 299 possibly related references were added
to 'Classification pending references' of the review.
 
H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 10, 2010
 
Date Event Description
12 August 2012 Amended Update search of Cochrane Schizophrenia Group's Trial Regis-
ter (see Search methods for identification of studies), 81 studies
added to awaiting classification.
6 October 2010 Amended Contact details updated.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Marina Dieterich: developed and wrote protocol, participated in literature searches, selected studies and extracted data, wrote report for
both versions.
Claire Irving: developed and wrote protocol, participated in studies selection and data extraction for original version.
Hanna Bergman: carried out trial selection and data extraction for 2015 update.
Mariam Khokhar: carried out trial selection and data extraction for 2015 update.
Bert Park: carried out meta-regression analysis, helped in writing the report for original version.
Max Marshall: developed and wrote protocol, helped in studies selection, final draP for original version.
D E C L A R A T I O N S   O F   I N T E R E S T
Marina Dieterich: none known.
Claire Irving: none known.
Hanna Bergman: none known.
Mariam Khokhar: none known.
Bert Park: none known.
Max Marshall: was involved in one included study and has written extensively in this area.
S O U R C E S   O F   S U P P O R T
Internal sources• University of Verona, Italy.
Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology
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External sources• NIHR, UK.
Cochrane Incentive Award 15/81/30 - Intensive case management for severe mental illness
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The following section follows the numbering system of the methods of the review.
1.) Types of outcome measures (see Types of outcome measures)
The time grouping of outcomes has been slightly amended in the review, introducing a diIerent timing for follow-up assessed once the
active intervention was stopped. We have reported the protocol version below.
Outcomes were grouped by time into short term (up to and including 6 months), medium term (7 months to up to and including 12 months)
and long term (over 12 months). Where available, 24 months was the preferred follow-up point for calculating mean days per months in
hospital. If more than one follow-up point within the same period were available, we reported the latest one.
2.) Some social functioning and costs outcomes have been slightly amended in the review (see Secondary outcomes). We have reported
the protocol version below.
4. Social functioning
4.1 Imprisonment (i.e. police contacts & arrests)
9. Economic
9.1 Costs of psychiatric hospital care
9.2 Costs of health care
9.3 Costs of all care
3.) Compliance with medication (see Secondary outcomes)
This secondary outcome was listed twice in the protocol due to inattention (both as global state and behaviour). We have amended it,
listing 'compliance with medication' just under 'global state' outcome.
4.) Data regarding criteria and outcomes (see Data extraction and management)
We further clarified this section in the review. We have reported the protocol version below.
1. Extraction
1.1 Data regarding criteria and outcomes
Authors MD and CBI independently extracted data from included studies. Again, any disagreement was discussed, decisions documented
and, if necessary, authors of studies were contacted for clarification. With remaining problems MM helped clarify issues and those final
decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but were included only if two
reviewers independently had the same result. Attempts were made to contact authors through an open-ended request in order to obtain
missing information or for clarification whenever necessary. Where possible, we extracted data relevant to each component centre of multi-
centre studies separately.
5.) Skewed data (see Data extraction and management)
We had not anticipated the following clarification in the protocol, but added it in the review.
We implemented one exception to the above rules in order to present more data, recognising that this is a post hoc decision, but also that
the rules with regards to management of skewed data and how robust skewed data are within meta-analysis are unclear (Higgins 2011).
Where mean number of days in hospital data were skewed, and they were provided by studies of fewer than 200 participants, we entered
those data into a subgroup of the overall analysis. We also presented the overall eIect from all data pooled.
6.) 'Summary of findings' table (see Data extraction and management)
The way the outcomes included in the 'Summary of findings' table were listed and presented were slightly rearranged, but not substantially
modified. We have reported the protocol version below. Besides, we decided not to apply the low and high control risk calculation as stated
in the protocol, and reported below.
Summary of findings table
We anticipate including the following long term main outcomes in a summary of findings table.
1. Global state
Intensive case management for severe mental illness (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
270
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
1.1 Hospitalisation: mean number of days per month in hospital
1.2 Relapse
1.3 Leaving the study early (lost to follow up)
2. Service use
2.1 Hospital admission across time
3. Adverse eIect
3.1 Death - suicide
4. Social functioning
4.1 Employment - unemployed at end of study
5. Mental state: general symptoms
5.1. Not improved to a clinically meaningful extent (as defined in trial)
Within the Summary of findings table we assumed for calculation of the low risk groups that the lowest control risk applied to all data. We
did the same for the assumption of the highest risk groups.
7.) Assessment of risk of bias in included studies (see Assessment of risk of bias in included studies)
We further clarified this section in the review. We have reported the protocol version below.
Again working independently, MD and CBI assessed risk of bias using the tool described in the Cochrane Collaboration Handbook (Higgins
2011). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at
outcome, the completeness of outcome data, selective reporting and other biases. We would have excluded studies where allocation was
clearly not concealed.
8.) Binary (see Dealing with missing data, 2.)
We have further clarified this paragraph in the review. We have reported the protocol version below.
In the case where attrition for a binary outcome is between 0 and 50% and where these data were not clearly described, data were
presented on a 'once-randomised-always-analyse' basis (an intention to treat analysis). Those leaving the study early were all assumed to
have the same rates of negative outcome as those who completed, with the exception of the outcome of death. A sensitivity analysis was
undertaken testing how prone the primary outcomes were to change when data from only those who completed the study were compared
with intention to treat data using the assumption outlined above.
9.) Standard deviation mean number of days per month in hospital (see Dealing with missing data, 3.2.2)
Substantially amended. For original protocol version, please see Appendix 5.
10.) Incomplete data for meta-regression (see Dealing with missing data, 3.4)
Substantially amended. For original protocol version, please see Appendix 6.
11.) Statistical heterogeneity (see Assessment of heterogeneity, 3.2)
We further clarified the last paragraph in the review. We have reported the protocol version below.
3.2 Employing the I2statistic
Heterogeneity between studies was investigated by considering the I2 method alongside the Chi2 'p' value. The I2 provides an estimate
of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I2 depends on i.
magnitude and direction of eIects and ii. strength of evidence for heterogeneity (e.g. 'p' value from Chi2 test, or a confidence interval for I2).
I2 estimate greater than or equal to 50% accompanied by a statistically significant Chi2 statistic, was interpreted as evidence of substantial
levels of heterogeneity (Section 9.5.2 - Higgins 2011) and reasons for heterogeneity were explored. If the inconsistency was high and the
clear reasons were found, data were presented separately.
12.) Subgroup analyses (see Subgroup analysis and investigation of heterogeneity, 1.)
No subgroup analyses had been anticipated in the protocol.
13. Subgroup analyses (see Subgroup analysis and investigation of heterogeneity, 2.)
We further clarified this section in the review. We have reported the protocol version below.
2. Investigation of heterogeneity
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2.1 Unanticipated heterogeneity
Should unanticipated clinical or methodological heterogeneity be obvious we will simply state hypotheses regarding these for future
reviews or versions of this review. We do not anticipate undertaking analyses relating to these.
14.) Sensitivity analysis (see Sensitivity analysis, 4.)
Substantially amended. We have reported the protocol version below.
4. Assumptions for incomplete data for meta-regression
Where assumptions had to be made regarding missing trial data for meta-regression (see Dealing with missing data) we compared the
findings of the meta-regression on primary outcome when we used our assumption compared with completer data only. A sensitivity
analysis was undertaken testing how prone result from meta-regression were to change when 'completed' data only were compared to
the imputed data using the above assumption. If there was a substantial diIerence, then only completed data were employed.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Case Management;  Community Mental Health Services  [*methods];  Employment  [statistics & numerical data];  Hospitalization
 [statistics & numerical data];  Mental Disorders  [*therapy];  Outcome and Process Assessment, Health Care  [*methods];  Randomized
Controlled Trials as Topic;  Regression Analysis;  Suicide  [statistics & numerical data]
MeSH check words
Humans
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